0001493152-23-012570.txt : 20230417 0001493152-23-012570.hdr.sgml : 20230417 20230417165452 ACCESSION NUMBER: 0001493152-23-012570 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230417 DATE AS OF CHANGE: 20230417 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NanoVibronix, Inc. CENTRAL INDEX KEY: 0001326706 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36445 FILM NUMBER: 23824551 BUSINESS ADDRESS: STREET 1: 525 EXECUTIVE BLVD CITY: ELMSFORD STATE: NY ZIP: 10523 BUSINESS PHONE: (914) 233-3004 MAIL ADDRESS: STREET 1: 525 EXECUTIVE BLVD CITY: ELMSFORD STATE: NY ZIP: 10523 FORMER COMPANY: FORMER CONFORMED NAME: Nano Vibronix, Inc. DATE OF NAME CHANGE: 20111206 FORMER COMPANY: FORMER CONFORMED NAME: Nano Vibronix Inc DATE OF NAME CHANGE: 20050510 10-K 1 form10-k.htm
0001326706 false FY 0001326706 2022-01-01 2022-12-31 0001326706 2022-06-30 0001326706 2023-04-17 0001326706 2022-12-31 0001326706 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2021-12-31 0001326706 2021-01-01 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-12-31 0001326706 us-gaap:CommonStockMember 2020-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001326706 us-gaap:RetainedEarningsMember 2020-12-31 0001326706 2020-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-12-31 0001326706 us-gaap:CommonStockMember 2021-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001326706 us-gaap:RetainedEarningsMember 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001326706 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001326706 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2022-12-31 0001326706 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2022-12-31 0001326706 us-gaap:CommonStockMember 2022-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001326706 us-gaap:RetainedEarningsMember 2022-12-31 0001326706 NAOV:SaleOfEquitySecuritiesMember 2022-12-31 0001326706 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001326706 us-gaap:OfficeEquipmentMember srt:MinimumMember 2022-01-01 2022-12-31 0001326706 us-gaap:OfficeEquipmentMember srt:MaximumMember 2022-01-01 2022-12-31 0001326706 2021-08-16 0001326706 2021-08-17 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2022-11-28 2022-11-29 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2022-11-29 0001326706 NAOV:HCWainwrightAndCoLLCMember us-gaap:IPOMember 2022-10-05 2022-10-06 0001326706 NAOV:HCWainwrightAndCoLLCMember 2022-10-05 2022-10-06 0001326706 NAOV:HCWainwrightAndCoLLCMember 2022-10-06 0001326706 us-gaap:SeriesEPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2022-09-12 2022-09-13 0001326706 NAOV:SeriesFCommonStockMember 2022-09-12 2022-09-13 0001326706 us-gaap:SeriesFPreferredStockMember 2022-01-01 2022-12-31 0001326706 NAOV:EmployeeOptionsMember 2022-01-01 2022-12-31 0001326706 NAOV:EmployeeOptionsMember 2021-01-01 2021-12-31 0001326706 us-gaap:EmployeeStockMember 2022-12-31 0001326706 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001326706 NAOV:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2020-12-01 2020-12-02 0001326706 NAOV:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2020-12-02 0001326706 NAOV:SecuritiesPurchaseAgreementMember NAOV:PreFundedWarrantsMember 2020-12-01 2020-12-02 0001326706 NAOV:SecuritiesPurchaseAgreementMember NAOV:PreFundedWarrantsMember 2020-12-02 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2020-12-01 2020-12-02 0001326706 NAOV:TwoInvestorsMember NAOV:WarrantsMember 2021-01-01 2021-01-31 0001326706 NAOV:TwoInvestorsMember NAOV:WarrantsMember 2021-01-31 0001326706 NAOV:AccreditorInvestorsMember NAOV:WarrantsMember 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-01-20 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-04-01 2021-06-30 0001326706 2021-09-30 0001326706 srt:MinimumMember 2021-09-30 0001326706 srt:MaximumMember 2021-09-30 0001326706 us-gaap:WarrantMember 2021-09-01 2021-09-30 0001326706 2022-06-14 0001326706 2022-06-13 2022-06-14 0001326706 2022-09-30 0001326706 2022-09-29 2022-09-30 0001326706 2022-11-29 0001326706 NAOV:EmployeeOptionsMember 2021-12-31 0001326706 NAOV:EmployeeOptionsMember 2022-12-31 0001326706 srt:MinimumMember 2022-12-31 0001326706 srt:MaximumMember 2022-12-31 0001326706 srt:MinimumMember 2021-12-31 0001326706 srt:MaximumMember 2021-12-31 0001326706 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001326706 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001326706 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2022-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2022-12-31 0001326706 us-gaap:WarrantMember NAOV:PrivateInvestorsMember 2020-12-31 0001326706 us-gaap:WarrantMember NAOV:PrivateInvestorsMember 2021-01-01 2021-12-31 0001326706 us-gaap:WarrantMember NAOV:PrivateInvestorsMember 2021-12-31 0001326706 us-gaap:WarrantMember NAOV:PrivateInvestorsMember 2022-01-01 2022-12-31 0001326706 us-gaap:WarrantMember NAOV:PrivateInvestorsMember 2022-12-31 0001326706 NAOV:DerivativeLiabilityWarrantsMember NAOV:InvestorsMember 2021-04-05 2021-04-06 0001326706 NAOV:DerivativeLiabilityWarrantsMember NAOV:InvestorsMember srt:MinimumMember 2021-04-06 0001326706 NAOV:DerivativeLiabilityWarrantsMember NAOV:InvestorsMember srt:MaximumMember 2021-04-06 0001326706 NAOV:DerivativeLiabilityWarrantsMember NAOV:InvestorsMember 2021-04-06 0001326706 us-gaap:WarrantMember srt:MinimumMember 2022-12-31 0001326706 us-gaap:WarrantMember srt:MaximumMember 2022-12-31 0001326706 us-gaap:WarrantMember srt:MinimumMember 2021-12-31 0001326706 us-gaap:WarrantMember srt:MaximumMember 2021-12-31 0001326706 us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputConversionPriceMember srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001326706 us-gaap:MeasurementInputConversionPriceMember srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001326706 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NAOV:DerivativeLiabilityMember 2022-12-31 0001326706 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NAOV:DerivativeLiabilityMember 2022-12-31 0001326706 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember NAOV:DerivativeLiabilityMember 2021-12-31 0001326706 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember NAOV:DerivativeLiabilityMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001326706 NAOV:StockOptionsEmployeeAndNonEmployeeMember 2022-01-01 2022-12-31 0001326706 NAOV:StockOptionsEmployeeAndNonEmployeeMember 2021-01-01 2021-12-31 0001326706 NAOV:WarrantsMember 2022-01-01 2022-12-31 0001326706 NAOV:WarrantsMember 2021-01-01 2021-12-31 0001326706 country:US 2022-01-01 2022-12-31 0001326706 country:US 2021-01-01 2021-12-31 0001326706 srt:EuropeMember 2022-01-01 2022-12-31 0001326706 srt:EuropeMember 2021-01-01 2021-12-31 0001326706 country:AU 2022-01-01 2022-12-31 0001326706 country:AU 2021-01-01 2021-12-31 0001326706 country:IN 2022-01-01 2022-12-31 0001326706 country:IN 2021-01-01 2021-12-31 0001326706 country:IL 2022-01-01 2022-12-31 0001326706 country:IL 2021-01-01 2021-12-31 0001326706 NAOV:OtherCountryMember 2022-01-01 2022-12-31 0001326706 NAOV:OtherCountryMember 2021-01-01 2021-12-31 0001326706 NAOV:LicensingAgreementMember NAOV:SanuwaveHealthIncMember 2020-04-09 0001326706 NAOV:PriceAtValuationMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 NAOV:PriceAtValuationMember srt:MinimumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 NAOV:PriceAtValuationMember srt:MaximumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputExercisePriceMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 us-gaap:MeasurementInputExercisePriceMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2020-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2020-12-31 0001326706 NAOV:DerivativeAssetMember 2021-01-01 2021-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2021-01-01 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2021-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2022-01-01 2022-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2022-01-01 2022-12-31 0001326706 NAOV:DerivativeAssetMember 2022-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2022-12-31 0001326706 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001326706 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001326706 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001326706 NAOV:JonaZumerisMember 2019-12-16 2019-12-17 0001326706 NAOV:FormerOfficerMember 2019-12-16 2019-12-17 0001326706 2020-11-30 0001326706 2021-01-01 2021-01-31 0001326706 2021-02-25 2021-02-26 0001326706 NAOV:ArbitratorMember 2022-03-14 2022-03-15 0001326706 us-gaap:DomesticCountryMember 2022-12-31 0001326706 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001326706 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001326706 us-gaap:SubsequentEventMember 2023-02-07 2023-02-08 0001326706 2022-12-14 2022-12-15 0001326706 us-gaap:SubsequentEventMember 2023-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number: 001-36445

 

 

NanoVibronix, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   01-0801232

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

525 Executive Blvd. Elmsford, New York   10523
(Address of principal executive office)   (Zip Code)

 

Registrant’s telephone number, including area code: (914) 233-3004

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common stock, par value $0.001 per share   NOAV   NASDAQ Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of our common stock held by non-affiliates as of June 30, 2022, was approximately $17,539,360.

 

The number of shares outstanding of the registrant’s Common Stock as of April 17, 2023 was 1,662,377 shares.

 

DOCUMENTS INCORPORATED BY REFERENCE

 

The information required by Part III of this Form 10-K, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders. Such proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.

 

 

 

 

 

 

PART I

 

ITEM 1. BUSINESS

 

Cautionary Note Regarding Forward-Looking Statements; Risk Factor Summary

 

This Annual Report on Form 10-K contains “forward-looking statements,” which include information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to a number of risks, and uncertainties and assumptions that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. These risks are more fully described in the “Risk Factors” section of this Annual Report on Form 10-K. The following is a summary of such risks:

 

  ● Our history of losses and expectation of continued losses.
  ● Global economic and political instability and conflicts, such as the conflict between Russia and Ukraine, could adversely affect our business, financial condition or results of operations
  ● Increasing inflation could adversely affect our business, financial condition, results of operations or cash flows.
  ● The geographic, social and economic impact of COVID-19 on the Company’s business operations.
  ● Our ability to raise funding for, and the timing of, clinical studies and eventual U.S. Food and Drug Administration (“FDA”) approval of our product candidates.
  ● Regulatory actions that could adversely affect the price of or demand for our approved products.
  ● Market acceptance of existing and new products.
  ● Favorable or unfavorable decisions about our products from government regulators, insurance companies or other third-party payers.
  ● Risks of product liability claims and the availability of insurance.
  ● Our ability to successfully develop and commercialize our products.
  ● Our ability to generate internal growth.
  ● Risks related to computer system failures and cyber-attacks.
  ● Our ability to obtain regulatory approval in foreign jurisdictions.
  ● Uncertainty regarding the success of our clinical trials for our products in development.
  ● Risks related to our operations in Israel, including political, economic and military instability.
  ● The price of our securities is volatile with limited trading volume
  ● Our ability to comply with the continued listing requirements of the Nasdaq capital market.
  ● Our ability to maintain effective internal control over financial reporting and to remedy identified material weaknesses.
  ● We are a “smaller reporting company” and have reduced disclosure obligations that may make our stock less attractive to investors.
  ● Our intellectual property portfolio and our ability to protect our intellectual property rights.
  ● Our ability to recruit and retain qualified regulatory and research and development personnel.
  ● Unforeseen changes in healthcare reimbursement for any of our approved products.
  ● The adoption of health policy changes and health care reform.
  ● Lack of financial resources to adequately support our operations.
  ● Difficulties in maintaining commercial scale manufacturing capacity and capability.
  ● Changes in our relationship with key collaborators.
  ● Changes in the market valuation or earnings of our competitors or companies viewed as similar to us.
  ● Our failure to comply with regulatory guidelines.

 

1

 

 

  ● Uncertainty in industry demand and patient wellness behavior.
  ● General economic conditions and market conditions in the medical device industry.
  ● Future sales of large blocks of our common stock, which may adversely impact our stock price.
  ● Depth of the trading market in our common stock.

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Item 1A. Risk Factors” for additional risks which could adversely impact our business and financial performance. Moreover, new risks regularly emerge, and it is not possible for us to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Form 10-K are based on information available to us on the date hereof. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Unless the context otherwise indicates or requires, the terms “we,” “our,” “us,” “NanoVibronix,” and the “Company,” as used in this Annual Report on Form 10-K, refer to NanoVibronix, Inc. and its subsidiaries as a combined entity, except where otherwise stated or where it is clear that the terms mean only NanoVibronix, Inc. exclusive of its subsidiaries.

 

Overview

 

We were organized as a Delaware corporation in October 2003. Through our wholly-owned subsidiary, NanoVibronix Ltd., a private company incorporated under the laws of the State of Israel, we focus on noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Our primary products, which are in various stages of clinical and market development, currently consist of:

 

  ● UroShield™, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which has been marketed in the U.S. under FDA’s policy of enforcement discretion during the COVID-19 pandemic and is currently undergoing clinical testing that will, hopefully, support 510(k) clearance;
     
  ● PainShield™, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Our PainShield family of products include:

 

  ● PainShield™ MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area.
     
  ● PainShield™ Plus, a dual patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Similar to PainShield MD, it has a dual ultrasound delivery; and,

 

  ● WoundShield™, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.

 

Each of our UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. Through their size, effectiveness and ease of use, these products are intended to eliminate the need for technicians and medical personnel to manually administer ultrasound treatment through large transducers, thereby promoting patient independence and enabling more cost-effective home-based care.

 

2

 

 

PainShield™, MD is currently cleared for marketing in the United States by the U.S. Food and Drug Administration (“FDA”). In September 2020, the FDA exercised its Enforcement Discretion to allow distribution of the UroShield device in the U.S. during the COVID-19 health emergency. While the permitted use is currently temporary, it does permit the import of the UroShield to the U.S. during the ongoing COVID-19 pandemic. Our understanding is that this permitted use will be terminated six months after the health emergency is officially ended. All three of our products have CE Mark approval in the European Union, and a certificate allowing us to sell PainShield and UroShield in Israel. We are able to sell PainShield and UroShield in India and Ecuador based on our CE Mark. We have consummated sales of PainShield and UroShield in the relevant markets, and we saw sales increase in 2021, but decline slightly in 2022. WoundShield has not generated significant revenue to date. Outside of the United States we generally apply, through our distributor, for approval in a particular country for a particular product only when we have a distributor in place with respect to such product.

 

In the United States, PainShield and UroShield require a prescription from a licensed healthcare practitioner. If FDA clearance is obtained, we anticipate that WoundShield will require a prescription from a licensed healthcare practitioner in the United States. As stated previously, UroShield has been approved through the FDA under Enforcement Discretion for the duration of the Covid-19 health emergency and is intended to be sold directly to health care facilities and individuals. Individuals will require a prescription but healthcare facilities will deploy based upon clinical need. However, in other countries in which we sell PainShield, UroShield, and WoundShield, such products are eligible for sale without a prescription.

 

In addition to the need to obtain regulatory approvals, we anticipate that sales volumes and prices of our UroShield and PainShield, products will depend in large part on the availability of insurance coverage and reimbursement from third party payers. Third party payers include governmental programs such as Medicare and Medicaid in the United States, private insurance plans and workers’ compensation plans. We do not currently have reimbursement codes for use of WoundShield in any of the markets in which we have regulatory authority to sell WoundShield. Of the markets in which we have regulatory authority to sell PainShield, prior to January 2020, we only had reimbursement codes in the United States (i.e., CPT codes) for clinical use only. Effective as of January 2020, the U.S. Centers for Medicare and Medicaid Services (“CMS”) approved our PainShield™ for reimbursement for Medicare beneficiaries on a national basis. However, the company continues to work toward a reimbursement value from CMS. We are working with qualified legal representation toward that goal. The company was denied reimbursement in September 2022 due to a lack of “life-cycle” testing. The company has engaged Carmel Labs in Israel to conduct this testing. We are approximately 85% of the way through this testing, with all devices working properly. In January 2023, we submitted another application to CMS with “life-cycle” testing pending. Along with our application, we submitted an interim report which was positive in nature. The latest CMS application will include both PainShield and UroShield products and supplies. With respect to UroShield, which may be used in a clinical and home setting, we do not currently have reimbursement codes in any of the markets in which we have regulatory authority to sell UroShield. We are seeking reimbursement codes for use of our products in the markets in which we have regulatory authority, including the United States, to sell such products. Our current ongoing research and planned research may facilitate our ability to obtain reimbursement codes and there is no guarantee that we will be successful in obtaining such codes quickly, or at all. We have engaged a reimbursement expert, the law firm of Brown and Fortunato as regulatory counsel, to help facilitate our applications, potentially leading to reimbursement.

 

We have completed seven separate clinical studies with UroShield that together evaluated approximately 220 patients with urinary catheters. In patients where the UroShield product was used there were no serious adverse events reported, while a variety of clinical beneficial observations were seen including: catheter biofilm reduction, reduction in catheter associated pain, reduction in urinary tract infections, and a significant decrease in bacteriuria rates. We completed a double blind clinical trial for UroShield in the United States in October 2018. The results of the study, entitled “The Effect of Surface Acoustic Waves on Bacterial Load and Preventing Catheter-Associated Urinary Tract Infections (CAUTI) in Long Term Indwelling Catheters,” were published in the December 2018 issue of Medical & Surgical Urology, a peer-reviewed journal in the field of urology. In the study, 55 patients in skilled nursing facilities treated with long term indwelling catheters were evaluated. There was a significant difference between the treated group and the placebo group in the number of colony forming units (“CFU”) present upon evaluation, as well as on the number of treated urinary tract infections (“UTI”), and the effect lasted beyond the time of active treatment. The study concluded that the UroShield™ device was shown to be effective in significantly reducing the number of CFUs in patients with indwelling catheters. The study also concluded that the UroShield™ device was shown to be effective in reducing the number of treated UTIs in this patient population, and surface acoustic waves in the form of the UroShield™ device is an effective tool in the prevention of catheter-associated UTI and while further evaluation is encouraged, can be safely utilized with a high likelihood of success. In July 2017, we engaged Idonea Solutions, Inc., an FDA consultant, to assist in our efforts to obtain clearance under the FDA’s Enforcement Discretion, and obtain 510(k) clearance which is still ongoing. If we are successful, we intend to pursue obtaining reimbursement codes and to target completion of partnerships with leading catheter product companies and distributors for sales and marketing efforts in the United States. The Company has entered into recent distribution partnerships for UroShield in the U.K., Australia, and Malta.

 

3

 

 

We have one clinical study recently completed for our product UroShield. We announced positive interim results from an independent, real world patient study of UroShield at Southampton University Health Sciences in December 2021. The independent study, which was launched in the first half of 2021, was devised to evaluate how UroShield helps to reduce infection by preventing bacteria colonization and the buildup of biofilms on long-term indwelling urinary catheters in real world patients and to better understand the patient benefits and experiences of using UroShield. The study consists of both laboratory and patient studies and is nearing completion. At the conclusion of the study, Southern Health reported a significant reduction in catheter blockage and a positive effect on the microbiome. Full results of the study are expected to be published in 2023.

 

In addition, we continue to expand our clinical development and marketing efforts in North America with respect to PainShield. In February 2018, we completed a clinical trial to evaluate the effect of PainShield in patients with trigeminal neuralgia. The double blinded, crossover trial was conducted across the United States and included 59 patients with a diagnosis of unilateral trigeminal neuralgia. Among the 59 patients, 30 were in the active treatment group and 29 were in the control group. The values which were assessed included the Visual Analog Scale (“VAS”) pain score, both baseline prior to trial and VAS pain score at the end of the study. The study also assessed breakthrough medications per week at the start of the trial and breakthrough medications per week at the end of the trial, with a particular focus on the use of opioids. Breakthrough medications are used for chronic pain directly related to the pre-existing trigeminal neuralgia condition. There was a significant difference in the outcomes of the two groups relative to pain, quality of life, and breakthrough medications taken, which was directly correlated to pain experienced during treatment. Specifically, the control group saw an improvement in baseline scores of 2.3% versus the treatment group, which saw a 55.2% improvement in baseline scores. Additionally, the control group saw a reduction in breakthrough pain medication of 1.5% versus the treatment group, which saw a 46.4% reduction in breakthrough pain medication.

 

We are currently in advanced negotiations with a major teaching medical university to conduct a study on UroShield, which is intended to satisfy the FDA requirements for traditional 510k clearance. We expect that study to commence in either the third or fourth quarter of 2023.

 

In 2019, the Company completed a study which was intended to assess the PainShield’s ability to effectively treat Lateral Epicondylitis (Tennis Elbow). This was a double blinded, randomized control trial. The study has been completed and we are contemplating submission to an appropriate journal. The interim results were reported as follows:

 

  ● 91% of the patients in the PainShield treatment group had complete or partial resolution of symptoms. Patients used PainShield in conjunction with over-the-counter medication, as needed, but without the benefit of opioid-based prescription medication.

 

We believe results of the Birmingham study could further reinforce that PainShield is safe, easy-to-use and highly effective in treating soft tissue pain. Patients in the study who wore our device reported marked reduction in pain and when combined with over-the-counter, anti-inflammatory medications, those same patients reported a complete resolution of symptoms within 10 days.

 

Dr. David Lemak, MD, Lead Investigator of the Birmingham Study, added, “Patient outcomes were markedly improved with the use of PainShield and importantly, no patients returned with signs or symptoms of an exacerbation. Most encouraging are the results we were able to achieve for our patients without the use of prescription opioid medications, which can often lead to prolonged use and addiction.”

 

WoundShield has been evaluated in two published clinical studies done to-date that suggest improved localized blood flow and oxygenation, and improved topical oxygen saturation (Morykwas M, “Oxygen Therapy with Surface Acoustic Waveform Sonication,” European Wound Management Association 2011; Covington S, “Ultrasound-Mediated Oxygen Delivery to Lower Extremity Wounds,” Wounds 2012; 24(8)). We supplied devices for these studies but had no further involvement with them.

 

4

 

 

Recent Developments

 

On March 21, 2023 we announced that we filed a new provisional patent application with the United States Patent and Trademark Office (“USPTO”) entitled “Multiple Frequency Surface Acoustic Waves for Internal Medical Device” (the “Patent Application”) related to its UroShield. The Patent Application covers a recently developed enhancement to the UroShield product, UroShield “Ultra”, which incorporates improvements to the Company’s original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering SAWs at multiple frequencies directly to indwelling catheters.

 

On March 15, 2023 we announced the positive evaluation results for our UroShield device, presented at a recent medical conference by clinicians from the Royal National Orthopaedic Hospital (“RNOH”). The report concluded that our UroShield device showed a decrease in the number of blockages and infections and an increase in catheter satisfaction in the patients studied. In addition, evaluators concluded that the device has the potential to improve quality of life and reduce healthcare associated costs for patients with spinal cord injuries who experience recurrent blockages or infections and who have complicated catheter issues.

 

In April 2022, we announced that UroShield was approved for sale by NHS Supply Chain through a new contract. This new contract with NHS Supply Chain provides a dedicated end-to-end supply chain service of our UroShield for every NHS healthcare organization. UroShield will be available to all patients who need the device with full clinical support, through the NHS supply chain. On September 23, 2022, UroShield was approved for sale by the NHS Supply Chain through a new contract. The new contract, which is designed to provide new innovative products for healthcare providers, begins in October 2022 and will merge with the existing Urology and Stoma framework contract in February 2024 with optional extension periods.

 

PainShield was granted a dedicated reimbursement code (K1004) by CMS in 2021, which was an initial step towards paving the way for many millions of beneficiaries enrolled in Medicare to have access to our product. In addition, CMS expanded its reimbursement approval of the company’s PainShield™ product by adding the device to its Durable Medical Equipment (DME) schedule. ricing was not established at that time, and our efforts to obtain favorable pricing resulted in a denial, pending further testing of the device’s life expectancy. Testing to gather life expectancy data began in October 2022, and we are preparing to demonstrate the life expectancy in the next few months. We are hopeful of a positive outcome that will allow us to secure pricing and remove the barriers for distribution to beneficiaries under Medicare.

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims asserted by Protrade.

 

5

 

 

On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $1.5 million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.

 

On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.

 

On July 22, 2022, the Company filed a cross-motion seeking to vacate the arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.

 

On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion.

 

On November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newel information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. On March 21, 2023, the Court denied the motion to re-argue and renew. The Company intends to file a notice of appeal with the Appellate Division, Second Department and to continue to vigorously pursue its opposition to the award in all appropriate fora. As of December 31, 2022, the Company accrued the amount of the award to Protrade amounting to $1,846,794 with $1,500,250 as part of “General and administrative expenses” and $346,544 as part of “Interest expense”, and the full amount included in “Other accounts payable and accrued expenses”.

 

Business Model

 

All of our products consist of a reusable controller device and a disposable component, which includes a transducer, and in the case of PainShield, a 30 day supply of adhering patches. The controllers have a life expectancy of three years, while the UroShield disposable transducer has a life expectancy of up to a month and must be replaced to provide the intended therapy. The components are purchased by either the distributor or end user for use in any of the intended applications. Once the controller is purchased by the end user, recurring revenue will be realized by purchases of replacement disposables to the extent that the end user continues treatment with our product.

 

Our products are intended to be distributed directly by the company, independent distributors, and potential licensees. Distributor cost is discounted to account for their intended margins, based upon purchase volumes and/or periodic purchase commitments, with the disposable transducer sold and distributed in the same fashion. We currently have an established distributor network and are implementing certain criteria within such network to ensure the appropriate assignment of a distributor or licensee. We are in the process of adding additional distributors to our network, and continue our efforts to identify market leaders in various segments to private label both PainShield and UroShield.

 

We also have a direct sales component, where we sell directly to consumers, in order to satisfy customer demand generated through on-line advertising and social media. We have seen an increase in demand as a direct result of an expanded social media and on-line advertising presence.

 

Our business plan continues to focus on these types of transactions/agreements. We continue to focus on the foundational aspects of each respective product, including the design and performance of each, the reimbursement, regulatory status, and quality control, in order to strengthen our position with prospective partners.

 

6

 

 

Ultrasound Technology and Our Products

 

As noted above, our primary products are based on the use of low frequency ultrasound, which delivers energy through mechanical vibrations in the form of sound waves. Ultrasound has long been used in physical therapy, physical medicine, rehabilitation and sports medicine.

 

Our proprietary PainShield technology consists of a small, thin (1 millimeter) transducer that is capable of transmitting ultrasonic acoustic waves onto treatment surfaces with a radius of up to 10 centimeters beyond the transducer. This technology allows us to treat pain by implanting our transducers into a small, portable self-adhering acoustic patch, thereby eliminating the need for technicians and medical personnel to manually administer ultrasound therapy, which should reduce the cost of therapy. Moreover, we believe that, based upon the body of evidence, the delivery of ultrasound through our portable devices may provide a competitive advantage over other existing therapies marketed for similar intended use(s) (e.g., to treat pain associated with muscle, tendon, and contractures), as our technology is positioned to directly target the affected areas of the body within the scope of the applicable FDA clearance.

 

While there are currently a number of products on the market that treat pain through ultrasound therapy, we believe that our products may be preferable in certain instances because they are portable, without the requirement to be plugged into an outlet and they have a frequency of 100kHz (in contrast to other devices, which have a frequency of closer to 1MHz and above), which means our products, when functioning as intended and in accordance with applicable design specifications, should not produce excessive heat that can damage tissue. Our products can therefore (i) be self-administered by the patient without the need to be moved about the treated area by the patient or a clinician, (ii) be applied for a significantly longer period without the risk of tissue damage and (iii) do not require the use of gel. We are also aware of one product, the SAM® Sport family of products, which received FDA approval and has CE Mark approval, marketed by ZetrOZ, Inc., that we understand may eliminate certain of these requirements and limitations, namely the requirement to be plugged in, the need for movement around the treated area and the relatively short safe treatment period. However, we understand that this product does not generate surface acoustic waves as our products do, which means that the treatment area is generally limited to that under the transducer, that the use of transmission gel is still required, and that the transducer thickness is significantly greater than ours (approximately 1.5cm). It is also our understanding that the FDA has issued contraindications which do not apply to the PainShield product.

 

There has been an article published in 2019 on SAM® Sport4 regarding clinical evidence demonstrating that ultrasound dose timing (i.e. daily treatment) and duration significantly impact benefits and treatment results, we are aware of a prospective randomized, double-blinded, placebo-controlled study on the effects of the long-duration low-intensity ultrasound treatment using SAM® Sport4 suggesting that ultrasound may be used as a conservative non-pharmaceutical and non-invasive treatment option for patients with knee osteoarthritis.

 

In general, ultrasound offers the benefits by increasing local blood circulation, increasing vascular wall permeability, promoting protein secretion, promoting enzymatic reactions, accelerating nitric oxide production, promoting angiogenesis (the formation of new blood vessels from pre-existing vessels) and promoting fibroblast proliferation (fibroblasts are a type of cell that play a critical role in soft tissue healing). We believe that the body of evidence, and the positive therapeutic effect that ultrasound has for various indications, potentially provides for future product development opportunities for us.

 

7

 

 

 

Traditional ultrasound device and our portable ultrasound patch-based device and a comparison of their energy distribution, where the X-axis represents treatment surface, and the Y-axis represents ultrasound energy penetration depth within tissue.

 

The PainShield Plus was introduced in March 2022. The new product design provides the same therapy as PainShield MD, but through two transducers which alternate in its duty cycle. This dual transducer design provides for a broader treatment are with three hours of therapy.

 

In a comparison of a traditional ultrasound device and our portable ultrasound patch-based device, the bulk wave conventional ultrasound machines with handheld transducers distribute the energy deeply into the body, as shown above in diagram (A) on the left. In comparison, our device distributes the energy on the surface, as shown in diagram (B), thereby meaningfully increasing the treatment area. Our transducers may also be incorporated into treatment patches, including patches that are designed to deliver medicine and other compounds through the skin. The generation and delivery of low frequency ultrasound over a period of time to a specific area has been termed “targeted slow-release ultrasound”. We believe that this delivery method of ultrasound may be comparable to that of slow release medication in the pharmaceutical industry. This “targeted slow-release” capability is intended to allow for more frequent targeting of the intended treatment area and thus may result in a more effective therapeutic response.

 

Micro Vibrations Technology and Our Products

 

In a 2007 study, mean blood flow increase was higher in the vibration group than the placebo group. Improvements in local blood flow may be beneficial in the therapeutic alleviation of pain or other symptoms resulting from acute or chronic injuries (C. Button et al., “The effect of multidirectional mechanical vibration on peripheral circulation of humans”, University of Otago New Zealand, Clinical Physiology and functional Imaging, 2007 27, p211-216). A study on the effect of whole body vibration on lower extremity skin blood flow suggests, that short duration vibration alone significantly increases lower extremity skin blood flow, doubling skin blood for a minimum of 10 minutes following treatment (Lohman et al., “The effect of whole body vibration on lower extremity skin blood flow in normal subjects”, Department of Physical Therapy, Loma Linda university, USA, Med Sci Monit, 2007; 13(2) 71-76). Vibration has also been shown to stimulate angiogenesis and growth factors such as vascular endothelial growth factor (Suhr F et al., “Effects of short-term vibration and hypoxia during high intensity cycling exercise on circulating level of angiogenic regulators in humans”, J Appl Physiol, 2007, 103:474-483, Yue Z. et al., “On the cardiovascular effects of whole-body vibration I. Longitudinal effects: hydrodynamic analysis”, Studies Appl Math, 2007, 119:95-109).

 

8

 

 

Relative to soft tissue repair, it is well established that increasing blood flow to the wound and peri-wound area helps accelerate the healing of ischemic wounds. Micro-vibrations applied on the skin tissue increase local blood flow and oxygen delivery to the wound area and stimulate angiogenesis and growth factors that are helpful for the wound healing process. Vibration therapy has been found to stimulate blood flow due to mechanical stresses of endothelial cells resulting in increased production of nitric oxide and vasodilation, as well as increase soft tissue and skin circulation. (Maloney-Hinds et al., “The Role of Nitric Oxide in Skin Blood Flow Increases due to vibration in healthy adults and adults with type 2 diabetes,” School of Medicine, Loma Linda University. Ca. Diabetes Technology & Therapeutics, 2009 p. 39-43). In addition, micro vibrations induce skin surface nerve axon reflex and type IIa muscle fibers contraction rates, resulting in vasodilation (Nakagami et al., “Effect of vibration on skin blood flow in an in vivo microcirculatory model”, The University of Tokyo, Bio-Science Trends 2007; 1 (3): 161-166). Ten minutes of vibration therapy with laser doppler revealed a consistent increase in water content of the upper dermis (TJ Ryan et al., “The effect of mechanical forces (vibration or external compression) on the dermal water content of the upper dermis and epidermis, assessed by high frequency ultrasound”, Oxford Wound Healing Institute, Journal of Tissue Viability, 2001. Of import with respect to diabetic wounds, in which a prolonged inflammatory phase occurs, vibration vasodilation has generated an indirect anti-inflammatory action, mainly by suppression of nuclear factor-kβ, the key gene for inflammatory mediators (Sackner, M.A., “Nitric Oxide is released into circulation with whole-body, periodic acceleration”, Chest 2005;127;30-39).

 

Urinary catheter usage is associated with pain and discomfort caused by the friction between the catheter surface and the urethral tissue. Generally, this friction is treated by applying lubricating gels and low friction catheter coatings. These methods are effective for a short term during the catheter insertion as the lubricating gel is quickly absorbed into the surrounding tissue and loses its effect and the catheter coatings lose their lubricity within a few days, as the coating is covered by a thin film of mucous.

 

Our UroShield product provides vibrations along the surface of the urinary catheter that is in contact with urethral tissue. We believe that these vibrations create a continuous acoustic lubrication effect along the surface of the indwelling catheter that is in contact with the surrounding tissue, thus reducing catheter-tissue contact time, which may lessen trauma from urethra abrasion and adhesion. We have also shown in animals and in humans that the micro-vibration technology can reduce the level of biofilm formation on urinary catheters.

 

Our Products

 

Product Design, Packaging, Identity

 

All products were redesigned in the fourth quarter 2019, with an updated look and improved performance. These new designs were coupled with new branding, packaging, instructional manuals, and marketing materials. Beginning in the fourth quarter of 2019, our manufacturing in China, Singapore, and Israel have commenced producing the redesigned products for distribution and delivered their first completed units in April 2020.

 

UroShield

 

UroShield is intended to prevent bacterial colonization and biofilm formation, increase antibiotic efficacy in the catheter lumen and decrease pain and discomfort associated with urinary catheter use. It is designed to be used with any type of indwelling urinary catheter regardless of the material or coating. Use of the device is contraindicated for use while there is an active Urinary Tract Infection. We believe that UroShield may be the first medical device on the market that attempts to simultaneously address all of the aforementioned catheter-related issues. UroShield is similar in design to PainShield, in that it uses a driver unit that produces low frequency, low intensity ultrasound. The driver unit connects to a disposable transducer that is clipped onto the external portion of the catheter to deliver ultrasound therapy to all catheter surfaces as well as the tissue surrounding the catheter.

 

9

 

 

 

Picture of UroShield with actuator

 

Clinical studies of the UroShield system have supported the following advantageous effects:

 

  ● Prevention or Reduction of Biofilm. The low frequency ultrasound generated by UroShield has been shown to decrease adherence of bacteria to catheter surfaces, thereby reducing biofilm. Biofilm is the complex matrix required for bacteria to grow and cause infection. See the discussion of our Heidelberg 1 trial below.
     
  ● Decreased Catheter Associated Pain and Discomfort. We believe that UroShield creates an acoustic envelope on the surfaces of the catheter, which decreases friction and tissue trauma, pain and discomfort caused by the catheter. In addition, in vivo (rabbit) studies have shown the tissue in contact with the catheter remains healthier and less traumatized as a result of the application of low frequency and low intensity ultrasound (Applebaum I, et.al., “The Effect of Acoustic Energy Induced By UroShield on Foley Catheter Related Trauma and Inflammation in a Rabbit Model” Department of Urology, Shaarey Zedek Medical Center and the Hadassah Hebrew University Medical School).
     
  ● Acoustically Augmented Antibiotic Therapy. Antibiotic resistance in biofilm bacteria is a well-known phenomenon. Although it has been known that ultrasound can increase antibiotic efficacy in in-vitro models, we do not believe that there has been a practical ultrasound-based medical device that was able to augment antibiotic efficacy in the clinical setting. In a clinical study, UroShield technology has been shown to eradicate biofilm-residing bacteria by greater than 85% when applied simultaneously with an antibiotic in three clinically relevant species, escherichia coli, staphylococcus epidermidis and pseudomonas aeruginosa (Banin E, et al., “Surface acoustic waves increase the susceptibility of Pseudomonas aeruginosa biofilms to antibiotic treatment,” Biofouling, August 2011; we supplied devices for this study, but had no further involvement with it).
     
  ● Preservation of the Patency of Catheters. We believe that low frequency ultrasound applied to catheters will add an anti-clogging effect and will preserve patency of catheters. This effect is achieved by ultrasound waves creating an acoustic layer on the inner lumen of the urinary catheter, thereby preventing adherence of biological material and biofilm formation. We believe that this anti-clogging benefit will help prevent local infection and sepsis secondary to catheter obstruction.

 

UroShield has undergone a number of clinical trials. The Heidelberg 1 trial, conducted in 2005-2006, which we sponsored, was a 22 patient randomized, double blind, sham-controlled, independent trial that tested UroShield’s safety and ability to prevent biofilm in patients with an indwelling Foley catheter. The trial demonstrated that UroShield prevented biofilm in all patients with the active device as compared to biofilm being found in seven of eleven of the control patients. In addition, there was a marked decrease in pain, discomfort and spasm in the active UroShield patients, as evidenced by a statistically significant decrease in the requirement for the medications required to treat urinary catheter associated pain and discomfort (Ikinger U, “Biofilm Prevention by Surface Acoustic Nanowaves: A New Approach to Urinary Tract Infections?,” 25th World Congress of Endourology and SWL, Cancun, Mexico, October 2007).

 

10

 

 

In a subsequent physician-sponsored trial, known as Heidelberg 2, conducted in 2007, 40 patients who underwent radical prostatectomies were divided into two groups, with the active group receiving one intra-operative dose of antibiotics and UroShield and the control group receiving one intra-operative dose of antibiotics and then five subsequent doses over three days. At the end of the trial, the control group had four cases of bacteriuria, as compared to one in the active group. In a third trial, a physician-sponsored open label trial, 10 patients who received emergency placement of a urinary catheter due to acute obstruction were given a UroShield device and followed with regard to their pain, discomfort, spasm and overall well-being. Within 24 hours, all patients showed improvement and increased toleration of the catheter (Zillich S., Ikinger U, “Biofilmprävention durch akustische Nanowellen: Ein neuer Aspekt bei katheterassoziierten Harnwegsinfektionen?,” Gesellschaft für Urologie, Heilbronn, Germany, May 2008). We supplied devices for this trial, but had no further involvement with it.

 

As recently announced, the Company submitted to The National Institute for Health and Care Excellence, for review, the findings from an independent evaluation of its UroShield® device on patients who had used the device for up to two years. Clinical data from the study conducted by Coventry University’s Assistant Professor, Ksenija Maravic da Silva, during 2020 reported statistically significant outcomes for the device including a reduced number of urinary tract infections (UTIs), reduced instances of prescribed antibiotics, reduced catheter blockages, reduced the need for unplanned catheter changes and reduced pain reported as a result of catheter associated complications. The study also provided important insights into the lives of those using the device including improvement of overall well-being, relating specifically to decreased levels of worry and increased ability to socialize. In addition, patient feedback on product improvements was addressed and has been incorporated in the present commercially available device.

 

In September 2022, UroShield was approved for sale by the U.K.’s National Health System’s (NHS) internal supply organization, NHS Supply Chain, through a new contract.

 

This new contract with NHS Supply Chain provides dedicated end-to-end supply chain service of our UroShield for every NHS healthcare organization. UroShield will be available to all patients who the need the device with full clinical support, through the NHS supply chain. It represents a significant opportunity for us to expand distribution of UroShield as it will now be made available to all clinicians and their patients through the NHS organization’s own supply channel. NHS Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organizations across England and Wales. The organization processes more than eight million orders per year across 94,000 order points and 17,465 locations serving as an integral part of the national healthcare system in the U.K. We are ramping up production to meet an increase in demand that we anticipate as a result of this exciting development.

 

The new contract, which is designed to provide new innovative products for healthcare providers, begins in October 2022 and will merge with the existing Urology and Stoma framework contract in February 2024 with optional extension periods.

 

Under the contract, NHS Supply Chain describes UroShield as a disposable ultrasound device designed to reduce the risk of catheter-associated urinary tract infection (CAUTI) by reducing bacterial colonization and biofilm formation on indwelling urinary catheters. This ultimately translates into improved outcomes for patients and care provides, reduces the need for antibiotics, catheter changes and washouts and incidence of hospital visits, thereby reducing nursing time, bed days and ambulance transfers.

 

On March 1, 2023 the Company launched its month-to-month rental program for UroShield.

 

Market for UroShield

 

According to the Centers for Disease Control and Prevention, urinary tract infection (UTI) is an infection involving any part of the urinary system, including urethra, bladder, ureters, and kidney. UTIs are the most common type of healthcare-associated infection reported to the National Healthcare Safety Network (NHSN). Among UTIs acquired in the hospital, approximately 75% are associated with a urinary catheter, which is a tube inserted into the bladder through the urethra to drain urine. Between 15-25% of hospitalized patients receive urinary catheters during their hospital stay. The most important risk factor for developing a catheter-acquired urinary tract infection (CAUTI) is prolonged use of the urinary catheter.

 

This study was written up in the December 2018 issue of “Medical & Surgical Urology”, a leading peer-reviewed journal in the field of urology.

 

Approximately 15-25% of patients who are admitted to a hospital will have an indwelling catheter at some point during their stay and 7% of nursing home residents are managed by long term catheterization.

 

CAUTI is the most common nosocomial infection in hospitals and nursing homes, representing over 40% of all hospital-acquired infections (HAIs) and 20% of intensive care unit HAIs (Maki, P and Tambyah, D. Engineering Out the Risk for Infection with Urinary Catheters., Emerging Infectious Diseases., Vol. 7, No. 2, March–April 2001). In addition, CAUTIs are the source for approximately 20% of healthcare acquired bacteremia in acute care and 50% in long-term care facilities (Nicolle, Lindsay E. “Catheter Associated Urinary Tract Infections.” Antimicrobial Resistance and Infection Control 3 (2014). The risk of acquiring CAUTI depends on the method and duration of catheterization and patient susceptibility. Patients requiring a urinary catheter have a daily risk of approximately five percent of developing bacteriuria and approximately 25% of patients develop nosocomial bacteriuria or candiduria over one week (Maki, P and Tambyah, D. Engineering Out the Risk for Infection with Urinary Catheters., Emerging Infectious Diseases., Vol. 7, No. 2, March–April 2001). Virtually all patients requiring indwelling urinary catheters for longer than a month become bacteriuric.

 

CAUTI occurs because urethral catheters inoculate organisms into the bladder and promote colonization by providing a surface for bacterial adhesion and causing mucosal irritation. The presence of a urinary catheter is the most important risk factor for bacteriuria. Once a catheter is placed, the daily incidence of bacteriuria is 3-10%. Between 10% and 30% of patients who undergo short-term catheterization (i.e., 2-4 days) develop bacteriuria and are asymptomatic. Between 90% and 100% of patients who undergo long-term catheterization develop bacteriuria. About 80% of nosocomial UTIs are related to urethral catheterization; only 5-10% are related to genitourinary manipulation. (John L. Brusch, Catheter-Related Urinary Tract Infection, Medscape, August 18, 2015).

 

11

 

 

The global catheter market size was valued at USD 37.3 billion in 2018 and is expected to witness a CAGR of 9.7% through 2026. Rising prevalence of chronic disorders leading to hospitalization has fueled the growth of this market. Presence of multi-national manufacturers, improving medical facilities, supportive insurance policies are also some of the key factors propelling the market growth. North America is the largest regional market due to the presence of multi-national manufacturers and sophisticated healthcare infrastructure along with high product awareness levels. Asia Pacific is projected to expand at the maximum CAGR of 10.4%, over the study period. According to a Grandview research report published 2018, there are 25 million Foley catheters sold annually in the United States and 75 million catheters sold elsewhere yielding a total global Foley catheter market of 100 million units worldwide. The cost to treat a simple CAUTI has been estimated at $13,793 per case (AHRQ), and the cost of treating bacteremia has been estimated at $8,355 (NIH) per case, yielding a total healthcare burden of $830 million per year. While there are currently both antibiotic and silver coated catheters in the market, they often sell for approximately $10 above the non-antimicrobial equivalent.

 

In addition, as of October 1, 2008, Medicare stopped authorizing its payment to hospitals in which patients have developed a catheter-associated urinary tract infection that was not present on admission. This provides hospitals in the United States with a substantial financial incentive to reduce the occurrence of such infections through the use of products such as UroShield, which help prevent infections hospitals would otherwise have to treat without reimbursement. In addition, it has been noted that the Centers for Medicare & Medicaid Services may fine hospitals in the future when their patients develop CAUTI, which will likely increase the incentive of hospitals to invest in technologies that may prevent this complication (Brown J, et al. “Never Events: Not Every Hospital-Acquired Infection Is Preventable, Clinical Infectious Diseases, 2009, 49 (5)).

 

Competition for UroShield

 

Several types of products have been introduced to address the growing problem of catheter-acquired infection and biofilm formation on catheter surfaces. Manufacturers offer antibiotic-coated and antiseptic-impregnated catheters. In addition, manufacturers have produced silver-coated catheters, which have been shown in small studies to delay bacteriuria for about two to four days. However, larger studies did not corroborate this result; on the contrary, silver hydrogel was associated with overgrowth of gram positive bacteria in the urine (Riley DK, Classen DC, “A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection,” Am. J. Med. 1995 April; 98(4):349-56).

 

UroShield has been designed to be added to any type of catheter, including Foley catheters and silver-coated catheters, to improve a catheter’s infection prevention performance. However, in the United States, we do not have the requisite regulatory authorization to market UroShield for such use, as we have not yet obtained FDA clearance or approval for UroShield, and the FDA’s temporary, COVID-19-related policy of Enforcement Discretion under which we have been marketing UroShield since September 2020 expressly excludes use with a coated catheter. UroShield is not intended to replace any existing products or technologies, but instead is intended to assist these existing products or technologies in preventing catheter-acquired urinary injury and catheter associated complications. While UroShield was temporarily authorized for use in the United States per FDA’s Enforcement Discretion during the COVID-19 health emergency, the public health emergency has since-been terminated, and the applicable FDA policy under which we have been marketing UroShield will similarly terminate before the end of 2023. In particular, recent FDA guidance confirmed that its medical-device enforcement policies issued during the COVID-19 pandemic will officially expire on November 7, 2023. The guidance outlines a three-phase plan for ensuring that any devices marketed under a specifically listed enforcement policy will be able to be marketed lawfully after the termination of those enforcement policies. During the 180-day period between the termination of the public health emergency and the expiration of FDA’s relevant enforcement policies, manufacturers, like us, who desire to continue marketing their respective devices must submit an appropriate premarket submission, such as a 510(k) application or de novo reclassification request, and bring the device into compliance with applicable FDA regulations. If we do not obtain permanent clearance from the FDA by November 7, 2023, we will have to discontinue distribution of UroShield in the United States until the necessary FDA clearance or approval is granted. We cannot guarantee that FDA will clear or approve UroShield for continued marketing in the United States in a timely manner or at all.

 

Regulatory Strategy

 

UroShield received CE Mark approval in September 2007 and was also approved for sale by the Israeli Ministry of Health in 2008. We are able to sell UroShield in India and Ecuador based on our CE Mark. UroShield was granted a Canadian medical device license in September 2016, although, due to a modification of regulatory standards in Canada, we have lost our Canadian license. We are working toward reinstatement of our Canadian license. To that extent, we passed an audit in or around October 2022.

 

In the European Union, UroShield has been marketed for the prevention of CAUTI and biofilm formation, decreased pain and discomfort associated with urinary catheters and increased antibiotic efficacy.

 

12

 

 

In September 2020, the FDA exercised its Enforcement Discretion to allow distribution of the UroShield device in the United States. According to the FDA, “UroShield® device can use Intended Use Code (IUC) 081.006: Enforcement discretion per final guidance, and FDA product code QMK (extracorporeal acoustic wave generating accessory to urological indwelling catheter for use during the COVID-19 pandemic)”.

 

Accordingly, the FDA’s Enforcement Discretion temporarily cleared the way for import of UroShield to the U.S. during the Covid-19 pandemic, immensely expanding the company’s addressable market for the device during this time period, which will officially end in November 2023. The device is designed to aid in the prevention of CAUTI incidence in patients requiring long-term indwelling catheterization, defined as 14 days or greater.

 

After reviewing the body of scientific evidence that we presented, the FDA took decisive action to clear the way for patient access to UroShield for the duration of the Covid-19 pandemic. We believe the evidence presented to the FDA on UroShield demonstrated decreases in the risk of catheter-associated urinary tract infections and related complications in patients using UroShield who required long-term indwelling catheterization.

 

We intend to seek long-term marketing authorization from the FDA through the de novo classification process for UroShield, which is a premarket pathway intended for devices that cannot pursue 510(k) clearance because there is no substantially equivalent predicate device but which the applicant believes are sufficiently low-risk that they need not undergo the rigorous premarket approval pathway to be deemed safe and effective for the applicable indications for use. We are currently seeking advice from the FDA prior to submission. We also intend to seek advice and validation of supporting studies we intend to undertake in advance of a De Novo application.

 

The FDA has made it clear that we will need to generate more clinical study data in order to achieve) de novo reclassification. Our intent is to conduct a community based PRO study (Patient Reported Outcomes) measuring the impact UroShield will have on prevention of CAUTI, Prevention of Blockage, and prevention of Pain. We currently are in the early stages of putting together a team and plan to start this process.

 

Studies completed to assess the safety of UroShield for human use:

 

  ●

A large animal model (female sheep) study has been conducted to establish local tissue response from a urinary catheter with UroShield attached as compared to a control group of animals with a urinary catheter with no UroShield attached.

 

The pre-clinical animal study was intended to demonstrate safety of UroShield device when used for 30-days with a urinary catheter. The study compared local tissue and organ response in two groups of 4 (female) sheep where one group was catheterized (urethral) using an uncoated silicone Foley catheter (only) and the other group was catheterized using an uncoated silicone Foley catheter with UroShield device attached to it. All catheters were identical in their size, material composition and manufacturer.

 

After 30 days the animals were euthanized and local tissue and organs were examined. The results showed the group with UroShield device had fewer observations of swelling, redness or discharge at the vulva as compared to the group without UroShield. The animals did not exhibit signs of discomfort or pain during study period (of 30 days). The gross and histopathology findings were also very similar between the two groups.

     
  ●

A comparative study of leachables from a urinary catheter with and without UroShield attached has been performed to demonstrate that the leachables with UroShield attached do not exceed toxicological safe limits allowed for a medical device.

 

The chemical characterization of leachables was intended to demonstrate safety for UroShield device for 30-day use with a urinary catheter. The study compared leachables from a group consisting of 3 uncoated silicone catheters with leachables from a group consisting of 3 uncoated silicone catheters with UroShield attached to it. All catheters were identical in their size, material composition and manufacturer.

 

The exhaustive extractions were performed with non-polar, polar and aqueous solvents. An additional simulated use extraction using Saline and Ethanol was performed. Overall the extractables from both groups were comparable and toxicological evaluation showed that all compounds from extraction with UroShield were below the tolerable exposure limits. Most of compounds had a margin of safety greater than 10 and 4 compounds had margin of safety between 1.5 and 10. Overall, the toxicological risk for using UroShield with a urinary catheter is similar and at even lower as compared to a catheter without UroShield attached.

 

Sales and Marketing

 

Since the FDA exercised its Enforcement Discretion to allow the distribution of the UroShield device in the United States, we have been actively seeking partnerships for marketing our product in the United States. We believe the business opportunity for UroShield is in the hundreds of millions in U.S. dollars to the extent that UroShield obtains permanent marketing authorization from the FDA, is recognized as effective and becomes widely adopted for use on catheters, none of which can be guaranteed. To that end, we are seeking a strategic partnership with various companies which have an existing “footprint” in the Urology market. Those discussions and negotiations are ongoing at this time. We have appointed distributors for UroShield in the United Kingdom. Malta, and Australia. We recently appointed the Benion group to identify distributor opportunities outside of the United States.

 

We announced in December 2022 that we have appointed a new distributor in the United Kingdom. The newly appointed distributor is Peak Medical.

 

From time to time we have had interest from strategic companies in the catheter market to partner, license or acquire the UroShield technology. These strategic partners are active in the urology market and may be interested in integrating UroShield as an accessory, into its range of products. Discussions with these partners are ongoing. There has also been interest from other companies with various invasive line applications.

 

13

 

 

Clinical Trials

 

To date, we have conducted the clinical trials set forth below:

 

Purpose   Doctor/Location  

Time,

subjects

   Objectives   Results

To assess the safety of the UroShield Double Blind, Comparative, Randomized Study for the Safety Evaluation of the UroShield System (HD1)

 

   Dr. U. Ikinger, Salem Academic Hospital, University of Heidelberg, Germany  

2005-2006

22 patients

  

To demonstrate that the use of the UroShield is safe and that the device is well tolerated by the patients and user friendly to the medical staff.

Efficacy objectives were to demonstrate that the UroShield helps in prevention of biofilm formation in comparison with the urinary catheter alone, as well as bacteriuria.

  

UroShield was both safe and well tolerated.

UroShield proved efficacious in prevention of biofilm. Subjects required significantly less medications than the control group for catheter related pain and discomfort.

                 

Double Blind, Comparative, Randomized Study for the Safety Evaluation of the UroShield System (HD2 )

Physician initiated

   Dr. U. Ikinger, Salem Academic Hospital, University of Heidelberg, Germany  

2007

40 patients

 

   To demonstrate that the use of the UroShield is safe and helps in prevention of biofilm formation and UTI in comparison with the urinary catheter alone, as well as decrease antibiotic use.   In this trial, only 1/20 patients in UroShield device (no antibiotics) group developed urinary tract infection compared to 4/20 patients within control group treated with the antibiotic prophylaxis alone.
                 

The Effect of UroShield on Pain and Discomfort in Patients Released from the Emergency Room with Urinary Catheter Due to Urine Incontinence

Physician initiated

   Shaare Zedek Medical Center Jerusalem, Israel.  

2007

10 patients

 

   The study aimed to assess the effectiveness of the UroShield in reducing pain and discomfort levels and improve the well-being of the subjects. Efficacy objectives included reduction of pain, spasm, burning and itching sensation levels of the subjects.   The results demonstrated a reduction in pain, itching, burning and spasm levels. Additionally, the well-being of the subjects showed a significant increase.
                 
The Use of the UroShield Device in Patients with Indwelling Urinary Catheters Open labeled, comparative, randomized study  

Dr. Shenfeld

Shaare Zedek Medical Center Jerusalem, Israel.

 

  

2007-2009

40 patients

 

  

Patient complaints related to catheter regarding pain according to VAS scale and discomfort according to 0-10 scale

Presence of Clinically Significant UTI

Presence of Bacteriuria

Presence of Biofilm

Use of medication

   UroShield device was effective in reducing postoperative catheter related pain discomfort and bladder spasms. There was also a notable trend towards reduction of bacteriuria.

 

14

 

 

Purpose   Doctor/Location  

Time,

subjects

   Objectives   Results
Evaluation of the UroShield in urinary and nephrostomies to reduce bacteriuria Physician initiated  

Prof. P.Tenke,

Hungary

 

  

2010-2011

27 patients

 

  

● Pain, disability and QOL

● Catheter patency

● Bacteriuria / UTI

● Hospitalization period

● Analgesics and Antibiotics intake

   Showed reduction in pain and significant decrease in bacteriuria rate.
                 
Double Blind, Randomized Control Study for Prevention of Bacterial Colonization and UTI associated with Indwelling Urinary Catheters  

Dr. Shira Markowitz

Buffalo, NY

 

  

2017

55 patients

 

   To demonstrate the use of the UroShield reduces bacterial colonization on the urinary catheter   Final results entitled “The Effect of Surface Acoustic Waves on Bacterial Load and Preventing Catheter-Associated Urinary Tract Infections (CAUTI) in Long Term Indwelling Catheters,” which was published in the December 2018 issue of Medical & Surgical Urology, a leading peer-reviewed journal in the field of urology.
                Mean improvement advantage in treatment vs control was 87.2K CFU, (t (53) 18.1, p<0.001) at thirty days. At 60 days the mean improvement advantage in treatment vs control was 87.5K CFU, (t (53) 18.1, p<0.001). At 90 days the mean improvement advantage in treatment vs control was 79.3K CFU, (t (53) 12.4, p<0.001).

 

15

 

 

Purpose   Doctor/Location  

Time,

subjects

   Objectives   Results
               

After cessation of treatment in the active group at 30 days, there was a minimal increase in CFU count at both 60 and 90 days. In the same group, there was no statistical difference in the decrease of CFU count from 30 to 60 days after treatment, t (28)=1. p= .326, however there was a marginally significant increase in CFU from 60 to 90 days for the active group (28)=1.7 p= 0.09.

 

At baseline, every enrolled patient had been treated for infection during the 90 days prior to enrollment. Compared to baseline, the treatment group showed significant statistical and clinical improvement (100%) at 30 days relative to the sham control (73%). There were no reported infections in the Treatment Group while in the control group there were seven reported infections.

 

At 90 days after treatment, the treatment group showed a significantly stronger improvement (89.7%) compared to the sham control (46.2%). There were three reported infection in the Treatment group, while in the control group there were fourteen reported infections requiring antimicrobial therapy. (logistic regression B=2.3, Wald Chi-Square (df=1) =10.1, p=0.001.)

 

16

 

 

Purpose   Doctor/Location  

Time,

subjects

   Objectives   Results
UroShield Randomized Control trial   5 different nursing facilities  

2017 - 2018

51 subjects

   51 subjects were evaluated with 26 in the active/treatment group and 25 in the control group. All patients had been treated for at least one incident of a catheter-acquired urinary tract infection (CAUTI) requiring antibiotics in the preceding 6 months prior to trial initiation.   At the 90-day evaluation, 13 of 25 subjects (52%) in the control group developed a CAUTI requiring systemic antibiotics while only 1 of 26 patients (4%) in the UroShield™ group required antibiotic. All study subjects had an initial colony count of greater than 100,000 CFU cultured from their urinary tract. At thirty days, all subjects within the control group showed no change in the number of their bacteria count which was greater than 100,000 CFU, while those in the treatment group showed a reduction to 10,000 CFU in 15 of 26 subjects and only 1,000 CFU in 10 of 26 subjects, proving a decrease in both bacterial colonization and the incidence of Urinary Tract Infection.

 

17

 

 

Recently Completed, Current, Ongoing and Planned Clinical Trial

 

If we are able to locate a strategic partner or otherwise obtain sufficient funding, we anticipate conducting the following clinical trial:

 

Trial   Place   Start Date/Timing   Objectives
UroShield FDA Administration trial ~300 patient trial   To be determined  

To be determined

Intended to begin in 2023

  

Safety and efficacy of UroShield in urinary catheter related pain and infection and biofilm formation.

 

The results of previous clinical trials may not be predictive of future results, and the results of our planned clinical trial, if we are able to locate a strategic partner or otherwise obtain sufficient funding, may not satisfy the requirements of the FDA.

 

PainShield®

 

PainShield is an ultrasound device, consisting of a reusable driver unit and a disposable patch, which contains our proprietary therapeutic transducer. It delivers a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area, while keeping the level of ultrasound energy at a safe and consistent level of 0.4 watts. We believe that PainShield is the smallest and most portable therapeutic ultrasound device on the market and the only product in which the ultrasound transducer is integrated in a therapeutic disposable application patch.

 

We believe the existing ultrasound therapy devices being used for pain reduction are primarily large devices used exclusively by clinicians in medical settings. PainShield is able to deliver ultrasound therapy without being located in a health care facility or clinic because it is portable, due to it being lightweight and battery operated. Because it is patch based and easy to apply, PainShield does not require medical personnel to apply ultrasound therapy to the patient. Some patient benefits reported in prior studies included ease of application and use, relatively quick recovery time, high patient compliance, and potentially increased safety and efficacy over certain other devices that rely on higher-frequency ultrasound (Adahan M, et al, “A Sound Solution to Tendonitis: Healing Tendon Tears With a Novel Low-Intensity, Low-Frequency Surface Acoustic Ultrasound Patch,” American Academy of Physical Medicine and Rehabilitation Vol. 2, 685-687, July 2010). PainShield can be used by patients at home or work or in a clinical setting and can be used even while the patient is sleeping. Its range of applications includes acute and chronic pain reduction and anti-inflammatory treatment.

 

 

Picture of PainShield with Patch

 

In other countries outside the United States where the product is approved for such use, PainShield is used to treat tendon disease and trigeminal neuralgia (a chronic pain condition that affects the trigeminal or 5th cranial nerve, one of the most widely distributed nerves in the head); previously, the therapeutic options for these disorders have been very limited. In the United States, PainShield is only cleared to treat pain, muscle spasms, and joint contractures associated with or caused by various conditions or diseases. It has also been used to treat pelvic and abdominal pain. To date, to the best of our knowledge, the primary treatment options for several of these conditions are pain medication and surgery. Several additional causes of pain, and the treatment of that pain with the PainShield product, can be explored through clinical trials.

 

18

 

 

On March 1, 2023 the Company launched its month-to-month rental program for Painshield.

 

Market for PainShield

 

Pain-related complaints are one of the most common reasons patients seek treatment from physicians (Prince V, “Pain Management in Patients with Substance-Use Disorders,” Pain Management, PSAP-VII, Chronic Illnesses). According to Landro L, “New Ways to Treat Pain: Tricking the Brain, Blocking the Nerves in Patients When all Else Has Failed,” Wall Street Journal, May 11, 2010, approximately 26% of adult Americans, or approximately 76.5 million people, suffer from chronic pain. The National Center for Health Statistics has estimated that approximately 54% of the adult population experiences musculoskeletal pain. Studies have shown that low-frequency ultrasound treatment has yielded positive results for a variety of indications, including tendon injuries and short-term pain relief (Warden SJ, “A new direction for ultrasound therapy in sports medicine,” Sports Med. 2003; 33 (2):95-107), chronic low back pain (Ansari NN, Ebadi S, Talebian S, Naghdi S, Mazaheri H, Olyaei G, Jalaie SA, “Randomized, single blind placebo controlled clinical trial on the effect of continuous ultrasound on low back pain,” Electromyogr Clin Neurophysiol. 2006 Nov; 46(6):329-36) and sinusitis (Ansari NN, Naghdi S, Farhadi M, Jalaie S, “A preliminary study into the effect of low-intensity pulsed ultrasound on chronic maxillary and frontal sinusitis,” Physiother Theory Pract. 2007 Jul-Aug; 23(4):211-8). We believe that PainShield’s technology, portability and ease of use may result in it becoming an attractive product in the pain management and therapy field.

 

Competition

 

There are numerous products and approaches currently utilized to treat chronic pain. The pharmacological approach, which may be the most common, focuses on drug-related treatments with the over-the-counter internal analgesic market estimated at $19 billion in 2019. Alternatively, there are a large number of non-pharmacological pain treatment options available, such as ultrasound, transcutaneous electrical nerve stimulation, or TENS, laser therapy and pulsed electromagnetic treatment. In addition, there are some technologies and devices in the market that utilize low frequency ultrasound or patch technology. Many patients are initially prescribed anti-pain medication; however, ongoing use of drugs may cause substantial side effects and lead to addiction. Therefore, patients and clinicians have shown increased interest in alternative pain therapy using medical devices that do not carry these side effects.

 

The currently available ultrasound treatments for chronic pain have generally been accepted by the medical community as standard treatment for pain management. However, the traditional ultrasound treatments, such as those manufactured or distributed by Mettler Electronics Corp, Metron USA and Zimmer MedizinSysteme, are stationary devices found only in clinics and other health care facilities that need to be administered to patients by health care professionals. We are aware of three companies that market smaller ultrasound devices capable of certain self-administered use for the treatment of pain: Koalaty Products, Inc., Sun-Rain System Corp. and PhysioTEC. These devices generally function in the same manner, at the same frequency and with the same administration and safety requirements and limitations as traditional, larger ultrasound devices. We are also aware of one product, the SAM® Sport4, which has recently received FDA approval and also has CE Mark approval, marketed by ZetrOZ, Inc., that we understand may eliminate certain of these requirements and limitations, namely the requirement to be plugged in, the need for movement around the treated area and the relatively short safe treatment period. However, we understand that this product does not generate surface acoustic waves as our products do, which means that the treatment area is generally limited to that under the transducer, that the use of transmission gel is still required, and that the transducer thickness is significantly greater than ours (approximately 1.5cm). It is also our understanding that the FDA has issued contraindications which do not apply to the PainShield product. In addition, there are other patch-based methods of pain treatment, such as TENS therapy. TENS therapy may be painful and irritating for the patient due to the muscle contractions resulting from the electrical pulses. PainShield combines the efficacy of ultrasound treatment for pain with the ease of use and portability of a patch-based system. PainShield also may be self-administered by the patient, including while the patient is sleeping. However, if we are unable to obtain widespread insurance coverage and reimbursement for PainShield, its acceptance as a pain management treatment would likely be hindered, as patients may be reluctant to pay for the product out-of-pocket.

 

CMS has approved PainShield for reimbursement for Medicare beneficiaries on a national basis effective January 2020, we are currently awaiting reimbursement values to be determined. We will be notified in May 2023. A positive determination would become effective on October 1st, 2023. If we are denied, the appeal process would begin in June 2023.

 

19

 

 

Our marketing efforts continue to expand in the Direct to Consumer, Veterans Administration facilities, and Workers’ Compensation market. Relative to the VA market, we are currently represented by Applied Medical and Delta Medical. Delta Medical is a Service Disabled Veteran Organization Small Business (SDVOSB). PainShield is approaching the Workers’ Compensation market through various sales agents and on a direct basis. Additionally, on March 1st, 2023, we established a rental program for Direct to Consumer marketing for patients without health insurance coverage.

 

Regulatory Strategy

 

PainShield received 510(k) clearance from the FDA in August 2008 as an ultrasonic diathermy device intended to apply ultrasonic energy to generate deep heat within body tissues for the treatment of selected medical conditions, such as relief of pain, muscle spasms, and joint contractures. PainShield received CE Mark approval in July 2008 and was also approved for sale by the Israeli Ministry of Health in 2010. We are able to sell PainShield in India and Ecuador based on our CE Mark.

 

In the United States, a prescription from a licensed healthcare practitioner is required for the use of PainShield.

 

Recently, we announced our intention to pursue marketing authorization for a non-prescription version of PainShield MD, which we refer to as PainShield Relief. The PainShield Relief is intended to be an Over-The Counter (OTC) product, not requiring a prescription from a medical professional. We believe that such reclassification, if approved by the FDA, will open up mass market opportunities which are currently not available to us due to the prescription requirement. However, there is no assurance that we will be able to remove the prescription requirement for the use of PainShield Relief or that, even if we accomplish such reclassification and the use of PainShield Relief no longer requires a prescription, PainShield Relief will be successful commercially in the mass market or we will be able to generate significant revenues from the mass market opportunities, if any.

 

In order to prove to the FDA that the requirement for a physician prescription is not necessary to ensure safe and effective use of the product, proof of safety and consumer “usability” need to be established. We engaged User-View, Inc to facilitate our Usability study and received the favorable results we expected. The product packaging and all instruction documents have been modified in an effort to meet OTC standards. We also engaged an outside laboratory to perform acoustic testing on all PainShield products. We previously anticipated submission of a 510(k) for PainShield Relief to the FDA, for OTC use as a class 1 device, in early April 2022, but we are reconsidering our target timeline for such submission and whether any additional data or action steps are needed including potentially redesigning the product in appearance and functionality.

 

The PainShield Plus, is a dual applicator device, which will also be submitted for specific clearance from the FDA. Submission for PainShield Plus was made in late February 2022. We received FDA clearance in November 2023.

 

In the United States, PainShield falls under the diathermy classification for the treatment of pain for initial reimbursement purposes. The permitted reimbursement codes can be used in the outpatient supervised medical setting. We continue to work with the Centers for Medicare and Medicaid Services and private insurers so that reimbursement can be extended to cover the administration of PainShield outside of health care facilities and clinics. We have engaged outside legal counsel to assist with all aspects of reimbursement and FDA regulatory actions. In addition, we intend to conduct clinical trials in order to pursue FDA authorization to market PainShield for a larger range of indications. The targeted reimbursement would be based upon specific indications, where study data serves as justification for payment.

 

Sales and Marketing

 

PainShield was introduced in 2009 as a treatment for pain, such as tendonitis, sports injuries, pelvic pain, and neurologic pain, depending on the scope of the approval or clearance from each applicable jurisdiction, and we have sold over 5,000 units since its introduction. We have entered into distribution agreements in United States, Europe, Australia, and India for the distribution of PainShield. We intend to seek additional distribution opportunities in Europe, East Asia and Ecuador. In addition, we sell PainShield directly to patients through our website in jurisdictions where direct-to-consumer sale is permitted. We are currently ramping up our marketing efforts in the U.S. market and throughout the world to establish licensing and private label partnerships as well.

 

20

 

 

We have identified a unique application for PainShield in applicable foreign jurisdictions where such application is authorized, which is the treatment of a severe facial nerve pain called Trigeminal Neuralgia, otherwise known as tic douloureux. The FDA lists facial application as a contraindication and has not cleared or approved PainShield for such use in the United States. We are considering pursuing FDA approval of the PainShield for Trigeminal Neuralgia, which will likely require additional data and clinical investigation to support an application for premarket approval (“PMA”) for this indication, if such PMA is required by FDA. Two studies were performed in Israel, “a randomized control trial examining the efficacy of low intensity low frequency Surface Acoustic wave ultrasound in trigeminal neuralgia pain”, and “A sound solution for Trigeminal Neuralgia”. Two trials which enrolled a total of 16 and 15 patients respectively, both conducted at the Sheba Medical Center in Israel, concluded that this study supports the hypothesis that the application of Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (LILF/SAW) may be associated with a clinically significant reduction of pain severity among patients suffering from trigeminal neuralgia disease. One of the studies showed a reduction in pain among 73% of the participants. We believe this to be an ideal market to address with the PainShield. With few existing treatment alternatives, we believe the PainShield could prove to be a practical and safe alternative. A broader RCT, targeting 60 patients suffering from unilateral trigeminal neuralgia, was also completed. The article was published on January 22, 2019, in the Journal of Anesthesiology and Pain Research, under the title “The Effect of a Surface Acoustic Wave (SAW) Device on the Symptomatology of Trigeminal Neuralgia”. We cannot predict the success of any future trials, nor can we guarantee that FDA will grant approval for such use.

 

GlobalData’s epidemiological analysis forecasts that the total prevalent cases of trigeminal neuralgia in the seven major markets (United States, France, Germany, Italy, Spain, U.K and Japan) will grow at 15% between 2012 and 2022. According to an estimate by Ronald Brisman, M.D., in 2013 the prevalence of trigeminal neuralgia in the U.S. may have been as high as approximately 280,000 patients. With the favorable results from our current, ongoing study (explained in detail below), we continue to plan to aggressively pursue this market in the foreign jurisdictions where PainShield has been approved through direct marketing efforts and distributor relationships.

 

We have also identified a market for PainShield in the professional sports industry, where in some cases, reimbursement may be available from sports alumni organizations or, more likely, self-pay. In order to pursue this market, we are exhibiting at sports trainers meetings, pursuing alumni associations, advertising in their media, and have recently engaged a national distributor in the United States. Discussions and ongoing negotiations continue with other appropriate distributors in these various market segments.

 

Clinical Trials

 

To date, we have conducted or are in the process of conducting the clinical trials set forth below:

 

Purpose   Doctor/Location   Time, subjects   Objectives   Results

A sound solution for Trigeminal Neuralgia Physician initiated

 

  

Dr. Ch. Adahan

Sheba Medical Center

 

  

2009

15 patients

 

  

●Reduction in pain

●Reduction in disability

●Improvement of function and quality of life

●Accelerating of healing

   73% of the subjects experienced complete or near complete relief.
                 
Randomized control trial examining the efficacy of low intensity low frequency Surface Acoustic wave ultrasound in trigeminal neuralgia pain For Ph.D., Funded by Israeli Ministry of Health  

Dr. M. Zwecker

Chaim Sheba Medical Center, Tel Hashomer, Israel

 

  

2012-2012

16 patients

 

  

●Reduction in pain

●Reduction in disability

●Improvement of function and quality of life

●Accelerating of healing

 

   In conclusion this study supports the hypothesis that the application of Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (LILF/SAW) may be associated with a clinically significant reduction of pain severity among patients suffering from trigeminal neuralgia disease.

 

21

 

 

Purpose   Doctor/Location   Time, subjects   Objectives   Results
Treating Rutgers university athletic injuries with bandaid sized ultrasound unit PainShield  

R. Monaco,

G. Sherman,

Rutgers University Athletic, Rutgers, New Jersey

 

  

2011

35 patients

 

  

●To assess the pain, functional capacity and discomfort of the subject

●To assess the subject’s quality of life

●To assess the injury status

●To assess the efficacy of the treatment

●To assess compliance factors

  

Active group:

74% had improvement, 26% no change

Sham group:

56% no change, 44% had improvement

This is an indication of the effectiveness of the device.

Lack of funding for statistical analysis has stopped this trial prior to fulfillment.

                 
Reduction of chronic abdominal and pelvic pain, urological and GI symptoms using wearable device delivering low frequency ultrasound  

D. Wiseman,

Synechion Institute for Pelvic Pain

 

  

2011

19 patients

 

   ●To assess the efficacy of PainShield for pelvic and related pain   Improvement in pain related symptoms noted for all symptoms.
                 
The Effects of the NanoVibronix’s PainShield® Surface Acoustic Waves on the Symptoms of Lateral Epicondylitis   Dr. David Lemak, a leading orthopedic surgeon with Birmingham Orthopedic and Sports Specialists.   2019, 24 patients   A randomized, double blinded study for 30 days that evaluated the effectiveness and safety of PainShield™ Surface Acoustic Wave (SAW) technology on patients suffering from pain and discomfort, as well as limited mobility caused by the effects of chronic or acute lateral epicondylitis (LE) (“tennis elbow”).   We plan to publish an article at the time and in conjunction with adding a marketing partner.
                 
The Effect of a Surface Acoustic Wave (SAW) Device on the Symptomatology of Trigeminal Neuralgia   Shira Markowitz, MD, New York, NY   Early 2018 59 patients   To measure pain scores, quality of life, and breakthrough drug use of 59 patients with a diagnosis of unilateral trigeminal neuralgia.   There was a significant difference in the outcomes of the two groups relative to pain, quality of life, and breakthrough medications taken, which was directly correlated to pain experienced during treatment. Specifically, the treatment group experienced a 55.2% improvement in baseline pain scores versus 2.3% for the control group. The treatment group experienced a 46.4% reduction in breakthrough pain medication versus 1.5% for the control group.

 

22

 

 

If we are able to obtain sufficient funding, we anticipate conducting the following clinical trials:

 

Trial   Place   Start Date/Timing   Objectives

PainShield for Pelvic Pain

200 patient trial

   To be determined   To be determined   Safety and Efficacy of PainShield in Chronic Pelvic Pain

 

WoundShield®

 

Our WoundShield product was granted the European Wound Closure Customer Value Leadership Award, Ultrasound Therapy – Wound Closure in 2014. WoundShield is intended to treat acute and chronic wounds with a disposable treatment patch that delivers localized therapeutic low frequency ultrasound. The WoundShield patch has two configurations: one that is placed adjacent to the wound and another, called the instillation patch, that is placed on the wound to enable instillation through sonophoresis, a process that increases the absorption of semisolid topical compounds, including medications, into the skin. Based on studies conducted by BIO-EC Microbiology Laboratory and Rosenblum, we believe that our WoundShield product possesses significant potential for the treatment of, among other things, diabetic foot ulcers and burns (Gasser P, Study Report delivered by BIO-EC Microbiology Laboratory, Dec 2007, which we ordered, paid for, and provided devices for; Rosenblum J, “Surface Acoustic Wave Patch Diathermy Generates Healing In Hard To Heal Wounds,” European Wound Management Association 2011, for which we supplied devices but had no further involvement). In March 2020, we signed a license agreement with Sanuwave Health, Inc. (“Sanuwave”) for the manufacture and delivery of our WoundShield technology. Under the terms of the agreement, NanoVibronix received 127,000 warrants of Sanuwave stock upon signing, will receive a $250,000 milestone payment based on FDA approval, and 10% royalty on Sanuwave’s gross revenues from sales or rentals of WoundShield. In return, Sanuwave has received the worldwide, exclusive rights to the Company’s WoundShield product and technology. In addition, Sanuwave will bear the costs and clinical validation responsibilities associated with obtaining approval for WoundShield from the FDA and other regulatory agencies around the world.

 

 

Picture of WoundShield Driver and Instillation Patch

 

WoundShield delivers surface acoustic waves to the location of the wound. Surface acoustic waves move laterally across the surface of the wound, which enables the transfer of the acoustic energy of the waves along the entire wound surface in a continuous and consistent mode, providing access to the waves’ benefits for a longer treatment period than conventional ultrasound without the need for supervision or a treatment session by a clinician.

 

The technology has been found to have a positive effect on the epithelialization (healing by the growth of epithelial cells) of diabetic wounds, as well as on the stimulation of the precursors of dermal and epidermal (skin) growth. As such, it is a useful adjunct to wound care by increasing dermal and epidermal growth, including glycosaminoglycans, or GAGs (which bind to extracellular proteins like collagen, fibronectin, laminin, etc. and retain considerable amounts of water, thus preserving the skin structure) as well as the amount of collagen (a protein that helps skin heal) and decreasing the number of cells in mitosis (a type of cell division) (Rosenblum J, “Surface Acoustic Wave Patch Diathermy Generates Healing In Hard To Heal Wounds,” European Wound Management Association 2011, for which we supplied devices which were precursors to WoundShield, but had no further involvement). In addition, the WoundShield instillation patch allows for administration of therapeutic agents into the wound area through a sonophoresis effect.

 

23

 

 

Many key processes in wound healing are dependent upon an adequate supply of oxygen. Diabetic foot ulcers are particularly in need of an adequate oxygen supply because the disease often results from poor perfusion (blood flow) and decreased oxygen tension. Oxygen is also important for the immune system to combat bacteria, synthesize collagen, help with fibroblast proliferation (fibroblasts are a type of cell that play a critical role in wound healing), form oxidative (taking place in the presence of oxygen) pathways for adenosine triphosphate, or ATP, formation (ATP transports chemical energy within cells for metabolism), and the nitric oxide dependent signaling pathways. It is generally believed that a lack of available oxygen is a basic contributing factor in the perpetuation of these wounds. Wound healing experts have developed a technique of perfusing ischemic wounds (which occur when blood flow is blocked) with hyper-oxygenated saline, while the wound is being treated with ultrasound, also known as sonication. This localized oxygenation therapy has many advantages over the use of hyperbaric chambers (large chambers in which the oxygen pressure is above normal), a common method for delivering oxygen to wounds, as it is more cost-effective, can be done at the patient’s bedside and can be administered more frequently. The WoundShield instillation patch was tested as a potential ultrasound technology for this localized oxygen therapy. In one study (Morykwas M, “Oxygen Therapy with Surface Acoustic Waveform Sonication,” European Wound Management Association 2011; we supplied devices for this study, but had no further involvement with it), oxygen sensors were placed in the wound bed to directly measure partial pressure of oxygen in an ischemic wound bed on a pig. The wound was perfused with hyperbaric oxygen and sonicated using the WoundShield instillation patch. With surface acoustic wave ultrasound technology, tissue oxygen levels (partial pressure of oxygen in the blood, or PaO2) were raised from a range of 20 mmHg (millimeters of mercury) to 60 mmHg in peripheral (periwound) areas, a 3 centimeter distance away from the transducer, and from 40 mmHg to greater than 100 mmHg in the central wound bed lying below the WoundShield instillation patch (see table below). The results of this study illustrated that the WoundShield instillation patch allowed oxygen to directly enter into the wound. The direct entry of the oxygen increased the amount of oxygen reaching the wound, which has been shown to advance the healing process. In addition, we believe that WoundShield’s small size, lower cost and ease of use makes localized oxygen treatment commercially viable.

 

 

In 2012, results were published of a human feasibility trial for the WoundShield instillation patch that was performed at Duke University in North Carolina. Seven patients were treated with the WoundShield instillation patch for their wounds and average tissue oxygen levels (PaO2) increased by an average of 58% over baseline (Covington S, “Ultrasound-Mediated Oxygen Delivery to Lower Extremity Wounds,” Wounds 2012; 24(8)). We supplied devices for this trial, but had no further involvement with it.

 

24

 

 

Market for Wound-Healing Devices

 

The global wound care device market totaled approximately $20.8 billion in 2022 and it is expected to grow to $27.2 billion by 2027 at a CAGR of 65.4% during 2022-2027 (as reported by Markets and Markets in June 2022). According to the Global Report on Diabetes produced by the World Health Organization (“WHO”) in 2016, globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. According to a report entitled “Advances in Wound Closure Technology” by Frost and Sullivan (2005), foot complexities are the most frequent causes for patients with diabetes to get hospitalized, with complications usually starting with the formation of skin ulcers. In addition, according to the American Burn Association, approximately 486,000 patients received medical treatment annually for burn injuries in 2016 in the United States. There are also policy-based factors that may increase the size of the wound care market. We anticipate that reimbursement decisions with respect to hospital acquired wounds may create a large market opportunity for wound care products, including WoundShield. Furthermore, in 2009, the Centers for Medicare and Medicaid Services announced that they would stop reimbursements for treatment of certain complications that they believed were preventable with proper care. One such complication was surgical site infections after certain elective procedures, including some orthopedic surgeries and bariatric surgery. We believe that such developments incentivize medical care providers to invest in reducing the risk of infection through the use of wound care products, including WoundShield.

 

Competition for WoundShield

 

The market for advanced wound care includes a number of competitors, such as Kinetic Concepts, Inc. (a subsidiary of the 3M Company), or KCI, Smith and Nephew plc and Convatec Inc., all of whom market wound-healing medical devices. Due to their size, in general these companies may have significant advantages over us. These competitors have their own distribution networks for their products, which gives them an advantage over us in reaching potential customers. In addition, they are vertically-integrated, which may allow them to maximize efficiencies that we cannot achieve with our third-party suppliers and distributors. Finally, because of their significantly greater resources, they could potentially choose to focus on research and development of technology similar to ours, more than we are able to. In general, we believe that these competitors have, and will continue to have, substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do. However, we believe that our products differentiate us from these competitors, and we will be competitive on the basis of our technology. We believe that the strength of these competitors may create an opportunity through strategic partnerships.

 

At present, ultrasound treatment for wounds is limited only to wound debridement (removal of damaged tissue or foreign objects from a wound) and such products are marketed by Arobella Medical, LLC, which produces the Qoustic Wound Therapy System, Misonix Inc., which produces SonicOne products, and Alliqua Biomedical, Inc., which produces the MIST Therapy System. Due to their size, in general these companies may have the same advantages over us as discussed with respect to our competitors in the paragraph above. However, these ultrasound devices are indicated for use only in medical clinics and require an operator to deliver their treatment, thus limiting their use and application. The MIST Therapy System and Quostic Therapy System are a non-contact ultrasound device that delivers ultrasound through a mist that is applied directly on the wound.

 

We believe that these therapies are less advantageous than WoundShield because they require an operator to deliver the treatment and the removal of bandages to target the wound bed. In contrast, the WoundShield patch sits on normal skin bordering the open wound and no manipulation of the wound bandage is required. Moreover, WoundShield can be self-administered, without an operator, in both clinics and home settings. We also believe that WoundShield will prove to be an effective alternative to treating chronic wounds at a lower price than the existing products being used by medical practitioners. As such, we believe that facilities that are reimbursed based upon diagnosis-related groups will be more inclined to adopt WoundShield because it will provide the same therapeutic results at a significantly lower cost than traditional ultrasound therapies.

 

We are also aware of a small clinical study, for which results were reported in August 2013, in which a small ultrasound device showed positive results in the treatment of venous ulcers, a type of chronic wound. We understand that this product does not generate surface acoustic waves as our products do, which means that the treatment area is generally limited to that of the transducer’s diameter. We believe our products would have certain other advantages over this potential device, if developed, including that our products weigh less and are thinner. However, given the early stage of development of this potential device, we cannot say with certainty how our products would compare.

 

25

 

 

The most common method of oxygen administration for wound healing is hyperbaric oxygen therapy, especially to treat specific ulcerations in diabetic patients. Hyperbaric oxygen therapy has been shown to increase vascular endothelial growth factor expression, which measures the creation of new blood vessels (Fok TC, at el, “Hyperbaric oxygen results in increased vascular endothelial growth factor (VEGF) protein expression in rabbit calvarial critical-sized defects”, Schulich School of Medicine and Dentistry, University of Western Ontario, Canada). The activation of endothelial cells by VEGF sets in motion a series of steps toward the creation of new blood vessels (J Lewis et al, National Cancer Institute, Understanding Cancer and Related Topics, Understanding Angiogenesis). We believe that the WoundShield instillation patch, which can be used as an oxygen instillation system, will be complementary to, or in some cases an alternative to, the use of hyperbaric chamber therapy. This complementary treatment option will allow the treating physician greater therapeutic versatility in treating wounds. For a certain populace of patients, we believe that the WoundShield instillation patch could provide physicians with an alternative to hyperbaric oxygen therapy because it provides the same benefits as hyperbaric oxygen therapy at a lower cost to the patient. There are a number of competitors in the hyperbaric chamber therapy market, including approximately eight companies in the United States. Due to their size, in general these companies may have the same advantages over us discussed with respect to our competitors in the first paragraph of this section. However, we believe that the WoundShield instillation patch possesses certain advantages over the existing hyperbaric chamber therapy, including lower cost and greater ease of use. In addition, we believe that the WoundShield instillation patch will not necessarily compete with hyperbaric chamber therapy, but rather will often complement such therapy.

 

While we believe that WoundShield is well positioned to capture a share of the wound care market, WoundShield may be unable to achieve its anticipated place in the wound care market due to a number of factors, including, but not limited to, an inability to obtain the approval of the FDA , for which it is indicated and its failure to be adopted by health care practitioners and facilities or patients because of its status as a new product in a market that relies on patient-focused initiative to treat wounds.

 

Regulatory Strategy

 

For a general discussion of the FDA approval process with respect to our products, and regulation of our products in general, see “– Government Regulation” below.

 

Our general regulatory strategy for WoundShield has been to allow our licensee to pursue FDA clearance. To date, SanuwaveHealth, Inc. has not met their contracted milestones to retain the license for WoundShield.

 

Sales and Marketing

 

WoundShield has generated minimal revenues to date. In March 2020, we signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of our WoundShield technology.

 

Clinical Trials

 

With respect to WoundShield, to date, we have conducted the following evaluation studies:

 

Purpose   Doctor/Location   Time, subjects   Objectives   Results

Clinical evaluation

Physician initiated

 

  

Dr. J. Rosenblum,

Shaare Zedek

Medical Center

  

2008

8 patients

   To evaluate novel technology on wound healing in diabetic foot ulcers.   Therapy showed significant changes in wound, wound size was reduced, patients felt less pain, necrotic tissue was less adhesive, necrotic tissue decreased in size. The duration of the trial was one week.
                 

Clinical evaluation

Physician initiated

 

  

Dr. J. Rosenblum,

Shaare Zedek

Medical Center

  

2010

8 patients

   To evaluate novel technology on wound healing in diabetic foot ulcers.   The device, a precursor device to WoundShield using the same technology as WoundShield, had a positive effect on both epithelization of diabetic wounds and stimulating the precursors of dermal and epidermal growth. The duration of the trial was one week.
                 

Clinical evaluation

Physician initiated

 

   Dr. S. Covington  

2010

7 patients

   The study aimed to determine if hyper oxygenated saline delivered by surface acoustic waves improves tissue oxygenation in lower extremity wounds.   Surface acoustic wave technology in conjunction with oxygenated saline can increase interstitial oxygen in wound bed. This trial to validate proof of concept was put on hold due to financial constraints. The duration of the trial was two weeks.

 

26

 

 

Third Party Reimbursement

 

We anticipate that sales volumes and prices of the products we commercialize will depend in large part on the availability of coverage and reimbursement from third party payers. Third party payers include governmental programs such as Medicare and Medicaid, private insurance plans and workers’ compensation plans, among others. These third -party payers may deny coverage and reimbursement for a product or therapy, in whole or in part, if they determine that the product or therapy was not medically appropriate or necessary. The third-party payers also may place limitations on the types of physicians or clinicians that can perform specific types of procedures. In addition, third party payers are increasingly challenging the prices charged for medical products and services. Some third -party payers must also pre-approve coverage for new or innovative devices or therapies before they will reimburse health care providers who use the products or therapies. Even though a new product may have been approved or cleared by the FDA for commercial distribution, we may find limited demand for the device until adequate reimbursement has been obtained from governmental and private third -party payers.

 

Over-the-counter products, such as the anticipated PainShield Relief product that we are developing, if ultimately cleared for marketing by the FDA, are generally not reimbursed by any third-party payers.

 

In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific product lines and procedures. There can be no assurance that procedures using our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third party payers, that an adequate level of reimbursement will be available or that the third -party payers’ reimbursement policies will not adversely affect our ability to sell our products profitably.

 

In the United States, some insured individuals are receiving their medical care through managed care programs, which monitor and often require pre-approval of the services that a member will receive. Some managed care programs are paying their providers on a per capita basis, which puts the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member per month, and consequently, may limit the willingness of these providers to use certain products, including ours.

 

One of the components in the reimbursement decision by most private insurers and governmental payers, including the Centers for Medicare and Medicaid Services, which administers Medicare, is the assignment of a billing code. Billing codes are used to identify the procedures performed when providers submit claims to third party payers for reimbursement for medical services. They also generally form the basis for payment amounts.

 

Obtaining reimbursement approval for a product from any government or other third -party payer is a time-consuming and costly process that could require us or our distributors to provide supporting scientific, clinical and cost-effectiveness data for the use of our product to each payer. Even if a code is obtained for a product, a third -party payer must still make coverage and payment determinations. When a payer determines that a product is eligible for reimbursement, the payer may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other foreign regulatory authorities. We believe that the overall escalating costs of medical products and services has led to, and will continue to lead to, increased pressures on the health care industry to reduce the costs of products and services. In addition, health care reform measures, as well as legislative and regulatory initiatives at the federal and state levels, create significant additional uncertainties. There can be no assurance that third party coverage and reimbursement will be available or adequate, or that future legislation, regulation, or reimbursement policies of third -party payers will not adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition.

 

27

 

 

UroShield. If cleared or approved by the FDA for the U.S. market, we expect these products to be used in inpatient settings and therefore reimbursed under the Diagnosis Related Group (DRG) or per diem reimbursement system. In addition, in an outpatient or home setting, we anticipate that these products will initially be purchased privately until a reimbursement code is obtained. However, we believe that if we can empirically demonstrate UroShield’s efficacy in preventing recurrent hospitals admission in chronic Foley catheter patients and reducing overall per-patient cost, third party payers may accelerate the reimbursement approval process since the device could reduce their overall per-patient cost. We believe the natural progression of the adoption of this technology will allow for use in the home setting. We intend to pursue reimbursement in the Medicare Part B code to support the use for long term catheter use and infection prevention in the home.

 

PainShield. Effective as of January 2020, CMS approval for Medicare reimbursement was added through code K1004. The value of the reimbursement has not yet been confirmed. We continue to work toward a favorable reimbursement with outside legal counsel and reimbursement consultants. The most recent application for reimbursement from CMS/Medicare was submitted on January 3rd, 2023. A determination should be provided in or around May 2023.

 

WoundShield. We believe that the initial usage of these products, if approved or cleared by the FDA, will be in the hospital setting. Reimbursement in the hospital setting is typically governed by the DRG system, which is a prospective payment methodology that assigns a predetermined, fixed amount based on the patient’s diagnoses. Sanuwave Health Inc., as the licensee of this technology, is responsible to apply for such reimbursement, but has not yet done so.

 

New Product Under Development

 

Renooskin

 

In 2016, we started developing a device candidate for the facial rejuvenation market called Renooskin. Previous in vitro studies on human skin were done showing that the SAW technology provided skin rejuvenation comparable to Retinol A which is a well-accepted anti-aging cream. We have developed a head band like applicator for the PainShield SAW treatment and are in the process of arranging for a pilot trial with a cosmetic dermatologist and/or plastic surgeon. We believe that, subject to proof of efficacy of the Renooskin and receiving regulatory approval, neither of which are guaranteed, the device candidate could potentially be sold in a non-reimbursement market since cosmetic devices are private pay. We are still considering several paths towards commercialization.

 

Intellectual Property

 

Stemming from a combination of patent, copyright, trademark and trade secret laws, as well as non-disclosure agreements and other contracts, our intellectual property rights represent a vital resource to the management of our company. Therefore, we are continuing our practice of investing in obtaining appropriate legal protection for our innovations whenever possible and have adopted a more fully integrative approach to the management of our intellectual property that mutually aligns with our ongoing R&D strategies, commercial opportunities based on market analyses, and longer-term business objectives.

 

From our patented technologies to our trademarked brands, we believe our intellectual property has substantial value and has significantly contributed to our success to date.

 

28

 

 

From our patented technologies to our trademarked brands, we believe our intellectual property has substantial value and has significantly contributed to our success to date.

 

Patents

 

We seek patent protection for our inventions not only to differentiate our products and technologies, but also to develop opportunities for licensing and securing our rights to profits therefrom. With the aim of optimizing commercial and regulatory success, our proprietary technology and innovative applications thereof are protected by a variety of patent claims. We believe that our granted patents and pending applications collectively protect our technology, both in terms of our existing products, as well as our anticipated pipeline of new offerings.

 

Our patent portfolio includes at least the following issued patents, as well as a number of corresponding foreign patents in relevant jurisdictions: (1) U.S. Patent No. 7,393,501 to “Method, Apparatus and System for Treating Biofilms Associated With Catheters” (expiring on December 19, 2023); (2) U.S. Patent No. 7,829,029 to “Acoustic Add-On Device for Biofilm Prevention in Urinary Catheter” (expiring on October 27, 2025); (3) U.S. Patent No. 9,028,748 to “System and Method for Surface Acoustic Wave Treatment of Medical Devices” (expiring on July 11, 2030); and (4) U.S. Patent No. 9,585,977 directed to “System and Method for Surface Acoustic Waves Treatment of Skin” (expiring on August 20, 2033). These patents cover a wide range of embodiments and applications of our proprietary surface acoustic wave (SAW) technology, including our commercialized PAINSHIELD®, PAINSHIELD PLUSTM, WOUNDSHIELD® and UROSHIELD® devices. Specifically, the patents provide for methods of generating SAW on surfaces of indwelling medical devices and to topical and urological applications therefor, for alleviating pain and for wound healing, and for preventing formation of bacterial biofilms on catheters.

 

In addition to the above patents, our pending patent applications and new filings are representative of our ongoing efforts to broaden our portfolio as we continue to develop new applications for our ultrasound technology. Pending patent applications related to UROSHIELD® devices are directed to Multiple Frequency Surface Acoustic Waves for Internal Medical Device and System, Device, and Method for Mitigating Bacterial Biofilms Associated with Indwelling Medical Devices. Ths new patent applications cover the next generation of UROSHIELD® devices operating at multiple frequencies and devices which are compatible in portable and wireless systems.

 

Pending patent applications related to PAINSHIELD®, PAINSHIELD PLUSTM, WOUNDSHIELD® devices are directed to Transdermal Patch of a Portable Ultrasound-Generating System for Improved Delivery of Therapeutic Agents and Associated Methods of Treatment; Portable Ultrasound System and Methods of Treating Facial Skin by Application of Surface Acoustic Waves and Improved Injection Needle Assembly.

 

Although not yet granted, the aim of our growing number of patent applications is to secure our rights within additional industry sectors we foresee as most readily benefiting from our technology. Therefore, looking beyond just pain management and urology, our patent applications relate to, inter alia: novel transdermal patches uniquely configured to work with our ultrasound technology to additionally provide for improved absorption and transdermal delivery of therapeutic agents during treatment; cosmetic applications of our ultrasound technology to provide anti-aging benefits; and certain new or improved stand-alone therapeutic medical devices or so-called “indwelling medical devices” (e.g., catheters, intravenous (IV) needle assemblies, and percutaneous endoscopic gastronomy (PEG) tubes) that include our SAW-generating technology to provide the accompanying antimicrobial effect for preventing infections typically associated with available indwelling devices.

 

We intend to further grow our patent portfolio by continuing to patent new technology as it is developed, to defend intellectual property as we believe necessary by actively pursuing any infringements, to pursue commercial opportunities our patents provide for our innovations, and to continue to develop our brands and trademarks.

 

Trademarks

 

In addition to patent protection, we own numerous registered trademarks for our commercialized WOUNDSHIELD® (in the U.S. and Canada), NanoVibronix® (in the U.S. and Canada), WOUNDSHIELD® (in the U.S. and Canada), PAINSHIELD®. (in the U.S. and Canada), and UROSHIELD® (in the U.S.). Generally, the protection afforded by trademarks is perpetual, subject to paying timely renewals and continuing proper use in commerce. In addition to the above, we expect to pursue additional trademark registrations to the extent we believe they would be beneficial and cost-effective.

 

29

 

 

Other Rights

 

We regularly enter into, and rely on, confidentiality and proprietary rights agreements with our employees, consultants, contractors and business partners to protect our trade secrets, proprietary technology and other confidential information. We control the use of our proprietary technology through relevant provisions, notifications, and disclaimers provided on our website, our customer terms of use, and our vendor terms and conditions.

 

Government Regulation

 

U.S. Food and Drug Administration Regulation

 

Each of our products must be approved, cleared by, or registered with the U.S. Food and Drug Administration (“FDA”) before they can be marketed in the United States, and they can only be marketed consistently with their respective approved or cleared indication(s) of use. Before and after approval or clearance in the United States, our products, approved or cleared products and product candidates, are subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act and/or the Public Health Service Act, as well as by other regulatory bodies. The FDA regulations govern, among other things, the development, testing, manufacturing, labeling, safety, storage, record-keeping, market clearance or approval, advertising and promotion, import and export, marketing and sales, distribution and market withdrawal and recalls of medical devices and pharmaceutical products. PainShield MD and PainShield MD Plus have each already obtained 510(k) marketing clearance by the FDA. We are in the process of conducting clinical and non-clinical testing to support a submission for FDA clearance for PainShield Relief as an over-the-counter drug.

 

In September 2020, the FDA exercised its Enforcement Discretion to allow distribution of the UroShield device in the United States. According to the FDA, “UroShield® device can use Intended Use Code (IUC) 081.006: Enforcement Discretion per final guidance, and FDA product code QMK (extracorporeal acoustic wave generating accessory to urological indwelling catheter for use during the COVID-19 pandemic)”. Accordingly, the FDA’s Enforcement Discretion temporarily cleared the way for import of UroShield to the U.S. for limited use during the Covid-19 pandemic. The public health emergency has since-been terminated in the U.S., and the FDA, accordingly, issued guidance confirming that devices marketed under Enforcement Discretion must be cleared or approved by November 2023 to remain on the market. The fact that FDA authorized UroShield’s use under the COVID-19 Enforcement Discretion does not ensure that UroShield will be granted marketing approval or clearance under any of the traditional pathways.

 

FDA Approval or Clearance of Medical Devices

 

In the United States, medical devices are subject to varying degrees of regulatory control and are classified in one of three classes depending on the extent of controls FDA determines are necessary to reasonably ensure their safety and efficacy:

 

  ● Class I: general controls, such as labeling and adherence to quality system regulations, and a pre-market notification (510(k)) unless exempt;
     
  ● Class II: special controls, pre-market notification (510(k)) unless exempt, specific controls such as performance standards, patient registries and post-market surveillance and additional controls such as labeling and adherence to quality system regulations; and
     
  ● Class III: special controls and approval of a Pre-Market Approval, or PMA, application.

 

WoundShield and PainShield are classified as Class II medical devices and require U.S. Food and Drug Administration authorization prior to marketing, by means of 510(k) clearance. Due to its nature and the lack of existing predicate devices on the market, UroShield is automatically classified as a Class III device for which a PMA is required, unless our request for de novo reclassification is successful, in which case, it will be classified as a Class II device and subject to the same postmarket framework as 510(k)-cleared devices.

 

30

 

 

To request marketing authorization by means of a 510(k) clearance, we must submit a pre-market notification demonstrating that the proposed device is substantially equivalent to a legally marketed medical device (referred to as a “predicate device”). A finding of substantial equivalence requires that the proposed new device (i), has the same intended use as a predicate device; (ii) has the same or similar technological characteristics as the predicate device; (iii) is as safe and effective as the predicate device; and (iv) does not raise different questions of safety and effectiveness than the predicate device. 510(k) submissions generally include, among other things, a description of the device and its manufacturing, device labeling, medical devices to which the device is substantially equivalent, safety and biocompatibility information and the results of performance testing. In some cases, a 510(k) submission must include data from human clinical studies. Marketing may commence only when the FDA issues a clearance letter finding substantial equivalence. The typical duration to receive 510(k) approval is approximately nine months from the date of the initial 510(k) submission, although there is no guarantee that the timing will not be longer.

 

The FDA may require us to perform clinical studies to show a product candidate’s safety and efficacy in addition to technological equivalence in support of our filed 510(k). No matter which regulatory pathway we may take in the future towards marketing products in the United States, we believe we will be required to provide clinical proof of device effectiveness and safety.

 

After a device receives 510(k) clearance, any product modification that could significantly affect the safety or effectiveness of the product, or that would constitute a significant change in intended use, requires a new 510(k) clearance or, if the device would no longer be substantially equivalent, would require a PMA. If the FDA determines that the product does not qualify for 510(k) clearance, then a company must submit and the FDA must approve a PMA before marketing can begin. An alternative to a new 510(k) submission is a “letter to File”, citing substantial equivalence to a product which has been granted 510(k) clearance.

 

A PMA application must provide a demonstration of safety and effectiveness, which generally requires extensive nonclinical and clinical trial data. Information about the device and its components, device design, manufacturing and labeling, among other information, must also be included in the PMA. As part of the PMA review, the FDA will inspect the manufacturer’s facilities for compliance with quality system regulation requirements, which govern testing, control, documentation and other aspects of quality assurance with respect to manufacturing. If the FDA determines the application or manufacturing facilities are not acceptable, the FDA may outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. During the review period, a FDA advisory committee, typically a panel of clinicians and statisticians, is likely to be convened to review the application and recommend to the FDA whether, or upon what conditions, the device should be approved. The FDA is not bound by the advisory panel decision. While the FDA often follows the panel’s recommendation, there have been instances where the FDA has not. If the FDA finds the information satisfactory, it will approve the PMA. The PMA approval can include post-approval conditions, including, among other things, restrictions on labeling, promotion, sale and distribution, or requirements to do additional clinical studies post-approval. Even after approval of a PMA, a new PMA or PMA supplement is required to authorize certain modifications to the device, its labeling or its manufacturing process. Supplements to a PMA often require the submission of the same type of information required for an original PMA, except that the supplement is generally limited to that information needed to support the proposed change from the product covered by the original PMA. The typical duration to receive PMA approval is approximately two years from the date of submission of the initial PMA application, although there is no guarantee that the timing will not be longer.

 

As stated above, we anticipate that we will seek FDA authorization to market our UroShield product via the de novo reclassification process. Medical device types that the FDA has not previously classified as Class I, II, or III are automatically classified into Class III regardless of the level of risk they ultimately pose to patients and/or users. The Food and Drug Administration Modernization Act of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the “Request for Evaluation of Automatic Class III Designation,” or the de novo classification procedure. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II based on a benefit-risk analysis demonstrating the device actually presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. If the manufacturer seeks reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. In addition, the FDA may reject the reclassification petition if it identifies a legally marketed predicate device that would be appropriate for a 510(k) or determines that the device is not low-to-moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. De novo reclassification requests are also subject to user fees, unless a specific exemption applies. If the device is not approved through de novo review, then it must go through the standard PMA process for Class III devices.

 

31

 

 

Clinical Trials of Medical Devices

 

Clinical trials are almost always required to support a PMA application and are sometimes required for a de novo classification request or 510(k) pre-market notification. In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical device, an investigator acting on behalf of the company must, among other things, apply for and obtain IRB approval of the proposed investigation. In addition, if the clinical study involves a “significant risk” (as defined by the FDA) to human health, the company sponsoring the investigation must also submit and obtain FDA approval of an IDE. An IDE must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specified number of study participants, unless the product is deemed a non-significant risk device and eligible for abbreviated IDE requirements. Generally, clinical trials for a significant risk device may begin once the IDE is approved by the FDA and the study protocol and informed consent are approved by a duly-appointed IRB at each clinical trial site.

 

FDA’s IDE regulations govern investigational device labeling, prohibit promotion, and specify an array of GCP requirements, which include, among other things, recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Clinical trials must further comply with the FDA’s regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant approval or clearance of a product. 

 

Post-Approval Regulation of Medical Devices

 

After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include:

 

  ● the FDA quality systems regulation, which governs, among other things, how manufacturers design, test, manufacture, exercise quality control over, and document manufacturing of their products;
     
  ● labeling and claims regulations, which prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling;
     
  ● if applicable, the Electronic Product Regulations found in 21 CFR parts 1000-1050, which provide additional requirements applicable to electronic products, including records and reporting requirements; and
     
  ● the Medical Device Reporting regulation, which requires reporting to the FDA of certain adverse experiences associated with use of the product.

 

Under the FDA medical device reporting (“MDR”) regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury if the malfunction of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a judgment by the manufacturer. If the FDA disagrees with the manufacturer’s determination, the FDA can take enforcement action.

 

Additionally, the FDA has the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious adverse health consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed devices fail to meet established specifications, are otherwise misbranded or adulterated, or if any other material deficiency is found. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated.

 

The failure to comply with applicable device regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:

 

●warning letters, fines, injunctions, or civil penalties;

●recalls, detentions or seizures of products;

●operating restrictions;

●delays in the introduction of products into the market;

●total or partial suspension of production;

●delay or refusal of the FDA or other regulators to grant 510(k) clearance or PMA approvals of new products;

●withdrawals of marketing authorization; or

●in the most serious cases, criminal prosecution.

 

To ensure compliance with regulatory requirements, medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA, and these inspections may include the manufacturing facilities of subcontractors and third-party component suppliers

 

Good Manufacturing Practices Requirements

 

As noted above, manufacturers of medical devices are required to comply with the good manufacturing practices set forth in the quality system regulations promulgated under section 520 of the Food, Drug and Cosmetic Act as further set forth in the Code of Federal Regulations as 21 CFR Part 820. Current good manufacturing practices (“CGMP”) regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. The manufacturing facility for an approved product must meet current good manufacturing practices requirements to the satisfaction of the FDA pursuant to a pre-PMA approval inspection before the facility can be used. Manufacturers, including third party contract manufacturers, are also subject to periodic inspections by the FDA and other authorities to assess compliance with applicable regulations. Failure to comply with or to promptly comply with statutory and regulatory requirements subjects a manufacturer, and possibly us, to possible legal or regulatory action, including the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, and civil and criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the imposition of marketing restrictions through labeling changes or in product recall. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following the approval.

 

32

 

 

International Regulation

 

We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements, labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from UFDA requirements.

 

The primary regulatory environment in Europe is the European Union, which consists of 27 member states and 32 competent authorities encompassing most of the major countries in Europe. In the European Union, the European Medicines Agency and the European Union Commission determined that PainShield, UroShield, and WoundShield are to be regulated as medical device products. These products are classified as Class II devices. These devices are CE Marked and as such can be marketed and distributed within the European Economic Area. We are required to be recertified each year for CE by Intertek, which conducts an annual audit. The audit procedure, which includes on-site visits at our facility, requires us to provide Intertek with information and documentation concerning our management system and all applicable documents, policies, procedures, manuals, and other information.

 

The primary regulatory bodies and paths in Asia, Australia, and Latin America are determined by the requisite country authority. In most cases, establishment registration and device licensing are applied for at the applicable Ministry of Health through a local intermediary. The requirements placed on the manufacturer are typically the same as those contained in ISO 9001 or ISO 13485, requirements for quality management systems published by the International Organization of Standardization. In some countries outside Europe, we are or will be able to sell on the basis of our CE Mark. We have the Health for PainShield, WoundShield and UroShield, a certificate by the Israel Ministry of Health allowing us to sell PainShield, WoundShield and UroShield in Israel, a certificate allowing us to sell PainShield in Australia, and we are able to sell PainShield, WoundShield and UroShield in India and Ecuador based on our CE Mark. In addition, our distributor in Korea has applied for approval to sell PainShield and UroShield. We generally apply, through our distributor, for approval in a particular country for a particular product only when we have a distributor in place with respect to such product.

 

European Good Manufacturing Practices

 

In the European Union, the manufacture of medical devices is subject to good manufacturing practice, as set forth in the relevant laws and guidelines of the European Union and its member states. Compliance with good manufacturing practice is generally assessed by the competent regulatory authorities. Typically, quality system evaluation is performed by a notified body, which also recommends to the relevant competent authority for the European Community CE Marking of a device. The competent authority may conduct inspections of relevant facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for each product, in many cases each device manufacturing facility must be audited on a periodic basis by the notified body. Further inspections may occur over the life of the product.

 

U.S. Fraud and Abuse and Other Health Care Laws

 

In the United States, federal and state fraud and abuse laws prohibit the payment or receipt of kickbacks, bribes or other remuneration intended to induce the purchase or recommendation of health care products and services. Other provisions of federal and state laws prohibit presenting, or causing to be presented, to third party payers for reimbursement, claims that are false or fraudulent, or which are for items or services that were not provided as claimed. In addition, other health care laws and regulations may apply, such as transparency and reporting requirements, and privacy and security requirements. Violations of these laws can lead to civil and criminal penalties, including exclusion from participation in federal and state health care programs. These laws are potentially applicable to manufacturers of products regulated by the FDA as medical devices, such as us, and hospitals, physicians and other potential purchasers of such products. The health care laws that may be applicable to our business or operations include:

 

  ● The federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable by Medicare, Medicaid or any other federal health care program.

 

33

 

 

  ● Federal false claims laws and civil monetary penalty laws, including the False Claims Act, that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.
     
  ● The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, and for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for health care benefits, items or services.

 

  ● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also impose obligations and requirements on health care providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform certain services for them that involve the use or disclosure of individually identifiable health information, with respect to safeguarding the privacy and security of certain individually identifiable health information.
     
  ● The federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or Children’s Health Insurance Program to report annually to Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members.
     
  ● Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply to referrals and items or services reimbursed by both governmental and non-governmental third-party payers, including private insurers, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.

 

Manufacturing and Suppliers

 

In December 2018, we announced we appointed Quasar Engineering Ltd, as contract manufacturer for the PainShield®, UroShield® and WoundShield®, as well as other devices. Following our agreement with Sanuwave, Quasar is no longer the manufacturer of the WoundShield®. Quasar is a medical device manufacturer, located in China, with over 30 years of experience, serving major brands worldwide, with complex catheters, disposables, and FDA regulated assemblies. Starting in the fourth quarter of 2019, we started using Quasar to manufacture all of our newly redesigned products. Quasar temporarily shut down for sixty days in early 2020, due to the COVID-19 outbreak which lead to a significant delay in the production of goods needed to fulfill our sales orders, and became fully operational in April 2020. Presently, we are no longer experiencing delays in the production of our products.

 

Quasar added a new manufacturing facility in Singapore late in the third quarter of 2022. Our product manufacturing moved to this plant for final production and packaging.

 

We order certain component parts on an as-needed basis, generally from the manufacturer that provides us with the most competitive pricing. Our most significant suppliers for these components are B Star, Inc, Plastic One, We do not have written agreements with any of these suppliers, but we believe anyone could be easily replaced if necessary.

 

Customers

 

We currently sell our products both directly, through our website, and indirectly via distribution agreements, with approximately 99% of our sales coming through distributors and Sales Agents in 2022. We expect that percentage to decline as we enter into additional sales agent agreements We have exclusive and non-exclusive distribution agreements for our products with medical product distributors based in the United States, in the United Kingdom and various countries throughout Europe, India, Canada and Asia. For the year ended December 31, 2022, our two largest customers were Applied Medical Solutions LLC who comprised approximately 44% of total sales and Ultra Pain Products Inc, who comprised approximately 36% of total sales.

 

34

 

 

We are currently in discussions with several distribution companies with access to various markets in the United States, Europe, and Asia, as well as Veterans Administration facilities. Our current agreements stipulate that distributors will be responsible for carrying out local marketing activities and sales. We are responsible for training, providing marketing guidance, marketing materials, and technical guidance. In addition, in most cases, all sales costs, including sales representatives, incentive programs, and marketing trials, will be borne by the distributor. We expect any future distribution agreements to contain substantially similar stipulations. Under our current agreements, distributors purchase our products from us at a fixed price. Our current agreements with distributors are generally for a term of approximately two to three years and automatically renew for an additional annual terms unless modified by either party.

 

Employees

 

Our People and Human Capital Resources

 

Employees

 

As of December 31, 2022, we had 9 full-time employees and 5 part-time employees, which is a decrease from the 12 full-time employees and an increase of one-part-time employee we had as of December 31, 2021, and as of March 31, 2023, we have added one additional full-time employee in 2023. We also regularly work with several independent consultants and other contract organizations to support our business and we regularly evaluate additional talent to help support our product manufacturing, development, financial, and other capabilities.

 

Diversity and Inclusion

 

We believe that an inclusive culture is required to understand and develop products that benefit all patients. By embracing differences, we aim to foster an environment of respect and trust in an effort to facilitate creativity, spark passion, and help us achieve better outcomes for all those who work at the Company. We are committed to creating and maintaining a workplace free from discrimination or harassment, including on the basis of any class protected by applicable law, and our recruitment, hiring, development, training, compensation, and advancement practices are based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity. Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace, including adhering to the standards for appropriate behavior set forth in our code of conduct.

 

Compensation and Benefits

 

We operate in a highly competitive environment for human capital, particularly as we seek to attract and retain talent with relevant experience in the medical device sector. Therefore, we strive to provide a total rewards package to our employees that is competitive with our peer companies, including competitive healthcare benefits and in certain cases, stock options. We also offer paid leave as mandated by government regulations, flexible work schedules, and other benefits as mandated by government regulations.

 

We also offer key employees the benefit of equity ownership in NanoVibronix through stock option grants. We believe these grants both help promote alignment between our employees and our stockholders and provide retention benefits, as the awards generally vest over a three-year period.

 

We do not have any employees that are represented by a labor union or that have entered into a collective bargaining agreement with the Company.

 

Safety, Wellness, and Our Response to COVID-19

 

At NanoVibronix, we believe that health matters to everyone, and the safety health, and wellness of our employees is one of our top priorities. We are committed to developing and fostering a work environment that is safe, professional, and promotes teamwork, diversity, and trust in order to afford all of our employees the opportunity to contribute to the best of their abilities.

 

35

 

 

During 2020 and 2021, in response to the COVID-19 pandemic, we took certain measures and responded to changes in our operational needs, including actions designed to provide a safe work environment for our employees. These actions included investing in technology solutions to support increased work-from-home capabilities, shifting work schedules to reduce the number of people present in our offices, requiring mask wearing and social distancing, making hand sanitizer readily available, and other measures intended to comply with health and safety protocols as required by federal, state, and local governmental agencies, as well as guidance from the U.S. Centers for Disease Control and Prevention and similar public health authorities.

 

Available Information

 

The Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments thereto, are filed with the SEC. The Company is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and files or furnishes reports, proxy statements and other information with the SEC. Such reports and other information filed by the Company with the SEC are available free of charge on the Company’s website at nanovibronix.com, as soon as reasonably practicable after we have electronically filed with, or furnished to, the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The contents of these websites are not incorporated into this filing. Further, the Company’s references to website URLs are intended to be inactive textual references only.

 

ITEM 1A. RISK FACTORS

 

Risks Related to Our Business

 

●We have a history of losses and we expect to continue to incur losses and may not achieve or maintain profitability
●Increasing inflation could adversely affect our business, financial condition, results of operations or cash flows.
●The ongoing COVID-19 pandemic has and may continue to adversely impact our business.
●If we are unable to raise additional capital, our clinical trials and product development will be limited and our long-term viability will be threatened; however, if we do raise additional capital, your percentage ownership as a stockholder could decrease and constraints could be placed on the operations of our business.
●If we fail to obtain an adequate level of reimbursement for our approved products by third party payers, there may be no commercially viable markets for our approved products or the markets may be much smaller than expected.
●The medical device and therapeutic product industries are highly competitive and subject to rapid technological change. If our competitors are able to develop and market products that are safer and more effective than any products we may develop, our commercial opportunities will be reduced or eliminated.
●We face the risk of product liability claims and may not be able to obtain insurance.
●Our product candidates may not be developed or commercialized successfully.
●If we fail to retain our key management, or to attract and keep additional key personnel, we may be unable to successfully execute our business plan.
●Our need to increase the size of our organization in order to successfully manage our growth.
●Our failure to protect our intellectual property rights could diminish the value of our solutions, weaken our competitive position and reduce our revenue.
●We could incur substantial costs and disruption to our business as a result of any dispute related to, or claim of infringement of another party’s intellectual property rights, which could harm our business and operating results.
●We face risks associated with litigation and claims.
●The Company’s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management has substantial doubt about the Company’s ability to continue as a going concern.
●Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.

 

36

 

 

Risks Related to the Regulation of Our Products

 

●We are subject to extensive governmental regulation, including the requirement of U.S. Food and Drug Administration approval or clearance before our product candidates may be marketed and after approval or clearance and during the marketing of our products.
●UroShield has not been cleared or approved by the FDA, nor has it undergone the same type of review as an FDA-approved or cleared device.
●Failure to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.
●We are uncertain regarding the success of our clinical trials for our products in development.
●We depend on Sanuwave for developing and commercializing our WoundShield technology.
●Healthcare reform measures could adversely affect our business and financial results.
●If we fail to comply with the U.S. federal and state fraud and abuse and other health care laws and regulations, we could be subject to criminal and civil penalties and exclusion from the Medicare and Medicaid programs, which would have a material adverse effect on our business and results of operations.

 

Risks Related to our Operations in Israel

 

●We conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.
●Because a certain portion of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by currency fluctuations and inflation.
●It may be difficult for investors in the United States to enforce any judgments obtained against us or any of our directors or officers.

 

Risks Related to Our Organization and Our Securities

 

●The price of our securities may be volatile, and the market price of our securities may drop below the price you pay.
●We have a significant number of warrants and options, and future sales of our common stock upon exercise of these options or warrants, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.
●Although our shares of common stock are listed on the Nasdaq Capital Market, we currently have a limited trading volume, which results in higher price volatility for, and reduced liquidity of, our common stock.
●If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.
●We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to our filing status will make our common stock less attractive to investors.
●Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.
●If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our securities and their trading volume could decline.
●We may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.
●Because we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return on your investment. Even if we change that policy, we may be restricted from paying dividends on our common stock.
●Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.
●If we fail to maintain effective internal control over financial reporting, our business, financial condition or results of operations may be adversely affected.

 

37

 

 

Risks Related to Our Business

 

We have a history of losses and we expect to continue to incur losses and may not achieve or maintain profitability.

 

For the fiscal year ended December 31, 2022 we had a net loss of approximately $5.4 million, with revenues of approximately $0.8 million. As of December 31, 2022, we had an accumulated deficit of approximately $62.4 million. We expect to incur losses for at least the next year, as we continue to incur expenses related to seeking U.S. Food and Drug Administration (“FDA”) approval for UroShield, and market acceptance of PainShield, which will require costly additional clinical trials and research, further product development and professional fees associated with regulatory compliance. Even if we succeed in commercializing our new products, we may not be able to generate sufficient revenues to cover our expenses and achieve profitability or be able to maintain profitability.

 

Global economic and political instability and conflicts, such as the conflict between Russia and Ukraine, could adversely affect our business, financial condition or results of operations.

 

Our business could be adversely affected by unstable economic and political conditions within the United States and foreign jurisdictions and geopolitical conflicts, such as the conflict between Russia and Ukraine. While we do not have any customer or direct supplier relationships in either country at this time, the current military conflict, and related sanctions, as well as export controls or actions that may be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.) and other potential uncertainties could adversely affect our business and/or our supply chain, business partners, employees or customers, and interrupt our ability to supply products, or otherwise adversely impact our business.

 

Increasing inflation could adversely affect our business, financial condition, results of operations or cash flows.

 

Inflation, as well as some of the measures taken by or that may be taken by the governments in countries where we operate in an attempt to curb inflation may have negative effects on the economies of those countries generally. If the United States or other countries where we operate experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse effect on our business, financial condition, results of operations, or cash flows. Specifically, our existing distributor agreements limit the amount that we can increase the price that we sell our products to the distributors. Accordingly, an inflationary environment, including factors such as increasing freight and materials prices, could make it less profitable for us to do business.

 

The ongoing COVID-19 pandemic has and may continue to adversely impact our business.

 

The ongoing COVID-19 pandemic has and may continue to adversely impact our business, as our operations are based in and rely on third parties located in countries affected by the pandemic. Our third-party manufacturer, which is based in China, temporarily shut down for sixty days during 2020 due to the pandemic and became fully operational in April 2020 which led to a significant delay in the production of goods needed to fulfill our sales orders which were scheduled to be fulfilled in our first quarter of 2020. We were able to fulfill these orders in the second quarter of 2020. Additionally, the notified regulatory body we rely on to obtain European CE approval is located in Italy and was shut down for approximately six weeks from March to April 2020, which delayed our submission for CE mark approval for the year 2020. The CE Mark approval was subsequently approved in April 2020. The various precautionary measures taken by many governmental authorities around the world in order to limit the spread of COVID-19 have had and may continue to have an adverse effect on the global markets and global economy, including on the availability and pricing of employees, resources, materials, manufacturing and delivery efforts and other aspects of the global economy. The financial downturn had compelled us to furlough or reduce working hours for much of our operating staff in 2020, and continue to force remaining staff as well as third-party contractors, to work remotely from time to time. In addition, many staff members continue to operate remotely from their homes, which is continuing to result in delays in obtaining certain financial records. We also rely on third-party professionals to provide services such as the preparation of our financial statements and to conduct audits, and many of these parties have been affected by government-imposed precautionary measures, thereby delaying our receipt of these services. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Therefore, the COVID-19 pandemic has and may again disrupt production and cause delays in the development, supply and delivery of our products, our operation, further divert the attention and efforts of the medical community coping with COVID-19 and disrupt the marketplace in which we operate. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, its variants and the actions to contain COVID-19 or treat its impact, among others. The COVID-19 pandemic could continue to materially disrupt our business and operations, hamper our ability to raise additional funds or sell or securities, continue to slow down the overall economy, curtail consumer spending, interrupt our sources of supply, and make it hard to adequately staff our operations.

 

38

 

 

If we are unable to raise additional capital, our clinical trials and product development will be limited and our long-term viability will be threatened; however, if we do raise additional capital, your percentage ownership as a stockholder could decrease and constraints could be placed on the operations of our business.

 

We have experienced negative operating cash flows since our inception and have funded our operations primarily from proceeds of the sale of our securities, with only limited revenue being generated from our product sales. In order to fully realize our business objectives, we may need to raise additional capital. We will seek to raise such additional funds through equity or debt financings, or strategic alliances with third parties, either alone or in combination with equity financings. These financings could result in substantial dilution to the holders of our common stock, or require contractual or other restrictions on our operations or on alternatives that may be available to us. If we raise additional funds by issuing debt securities, these debt securities could impose significant restrictions on our operations through the imposition of restrictive covenants and requiring us to pledge assets in order to secure repayment. In addition, if we raise funds through the sale of equity, we may issue equity securities with rights superior to our common stock, including voting rights, rights to proceeds upon our liquidation or sale, rights to dividends and rights to appoint board members. There can be no assurance that we will be able to complete a required financing on acceptable terms or at all. If such financing is not available on satisfactory terms, or is not available in sufficient amounts, we may be required to delay, limit or eliminate the development of business opportunities. The failure to procure such required financing could have a material adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a going concern.

 

A variety of factors could impact the timing and amount of any required financings, including, without limitation:

 

  ● unforeseen developments during our clinical trials;
  ● delays in our receipt of required regulatory approvals;
  ● delayed market acceptance of our products;
  ● unanticipated expenditures in our acquisition and defense of intellectual property rights, and/or the loss of those rights;
  ● the failure to develop strategic alliances for the marketing of some of our product candidates;
  ● unforeseen changes in healthcare reimbursement for any of our approved products;
  ● lack of financial resources to adequately support our operations;
  ● difficulties in maintaining commercial scale manufacturing capacity and capability;
  ● unanticipated difficulties in operating in international markets;
  ● unanticipated financial resources needed to respond to technological changes and increased competition;
  ● unforeseen problems in attracting and retaining qualified personnel;
  ● enactment of new legislation or administrative regulations;
  ● the application to our business of new regulatory interpretations;
  ● claims that might be brought in excess of our insurance coverage;
  ● the failure to comply with regulatory guidelines; and
  ● the uncertainty in industry demand;
  ● the delisting of our common stock from the Nasdaq Capital Market; and
  ● the geographic, social and economic impact of COVID-19 on the Company’s business operations.

 

Any required financing efforts may divert our management from their day-to-day activities, which may adversely affect its ability to develop and commercialize our products Moreover, if we complete additional financing by issuing equity securities, the percentage ownership of its existing stockholders may be reduced, and accordingly these stockholders may experience substantial dilution. Given our need for cash and that equity issuances are the most common type of fundraising for similarly situated companies, the risk of dilution is particularly significant for our stockholders.

 

39

 

 

In addition, although we have no present commitments or understandings to do so, we may seek to expand our operations and product lines through acquisitions or joint ventures. Any acquisition or joint venture would likely increase our capital requirements.

 

If we fail to obtain an adequate level of reimbursement for our approved products by third party payers, there may be no commercially viable markets for our approved products or the markets may be much smaller than expected.

 

The availability and levels of reimbursement by governmental and other third party payers affect the market for our commercial products. The efficacy, safety, performance and cost-effectiveness of our product and product candidates, and of any competing products, will determine the availability and level of reimbursement. Reimbursement and healthcare payment systems vary significantly by country, and include both government sponsored healthcare and private insurance. To obtain reimbursement or pricing approval in some countries, we may be required to produce clinical data, which may involve one or more clinical trials, that compares the cost-effectiveness of our approved products to other available therapies. We may not obtain reimbursement or pricing approvals in markets we seek to enter in a timely manner, if at all. Our failure to receive reimbursement or pricing approvals in target markets would negatively impact market acceptance of our products in these jurisdictions, placing us at a material cost disadvantage to our competitors.

 

Even if we obtain reimbursement approvals for our products, we believe that, in the future, reimbursement for any of our products or product candidates may be subject to increased restrictions both in the United States and in international markets. Future legislation, regulation or policies of third party payers that limit reimbursement may adversely affect the demand for our products currently under development and our ability to sell our products on a profitable basis. In addition, third party payers continually attempt to contain or reduce the costs of healthcare by challenging the prices charged for healthcare products and services.

 

In the United States, specifically, health care providers, such as hospitals and clinics, and individual patients, generally rely on third-party payers. Third-party reimbursement is dependent upon decisions by the Centers for Medicare and Medicaid Services, contracted Medicare carriers or intermediaries, individual managed care organizations, private insurers, other governmental health programs and other payers of health care costs. Failure to receive or maintain favorable coding, coverage and reimbursement determinations for our products by these organizations could discourage medical practitioners from using or prescribing our products due to their costs. In addition, with recent federal and state government initiatives directed at lowering the total cost of health care, the U.S. Congress and state legislatures will likely continue to focus on health care reform including the reform of the Medicare and Medicaid programs, and on the cost of medical products and services, which could limit reimbursement. Additionally, third-party payers are increasingly challenging the prices charged for medical products and services, and imposing conditions on payment. We may be unable to sell our products on a profitable basis if third-party payers deny coverage, provide low reimbursement rates or reduce their current levels of reimbursement.

 

The medical device and therapeutic product industries are highly competitive and subject to rapid technological change. If our competitors are able to develop and market products that are safer and more effective than any products we may develop, our commercial opportunities will be reduced or eliminated.

 

Our success depends, in part, upon our ability to maintain a competitive position in the development of technologies and products. We face competition from established medical device companies, such as Neurometrix Inc., Zetrox, Kinetic Concepts, Inc., (a subsidiary of the 3M Company) and Smith & Nephew plc, manufacturers of certain portable ultrasound devices capable of self-administered use, as well as from academic institutions, government agencies, and private and public research institutions in the United States and abroad. Most, if not all, of our principal competitors have significantly greater financial resources and expertise than we do in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, marketing approved products, protecting and defending their intellectual property rights and designing around the intellectual property rights of others. Other small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements, or mergers with, or acquisitions by, large and established companies, or through the development of novel products and technologies.

 

40

 

 

The industry in which we operate has undergone, and we expect it to continue to undergo, rapid and significant technological change, and we expect competition to intensify as technological advances are made. Our competitors may be able to respond to changes in technology or the marketplace faster than us. Our competitors may develop and commercialize medical devices that are safer or more effective or are less expensive than any products that we may develop. We also compete with our competitors in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in acquiring technologies complementary to our programs or advantageous to our business. Given our small size and lack of resources, we are often at a disadvantage with our competitors in all of these areas, which could limit or eliminate our commercial opportunities.

 

We face the risk of product liability claims and may not be able to obtain insurance.

 

Our business exposes us to the risk of product liability claims that are inherent in the development of medical devices and products. If the use of one or more of our products harms people, we may be subject to costly and damaging product liability claims brought against us by clinical trial participants, consumers, health care providers, pharmaceutical companies or others selling our products. We currently carry clinical trial and product liability insurance for the products we sell. However, we cannot predict all of the possible harms or side effects that may result and, therefore, the amount of insurance coverage we hold may not be adequate to cover all liabilities we might incur. We intend to expand our insurance coverage to include the sale of additional commercial products as we obtain marketing approval for our product candidates in development and as our sales expand, but we may be unable to obtain commercially reasonable product liability insurance for such products. If we are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims and we continue to make sales, or if our coverages turns out to be insufficient, we may be exposed to significant liabilities, which may materially and adversely affect our business and financial position. If we are sued for any injury allegedly caused by our products and do not have sufficient insurance coverage, our liability could exceed our total assets and our ability to pay the liability. A product liability claim or series of claims brought against us would decrease our cash and could reduce our value or marketability.

 

Our product candidates may not be developed or commercialized successfully.

 

Our product candidates are based on a technology that has not been used previously in the manner we propose and must compete with more established treatments currently accepted as the standards of care. Market acceptance of our products will largely depend on our ability to demonstrate their relative safety, efficacy, cost-effectiveness and ease of use.

 

We are subject to the risks that:

 

  ● the FDA or a foreign regulatory authority finds our product candidates ineffective or unsafe;
  ● we do not receive necessary regulatory approvals;
  ● the regulatory review and approval process may take much longer than anticipated, requiring additional time, effort and expense to respond to regulatory comments and/or directives;
  ● we are unable to get our product candidates in commercial quantities at reasonable costs; and
  ● the patient and physician community does not accept our product candidates.

 

In addition, our product development program may be curtailed, redirected, eliminated or delayed at any time for many reasons, including:

 

  ● adverse or ambiguous results;
  ● undesirable side effects that delay or extend the trials;
  ● the inability to locate, recruit, qualify and retain a sufficient number of clinical investigators or patients for our trials; and
  ● regulatory delays or other regulatory actions.

 

Additionally, we currently have limited experience in marketing or selling our products, and we have a limited marketing and sales staff and distribution capabilities. Developing a marketing and sales force is time-consuming and will involve the investment of significant amounts of financial and management resources, and could delay the launch of new products or expansion of existing product sales. In addition, we compete with many companies that currently have extensive and well-funded marketing and sales operations. If we fail to establish successful marketing and sales capabilities or fail to enter into successful marketing arrangements with third parties, our ability to generate revenues will suffer.

 

41

 

 

Furthermore, even if we enter into marketing and distributing arrangements with third parties, we may have limited or no control over the sales, marketing and distribution activities of these third parties, and these third parties may not be successful or effective in selling and marketing our products. If we fail to create successful and effective marketing and distribution channels, our ability to generate revenue and achieve our anticipated growth could be adversely affected. If these distributors experience financial or other difficulties, sales of our products could be reduced, and our business, financial condition and results of operations could be harmed.

 

We cannot predict whether we will successfully develop and commercialize our product candidates. If we fail to do so, we will not be able to generate substantial revenues, if any.

 

If we fail to retain our key management, or to attract and keep additional key personnel, we may be unable to successfully execute our business plan.

 

Our success depends on our ability to attract, retain and motivate highly qualified management and personnel. As a small company with nine full-time employees and five contract employees, our success depends on the continuing contributions of our management team and qualified personnel and on our ability to attract and retain highly qualified personnel. We face intense competition in our hiring efforts from other medical device companies, as well as from universities and nonprofit research organizations, and we may have to pay higher salaries to attract and retain qualified personnel. We are also at a disadvantage in recruiting and retaining key personnel as our small size and limited resources may be viewed as providing a less stable environment, with fewer opportunities than would be the case at one of our larger competitors. The loss of one or more of these individuals, or our inability to attract additional qualified personnel, could substantially impair our ability to implement our business plan. In addition, the replacement of key personnel likely would involve significant time and costs, and may significantly delay or prevent the achievement of our business objectives.

 

Our need to increase the size of our organization in order to successfully manage our growth.

 

We are a clinical-stage company with a small number of planned employees, and our management systems currently in place are not likely to be adequate to support our future growth plans. Our ability to grow and to manage our growth effectively will require us to hire, train, retain, manage and motivate additional employees and to implement and improve its operational, financial and management systems. These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the management level, would increase our expenses significantly. Moreover, if we fail to expand and enhance its operational, financial and management systems in conjunction with its potential future growth, such failure could have a material adverse effect on our business, financial condition and results of operations.

 

Our failure to protect our intellectual property rights could diminish the value of our solutions, weaken our competitive position and reduce our revenue.

 

We regard the protection of our intellectual property, which includes patents and patent applications, trade secrets, trademarks and domain names, as critical to our success. We strive to protect our intellectual property rights by relying on federal, state and common law rights, as well as contractual restrictions. We enter into confidentiality and invention assignment agreements with our employees, consultants and contractors, and confidentiality agreements with parties with whom we conduct business in order to limit access to, and disclosure and use of, our proprietary information. However, these contractual arrangements and the other steps we have taken to protect our intellectual property may not prevent the misappropriation of our proprietary information or deter independent development of similar technologies by others.

 

42

 

 

We have patents, as well as pending patent applications, in both the United States and relevant foreign jurisdictions. There can be no assurance that our patent applications will be approved, that any patents issued will adequately protect our intellectual property, or that these patents will not be challenged by third parties or found to be invalid or unenforceable or that our patents would prevent a competitor from designing around our claims in our patents. We have also obtained trademark registration in the United States and in foreign jurisdictions. Effective trade secret, trademark and patent protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of defending our rights. We may be required to protect our intellectual property in an increasing number of jurisdictions, a process that is expensive and may not be successful or which we may not pursue in every location. We may, over time, increase our investment in protecting our intellectual property through additional patent filings that could be expensive and time-consuming.

 

We have granted US issued patents, as well as issued patents in Europe and China and a number of corresponding foreign patents in other relevant jurisdictions, covering UROSHIELD® devices and have expiration dates ranging from May of 2023 to July of 2030. We also have pending patent applications related to UROSHIELD® devices, which would have expected expiration dates, if granted, ranging from December of 2041 to March of 2044.

 

Granted patents related to PAINSHIELD®, PAINSHIELD PLUSTM, WOUNDSHIELD® have expiration dates of August of 2033 in the United States, and February of 2027 in Europe, China and Israel. We also have pending patent applications related to PAINSHIELD®, PAINSHIELD PLUSTM, WOUNDSHIELD® devices, which would have expected expiration dates, if granted, ranging from September of 2040 to December of 2041.

 

Monitoring unauthorized use of our intellectual property is difficult and costly. Our efforts to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Further, our competitors may independently develop technologies that are similar to ours but which avoid the scope of our intellectual property rights. Further, the laws in the United States and elsewhere change rapidly, and any future changes could adversely affect us and our intellectual property. Our failure to meaningfully protect our intellectual property could result in competitors offering solutions that incorporate our most technologically advanced features, which could seriously reduce demand for our products. In addition, we may in the future need to initiate infringement claims or litigation. Litigation, whether as a plaintiff or a defendant, can be expensive, time-consuming and may divert the efforts of our technical staff and managerial personnel, which could harm our business, whether or not the litigation results in a determination that is unfavorable to us. In addition, litigation is inherently uncertain, and thus we may not be able to stop our competitors from infringing our intellectual property rights.

 

We could incur substantial costs and disruption to our business as a result of any dispute related to, or claim of infringement of another party’s intellectual property rights, which could harm our business and operating results.

 

In recent years, there has been significant litigation in the United States over patents and other intellectual property rights. From time to time, we may face allegations that we or customers who use our products have infringed the trademarks, copyrights, patents and other intellectual property rights of third parties, including allegations made by our competitors or by non-practicing entities, or that we or our customers have misappropriated the intellectual property rights of such third parties. We cannot predict whether assertions of third party intellectual property rights or claims arising from these assertions will substantially harm our business and operating results. If we are forced to defend any infringement or misappropriation claims or attacks on the validity of our intellectual property rights, whether they are with or without merit or are ultimately determined in our favor, we may face costly litigation and diversion of technical and management personnel. Most of our competitors have substantially greater resources than we do and are able to sustain the cost of complex intellectual property litigation to a greater extent and for longer periods of time than we could. Furthermore, an adverse outcome of a dispute may require us, among other things: to pay damages, potentially including treble damages and attorneys’ fees, if we are found to have willfully infringed a party’s patent or other intellectual property rights; to cease making, licensing or using products that are alleged to incorporate or make use of the intellectual property of others; to expend additional development resources to redesign our products; and to enter into potentially unfavorable royalty or license agreements in order to obtain the rights to use necessary technologies. Royalty or licensing agreements, if required, may be unavailable on terms acceptable to us, or at all. In any event, we may need to license intellectual property which would require us to pay royalties or make one-time payments. Even if these matters do not result in litigation or are resolved in our favor or without significant cash settlements, the time and resources necessary to resolve them could harm our business, operating results, financial condition and reputation.

 

43

 

 

We face risks associated with litigation and claims.

 

We may, in the future, be involved in one or more lawsuits, claims or other proceedings. These suits could concern issues including contract disputes, employment actions, employee benefits, taxes, environmental, health and safety, fraud and abuse, personal injury and product liability matters.

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. While the Company has vigorously defended the claims asserted by Protrade, the litigation is ongoing and we may be subject to other lawsuits, claims, or proceedings. See “Item 3. Legal Proceedings – Protrade Proceeding” for a full description of the Protrade proceeding.

 

The Company’s financial statements have been prepared on a going concern basis, and do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management has substantial doubt about the Company’s ability to continue as a going concern.

 

The Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. During the year ended December 31, 2022, the Company’s cash used in operations was $7,035 leaving a cash balance of $2,713 as of December 31, 2022. Because the Company does not have sufficient resources to fund our operations for the next twelve months from the date of this filing, management has substantial doubt of the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

The Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability. There are no assurances that the Company would be able to raise additional capital on terms favorable to it. If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail, or cease operations.

 

Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.

 

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, research data, our proprietary business information and that of our suppliers, technical information about our products, clinical trial plans and employee records. Similarly, our third-party providers possess certain of our sensitive data and confidential information. The secure maintenance of this information is critical to our operations and business strategy. Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, ransomware, cyber fraud, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, encrypted, lost or stolen. Any such access, inappropriate disclosure of confidential or proprietary information or other loss of information, including our data being breached at third-party providers, could result in legal claims or proceedings, liability or financial loss under laws that protect the privacy of personal information, disruption of our operations or our product development programs and damage to our reputation, which could adversely affect our business.

 

44

 

 

Risks Related to the Regulation of Our Products

 

We are subject to extensive governmental regulation, including the requirement of U.S. Food and Drug Administration approval or clearance before our product candidates may be marketed and after approval or clearance and during the marketing of our products.

 

The process of obtaining FDA approval is lengthy, expensive and uncertain, and we cannot be sure that our additional product candidates will be approved in a timely fashion, or at all. If the FDA does not approve or clear our product candidates in a timely fashion, or at all, our business and financial condition would likely be adversely affected.

 

Both before and after approval or clearance of our product candidates, we, our product candidates, our suppliers and our contract manufacturers are subject to extensive regulation by governmental authorities in the United States and other countries. Failure to comply with applicable requirements could result in, among other things, any of the following actions:

 

  ● FDA issuance of Form 483 or Warning Letters, which may be made public and may lead to further regulatory or enforcement actions, or similar letters by other regulatory authorities;
  ● fines and other monetary penalties;
  ● unanticipated expenditures;
  ● delays in FDA approval and clearance, or FDA refusal to approve or clear a product candidate;
  ● product recall or seizure;
  ● interruption of manufacturing or clinical trials;
  ● operating restrictions;
  ● injunction or other restrictions imposed on our operations, including closing our facilities or our contract manufacturers’ facilities; or
  ● criminal prosecutions.

 

In addition to the approval and clearance requirements, numerous other regulatory requirements apply, both before and after approval or clearance, to us, our products and product candidates, and our suppliers and contract manufacturers. These include requirements related to the following:

 

 

●

testing and quality control;

  ● manufacturing;
  ● quality assurance;
  ● labeling;
  ● advertising;
  ● promotion (including the prohibition on promoting devices for “off-label” uses);
  ● distribution;
  ● export;
  ● reporting to the FDA certain adverse experiences associated with the use of the products, as well as our discovery of defects or a product’s failure to comply with design specifications or applicable law; and
  ● obtaining additional approvals or clearances for certain modifications to the products or their labeling or claims.

 

We are also subject to inspection by the FDA to determine our compliance with regulatory requirements, as are our suppliers and contract manufacturers, and we cannot be sure that the FDA will not identify compliance issues that may disrupt production or distribution, or require substantial resources to correct. We also cannot be sure that the FDA will agree with our analysis of, conclusions regarding, or handling of various situations that arise with our products. If it is determined that we failed to comply with any of our regulatory obligations, we could be subject to a wide range of enforcement actions that could limit our ability to continue to successfully commercialize impacted products or otherwise adversely impact us.

 

The FDA’s requirements may change and additional government regulations may be promulgated that could affect us, our product candidates, and our suppliers and contract manufacturers. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action. There can be no assurance that we will not be required to incur significant costs to comply with such laws and regulations in the future, or that such laws or regulations will not have a material adverse effect upon our business.

 

45

 

 

UroShield has not been cleared or approved by the FDA, nor has it undergone the same type of review as an FDA-approved or cleared device.

 

In September 2020, the FDA exercised its Enforcement Discretion to allow distribution of our UroShield device in the United States. This temporary authorization is limited to use as an extracorporeal acoustic wave generating accessory to urological indwelling catheter for use during the COVID-19 pandemic. The U.S. government has since-terminated the public health emergency, and FDA recently confirmed via guidance that the applicable policy of Enforcement Discretion under which UroShield was maketed during the pandemic will expire in November 2023. Accordingly, if we do not obtain FDA approval or clearance by the expiration of the applicable Enforcement Discretion policy in November 2023, we will have to discontinue distribution of UroShield in the U.S. until FDA grants the requisite premarket authorization, which may not occur in a timely manner, if at all. There is no guarantee that our collaborators or customers will purchase or use the UroShield, that any sales of UroShield by us will generate any revenue or profits, or that we will ever be successful in obtaining FDA clearance or approval for the UroShield.

 

Failure to obtain regulatory approval in foreign jurisdictions will prevent us from marketing our products abroad.

 

International sales of our products and any of our product candidates that we commercialize are subject to the regulatory requirements of each country in which the products are sold. Accordingly, the introduction of our product candidates in markets outside the United States where we do not already possess regulatory approval will be subject to regulatory approvals in those jurisdictions. The regulatory review process varies from country to country. Many countries impose product standards, packaging and labeling requirements, and import restrictions on medical devices. In addition, each country has its own tariff regulations, duties and tax requirements, as well as reimbursement and healthcare payment systems. The approval by foreign government authorities is unpredictable and uncertain, and can be expensive. We may be required to perform additional pre-clinical, clinical or post-approval studies even if FDA approval has been obtained. Our ability to market our approved products could be substantially limited due to delays in receipt of, or failure to receive, the necessary approvals or clearances.

 

We are uncertain regarding the success of our clinical trials for our products in development.

 

We believe that all of our novel lines of product candidates in development, which currently consists of only RenooSkin, will require clinical trials to determine their safety and efficacy by regulatory bodies in their target markets, including the FDA and various foreign regulators. There can be no assurance that we will be able to successfully complete the U.S. and foreign regulatory approval processes for products in development. In addition, there can be no assurance that we will not encounter additional problems that will cause us to delay, suspend or terminate our clinical trials. In addition, we cannot make any assurance that clinical trials will be deemed sufficient in size and scope to satisfy regulatory approval requirements, or, if completed, will ultimately demonstrate our products to be safe and efficacious.

 

We depend on Sanuwave for developing and commercializing our WoundShield technology.

 

In March 2020, we entered into a license agreement with Sanuwave for the manufacture and delivery of our WoundShield technology. Under this agreement, Sanuwave has received the worldwide, exclusive rights to our WoundShield technology. Sanuwave will bear the cost and clinical validation responsibilities associated with obtaining approval for WoundShield from the FDA and other regulatory agencies around the world. Sanuwave is also responsible for manufacturing and commercializing the WoundShield product and technology. Our right to receive a milestone payment under the license agreement depends on the achievement of FDA approval by Sanuwave and our ability to receive royalties under the agreement depends on Sanuwave’s successful commercialization of the WoundShield product and technology.

 

The development and commercialization of the WoundShield product and technology and our ability to receive a potential milestone and royalty payments under the license agreement with Sanuwave, could be adversely affected if Sanuwave:

 

● lacks or does not devote sufficient time and resources to the development and commercialization of the WoundShield product and technology;
● lacks or does not devote sufficient capital to fund the development and commercialization of the WoundShield product and technology;
● develops, either alone or with others, products that compete with the WoundShield product and technology;
● fails to gain the requisite regulatory approvals for the WoundShield product and technology;
● does not successfully commercialize the WoundShield product and technology;

 

46

 

 

● does not conduct its activities in a timely manner;
● terminates its license with us; or
● does not effectively pursue and enforce intellectual property rights relating to the WoundShield product and technology.

 

We have limited or no control over the occurrence of any of the foregoing. Furthermore, disagreements with Sanuwave could lead to disputes, which could be time-consuming and expensive. If any of these issues arise, it may delay the development and commercialization milestone and royalties based on further development and sales of the WoundShield product and technology.

 

Healthcare reform measures could adversely affect our business and financial results.

 

In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may adversely affect our business and financial results. Federal and state lawmakers regularly propose and, at times, enact legislation that could result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for our products. The cost containment measures that payers and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products. For example, the Patient Protection and Affordable Act of 2010, commonly referred to as the Affordable Care Act, contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.

 

There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act for over a decade. However, as of the Supreme Court’s ruling ordering the dismissal of, arguably, the most promising case challenging the Affordable Care Act to-date in June 2021, it appears that the Affordable Care Act will remain in-effect in its current form for the foreseeable future. We cannot predict what additional challenges to the Affordable Care Act may arise in the future, the outcome thereof, or the impact any such actions may have on our business. Additionally, the Biden administration has introduced various measures in recent years, focusing on healthcare and medical-product pricing, in particular. It remains to be seen how these measures will affect our business and there is uncertainty as to what other healthcare programs and regulations may be implemented or changed at the federal and/or state level in the U.S., but it is possible that such initiatives could have an adverse effect on our ability to obtain FDA approval or clearance and/or successfully commercialize products in the U.S. in the future. For example, any changes that reduce, or impede the ability of healthcare providers to obtain reimbursement for medical procedures in which the products we currently, or intend to, commercialize are used, or that reduce medical procedure volumes, could adversely affect our operations and/or future business plans. The financial impact of U.S. healthcare reform legislation over the next few years will depend on a number of factors, including the policies reflected in implementing regulations and guidance and changes in sales volumes for medical devices affected by the legislation. From time to time, legislation is drafted, introduced, and passed that could significantly change the statutory provisions governing coverage, reimbursement, pricing, and marketing of medical device products. In addition, third-party payor coverage and reimbursement policies are often revised or interpreted in ways that may significantly affect our business and our products.

 

47

 

 

If we fail to comply with the U.S. federal and state fraud and abuse and other health care laws and regulations, we could be subject to criminal and civil penalties and exclusion from the Medicare and Medicaid programs, which would have a material adverse effect on our business and results of operations.

 

All of our financial relationships with health care providers and others who provide products or services to federal health care program beneficiaries are potentially governed by the federal and state fraud and abuse laws, and other health care laws and regulations may be or become applicable to our business and operations and expose us to risk. For example:

 

  ● The federal Anti-Kickback Statute, which prohibits the offer, payment, solicitation or receipt of any form of remuneration in return for referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable by Medicare, Medicaid or any other federal health care program.
     
  ● Federal false claims laws and civil monetary penalty laws, including the False Claims Act, that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.
     
  ● The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, and for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for health care benefits, items or services.
     
  ● HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and its implementing regulations, which also impose obligations and requirements on health care providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform certain services for them that involve the use or disclosure of individually identifiable health information, with respect to safeguarding the privacy and security of certain individually identifiable health information.
     
  ● The federal transparency requirements under the Affordable Care Act, including the provision commonly referred to as the Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or Children’s Health Insurance Program to report annually to Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members.
     
  ● Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply to referrals and items or services reimbursed by both governmental and non-governmental third-party payers, including private insurers, many of which differ from each other in significant ways and often are not preempted by federal law, thus complicating compliance efforts.

 

48

 

 

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. Efforts to ensure that our business arrangements with third parties and our operations are compliant with applicable health care laws and regulations will involve the expenditure of appropriate, and possibly significant, resources. If we are found to be in violation of any current or future statutes or regulations involving applicable fraud and abuse or other health care laws and regulations, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, which could have a material adverse effect on our business, results of operations and financial condition. If any physicians or other health care providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs, which could adversely affect our ability to operate our business and our results of operations.

 

Risks Related to our Operations in Israel

 

We conduct our operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.

 

Our principal offices and manufacturing facilities are located in Israel and most of our officers and employees are residents of Israel. Accordingly, political, economic and military conditions in Israel and the surrounding region may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect our operations and results of operations and could make it more difficult for us to raise capital. Civil unrest and political turbulence has occurred in other countries in the region, including Syria which shares a common border with Israel, and is affecting the political stability of those countries. The civil war that has been ongoing in Syria has escalated, and this instability and any intervention may lead to additional conflicts in the region. In addition, Iran has threatened to attack Israel and is widely believed to be developing nuclear weapons. Iran also has a strong influence among extremist groups in the region. These situations may potentially escalate in the future to more violent events which may affect Israel and our operations. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could harm our results of operations. For example, any major escalation in hostilities in the region could result in a portion of our employees being called up to perform military duty for an extended period of time. Our operations could be disrupted by the absence of a significant number of our employees. Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.

 

Our commercial insurance does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.

 

Further, in the past, the State of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business and trade activity with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.

 

Because a certain portion of our expenses is incurred in currencies other than the U.S. dollar, our results of operations may be harmed by currency fluctuations and inflation.

 

We expect our revenues from future licensing agreements to be denominated mainly in U.S. dollars or in Euros. We pay a substantial portion of our expenses in U.S. dollars; however, a portion of our expenses, related to salaries of the employees in Israel and payment to part of the service providers in Israel and other territories, are paid in New Israeli Shekels, or NIS, and in other currencies. In addition, a portion of our financial assets is held in NIS and in other currencies. As a result, we are exposed to the currency fluctuation risks, and we do not attempt to hedge against such risks. For example, if the NIS strengthens against the U.S. dollar, our reported expenses in U.S. dollars may be higher than anticipated. In addition, if the NIS weakens against the U.S. dollar, the U.S. dollar value of our financial assets held in NIS will decline.

 

49

 

 

It may be difficult for investors in the United States to enforce any judgments obtained against us or any of our directors or officers.

 

Almost all of our assets are located outside the United States, although we do maintain a permanent place of business within the United States. In addition, some of our officers and directors are nationals and/or residents of countries other than the United States, and all or a substantial portion of such persons’ assets are located outside the United States. As a result, it may be difficult for investors to enforce within the United States any judgments obtained against us or any of our non-U.S. directors or officers, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state thereof. Additionally, it may be difficult to assert U.S. securities law claims in actions originally instituted outside of the United States. Israeli courts may refuse to hear a U.S. securities law claim because Israeli courts may not be the most appropriate forums in which to bring such a claim. Even if an Israeli court agrees to hear a claim, it may determine that the Israeli law, and not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, certain content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the Israeli law. Consequently, you may be effectively prevented from pursuing remedies under U.S. federal and state securities laws against us or any of our non-U.S. directors or officers.

 

Risks Related to Our Organization and Our Securities

 

The price of our securities may be volatile, and the market price of our securities may drop below the price you pay.

 

We expect that the price of our securities will fluctuate significantly. Market prices for securities of early-stage medical device companies have historically been particularly volatile. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this report, these factors include:

 

  ● progress, or lack of progress, in developing and commercializing our products;
  ● favorable or unfavorable decisions about our products or intellectual property from government regulators, insurance companies or other third-party payers;
  ● our ability to recruit and retain qualified regulatory and research and development personnel;
  ● changes in investors’ and securities analysts’ perception of the business risks and conditions of our business;
  ● changes in our relationship with key collaborators;
  ● changes in the market valuation or earnings of our competitors or companies viewed as similar to us;
  ● changes in key personnel;
  ● depth of the trading market in our common stock;
  ● changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;
  ● the granting or exercise of employee stock options or other equity awards;
  ● realization of any of the risks described under this section entitled “Risk Factors”; and
  ● general market and economic conditions.

 

In recent years, the stock markets, in general, have experienced extreme price and volume fluctuations especially in the biotechnology sector. Broad market and industry factors may materially harm the market price of shares of our common stock. In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted against that company. If we were involved in any similar litigation, we could incur substantial costs and our management’s attention and resources could be diverted. On March 12, 2020, the WHO declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty since then. In addition, U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. A continuation or worsening of the levels of market disruption and volatility could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares.

 

50

 

 

We have a significant number of warrants and options, and future sales of our common stock upon exercise of these options or warrants, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.

 

Sales of a significant number of shares of our common stock in the public market could harm the market price of our common stock and make it more difficult for us to raise funds through future offerings of common stock. Our stockholders and the holders of our outstanding warrants and options, upon exercise of these options or warrants, may sell substantial amounts of our common stock in the public market. The availability of these shares of our common stock for resale in the public market has the potential to cause the supply of our common stock to exceed investor demand, thereby decreasing the price of our common stock.

 

In addition, the fact that our stockholders and holders of our warrants and options can sell substantial amounts of our common stock in the public market, whether or not sales have occurred or are occurring, could make it more difficult for us to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 

Although our shares of common stock are listed on the Nasdaq Capital Market, we currently have a limited trading volume, which results in higher price volatility for, and reduced liquidity of, our common stock.

 

Although our shares of common stock are listed on the Nasdaq Capital Market under the symbol “NAOV,” trading volume in our common stock has been limited and an active trading market for our shares of common stock may never develop or be maintained. The absence of an active trading market increases price volatility and reduces the liquidity of our common stock. As long as this condition continues, the sale of a significant number of shares of common stock at any particular time could be difficult to achieve at the market prices prevailing immediately before such shares are offered.

 

If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

Our common stock is currently listed for trading on the Nasdaq Capital Market. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum stockholders’ equity of $2.5 million and a minimum closing bid price of $1.00 per share or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from the Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities.

 

On March 2, 2022, the Company received notice from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between January 14, 2022, through March 1, 2022, we did not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 555(a)(2). The letter also indicated that the Company will be provided with a compliance period until August 29, 2022 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

 

On August 30, 2022, the Company received notice from Nasdaq indicating that the Company’s securities would be subject to delisting due to the Company’s continued non-compliance with the minimum bid price requirement unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which stayed any further action by Nasdaq at least pending the issuance of a decision by the Panel and the expiration of any extension the Panel may grant to the Company following the hearing. On October 17, 2022, the Panel granted the Company’s request for continued listing on The Nasdaq Capital Market until December 15, 2022, subject to the Company providing a written update to the Panel on December 15, 2022.

 

51

 

 

On February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The Company’s common stock continued to be traded on the Nasdaq Capital Market under the symbol NAOV and began trading on a split-adjusted basis at market open on February 9, 2023.

 

On February 28, 2023 The Company was notified by Nasdaq that it regained compliance with all Nasdaq listing requirements and the matter was closed. See “Item 3. Legal Proceedings – Nasdaq Deficiency and Hearings Panel Decision,” for a full description of the Nasdaq hearing and the Company’s actions to regain compliance.

 

There is no assurance that we will maintain compliance with such minimum listing requirements. If our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.

 

We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to our filing status will make our common stock less attractive to investors.

 

We are a “smaller reporting company” and, thus, have certain decreased disclosure obligations in our SEC filings, including, among other things, simplified executive compensation disclosures and only being required to provide two years of audited financial statements in annual reports. Decreased disclosures in our SEC filings due to our status as a “smaller reporting company” may make it harder for investors to analyze our results of operations and financial prospects and may make our common stock a less attractive investment. If some investors find our common stock less attractive, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.

 

Certain provisions of our amended and restated certificate of incorporation and bylaws could discourage, delay or prevent a merger, acquisition or other change of control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove members of our board of directors. These provisions also could limit the price that investors might be willing to pay in the future for our securities, thereby depressing the market price of our securities. Stockholders who wish to participate in these transactions may not have the opportunity to do so. These provisions, among other things:

 

  ● allow the authorized number of directors to be changed only by resolution of our board of directors;
  ● authorize our board of directors to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board of directors does not approve;
  ● establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; and
  ● limit who may call a stockholder meeting.

 

52

 

 

In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law that may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time.

 

If securities or industry analysts do not publish research or reports or publish unfavorable research about our business, the price of our securities and their trading volume could decline.

 

The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. Currently there is only one research coverage by a securities and industry analyst. If one or more of the analysts who covers us downgrades our securities, the price of our securities would likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, interest in the purchase of our securities could decrease, which could cause the price of our securities and their trading volume to decline.

 

We may be subject to ongoing restrictions related to grants from the Israeli Office of the Chief Scientist.

 

Through our Israeli subsidiary, as of December 31, 2017, we received grants of $437,000 from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor, or the Office of the Chief Scientist, for research and development programs related to products that we are not currently commercializing or marketing. Because we are no longer developing the product to which the grants relate, we do not believe that we are subject to any material conditions with respect to the grants, except for the restrictions on our ability to make certain transfers of the technology or intellectual property related to these grants described below. We could in the future determine to apply for further grants. If we receive any such grants, we would have to comply with specified conditions, including paying royalties with respect to grants received. If we fail to comply with these conditions in the future, sanctions might be imposed on us, such as grants could be cancelled and we could be required to refund any payments previously received under these programs.

 

Pursuant to the Israeli Encouragement of Industrial Research and Development Law, any products developed with grants from the Office of the Chief Scientist are required to be manufactured in Israel and certain payments may be required in connection with the change of control of the grant recipient and the financing, mortgaging, production, exportation, licensing and transfer or sale of its technology and intellectual property to third parties, which will require the Office of the Chief Scientist’s prior consent and, in case such a third party is outside of Israel, extended royalties and/or other fees. This could have a material adverse effect on and significant cash flow consequences to us if, and when, any technologies, intellectual property or manufacturing rights are exported, transferred or licensed to third parties outside Israel. If the Office of the Chief Scientist does not wish to give its consent in any required situation or transaction, we would need to negotiate a resolution with the Office of the Chief Scientist. In any event, such a transaction, assuming it was approved by the Office of the Chief Scientist, would involve monetary payments, such as royalties or fees, of not less than the applicable funding received from the Office of the Chief Scientist plus interest, not to exceed, in aggregate, six times the applicable funding received from the Office of the Chief Scientist.

 

Because we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return on your investment. Even if we change that policy, we may be restricted from paying dividends on our common stock.

 

We do not intend to pay cash dividends on shares of our common stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend upon results of operations, financial performance, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. Accordingly, you will have to rely on capital appreciation, if any, to earn a return on your investment in our common stock. Investors seeking cash dividends in the foreseeable future should not purchase our common stock.

 

53

 

 

Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.

 

Our ability to utilize our federal net operating loss, carryforwards and federal tax credit may be limited under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an “ownership change,” as defined by Section 382, occurs. Generally, an ownership change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect “five percent shareholders” increases by more than 50% over their lowest ownership percentage at any time during the applicable testing period (typically three years). If we have experienced an “ownership change” at any time since our formation, we may already be subject to limitations on our ability to utilize our existing net operating losses and other tax attributes to offset taxable income. In addition, future changes in our stock ownership, which may be outside of our control, may trigger an “ownership change” and, consequently, Section 382 and 383 limitations. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.

 

If we fail to maintain effective internal control over financial reporting, our business, financial condition or results of operations may be adversely affected.

 

As a public reporting company, we are required to establish and maintain effective internal control over financial reporting. Failure to establish such internal control, or any failure of such internal control once established, could adversely impact our public disclosures regarding our business, financial condition or results of operations. Any failure of our internal control over financial reporting could also prevent us from maintaining accurate accounting records and discovering accounting errors and financial frauds.

 

Rules adopted by the Securities and Exchange Commission pursuant to Section 404 of Sarbanes-Oxley Act of 2002 require annual assessment of our internal control over financial reporting. The standards that must be met for management to assess the internal control over financial reporting as effective are complex, and require significant documentation, testing and possible remediation to meet the detailed standards. We may encounter problems or delays in completing activities necessary to make an assessment of our internal control over financial reporting. If we cannot assess our internal control over financial reporting as effective, investor confidence and share value may be negatively impacted. In addition, management’s assessment of internal control over financial reporting may identify weaknesses and conditions that need to be addressed in our internal control over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting (including those weaknesses identified in our periodic reports), or disclosure of management’s assessment of our internal control over financial reporting may have an adverse impact on the price of our securities.

 

As disclosed in Part II, Item 9A, “Controls and Procedures,” we have identified material weaknesses in our internal control over financial reporting due to a lack of a full and complete testing of our disclosure controls and procedures. We concluded that our internal control over financial reporting and related disclosure controls and procedures were not effective as of December 31, 2022. Our management is in the process of implementing remediation measures with respect to the controls and written policies and procedures as described in Part II, Item 9A, “Controls and Procedures,” and management expects that such measures, once fully implemented, will be sufficient to remediate such material weaknesses in our internal control over financial reporting that existed as of December 31, 2022.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None

 

ITEM 2. PROPERTIES

 

We lease an office and manufacturing facility in Nesher, Israel and maintain an office in Tyler, Texas. Our lease for the facility in Nesher expires on December 31, 2023 with an option to renew the lease for an additional 24 months. The space is approximately 284 square meters. We pay approximately $4,200 per month under our lease. We also use a facility in Tyler, Texas from an unrelated party, for which we pay rent of $1,200 a month although we do not have a lease. This space is approximately 200 square meters. We believe that our facilities are adequate to meet our current and proposed needs.

 

54

 

 

ITEM 3. LEGAL PROCEEDINGS

 

From time to time, we may be involved in certain claims and litigation arising out of the ordinary course and conduct of business. Management assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the amount of loss can be reasonably estimated, provisions for loss are made based on management’s assessment of the most likely outcome.

 

See “Item 8. Financial Statements and Supplementary Data – Note 12. Commitments and Contingencies,” which information is incorporated herein by reference, for a description of pending and recent litigation.

 

Protrade Proceeding

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims asserted by Protrade.

 

On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $1.5 million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.

 

On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.

 

On July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.

 

On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion.

 

On November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newel information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. On March 21, 2023, the Court denied the motion to re-argue and renew. The Company intends to file a notice of appeal with the Appellate Division, Second Department and to continue to vigorously pursue its opposition to the award in all appropriate fora.

 

As of December 31, 2022, the Company accrued the amount of the award to Protrade amounting to $1,500,250 as part of “General and administrative expenses”. In addition, as the Company has not made payments on this award since it continues to appeal, the Company accrued the amount of $346,544 as part of “Interest Expense”, with the total amount of $1,846,794 included in “Other accounts payable and accrued expenses”.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

55

 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our common stock has been quoted on the NASDAQ Capital Market under the symbol “NAOV” since November 8, 2017. Prior to that date, our common stock had been quoted on the OTCQB over-the-counter marketplace under the symbol “NAOV” since April 10, 2015. Prior to April 10, 2015, there was no established public trading market for our common stock.

 

As of April 17, 2023, we had 1,662,377 issued and outstanding shares of common stock. The common stock was held by 96 holders of record. The actual number of holders of our common stock is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street names by brokers or other nominees.

 

On March 3, 2021, we filed a proxy statement in connection with a special meeting of stockholders that was held on March 31, 2021, and ultimately adjourned until May 6, 2021, to (i) ratify the increase in the number of authorized shares of common stock from 20,000,000 to 24,109,635 and the issuance of such 4,109,635 shares of common stock, and (ii) further increase the number of our authorized shares of common stock. On May 6, 2021, the Company’s stockholders voted to approve the ratification of the increase in the number of authorized shares of common stock from 20,000,000 to 24,109,635 and the issuance of such 4,109,635 shares of common stock to be effective as of December 4, 2020, but the stockholders did not approve a further increase in the number of its authorized shares of common stock.

 

On August 17, 2021, the Company’s stockholders voted to approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of shares of our common stock authorized for issuance from 24,109,635 shares to 40,000,000 shares.

 

As of April 17, 2023, we had a total of no shares of our Series C Preferred Stock issued and outstanding. Each share of our Series C Preferred Stock is convertible into one share of our common stock (subject to adjustment as provided in the related designation of preferences) at any time at the option of the holder, provided that the holder would be prohibited from converting Series C Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days’ prior written notice to us.

 

As of April 17, 2023, we had a total of no shares of our Series D Preferred Stock outstanding. Each share of our Series D Preferred Stock is convertible into one thousand shares of our common stock (subject to adjustment as provided in the related designation of preferences) at any time at the option of the holder, provided that the holder would be prohibited from converting Series D Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days’ prior written notice to us.

 

As of April 17, 2023, we had a total of no shares of our Series E Preferred Stock issued and outstanding. Each share of our Series E Preferred Stock is convertible into one share of our common stock (subject to adjustment as provided in the related designation of preferences) at any time at the option of the holder, provided that the holder would be prohibited from converting Series E Preferred Stock into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of our common stock then issued and outstanding. This limitation may be waived upon not less than 61 days’ prior written notice to us.

 

As of April 17, 2023, we held no shares of our Series F Preferred Stock issued and outstanding. Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate of Incorporation to reclassify the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series F Preferred Stock is not entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

 

56

 

 

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Company’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). As of December 31, 2022, both the Initial Redemption and the Subsequent Redemption have occurred. As a result, no shares of Series F Preferred Stock remain outstanding.

 

Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.10 in cash for each one hundred whole shares of Series F Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the Certificate of Designation) thereof as of the applicable redemption time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder to the corporate secretary of the Company (each a “Redemption Payment Request”) following the applicable redemption time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company (ii) set forth in reasonable detail the number of shares of Series F Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by the Company with respect to the shares of Series F Preferred Stock that were redeemed at the applicable redemption time. However, the redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than one hundred whole shares of Series F Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of one hundred, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of one hundred (such, that for example, the former beneficial owner of 150 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 100 shares of Series F Preferred Stock redeemed pursuant to such redemption).

 

Recent Sales of Unregistered Securities

 

All sales of unregistered securities during the year ended December 31, 2022 were previously disclosed in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

 

Issuer Purchases of Equity Securities

 

We did not purchase any of our registered equity securities during the period covered by this Annual Report.

 

ITEM 6. RESERVED

 

57

 

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity, and certain other factors that may affect our future results. You should read the following discussion and analysis of financial condition and results of operations in conjunction with our consolidated financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Item 1A. Risk Factors” and elsewhere in this Form 10 -K. See “Cautionary Note Regarding Forward-Looking Statements” included elsewhere in this Form 10 -K.

 

Overview

 

We are a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. Our WoundShield, PainShield and UroShield products are backed by novel technology which relates to ultrasound delivery through surface acoustic waves.

 

Recent Events

 

COVID-19

 

The ongoing COVID-19 pandemic has and may continue to adversely impact our business, as our operations are based in and rely on third parties located in countries affected by the pandemic. Our third-party manufacturer, which is based in China, temporarily shut down for sixty days during 2020 due to the pandemic and became fully operational in April 2020 which led to a significant delay in the production of goods needed to fulfill our sales orders which were scheduled to be fulfilled in our first quarter of 2020. We were able to fulfill these orders in the second quarter of 2020. Additionally, the notified regulatory body we rely on to obtain European CE approval is located in Italy and was shut down for approximately six weeks from March to April 2020, which delayed our submission for CE mark approval for the year 2020. The CE Mark approval was subsequently approved in April 2020. The various precautionary measures taken by many governmental authorities around the world in order to limit the spread of COVID-19 have had and may continue to have an adverse effect on the global markets and global economy, including on the availability and pricing of employees, resources, materials, manufacturing and delivery efforts and other aspects of the global economy. During the first six months of 2020, the financial downturn compelled us to furlough or reduce working hours for much of our operating staff, and forced our remaining staff as well as third-party contractors, to work remotely. In addition, many staff members continue to operate remotely from their homes which is continuing to result in delays in obtaining certain financial records. We also rely on third-party professionals to provide services such as the preparation of our financial statements and to conduct audits, and many of these parties have been affected by government-imposed precautionary measures, thereby delaying our receipt of these services. Such government-imposed precautionary measures may have been relaxed in certain countries or states, but there is no assurance that more strict measures will be put in place again due to a resurgence in COVID-19 cases. Although there were no material disruptions during 2021, the COVID-19 pandemic again disrupt production and cause delays in the development, supply and delivery of our products, our operation, further divert the attention and efforts of the medical community coping with COVID-19 and disrupt the marketplace in which we operate. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19, its variants and the actions to contain COVID-19 or treat its impact, among others. The COVID-19 pandemic could continue to materially disrupt our business and operations, hamper our ability to raise additional funds or sell or securities, continue to slow down the overall economy, curtail consumer spending, interrupt our sources of supply, and make it hard to adequately staff our operations.

 

Protrade Proceeding

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims asserted by Protrade.

 

58

 

 

On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $1.5 million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.

 

On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.

 

On July 22, 2022, the Company filed a motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.

 

On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion.

 

On November 9, 2022, the Company filed a motion to re-argue and re-plead the arbitration decision based on additional information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. The Company expects to continue to vigorously pursue its opposition to the award in all appropriate fora.

 

As of December 31, 2022 and 2021, the Company accrued the amount of the award to Protrade amounting to approximately $1.9 million and $1.5 million, respectively, with the $0.4 million of interest accrued in 2022 as part of “Interest expense” and “Other accounts payable and accrued expenses”.

 

Business Developments

 

Effective as of January 2020, the U.S. CMS approved our PainShield™ for reimbursement for Medicare beneficiaries on a national basis. We were notified on March 30, 2020 that our Medicare Enrollment Application was approved, and we are now an approved Medicare Supplier for DME through the National Supplier Clearinghouse, Palmetto-GBA as well as Noridian Administrative Services, LLC, the two Medicare Administrative Contractors that handle DME reimbursement nationwide. PainShield is currently available for Medicare reimbursement on a national level under new HCPCS (Healthcare Common Procedure Coding System) code K1004.

 

In March 2020, we signed a license agreement with Sanuwave Health, Inc. for the manufacture and delivery of our WoundShield technology. Under the terms of the agreement, we will receive warrants to purchase 127,000 shares of Sanuwave stock, a $250,000 milestone payment based on receipt of FDA approval, and 10% royalty on Sanuwave’s gross revenues from sales or rentals of WoundShield. In return, Sanuwave has received the worldwide, exclusive rights to our WoundShield product and technology. In addition, Sanuwave will bear the costs and clinical validation responsibilities associated with obtaining approval for WoundShield from the FDA and other regulatory agencies around the world.

 

In September 2020, the FDA exercised its Enforcement Discretion to allow distribution of our UroShield device in the United States. This temporary authorization is limited to use as an extracorporeal acoustic wave generating accessory to urological indwelling catheter for use during the COVID-19 pandemic.

 

59

 

 

Nasdaq Deficiency and Hearings Panel Decision

 

On March 2, 2022, the Company received a letter from Nasdaq indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between January 14, 2022, through March 1, 2022, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until August 29, 2022 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).

 

On August 30, 2022, the Company received notice from Nasdaq indicating that the Company’s securities would be subject to delisting due to the Company’s continued non-compliance with the minimum bid price requirement unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel, which stayed any further action by Nasdaq at least pending the issuance of a decision by the Panel and the expiration of any extension the Panel may grant to the Company following the hearing. On October 17, 2022, the Panel granted the Company’s request for continued listing on The Nasdaq Capital Market until December 15, 2022, subject to the Company providing a written update to the Panel on December 15, 2022.

 

On September 13, 2022, subject to stockholder approval, the Board approved an amendment to our Certificate of Incorporation to, at the discretion of the Board, effect the reverse stock split of our common stock at a ratio of 1-for-2 to 1-for-50, with the exact ratio within such range to be determined by the Board at its discretion. The primary goal of the reverse stock split is to increase the per share market price of the Company’s common stock to meet the minimum per share bid price requirements for continued listing on Nasdaq. As indicated by the Company’s proxy statement filed on October 31, 2022, stockholders of the Company’s common stock and Series F Preferred Stock were able to vote on the reverse stock split at the annual meeting held on December 15, 2022.

 

At an annual meeting of stockholders held on December 15, 2022, the Company’s stockholders granted Board the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50, such ratio to be determined by the Board.

 

On February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The Company’s common stock continued to be traded on the Nasdaq Capital Market under the symbol NAOV and began trading on a split-adjusted basis at market open on February 9, 2023.

 

On February 28, 2023 the Company was notified by Nasdaq that it regained compliance with all Nasdaq listing requirements and the matter was closed.

 

Regulatory Update

 

On May 26, 2022, we were notified by the U.S. Food and Drug Administration (the “FDA”) that we should discontinue any new marketing of our PainShield Plus products until we receive the requisite regulatory clearance. The Company retained a qualified third-party laboratory to prepare and submit the appropriate 510(k) premarket notification to FDA. And, on November 28, 2023, the Company announced that the FDA officially granted 510(k) clearance of PainShield â MD PLUS to apply ultrasonic energy to generate deep heat within body tissues for the treatment of selected medical conditions, such as relief of pain, muscle spasms, and joint contractures.

 

In addition, the Company is working with the laboratory on our PainShield Relief product so that it meets the predicate product category specifications, There is no guarantee that we will ever be successful in obtaining FDA clearance or approval for the Painshield Relief products.

 

We also filed an application with the Centers for Medicare and Medicaid Services for reimbursement earlier this year. The application was rejected due to a lack of data supporting PainShield MD’s life expectancy. We subsequently entered into an agreement with a qualified third-party laboratory to conduct testing that we hope will provide the necessary independent data to support our resubmission of an application for reimbursement.

 

60

 

 

Critical Accounting Policies and Significant Estimates

 

This management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reported period. In accordance with U.S. GAAP, we base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances. Actual results may differ from these estimates if conditions differ from our assumptions. While our significant accounting policies are more fully described in Note 3 in the “Notes to Financial Statements”, we believe the following accounting policies are critical to the process of making significant estimates in preparation of our financial statements.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.

 

Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was no allowance on inventory.

 

Impairment of Long-Lived Assets

 

Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.

 

Sequencing

 

The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

 

Revenue recognition

 

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

 

Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.

 

61

 

 

Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

 

Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

 

Stock-based compensation

 

We rely on the Black-Scholes option pricing model for estimating the fair value of stock-based awards granted, and expected volatility is based on the historical volatilities of peer company’s common stock. Stock options generally vest over one or two years from the grant date and generally have ten-year contractual terms. Information about the assumptions used in the calculation of stock-based compensation expense is set forth in Notes 3 and 6 in the “Notes to Financial Statements”.

 

Income taxes

 

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company has been consistently in a loss position in the U.S. and at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to the Company.

 

We account for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

We implemented a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.

 

We recognize interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

 

Recently issued accounting standards

 

For a summary of recent accounting pronouncements applicable to our consolidated financial statements see Note 3, “Summary of Significant Accounting Policies” to the Consolidated Financial Statements included in Part IV, Item 15 of this Annual Report on Form 10-K.

 

62

 

 

Results of Operations

 

Year Ended December 31, 2022 Compared to Year Ended December 31, 2021

 

Revenues. For the years ended December 31, 2022 and 2021, our revenues were approximately $752,000 and $1,695,000, respectively, a decrease of approximately 56%, or $943,000, between the periods. The decrease was attributable to absence of sales from our Ultra Pain Products distributor in the third and fourth quarter of 2022 due to suspension of PainShield Plus by the FDA. Our revenues may fluctuate as we add new customers or when existing distributors make large purchases of our products during one period and no purchases during another period. Our revenues by quarter may not be linear or consistent. We do not anticipate that our revenues will be impacted by inflation or changing prices in the foreseeable future.

 

For the years ended December 31, 2022, the percentage of revenues attributable to our products was: PainShield – 96% and UroShield – 4%. For the year ended December 31, 2021, the percentage of revenues attributable to our products was: PainShield – 99% and UroShield – 1%. For the years ended December 31, 2022 and 2021, the portion of our revenues that was derived from distributors was 89% and 93%, respectively.

 

Gross Profit. For the years ended December 31, 2022 and 2021, gross profit was approximately $167,000 and $770,000, respectively. The decrease was mainly due to the large decrease in revenues as we suspended sales of our most popular product, Painshield Plus, until we received marketing clearance from the FDA, which was not received until very late in the fourth quarter in 2022, and to a lesser degree due to (i) incurring additional labor and material costs due to in the third and fourth quarter of 2022 which usually produced higher margins in the prior years, production delays caused by the suspension of Painshield Plus by the FDA and minor changes we made to the product and its packaging to regain compliance, (ii) increases in certain components of our devices due to inflation, (iii) increased importing and delivery costs because of inflation and transportation supply chain issues and (iv) to a lesser degree obsolescence costs pertaining to certain components that were changed to regain compliance with the FDA as well as the retirement of inventory repurchased from a former customer pursuant to an agreement to cancel a contract that had certain exclusive international distribution rights.

 

Gross profit as a percentage of revenues were approximately 22% and 45% for the years ended December 31, 2022 and 2021, respectively. The decrease in gross profit as a percentage is mainly due to the reasons described above.

 

Research and Development Expenses. For the years ended December 31, 2022 and 2021, research and development expenses were approximately $283,000 and $293,000, respectively, a decrease of approximately 3%, or $10,000 between the periods. This decrease was mainly due to studies performed in the prior year and development of an over-the-counter PainShield product and a CBD application for our PainShield product in 2021 that did not occur in 2022.

 

Research and development expenses as a percentage of total revenues were approximately 38% and 17% for the years ended December 31, 2022 and 2021, respectively.

 

Our research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, expenses related to subcontracting, patents, clinical trial and facilities expenses associated with and allocated to research and development activities.

 

Selling and Marketing Expenses. For the years ended December 31, 2022 and 2021, selling and marketing expenses were approximately $965,000 and $1,101,000, respectively, a decrease of approximately 12%, or $136,000 between the periods. The decrease in selling and marketing expenses was mainly due to 50% re-allocation of a sales executive’s payroll to administrative costs amounting to $120,000 as his roles and responsibilities changed in 2022.

 

Selling and marketing expenses as a percentage of total revenues were approximately 128% and 65% for the years ended December 31, 2022 and 2021, respectively. The increase in our percentage was due to the decrease in revenues.

 

Selling and marketing expenses consist mainly of payroll expenses to direct sales and marketing employees, stock-based compensation expenses, travel expenses, conventions, advertising and marketing expenses, rent and facilities expenses associated with and allocated to selling and marketing activities.

 

General and Administrative Expenses. For the years ended December 31, 2022 and 2021, general and administrative expenses were approximately $3,931,000 and $5,059,000, respectively, a decrease of approximately 22%, or $1,128,000 between the periods. The decrease was mainly due to the recognition of a $1,500,000 arbitration settlement expense in 2021 from final award of arbitration issued in favor of the Company’s former distributor to cover for “lost profits” and reimbursement of arbitration costs.

 

63

 

 

Interest expense. For the years ended December 31, 2022 and 2021, were $347,000 and $0, respectively. This pertain to the interest on the Company’s judgment liability in the current year.

 

Change in fair value of derivative liabilities. For the years ended December 31, 2022 and 2021, there was a change in fair value of derivative liabilities resulting in a loss of approximately $0 and $6,956,000, respectively. The loss in 2021 was derived from the Company’s total potentially dilutive shares exceed the Company’s authorized share limit.

 

Gain on purchase of warrants. For the years ended December 31, 2022 and 2021, there was a gain of approximately $0 and $64,000, respectively. The gain in 2021 was related to the settlement of derivative liabilities which was the result of the repurchase of warrants from certain investors.

 

Warrant modification expense. For the years ended December 31, 2022 and 2021, warrant modification expense was approximately $0 and $1,627,000, respectively. The warrant modification expense was due to the resolution of the over-issuance shares matter. The over-issuance shares matter resulted in a reclassification of derivative liabilities to equity during 2021. There was no warrant modification in 2022.

 

Income tax expense. For the years ended December 31, 2022 and 2021, our income tax expense was approximately $35,000 and $32,000, respectively. The low tax expense for 2021 was a result of favorable adjustments due to lapses of statutes of limitations on its Israel tax positions. In 2022, there was no such adjustment.

 

Net Loss. Our net loss decreased by approximately $8,834,000 or 62%, to approximately $5,448,000 for the years ended December 31, 2022 from approximately $14,282,000 during the same period in 2021. The decrease in net loss resulted primarily from the factors described above.

 

Liquidity and Capital Resources

 

We have incurred losses in the amount of approximately $5,448,000 during the year ended December 31, 2022, which primarily consisted of decreased revenues and increase in interest expense from judgement liability. We also had negative cash flow from operating activities of $7,035,000 for the year ended December 31, 2022. Although we received proceeds from sale of common stock amounting to $2,090,000 and had a cash balance of just over $2,713,000 as of December 31, 2022, we expect to continue to incur losses and negative cash flows from operating activities, and therefore, we do not have sufficient resources to fund our operation for the next twelve months from the date of this filing causing us to have substantial doubt of the Company’s ability to continue as a going concern The Company will need to continue to raise additional capital to finance its losses and negative cash flows from operations beyond the next years and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability. If we are unable to obtain stockholder ratification of certain prior issuances of our common stock and approval of an increase in the number of authorized shares of our common stock, we will be unable to issue common stock or convertible instruments. As a result, the Company will be limited in its ability to raise additional capital.

 

During the year ended December 31, 2022, we met our short-term liquidity requirements from our existing cash reserves and proceeds from sale of common stock. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products, our development of future products and competing technological and market developments as well as our ability to overcome obstacles that may be presented due to developments caused by the coronavirus outbreak. We expect to continue to incur losses and negative flows from operations. We intend to use the proceeds generated from equity financings, or strategic alliances with third parties, either alone or in combination with equity financing to meet our short-term liquidity requirements as well as to advance our long-term plans. There are no assurances that we are able to raise additional capital, as required, on terms favorable to us.

 

We do not have any material commitments to capital expenditures as of December 31, 2022, and we are not aware of any material trends in capital resources that would impact our business.

 

64

 

 

As of December 31, 2022, we have no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Years Ended December 31, 2022 Compared to Years Ended December 31, 2021

 

General. As of December 31, 2022, we had cash of approximately $2,713,000, compared to approximately $7,737,000 as of December 31, 2021. We have historically met our cash needs through a combination of issuance of equity, borrowing activities and sales. Our cash requirements are generally for product development, research and development cost, marketing and sales activities, general and administrative cost, capital expenditures and general working capital.

 

Cash used in our operating activities was approximately $7,035,000 for the years ended December 31, 2022 and approximately $4,367,000 for the same period in 2021. The increase in our net cash used in operating activities in the amount of $2,668,000 is mainly attributable to the increase in changes in working capital accounts, partially offset by decrease in noncash expense of arbitration settlement expense and warrant modification expense.

 

Cash used in our investing activities was approximately $3,000 for both years ended December 31, 2022 and 2021 from purchases of fixed assets.

 

Cash provided by financing activities during the year ended December 31, 2022 was approximately $2,092,000, which was composed of the net proceeds received from the sale of common stock and exercise of employee stock options in 2022 compared to $4,580,000 in 2021, which was the net proceeds received from the exercise of warrants completed in 2021. Our future capital requirements and the adequacy of available funds will depend on many factors, including our ability to successfully commercialize our products, our development of future products and competing technological and market developments.

 

Factors That May Affect Future Operations

 

We believe that our future operating results will continue to be subject to quarterly variations based upon a wide variety of factors, including the ordering patterns of our distributors, timing of regulatory approvals, the implementation of various phases of our clinical trials and manufacturing efficiencies due to the learning curve of utilizing new materials and equipment as well issues that may continue to occur due to the development of the coronavirus outbreak. While there were significant delays in the production of goods due to COVID-19 issues, presently, we are no longer experiencing such delays in the production of our products. That said, there are no assurances that if a second wave of the pandemic occurs that we will not experience significant delays in the future. Our operating results could also be impacted by a weakening of the Euro and strengthening of the New Israeli Shekel, or NIS, both against the U.S. dollar. Lastly, other economic conditions we cannot foresee may affect customer demand, such as individual country reimbursement policies pertaining to our products.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Our Consolidated Financial Statements and the relevant notes to those statements are attached to this report beginning on page F-1.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

65

 

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures.

 

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act) that are designed to ensure that information required to be disclosed in the Company’s Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to the Company’s management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

Evaluation of Disclosure Controls and Procedures

 

Under the PCAOB standards, a control deficiency exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit the attention by those responsible for oversight of the company’s financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act). Our management including the Chief Executive Officer and Chief Financial Officer has determined that, as of December 31, 2022, the Company’s disclosure controls and procedures are not effective due to the material weaknesses described below. In light of this fact, our management has performed additional analyses, reconciliations, and other post-closing procedures and has concluded that, notwithstanding the material weaknesses in our internal control over financial reporting, the consolidated financial statements for the periods covered by and included in this Annual Report fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with GAAP.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Internal control over financial reporting includes policies and procedures that:

 

  1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
     
  2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and
     
  3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

66

 

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate.

 

With the participation of the Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, known as COSO, in Internal Control — Integrated Framework (2013). Based on this evaluation, our management, including the Chief Executive Officer and Chief Financial Officer, has concluded that our internal control over financial reporting was not effective as of December 31, 2022, as the result of the material weaknesses described below.

 

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. In previously filed Annual Reports on Form 10-K’s, we disclosed material weaknesses related to the design and effectiveness of our internal control over financial reporting.

 

●We did not have adequate controls in place to ensure adequate review, including (1) effective controls over our information technology and information systems relevant to the preparation of our financial statements, (2) the controls over managements review procedures for processing, recording and reviewing transactions related to certain contracts, accounting memos and certain monthly closing procedures, (3) proper accounting of the number of shares of our common stock issued in connection with the conversion of shares of our preferred stock and the exercise of warrants, which resulted in the Company issuing more shares of common stock than are authorized under our governance documents, and (4) lacking a formalized written set of policies and procedures including testing documentation to provide evidence that our system of internal controls over financial reporting meets the requirements of the COSO 2013 framework.

 

●Additionally, we did not maintain effective controls over the operating effectiveness of information technology (“IT”) general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not establish or formalize appropriate IT policies, segregation of duties and monitoring procedures and without monitoring procedures over third-party service providers, did not evaluate whether the providers were appropriately managing its and the Company’s IT infrastructure, operations, and critical financial systems.

 

●As of December 31, 2022, we did not have adequate controls in place to ensure adequate review, including (1) effective controls over our IT and information systems relevant to the issuance of securities, (2) the controls over managements review procedures for processing, recording and reviewing such issuances of securities, and (3) we implemented a new inventory system in the fourth quarter of 2021 which lacked adequate inventory control procedures, (4) we lacked a formalized written set of policies and procedures including testing documentation to provide evidence that our system of internal controls over our issuance of securities meets the requirements of the COSO 2013 framework, and (5) we did not maintain effective controls over the operating effectiveness of IT general controls for information systems that are relevant to the preparation of their financial statements.

 

As a smaller reporting company, the Company is not required to include in this Annual Report on Form 10-K a report on the effectiveness of internal control over financial reporting by the Company’s independent registered public accounting firm.

 

Management’s Remediation Plans

 

To date, we have implemented certain measures to address the identified material weaknesses. These measures include adding personnel as well as improving our internal controls around financial systems and processes. We intend to continue to take steps to remediate the material weaknesses described above and further evolve our internal controls and processes. We will not be able to remediate these material weaknesses until these steps have been completed and have been operating effectively for a sufficient period of time. The following remedial actions were taken through the year ended December 31, 2021:

 

●We have been able to remediate the material weakness identified above with respect to the issuance of shares in excess of the number of authorized shares in 2021 and implemented a plan in place to have adequate controls in place to avoid future issuances in excess of authorized shares. The Company took steps to remediate the stock issuance material weakness through creating procedures over the approval of any new equity issuances to ensure that there are no further over-issuances which includes the creation of an equity roll forward master sheet that must be approved and signed off by senior management before the issuance of any new equity issuances, including warrants, stock options and issuances of any shares of stock.

 

67

 

 

The following remedial actions were taken during the year ended December 31, 2022:

 

●With assistance from a current finance and accounting third-party service provider, the Company is formalizing our risk assessment process, policies and procedures, implementing revised control activities, controls documentation, and ongoing monitoring activities related to the internal controls over financial reporting including testing documentation to provide evidence that our system of internal controls over financial reporting meets the requirements of the COSO 2013 framework, and provide a foundation for the Company to communicate internal control deficiencies in a timely manner to those parties responsible for taking corrective action.
●expanded consultations with third party specialists on complex accounting matters, financial reporting and regulatory filings,
●enhanced documentation to support a more precise review process,
●enhanced monitoring of the review process, and
●review of inventory recording system.

 

During the period covered by this Annual Report on Form 10-K, with exception for the issuance of excess shares, we have not been able to remediate the material weaknesses identified above. Although the Company has taken numerous steps, our remediation plan is not complete due to the lack of a written testing plan to conclude if our controls and procedures and management were operating effectively; and our remediation plan has not operated for a sufficient period of time for the Company to complete testing to conclude that our newly implemented controls and procedures were operating effectively as of December 31, 2022. We will look to develop a full testing plan and document to determine that management designs, implements and maintains adequate controls over our financial processes and reporting in the future our controls and procedures and management are operating effectively. To address these internal control deficiencies, management will continue to perform additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

 

In addition, under the direction of the audit committee of the Board of Directors, management will continue to review and make necessary changes to the overall design of the Company’s internal control environment, as well as to refine policies and procedures to improve the overall effectiveness of internal control over financial reporting of the Company.

 

Changes in Internal Control over Financial Reporting.

 

Other than described above in this Item 9A, there have been no changes in our internal control over financial reporting during the year ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required in response to this Item 10 will be set forth in our definitive proxy statement on Schedule 14A for the 2023 annual meeting of stockholders, which shall be filed with the Securities and Exchange Commission no later than May 1, 2023 (the “Proxy Statement”).

 

We have adopted a code of ethics that applies to all of our directors, officers and employees, including the principal executive officer and the principal financial officer. The full text of our code of ethics was filed as Exhibit 14.1 to the annual report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 31, 2017.

 

68

 

 

ITEM 11. EXECUTIVE COMPENSATION

 

The information required in response to this Item 11 will be set forth in our Proxy Statement and is incorporated herein by reference.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The information required in response to this Item 12 will be set forth in our Proxy Statement and is incorporated herein by reference.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

The information required in response to this Item 13 will be set forth in our Proxy Statement and is incorporated herein by reference.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

The information required in response to this Item 14 will be set forth in our Proxy Statement and is incorporated herein by reference.

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

The following documents are filed as part of this report:

 

  (1) Financial Statements:

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) F-1
Consolidated Balance Sheets as of December 31, 2022 and 2021 F-2
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022 and 2021 F-3
Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2022 and 2021 F-4
Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021 F-5
Notes to Consolidated Financial Statements F-6

 

  (2) Financial Statement Schedules:

 

None

 

  (3) Exhibits:

 

See “Index to Exhibits” for a description of our exhibits.

 

ITEM 16. FORM 10-K SUMMARY

 

None.

 

69

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

NanoVibronix, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of NanoVibronix, Inc. and Subsidiaries (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Explanatory Paragraph – Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

 

/s/ Marcum llp  
   
Marcum LLP  
   
We have served as the Company’s auditor since 2018.  
   
New York, NY  
April 17, 2023  

 

F-1

 

 

NanoVibronix, Inc.

Consolidated Balance Sheets

(Amounts in thousands except share and per share data)

 

   December 31, 2022   December 31, 2021 
ASSETS:          
Current assets:          
Cash  $2,713   $7,737 
Trade receivables   9    200 
Prepaid expenses and other accounts receivable   712    230 
Inventory   2,175    175 
Total current assets   5,609    8,342 
           
Noncurrent assets:          
Fixed assets, net   7    5 
Other assets   3    19 
Severance pay fund   179    207 
Operating lease right-of-use assets, net   81    49 
Total non-current assets   270    280 
Total assets  $5,879   $8,622 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY:          
           
Current liabilities:          
Trade payables  $66   $87 
Other accounts payable and accrued expenses   2,148    1,723 
Deferred revenue   21    44 
Operating lease liabilities, current   81    49 
Total current liabilities   2,316    1,903 
           
Non-current liabilities:          
Accrued severance pay   223    253 
Deferred licensing income   107    153 
Total liabilities   2,646    2,309 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity:          
Series C Preferred stock of $0.001 par value - Authorized: 3,000,000 shares at both December 31, 2022 and 2021; Issued and outstanding: 0 shares at both December 31, 2022 and 2021, respectively   -    - 
           
Series D Preferred stock of $0.001 par value - Authorized: 506 shares at both December 31, 2022 and 2021; Issued and outstanding: 0 shares at both December 31, 2022 and 2021, respectively   -    - 
           
Series E Preferred stock of $0.001 par value - Authorized: 1,999,494 shares at both December 31, 2022 and 2021, respectively; Issued and outstanding: 0 shares at both December 31, 2022 and 2021, respectively   -    - 
           
Series F Preferred stock of $0.01 par value - Authorized: 40,000 and 0 shares at December 31, 2022 and 2021, respectively; Issued and outstanding: 0 shares at both December 31, 2022 and 2021, respectively   -    - 
Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 1,641,146 and 1,399,890 shares at December 31, 2022 and December 31, 2021, respectively   2    1 
           
Additional paid in capital   65,634    63,189 
Accumulated other comprehensive income   (18)   60 
Accumulated deficit   (62,385)   (56,937)
Total stockholders’ equity   3,233    6,313 
Total liabilities and stockholders’ equity  $5,879   $8,622 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-2

 

 

NanoVibronix, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands except share and per share data)

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
         
Revenues  $752   $1,695 
Cost of revenues   585    925 
Gross profit   167    770 
           
Operating expenses:          
Research and development   283    293 
Selling and marketing   965    1,101 
General and administrative   3,931    5,059 
           
Total operating expenses   5,179    6,453 
           
Loss from operations   (5,012)   (5,683)
           
Interest expense   (347)   - 
Financial expense, net   (54)   (48)
Change in fair value of derivative liabilities   -    (6,956)
Gain on purchase of warrants   -    64 
Warrant modification expense   -    (1,627)
           
Loss before taxes   (5,413)   (14,250)
           
Income tax expense   (35)   (32)
           
Net loss  $(5,448)  $(14,282)
           
Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock  $(3.84)  $(11.35)
           
Weighted average common shares outstanding:          
Basic and diluted   1,419,670    1,258,141 
           
Comprehensive loss:          
Net loss available to common stockholders   (5,448)   (14,282)
Change in foreign currency translation adjustments   (78)   (6)
Comprehensive loss available to common stockholders   (5,526)   (14,288)

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-3

 

 

NanoVibronix, Inc.

Consolidated Statement of Stockholders’ Equity

 

   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Income   Deficit   Equity 
   Series C Preferred Stock     Series D Preferred Stock   Series E Preferred Stock     Series F Preferred Stock   Common Stock   Additional Paid - in   Accumulated Other Comprehensive   Accumulated   Total Stockholders’  
   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Income   Deficit   Equity 
Balance, December 31, 2020   666,667   $     1    153   $     -    875,000   $1        -   $     -    1,062,326   $     1   $44,980   $66   $(42,655)  $          2,394 
Stock-based compensation   -    -    -    -    -    -    -    -    -    -    190    -    -    190 
Exercise of warrants   -    -    -    -    -    -    -    -    252,830    -    7,056    -    -    7,056 
Reclass of derivative liabilities to APIC   -    -    -    -    -    -    -    -    -    -    10,963    -    -    10,963 
Conversion of Series C Preferred Stock into Common Stock   (666,667)   (1)   -    -    -    -    -    -    33,333    -    -    -    -    (1)
Conversion of Series D Preferred Stock into Common Stock   -    -    (153)   -    -    -    -    -    7,650    -    -    -    -    - 
Conversion of Series E Preferred Stock into Common Stock   -    -    -    -    (875,000)   (1)   -    -    43,750    -    -    -    -    (1)
Currency translation adjustment   -    -    -    -    -    -    -    -    -    -    -     (6)   -    (6)
Net loss   -    -    -    -    -    -    -    -    -    -    -     -    (14,282)   (14,282)
Balance, December 31, 2021   -   $-    -   $-    -   $-    -   $-    1,399,890   $1   $63,189   $60   $(56,937)  $6,313 
Stock-based compensation   -    -    -    -    -    -    -    -    -    -    354    -    -    354 
Issuance of common stock, net of offering costs of $310,424   -    -    -    -    -    -    -    -    240,000    1    2,089    -    -    2,090 
Issuance of redeemable Series F preferred stock   -    -    -    -    -    -    27,998    -    -    -    -    -    -    - 
Redemption of redeemable Series F preferred stock   -    -    -    -    -    -    (27,998)   -    -    -    -    -    -    - 
Exercise of options   -    -    -    -    -    -    -    -    1,256    -    2    -    -    2 
Other comprehensive loss   -    -    -    -    -    -    -    -    -    -    -    (78)   -    (78)
Net loss   -    -    -    -    -    -    -    -    -    -    -    -    (5,448)   (5,448)
Balance, December 31, 2022   -   $-    -   $-    -   $-    -   $-    1,641,146   $2   $65,634   $(18)  $(62,385)  $3,233 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-4

 

 

NanoVibronix, Inc.

Consolidated Statements of Cash Flows

(Amounts in thousands except share and per share data)

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Cash flows from operating activities:          
Net loss  $(5,448)  $(14,282)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   1    2 
Stock-based compensation   354    382 
Noncash interest expense   347    - 
Arbitration settlement expense   -    1,500 
Warrant modification expense   -    1,627 
Change in fair value of equity investment   16    6 
Change in fair value of derivative liabilities   -    6,956 
Gain on purchase of warrants   -    (64)
Changes in operating assets and liabilities:          
Trade receivable   191    (175)
Other accounts receivable and prepaid expenses   (482)   37 
Inventory   (2,000)   (30)
Trade payables   (21)   (59)
Other accounts payable and accrued expenses   78    (265)
Deferred revenue   (69)   (2)
Accrued severance pay, net   (2)   - 
Net cash used in operating activities   (7,035)   (4,367)
           
Cash flows from investing activities:          
Purchases of fixed assets   (3)   (3)
Net cash used in investing activities   (3)   (3)
           
Cash flows from financing activities:          
Proceeds from sale of common stock, net   2,090    - 
Proceeds from exercise of options   2    - 
Proceeds from exercise of warrants   -    4,968 
Buy back of warrants from investor   -    (388)
Net cash provided by financing activities   2,092    4,580 
           
Effects of currency translation on cash   (78)   (6)
           
Net (decrease) increase in cash   (5,024)   204 
Cash at beginning of period   7,737    7,533 
           
Cash at end of period  $2,713   $7,737 
Supplemental disclosures of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for taxes  $-   $- 
           
Supplemental non-cash financing and investing activities:          
Exchange of common stock into preferred stock  $-   $1 
Shares issued from exercise of warrants previously classified as derivative liability  $-   $2,087 
Reclass derivative liability to equity due to increase in authorized shares  $-   $8,706 
Reclass liability to equity after increase in authorized shares  $-   $2,257 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-5

 

 

NANOVIBRONIX, INC.

Notes to Consolidated Financial Statements

(Amounts in thousands except share and per share data)

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.

 

The Company’s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix Ltd., a company registered in Israel, which commenced operations in October 2003.

 

NOTE 2 - LIQUIDITY AND PLAN OF OPERATIONS

 

The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. In 2022, the Company’s cash used in operations was $7,035 and received net proceeds of $2,090 (net of offering costs of $310,424) from the sale of our equity securities, leaving a cash balance of $2,713 as of December 31, 2022. Because the Company does not have sufficient resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company’s ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation and principles of consolidation

 

The accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”).

 

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Foreign currency translation

 

Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2022 and 2021 were $85 and $6, respectively.

 

Earnings per share

 

Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred stock as of December 31, 2022 and 2021, respectively, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been antidilutive.

 

F-6

 

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.

 

Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was no allowance on inventory.

 

Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:

 

   Years 
     
Computers and peripheral equipment  3 
Office furniture and equipment  5-7 

 

Impairment of Long-Lived Assets

 

Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.

 

Sequencing

 

The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

 

Severance pay

 

The Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet. Accrued severance pay liability at December 31, 2022 and 2021 was $223 and $253, respectively.

 

Leases

 

The Company accounts for its leases in accordance with ASU 2016-02, “Leases” (Topic 842). This topic requires that a lessee recognize the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classify them as operating leases. For leases with a term of 12 months or less, the Company elects to implement in a class of underlying asset not to recognize lease assets and lease liabilities. The right-of-use assets and lease liabilities have been measured by the present value of the Company’s remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.

 

Revenue recognition

 

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

 

F-7

 

 

Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.

 

Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

 

Income taxes

 

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.

 

The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

 

Stock-based compensation

 

The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical share price movements. The expected option term represents the period that the Company’s stock options are expected to be outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.

 

Recently adopted accounting standards

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect on the Company’s consolidated financial statements.

 

F-8

 

 

NOTE 4 - PREPAID EXPENSES AND OTHER RECEIVABLES

 

Prepaid expenses and other receivables consist of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Prepaid expenses  $612   $166 
Other receivables   100    64 
           
Prepaid expenses and other receivables  $712   $230 

 

NOTE 5 – INVENTORY

 

Inventory consists of the following components:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Raw materials  $30   $- 
Finished goods   2,145    175 
           
Inventory  $2,175   $175 

 

NOTE 6 - STOCKHOLDERS’ EQUITY

 

Common Stock

 

The common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the event of liquidation, dissolution or winding up of the Company.

 

On August 17, 2021, the Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of the Company’s Common Stock authorized for issuance from 24,109,635 shares to 40,000,000 shares. As a result of the vote to increase the number of shares authorized for issuance, the warrants that were previously accounted for as derivative liabilities were marked to market through the date of approval and then reclassified to additional paid in capital (equity), as the Company had sufficient authorized shares to settle the exercise of the warrants.

 

Issuance of common stock for cash

 

On November 29, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell in a registered direct offering (the “Offering”), 240,000 shares of the Company’s common stock at an offering price of $10.00 per share. The Company received net proceeds from the sale of such offering, after deducting placement agent fees and expenses and offering expenses payable by the Company, of approximately $2.1 million. The Company intends to use the net proceeds for general working capital purposes.

 

On October 6, 2022, the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (the “Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the Company, on a reasonable best-efforts basis, in connection with the Offering. The Company will pay Wainwright an aggregate cash fee equal to 7.5% of the gross proceeds of the Offering, a management fee equal to 1.0% of the gross proceeds of the Offering, a non-accountable expense allowance of $50,000 and $15,950 for clearing fees. Additionally, the Company has agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to 18,000 shares of common stock. The warrants expire on November 29, 2027 and have an exercise price of $12.50 per share.

 

F-9

 

 

Series C, D and E Preferred Stock conversion to common stock

 

Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one twentieth of a share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 875,000 shares of Series E Preferred Stock into 0 and 43,750 shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made to convert these shares.

 

Each share of Series D Preferred Stock is convertible into fifty shares of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 153 shares of Series D Preferred Stock into 0 and 7,650 shares of common stock, respectively, at a conversion rate of 1 to 50. No purchase was made in order to convert these shares.

 

Each share of Series C Preferred Stock is convertible into one twentieth of a share of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 666,667 shares of Series C Preferred Stock into 0 and 33,333 shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made in order to convert these shares.

 

Series F Preferred Stock

 

On September 13, 2022, the Board declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $0.001 per share (“Series F Preferred Stock”), for each one share of the Company’s common stock, par value $0.001 per share, to stockholders of record at 5:00 p.m. Eastern Time on October 14, 2022.

 

Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate of Incorporation to reclassify the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series F Preferred Stock is not entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

 

F-10

 

 

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Company’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). As of December 31, 2022, both the Initial Redemption and the Subsequent Redemption have occurred. As a result, no shares of Series F Preferred Stock remain outstanding.

 

Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.10 in cash for each one hundred whole shares of Series F Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the Certificate of Designation) thereof as of the applicable redemption time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder to the corporate secretary of the Company (each a “Redemption Payment Request”) following the applicable redemption time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company (ii) set forth in reasonable detail the number of shares of Series F Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by the Company with respect to the shares of Series F Preferred Stock that were redeemed at the applicable redemption time. However, the redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than one hundred whole shares of Series F Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of one hundred, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of one hundred (such, that for example, the former beneficial owner of 150 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 100 shares of Series F Preferred Stock redeemed pursuant to such redemption).

 

No shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of common stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred Stock equal to the number of shares of common stock to be transferred by such holder will be automatically transferred to the transferee of such shares of common stock. The holders of Series F Preferred Stock, as such, are not entitled to receive dividends of any kind.

 

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on September 14, 2022.

 

As described in the proxy statement filed on October 31, 2022, holders of The Company’s common stock and Series F Preferred Stock as of the close of business on October 17, 2022, are entitled to vote on the amendment to the Company’s Certificate of Incorporation to effect, at the discretion of the Company’s Board but prior to the six-month anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined by the Board in its discretion and included in a public announcement, and the proposal to adjourn the Annual Meeting to a later date at the Annual Meeting held on December 15, 2022.

 

F-11

 

 

Stock-based compensation and options

 

During the years ended December 31, 2022 and 2021, 1,256 and 0 employee options were exercised, and 21,875 and 43,875 options were granted, respectively. The options granted during 2022 and 2021 vest at different schedules ranging from date granted to 9 years and were recorded at fair values of $201 and $583, respectively. During the years ended December 31, 2022 and 2021, stock-based compensation expense of $148 and $258 was recorded for options that vested, respectively.

 

  

Shares Under

Options

  

Weighted

Average

Exercise Price

per Share

  

Weighted

Average

Remaining

Life (Years)

 
Outstanding – December 31, 2021   127,000   $31.86    7.77 
Granted   21,875    10.76    9.55 
Forfeited   -    -    - 
Expired   -    -    - 
Exercised   (1,256)   1.40    0.24 
Outstanding – December 31, 2022   147,619   $24.42    7.24 

 

The fair value for options granted in 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions:

 

   2022   2021 
Price at valuation  $0.45 – 0.78   $0.72 – 2.07 
Exercise price  $ 0.45 – 0.78   $0.72 – 2.07 
Risk free interest   2.32 – 3.58 %   0.27 – 1.29%
Expected term (in years)   5    5 
Volatility   125.3 – 127.9 %   60.9 – 82.7%

 

The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table.

 

   2022   2021 
   Year Ended 
   December 31, 
   2022   2021 
         
Research and development  $6   $13 
Selling and marketing   25    28 
General and administrative   323    341 
Total  $354   $382 

 

As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $328, which is expected to be recognized over a weighted average period of approximately 7.24 years.

 

Warrants

 

On December 2, 2020, we entered into a Securities Purchase Agreement with certain institutional and accredited investors pursuant to which the Company issued and sold to such investors in a private placement an aggregate of (i) 295,714 shares of the Company’s common stock at an offering price of $14.00 per share and (ii) pre-funded warrants to purchase up to 132,857 shares of common stock at a purchase price of $13.98 per pre-funded warrant, for gross proceeds of approximately $6.0 million, and net proceeds of approximately $5.4 million. In January 2021, two investors exercised an aggregate of 82,857 warrants at $0.02 per share.

 

On January 21, 2021, Company entered into letter agreements (the “Letter Agreements”) with certain existing accredited investors to exercise certain outstanding warrants (the “Existing Warrants”) to purchase up to an aggregate of 60,298 shares of the Company’s common stock at an exercise price per share of $23.30 (the “Exercise”). Certain of the Existing Warrants (the “Registered Existing Warrants”) and the shares of common stock underlying the Registered Existing Warrants have been registered pursuant to a registration statement on Form S-3 (File No. 333-251264) and a registration statement on Form S-1 (File No. 333-218871). In consideration for the exercise of the Existing Warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 60,298 shares of common stock (the “New Warrants”) at an exercise price of $20.80 per share and with an exercise period of seven years from the initial closing date. The gross proceeds to the Company from the Exercise were approximately $1.4 million.

 

F-12

 

 

The New Warrants were accounted for in warrant modification expense, which was measured at the amount equal to the incremental value reflecting the change in the fair value of the warrants before and after the Warrant Amendment. Accordingly, warrant modification expense in the amount of $1,627 was recorded with a corresponding increase in additional paid in capital.

 

In August and September 2021, investors exercised warrants to purchase 109,675 shares of common stock between $17.60 and $50.00 per share for proceeds of approximately $3.6 million.

 

On June 14, 2022, the Company issued warrants to two sales consultants to purchase 12,500 shares of common stock which will expire on June 14, 2029 and have an exercise price of $20.00 per share. Accordingly, expense related to these warrants in the amount of $135,000 was recorded with a corresponding increase in additional paid in capital.

 

On September 30, 2022, the Company and the two sales consultants mutually agreed to cancel the latter’s annual stock warrants to purchase 12,500 shares of common stock. Accordingly, expense related to these warrants were reversed in the amount of $135,000 with a corresponding decrease in additional paid in capital.

 

On November 29, 2022, the Company granted 18,000 warrants to purchase Company’s common stock in conjunction with the private placements.

 

In estimating the warrants’ fair value, the Company used the following assumptions:

 

   2022   2021 
Risk free interest   0.34%   1.44%
Dividend yield   0%   0%
Volatility   60.7%   55.6 - 56.5 % 
Contractual term (in years)   5    2 

 

 

   Warrants 
Outstanding – December 31, 2020   386,237 
Granted   60,298 
Exercised   (252,830)
Exercised - cashless   (14,071)
Expired   (31,000)
Canceled   (33,167)
Outstanding – December 31, 2021   115,467 
Granted   30,500 
Expired   (55,215)
Canceled   (12,500)
Outstanding – December 31, 2022   78,252 

 

NOTE 7 - DERIVATIVE LIABILITIES

 

During 2020, the Company established a sequencing policy to which common stock equivalents are exercisable to shares of common stock more than the Company’s authorized limit. It was determined that all options and warrants by the end of the year were no longer permitted to be classified as equity and were valued at fair market value using Black Scholes and recorded as derivative liabilities.

 

On April 6, 2021, the Company agreed to buy back 33,167 warrants from investors for a total of $368. The warrants had exercise prices between $17.6 and $18.8 per share. The value of the derivative liabilities associated with these warrants was $451. The Company recorded a $64 gain in connection with the buyback of the warrants.

 

F-13

 

 

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s purchase warrants that were categorized within Level 3 of the fair value hierarchy during the years ended December 31, 2022 and 2021 is as follows:

 

   2022    2021 
Stock price  $ 1.01 – 2.94   $1.01 – 2.94  
Conversion price  $ 0.72 – 6.90   $0.72 – 6.90   
Contractual term (in years)   0.67 – 6.56    0.67 – 6.56 
Volatility (annual)   82.70 – 211%    82.70 - 211%
Risk-free rate   0.09 – 1.21%    0.09 – 1.21%

 

The foregoing assumptions were reviewed quarterly and were subject to change based primarily on management’s assessment of the probability of the events described occurring.

 

NOTE 8 – LEASES

 

The Company has operating lease agreements with terms up to 2-3 years, including car and office space leases.

 

The Company’s weighted-average remaining lease term relating to its operating leases is 1.05 years, with a weighted-average discount rate of 10%.

 

The Company incurred $75 of lease expense for its operating leases for the year ended December 31, 2022.

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2022:

 

      
2023   73 
2024   4 
Total undiscounted operating lease payments   77 
Less: Imputed interest   4 
Present value of operating lease liabilities  $73 

 

NOTE 9 - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

 

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December 31, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented.

 

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

   December 31, 2022   December 31, 2021 
Stock options - employee and non-employee   147,619    127,000 
Warrants   78,252    115,467 
Total   225,871    242,467 

 

The diluted loss per share equals basic loss per share in the year ended December 31, 2022 and 2021 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.

 

F-14

 

 

NOTE 10 - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA

 

Summary information about geographic areas:

 

The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
United States  $710   $1,627 
Europe   25    18 
Australia   9    6 
India   3    - 
Israel   -    5 
Other   5    39 
Total  $752   $1,695 

 

The Company’s long-lived assets are all located in Israel.

 

NOTE 11 – OTHER ASSETS

 

On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:

  2022   2021 
Price at valuation  $0.02   $ 0.19 – 0.26   
Exercise price  $0.19   $0.19 
Risk free interest   3.96%   0.66 – 0.73 %
Expected term (in years)   8    10 
Volatility   155.6%   140.6 – 143.9%

 

The Company considers this to be Level 3 inputs and is valued at each reporting period. The fair value of these warrants for the years ended December 31, 2022 and 2021 was $3 and $19, respectively. There was a net $16 and $6 change in fair value during the year ended December 31, 2022 and 2021, respectively.

 

Financial Liabilities Measured at Fair Value on a Recurring Basis

 

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

 

● Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;
   
● Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and
   
● Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

There were no transfers between Level 3 during the years ended December 31, 2022 and 2021.

 

F-15

 

 

The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2022 and 2021:

 

   As of December 31, 2022 
   Asset   Liability 
Balance – December 31, 2020  $25   $2,471 
New Issuances   -    1,819 
Fair value adjustments – Sanuwave warrants   (6)   - 
Fair value adjustments – Warrant liability   -    6,956 
Reclassification liability to equity   -    (10,793)
Buy back of warrants   -    (453)
Balance – December 31, 2021  $19   $- 
New Issuances   -    - 
Fair value adjustments – Sanuwave warrants   (16)   - 
Balance – December 31, 2022  $3   $- 

 

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2022 
   Level I   Level II   Level III   Total 
Asset:                
Other assets  $     -   $     -   $    3   $3 

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2021 
   Level I   Level II   Level III   Total 
Asset:                    
Other assets  $     -   $     -   $19   $19 

 

NOTE 12 - COMMITMENTS AND CONTINGENCIES

 

Pending and settled litigation

 

On December 17, 2019, a lawsuit was filed by a former officer and director, Jona Zumeris, in the Haifa Israel District Financial Court, seeking damages of approximately $900 for breach of the Separation Agreement executed on July 4, 2018. The Israeli court issued a court order demanding that we restrict approximately $700 of the Company’s money until the matter is adjudicated. The Company appealed the court order and in February 2020, the Company agreed to restrict approximately 1,187 NIS (“New Israeli Shekel”) and agreed to try to settle the matter in mediation. On November 30, 2020, the Company funded the escrow account with $391. In January 2021, the parties reached a settlement in which the Company paid the plaintiff approximately $366 as settlement in full.

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims asserted by Protrade.

 

On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $1.5 million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.

 

On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.

 

On July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.

 

F-16

 

 

On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion.

 

On November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newel information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. On March 21, 2023, the Court denied the motion to re-argue and renew. The Company intends to file a notice of appeal with the Appellate Division, Second Department and to continue to vigorously pursue its opposition to the award in all appropriate fora.

 

Other Risks

 

On March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares.

 

NOTE 13 – RELATED PARTY TRANSACTION

 

The firm of FisherBroyles LLP is handling our Protrade litigation and appeals. For the year ended December 31, 2022, we have been billed and paid legal fees from Fisher Broyles amounting to $256,908 and recorded as part of “General and administrative expenses” in the condensed consolidated statements of operations. As has been previously disclosed, one of our board members, Aurora Cassirer, is a partner at Fisher Broyles. Ms. Cassirer does not provide any legal services or legal advice to the Company.

 

NOTE 14 – INCOME TAXES

 

As of December 31, 2022, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $33,000 and $6,000, respectively. $19,200 of the federal net operating loss can be carried forward indefinitely but can only offset up to 80% of taxable income in a given year, and $14,000 of the federal net operating loss can be used to fully offset taxable income in the period it is utilized but can only be carried forward for 20 years. Utilization of the U.S. net operating losses may be subject to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the fact that the respective DTAs are fully offset by a valuation allowance.

 

Income tax expense is comprised of the following:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
Current Tax          
Federal  $-   $- 
State   -    - 
Foreign   37    32 
Total  $37   $32 
           
Deferred Tax          
Federal  $(1,545)  $(1,263)
State   653   (131)
Foreign  $(1)   (4)
Total  $(893)  $(1,398)
Less: Valuation Allowance   893    1,398 
Total Tax  $37   $32 

 

F-17

 

 

The difference between the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation of the statutory U.S Federal rate to the Company’s effective tax rate is as follows:

   2022   2021 
   Year ended December 31, 
   2022   2021 
Federal income tax benefit at statutory rate   21.00%   21.00%
State income taxes, net of federal benefit   -12.06%   0.92%
Foreign rate differential   -0.03%   0.02%
Permanent Items   -0.61%   -13.04%
Change in valuation allowance   -16.61%   -9.81%
Return to provision adjustments   7.54%   -0.01%
Forfeited options   0.00%   -0.16%
Other   0.09%   0.86%
Effective tax rate   -0.68%   -0.22%

 

Foreign tax

 

Tax rates applicable to the income of the Israeli subsidiary:

 

The Israeli corporate tax rate in 2022 and 2021 is 23%.

 

The subsidiary has final tax assessments through 2016.

 

Loss before taxes:

   2022   2021 
   Year ended December 31, 
   2022   2021 
         
Domestic  $5,557   $14,333 
Foreign   (144)   (82)
Loss before taxes  $5,413   $14,250 

 

Deferred income taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carry forward  $7,306   $6,563 
Arbitration accrual   414    414 
Stock compensation and other   483    327 
Deferred tax assets before valuation allowance   8,203    7,304 
Valuation allowance   (8,203)   (7,304)
Net deferred tax asset  $-   $- 

 

For the year ended December 31, 2022 and 2021, the net increases in valuation allowance of $894 and $1,417, respectively was primarily driven by the increase in net operating loss carryforwards.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

 

F-18

 

 

The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance at December 31, 2022 and 2021.

 

The Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be indefinitely invested outside the United States.

 

Reconciliation of the theoretical tax expense to the actual tax expense

 

The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and its subsidiary due to the uncertainty of the realization of such tax benefits.

 

The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2022 and 2021, the Company does not have any liabilities recorded for uncertain tax positions and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company did not recognize any interest or penalties during fiscal 2022 or 2021 related to unrecognized tax benefits.

 

U.S. federal and New York State income taxes are open for examination for years 2019-2022 and Israel tax returns are open for examination for years 2018-2022.

 

NOTE 15 - SUBSEQUENT EVENTS

 

On February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The Company’s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023.

 

At an annual meeting of stockholders held on December 15, 2022, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50, with such ratio to be determined by the Company’s Board of Directors.

 

At the effective time of the reverse stock split, every 20 shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account had their shares automatically adjusted to reflect the 1-for-20 reverse stock split. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof.

 

Accordingly, on February 28, 2023, the Company received official notice from Nasdaq that the Company evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement. As previously disclosed, the Company was granted an extension by the Nasdaq Hearings Panel through February 23, 2023 to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).

 

F-19

 

 

Index to Exhibits

 

Exhibit No.   Description
     
3.1   Amended and Restated Certificate of Incorporation (as presently in effect) (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2015)
     
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014)
     
3.3   Certificate of Amendment of Certificate of Incorporation (creating the Series C Preferred Stock) (incorporated by reference to Exhibit 3.3 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014)
     
3.4   Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 7, 2017)
     
3.5   Certificate of Designation, Preferences, Rights and Limitations of Series E Preferred Stock (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2019)
     

3.6

 

   Certificate of Amendment of the Amended and Restated Certificate of Designation (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 21, 2019)
     
3.7   Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021)
     

3.8

 

  

Amendment to the Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on November 3, 2021)

     
3.9   Certificate of Designation, Preferences, Rights and Limitations of Series F Preferred Stock (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022)
     
3.10   Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report filed with the Securities and Exchange Commission on February 8, 2023)
     
4.1   Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
4.2   Form of Warrant Agency Agreement (incorporated by reference to Exhibit 4.4 to Amendment No. 4 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on October 31, 2017)
     
4.3   Form of Unit Purchase Option (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on October 18, 2017)
     
4.4   Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on October 18, 2017)

 

70
 

 

4.5   Form of May 10 and May 15, 2019 Warrants (incorporated by reference to Exhibit 4.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019)
     
4.6   Form of Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2019)
     
4.7   Form of Preferred Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019)
     
4.8   Form of Common Warrant (incorporated by reference to Exhibit 4.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019)
     
4.9   Form of Warrant Amendment (incorporated by reference to Exhibit 4.10 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on May 20, 2020)
     
4.10   Form of Underwriter Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 26, 2020).
     
4.11   Form of Underwriter Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2020).
     
4.12   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).
     

4.13

 

  

Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).

     
4.14   Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 1, 2020).
     
4.15*   Description of Securities
     
10.1   Fourteenth Amended and Restated Securities Purchase Agreement, dated June 16, 2014, by and between NanoVibronix, Inc. and Globis Overseas Fund, Ltd. (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015)
     
10.2   Fourteenth Amended and Restated Securities Purchase Agreement, dated December 11, 2014, by and between NanoVibronix, Inc. and Globis Capital Partners, L.P. (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015)
     
10.3   Fifteenth Amended and Restated Secured Convertible Promissory Note, dated December 11, 2014, by NanoVibronix, Inc. in favor of and Globis Overseas Fund, Ltd. (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015)
     
10.4   Fifteenth Amended and Restated Secured Convertible Promissory Note, dated December 11, 2014, by NanoVibronix, Inc. in favor of and Globis Capital Partners, L.P. (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form 10 filed with the Securities and Exchange Commission on February 9, 2015)

 

71
 

 

10.5   Form of Amended and Restated 2013 and 2014 Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.13 to Amendment No. 2 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 25, 2014)
     
10.6+   NanoVibronix, Inc. 2004 Global Share Option Plan (incorporated by reference to Exhibit 10.14 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.7+   Personal Employment Agreement, dated March 1, 2008, by and between Nano-Vibronix (Israel 2003) Ltd and Jona Zumeris (incorporated by reference to Exhibit 10.15 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.8+   Form of Indemnification Agreement between NanoVibronix, Inc. and certain of its officers and directors (incorporated by reference to Exhibit 10.16 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.9   Amendment to Subscription Agreement Convertible Promissory Notes, dated February 28, 2014, by and between NanoVibronix, Inc. and the note holders signatory thereto (incorporated by reference to Exhibit 10.17 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.10   Second Amendment to Subscription Agreement Series B Convertible Preferred Stock and Warrants), dated February 28, 2014, by and between NanoVibronix, Inc. and the holders signatory thereto (incorporated by reference to Exhibit 10.19 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.11   Third Amendment to Subscription Agreement Series B Convertible Preferred Stock and Warrants), dated February 28, 2014, by and between NanoVibronix, Inc. and the holders signatory thereto (incorporated by reference to Exhibit 10.20 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
10.12+   NanoVibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.27 to Amendment No. 3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on April 30, 2014)
     
10.13+   First Amendment to Personal Employment Agreement, dated June 16, 2014, by and between NanoVibronix, Inc. and Dr. Jona Zumeris (incorporated by reference to Exhibit 10.29 to Amendment No. 8 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on June 23, 2014)
     
10.14   Services Agreement, dated March 25, 2015, by and between Multigon Industries, Inc. and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.35 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.15+   Employment Agreement, dated March 25, 2015, by and between William Stern and NanoVibronix, Inc. (incorporated by reference to Exhibit 10.36 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.16+   Warrant to Purchase Common Stock, dated March 25, 2015 (incorporated by reference to Exhibit 10.38 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.17+   Letter Agreement, dated March 25, 2015, by and between NanoVibronix, Inc. and Martin Goldstein (incorporated by reference to Exhibit 10.39 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)

 

72
 

 

10.18+   Form of Incentive Stock Option Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.40 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.19+   Form of Nonqualified Stock Option Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.41 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.20+   Form of Restricted Stock Award Agreement under the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.42 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.21+   Form of 3(i) Award Agreement under the Israeli Appendix to the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.43 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.22+   Form of 102 Award Agreement under the Israeli Appendix to the 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.44 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2015)
     
10.23+   Employment Agreement, dated October 13, 2016, by and between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)
     
10.24   Form of Amendment to Warrant to Purchase Common Stock, effective as of January 27, 2017 (incorporated by reference to Exhibit 10.46 to the Annual Report on Form 10-K filed with the Securities Exchange Commission on March 31, 2017)
     
10.25   Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)
     
10.26   Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)
     
10.27   Convertible Promissory Note, dated March 23, 2017, by and between NanoVibronix, Inc. and an individual investor (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2017)
     
10.28   Warrant to Purchase Common Stock, dated March 23, 2017, by and between NanoVibronix, Inc. and an individual investor (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2017)
     
10.29+   First Amendment to Nonqualified Stock Option Agreement, dated March 30, 2017, between NanoVibronix, Inc. and Ira A. Greenstein (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed with the Securities Exchange Commission on March 31, 2017)
     
10.30+   First Amendment to Nonqualified Stock Option Agreement, dated March 30, 2017, between NanoVibronix, Inc. and Ira A. Greenstein (incorporated by reference to Exhibit 10.52 to the Annual Report on Form 10-K filed with the Securities Exchange Commission on March 31, 2017)
     
10.31+   Offer Letter, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)

 

73
 

 

10.32+   Nonqualified Stock Option Agreement, dated October 14, 2016, between NanoVibronix, Inc. and Christopher M. Fashek (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)
     
10.33   Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2017)
     
10.34   Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2017)
     
10.35   Form of Letter Agreement, dated September 7, 2017, between NanoVibronix, Inc. and holders of the 2017 Notes (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on September 14, 2017)
     
10.36   Consulting Agreement dated as of February 21, 2019, between NanoVibronix, Inc and Bespoke Growth Partners, Inc. (incorporated by reference to Exhibit 10.36 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019)
     
10.37   Convertible Promissory Note (incorporated by reference to Exhibit 10.37 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019)
     
10.38   Convertible Promissory Note (incorporated by reference to Exhibit 10.38 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019)
     
10.39   Form of Warrant (incorporated by reference to Exhibit 10.39 to the Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on May 13, 2019)
     
10.40   Convertible Promissory Note (Globis), May 10, 2019 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019)
     
10.41   Convertible Promissory Note (AiGH), May 15, 2019 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 20, 2019)
     
10.42+   CFO Consulting Agreement, dated as of June 1, 2019, between NanoVibronix Inc. and James S. Cardwell (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 4, 2019)
     
10.43   Securities Purchase Agreement, dated as of June 21, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2019)
     
10.44   Securities Purchase Agreement, dated as of July 31, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019)
     
10.45   Securities Purchase Agreement, dated as of July 31, 2019, by and among the Company and each investor identified on the signature pages thereto (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2019)
     
10.46   Form of Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2020).
     
10.47   Form of Warrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 26, 2020).

 

74
 

 

10.48   Note with Cross River Bank (SBA-Payroll Protection Program loan) dated May 14, 2020 (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 19, 2020).
     
10.49+   Employment Agreement, dated as of October 5, 2020, between NanoVibronix, Inc. and Stephen Brown (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2020).
     
10.50+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Brian Murphy (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.51+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Christopher Fashek (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.52+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Martin Goldstein (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.53+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Michael Ferguson (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.54+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Stephen Brown (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.55+   Option Cancellation and Release Agreement, dated November 2, 2020, by and between NanoVibronix, Inc. and Thomas Mika (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2020).
     
10.56   Form of Securities Purchase Agreement, dated December 2, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).
     
10.57   Form of Registration Rights Agreement, dated December 2, 2020 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020).
     
10.58#   Amended and Restated Distribution Agreement for “Private Labeled” Products dated December 10, 2020 by and between NanoVibronix, Inc. and Ultra Pain Products Inc (incorporated by reference to Exhibit 10.58 to the Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2021).
     
10.59+   Second Amendment to the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. (incorporated by reference to Annex A to the Company’s definitive proxy statement on Schedule 14A filed with the SEC on April 30, 2019).
     

10.60+

 

 

   Third Amendment to the Nanovibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 30, 2021).

 

75
 

 

10.61   Fourth Amendment to the Nanovibronix, Inc. 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 15, 2022)
     
10.62  

Form of Securities Purchase Agreement, dated November 29, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 1, 2022)

     
21.1   List of Subsidiaries (incorporated by reference to Exhibit 21.1 to Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 6, 2014)
     
23.1*   Consent of Marcum, LLP, Independent Registered Public Accounting Firm
     
31.1*   Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2**   Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101*   The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language), (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Changes in Stockholders’ Deficiency, (iv) Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.
   
** Furnished herewith.

 

+ Management contract or compensatory plan or arrangement.
# Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.

 

76
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NANOVIBRONIX, INC.
   
  By: /s/ Brian Murphy
    Brian Murphy
    Chief Executive Officer

 

Date: April 17, 2023

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Murphy as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ BRIAN MURPHY   Chief Executive Officer and Director   April 17, 2023
Brian Murphy   (principal executive officer)    
         
/s/ STEPHEN BROWN   Chief Financial Officer,   April 17, 2023
Stephen Brown   (principal financial and accounting officer)    
         
/s/ CHRISTOPHER FASHEK   Chairman of the Board of Directors   April 17, 2023
Christopher Fashek        
         
/s/ MARTIN GOLDSTEIN   Director   April 17, 2023
Martin Goldstein        
         
/s/ HAROLD JACOB M.D.   Director   April 17, 2023
Harold Jacob, M.D.        
         
/s/ MICHAEL FERGUSON   Director   April 17, 2023
Michael Ferguson        
         
/s/ THOMAS R. MIKA   Director   April 17, 2023
Thomas R. Mika        
         
/s/ Aurora Cassirer   Director   April 17, 2023
Aurora Cassirer        
         
/s/ Maria Schroeder   Director   April 17, 2023
Maria Schroeder        

 

77

 

 EX-4.15 2 ex4-15.htm

 

Exhibit 4.15

 

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

 

As of May 14, 2020, NanoVibronix, Inc., a Delaware corporation (“we,” “our” and the “Company”) has its common stock, par value $0.001 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended.

 

The following description is intended as a summary and is qualified in its entirety by reference to our amended and restated certificate of incorporation, as amended (the “Amended & Restated Certificate of Incorporation”) and the amended and restated by-laws, as amended (the “By-laws”) as currently in effect, copies of which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein.

 

Authorized Capital Stock

 

As of April 17, 2023, our authorized capital stock consists of shares, of which 40,000,000 shares are common stock, par value $0.001 per share, and 5,040,000 shares are preferred stock, par value $0.001 per share, 3,000,000 of which have been designated as Series C Convertible Preferred Stock (“Series C Preferred Stock”), 506 of which have been designated as Series D Convertible Preferred Stock (“Series D Preferred Stock”), 1,994,494 of which have been designated as Series E Convertible Preferred Stock (“Series E Preferred Stock”) and 40,000 of which have been designated as Series F Convertible Preferred Stock (“Series F Preferred Stock”). As of April 17, 2023, there were 1,662,377 shares of common stock issued and outstanding, 0 shares of Series C Convertible Preferred Stock issued and outstanding, 0 shares of Series D Convertible Preferred Stock issued and outstanding, 0 shares of Series E Convertible Preferred Stock issued and outstanding and 0 shares of Series F Convertible Preferred Stock issued and outstanding.

 

Our Board, in consultation with counsel, determined that it was in the best interests of the Company and our stockholders to ratify, pursuant to Section 204 of the Delaware General Corporation Law (“DGCL”) and Delaware common law, an increase in the number of authorized shares of our common stock from 20,000,000 to 24,109,635 (the “Authorized Share Increase”) and the issuance of 4,109,635 shares of common stock (the “Authorized Share Increase Issuance”) upon conversion of the Series C Preferred Stock and the exercise of certain December 2020 Warrants and Pre-Existing Warrants (the “Share Increase Ratification”). On March 3, 2021, we filed a proxy statement in connection with a special meeting of stockholders (the “Special Meeting”) to be held at 10:00 a.m. Eastern time on March 31, 2021 to (i) ratify the Authorized Share Increase and the Authorized Share Increase Issuance, and (ii) further increase the number of our authorized shares of common stock. On March 31, 2021, we did not have the requisite vote to approve the Share Increase Ratification and the meeting was adjourned. At the reconvened Special Meeting on May 6, 2021, our stockholders voted to approve the ratification of the Authorized Share Increase, but the stockholders did not approve the Share Increase Ratification.

 

On August 17, 2021, at our 2021 Annual Meeting of Stockholders, our stockholders voted to approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of shares of our common stock authorized for issuance from 24,109,635 shares to 40,000,000 shares.

 

Common Stock

 

Voting Rights

 

Each stockholder has one vote for each share of common stock held on all matters submitted to a vote of stockholders. A stockholder may vote in person or by proxy. Elections of directors are determined by a plurality of the votes cast and all other matters are decided by a majority of the votes cast by those stockholders entitled to vote and present in person or by proxy.

 

Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of common stock will be able to elect all of our directors. Our Amended & Restated Certificate of Incorporation and By-laws provide that stockholder actions may be effected at a duly called meeting of stockholders or pursuant to written consent of the majority of stockholders.

 

Dividend Rights

 

The holders of outstanding shares of common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that the board of directors (the “Board”) may determine, provided that required dividends, if any, on preferred stock have been paid or provided for. However, the current policy of our Board is to retain earnings, if any, for operations and growth.

 

No Preemptive or Similar Rights

 

The holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated solely by action of the Board and issued in the future.

 

 

 

 

Right to Receive Liquidation Distributions

 

Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all assets that are legally available for distribution.

 

The NASDAQ Capital Market Listing

 

Our common stock is listed on the NASDAQ Capital Market (“NASDAQ”) under the symbol “NAOV.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.

 

Options and Warrants

 

As of April 17, 2023, we had 147,619 shares of common stock issuable upon exercise of outstanding options and 78,252 shares of common stock issuable upon the exercise of warrants. There are no other outstanding warrants or options at this time.

 

Preferred Stock

 

We may issue any class of preferred stock in any series. The Board has the authority, subject to limitations prescribed under Delaware law and the rights of the holders of any series of preferred stock, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations and restrictions. The number of authorized shares of preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of all of the then-outstanding shares of our capital stock entitled to vote thereon, without a vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any preferred stock designation. The Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of common stock and the voting and other rights of the holders of common stock.

 

Series C Convertible Preferred Stock

 

Conversion Rights

 

Each share of the Series C Preferred Stock is convertible into one (1) share of common stock, provided that the holder will be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, the holder would own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series C Preferred Stock, or, at the election of a holder, together with its affiliates, would own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series C Preferred Stock. The conversion rate of the Series C Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and similar events.

 

 

 

 

Dividend Rights

 

Shares of Series C Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Board. However, holders of Series C Preferred Stock are entitled to receive dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not obligated to redeem or repurchase any shares of Series C Preferred Stock. Shares of Series C Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.

 

Voting Rights

 

Except as provided in the Designation, Preferences, Rights and Limitations of Series C Preferred Stock or as otherwise required by law, each holder of Series C Preferred Stock will be entitled to the number of votes equal to the number of shares of common stock into which such share of Series C Preferred Stock could be converted, provided that the holder would be prohibited from converting Series C Preferred Stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of our common stock then issued and outstanding, for purposes of determining the shares entitled to vote at any regular, annual or special meeting of stockholders of the Company, and shall have voting rights and powers equal to the voting rights and powers of the common stock (except as otherwise expressly provided herein or as required by law, voting together with the common stock as a single class) and shall be entitled to notice of any stockholders’ meeting in accordance with the By-laws of the Company. Fractional votes shall not, however, be permitted and any fractional voting rights shall be rounded to the nearest whole number (with one-half being rounded upward). We may not, without the written consent of holders of a majority of the then issued and outstanding shares of Series C Preferred Stock, increase the number of authorized shares of Series C Preferred Stock.

 

Liquidation Rights

 

Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series C Preferred Stock are entitled to receive, pari passu with the holders of common stock, out of the assets available for distribution to stockholders an amount equal to such amount per share as would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately before such liquidation, dissolution or winding up, without giving effect to any limitation on conversion as a result of the Beneficial Ownership Limitation, as described above.

 

Series D Convertible Preferred Stock

 

Conversion Rights

 

Each share of the Series D Preferred Stock is convertible into fifty (50) shares of common stock, provided that the holder will be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, the holder would own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series D Preferred Stock, or, at the election of a holder, together with its affiliates, would own more than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuable upon conversion of the Series D Preferred Stock. The conversion rate of the Series D Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and similar events.

 

Dividend Rights

 

Shares of Series C Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Board. Series D Preferred Stockholders (“Series D Holders”) are entitled to receive, and the Company shall pay, dividends on shares of Series D Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. No other dividends shall be paid on shares of Series D Preferred Stock.

 

 

 

 

Voting Rights

 

Except as provided in the Series D Preferred Stock Certificate of Designation or as otherwise required by law, Series D Holders shall have no voting rights. However, as long as any shares of Series D Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the Series D Holders of a majority of the then outstanding shares of the Series D Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series D Preferred Stock or alter or amend the Series D Preferred Stock Certificate of Designation, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the Series D Holders, (c) increase the number of authorized shares of Series D Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.

 

Liquidation Rights

 

Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the Series D Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series D Preferred Stock were fully converted (disregarding for such purpose any conversion limitations hereunder) to common stock which amounts shall be paid pari passu with all holders of common stock. The Company shall mail written notice of any such liquidation, not less than 30 days prior to the payment date stated therein, to each Series D Holder.

 

Series E Convertible Preferred Stock

 

Conversion Rights

 

Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock (a “Series E Holder”) into one twentieth (1/20) of a share of our common stock, provided that each holder is prohibited from converting Series E Preferred Stock into shares of our common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. The conversion rate of the Series E Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and similar events.

 

Dividend Rights

 

Shares of Series E Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Board. However, Series E Holders are entitled to receive dividends on shares of Series E Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not obligated to redeem or repurchase any shares of Series E Preferred Stock. Shares of Series E Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.

 

Voting Rights

 

Each Series E Holder shall be entitled to the number of votes equal to the number of shares of our common stock equal to the voting ratio, which, for each share of Series E Preferred Stock, is equal to $2.00 divided by $3.53. Fractional votes shall not, however, be permitted and any fractional voting rights resulting from the above formula (after aggregating all shares into which shares of Series E Preferred Stock held by each Series E Holder could be converted) shall be rounded to the nearest whole number (with one-half being rounded upward).

 

Liquidation Rights

 

Upon liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, each Series E Holder shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series E Preferred Stock if such shares had been converted to our common stock immediately prior to such liquidation.

 

 

 

 

Series F Convertible Preferred Stock

 

Conversion Rights

 

Each share of Series F Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock (a “Series E Holder”) into one twentieth (1/20) of a share of our common stock, provided that each holder is prohibited from converting Series E Preferred Stock into shares of our common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of our common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. The conversion rate of the Series F Preferred Stock is subject to proportionate adjustments for stock splits, reverse stock splits and similar events.

 

Dividend Rights

 

Shares of Series F Preferred Stock are not entitled to receive any dividends, unless and until specifically declared by the Board. However, Series E Holders are entitled to receive dividends on shares of Series F Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of the common stock when such dividends are specifically declared by the Board. The Company is not obligated to redeem or repurchase any shares of Series F Preferred Stock. Shares of Series F Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.

 

Voting Rights

 

Each Series F Holder shall be entitled to the number of votes equal to the number of shares of our common stock equal to the voting ratio, which, for each share of Series F Preferred Stock, is equal to $2.00 divided by $3.53. Fractional votes shall not, however, be permitted and any fractional voting rights resulting from the above formula (after aggregating all shares into which shares of Series F Preferred Stock held by each Series F Holder could be converted) shall be rounded to the nearest whole number (with one-half being rounded upward).

 

Liquidation Rights

 

Upon liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, each Series F Holder shall be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series F Preferred Stock if such shares had been converted to our common stock immediately prior to such liquidation.

 

 

 

 

Delaware Anti-Takeover Law and Provisions of our Certificate of Incorporation and Bylaws

 

Delaware Anti-Takeover Law

 

We are subject to Section 203 of the Delaware General Corporation Law (the “DGCL”). Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

 

  ● prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
     
  ● the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
     
  ● on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.
     
  Section 203 defines a business combination to include:
     
  ● any merger or consolidation involving the corporation and the interested stockholder;
     
  ● any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
     
  ● subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; or
     
  ● the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

 

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, or controlling, or controlled by, the entity or person. The term “owner” is broadly defined to include any person that, individually, with or through that person’s affiliates or associates, among other things, beneficially owns the stock, or has the right to acquire the stock, whether or not the right is immediately exercisable, under any agreement or understanding or upon the exercise of warrants or options or otherwise or has the right to vote the stock under any agreement or understanding, or has an agreement or understanding with the beneficial owner of the stock for the purpose of acquiring, holding, voting or disposing of the stock.

 

The restrictions in Section 203 do not apply to corporations that have elected, in the manner provided in Section 203, not to be subject to Section 203 of the DGCL or, with certain exceptions, which do not have a class of voting stock that is listed on a national securities exchange or authorized for quotation on the Nasdaq Stock Market or held of record by more than 2,000 stockholders. Our certificate of incorporation and bylaws do not opt out of Section 203.

 

Section 203 could delay or prohibit mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

 

 

 

Amended and Restated Certificate of Incorporation and By-laws

 

The provisions of our Amended and Restated Certificate of Incorporation and By-laws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our Certificate of Incorporation and By-laws:

 

  ● permit our board of directors to issue up to 11,000,000 shares of preferred stock, without further action by the stockholders, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change in control;
     
  ● provide that the authorized number of directors may be changed only by resolution of a majority of the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships (the “Whole Board”);
     
  ● provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
     
  ● do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);
     
  ● provide that special meetings of our stockholders may be called only by a resolution adopted by a majority of the Whole Board; and
     
  ● set forth an advance notice procedure with regard to the nomination, other than by or at the direction of our Board, of candidates for election as directors and with regard to business to be brought before a meeting of stockholders.

 

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in the Registration Statement of NanoVibronix, Inc. on Form S-3 (File Nos. 333-229106, 333-236000, 333- 239965 and 333-251264) and Form S-8 (File Nos. 333-259274 and 333-205577) of our report dated April 17, 2023, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of NanoVibronix, Inc. and Subsidiaries as of December 31, 2022 and 2021 and for each of the two years in the period ended December 31, 2022, which report is included in this Annual Report on Form 10-K of NanoVibronix, Inc. for the year ended December 31, 2022.

 

/s/ Marcum llp  
   
Marcum llp  
New York, NY  
April 17, 2023  

 

 

 

 

 EX-31.1 4 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a)

 

I, Brian Murphy, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of NanoVibronix, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023    
  By: /s/ Brian Murphy
  Name: Brian Murphy
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 
 EX-31.2 5 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a)

 

I, Stephen Brown, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of NanoVibronix, Inc. (the “registrant”);
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: April 17, 2023    
  By: /s/ Stephen Brown
  Name: Stephen Brown
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 
 EX-32.1 6 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2022 of NanoVibronix, Inc. (the “Company”). I, Brian Murphy, the Chief Executive Officer of the Company, certify that, based on my knowledge:

 

(1) The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: April 17, 2023 By: /s/ Brian Murphy
  Name: Brian Murphy
  Title: Chief Executive Officer (Principal Executive Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 
 EX-32.2 7 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION FURNISHED PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and accompanies the Annual Report on Form 10-K (the “Form 10-K”) for the year ended December 31, 2021 of NanoVibronix, Inc. (the “Company”). I, Stephen Brown, the Chief Financial Officer of the Company, certify that, based on my knowledge:

 

  (1) The Form 10-K fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods covered in this report.

 

Date: April 17, 2023 By: /s/ Stephen Brown
  Name: Stephen Brown
  Title:

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

The foregoing certification is being furnished as an exhibit to the Form 10-K pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Form 10-K for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 GRAPHIC 8 form10-k_001.jpg begin 644 form10-k_001.jpg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form10-k_002.jpg begin 644 form10-k_002.jpg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form10-k_003.jpg begin 644 form10-k_003.jpg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end GRAPHIC 11 form10-k_004.jpg begin 644 form10-k_004.jpg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end GRAPHIC 12 form10-k_005.jpg begin 644 form10-k_005.jpg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end GRAPHIC 13 form10-k_006.jpg begin 644 form10-k_006.jpg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end EX-101.SCH 14 naov-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - RELATED PARTY TRANSACTION link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - OTHER ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 naov-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 16 naov-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 17 naov-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Collateral Held [Axis] Sale of Equity Securities [Member] Long-Lived Tangible Asset [Axis] Computer Equipment [Member] Office Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreement [Member] Legal Entity [Axis] H.C. Wainwright &amp; Co., LLC [Member] Sale of Stock [Axis] IPO [Member] Series F Common Stock [Member] Employee Options [Member] Employee Stock [Member] Private Placement [Member] Pre Funded Warrants [Member] Related Party [Axis] Two Investors [Member] Award Type [Axis] Warrants [Member] Title of Individual [Axis] Accredited Investors [Member] New Warrants [Member] Warrant [Member] Income Statement Location [Axis] Research and Development Expense [Member] Selling and Marketing Expense [Member] General and Administrative Expense [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Price Volatility [Member] Private Investors [Member] Derivative Instrument [Axis] Derivative Liability Warrants [Member] Investors [Member] Measurement Input, Conversion Price [Member] Measurement Input, Expected Term [Member] Liability Class [Axis] Derivative Liability [Member] Antidilutive Securities [Axis] Stock Options Employee And Non Employee [Member] Geographical [Axis] UNITED STATES Europe [Member] AUSTRALIA INDIA ISRAEL Other Country [Member] Licensing Agreement [Member] Sanuwave Health, Inc. [Member] Price at Valuation [Member] Measurement Input, Exercise Price [Member] Derivative Asset [Member] Derivative Liabilities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Jona Zumeris [Member] Former Officer [Member] Arbitrator [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] State and Local Jurisdiction [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS: Current assets: Cash Trade receivables Prepaid expenses and other accounts receivable Inventory Total current assets Noncurrent assets: Fixed assets, net Other assets Severance pay fund Operating lease right-of-use assets, net Total non-current assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY: Current liabilities: Trade payables Other accounts payable and accrued expenses Deferred revenue Operating lease liabilities, current Total current liabilities Non-current liabilities: Accrued severance pay Deferred licensing income Total liabilities Commitments and contingencies Stockholders’ equity: Preferred stock, value Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 1,641,146 and 1,399,890 shares at December 31, 2022 and December 31, 2021, respectively Additional paid in capital Accumulated other comprehensive income Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses: Research and development Selling and marketing General and administrative Total operating expenses Loss from operations Interest expense Financial expense, net Change in fair value of derivative liabilities Gain on purchase of warrants Warrant modification expense Loss before taxes Income tax expense Net loss Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock Weighted average common shares outstanding: Basic and diluted Comprehensive loss: Net loss available to common stockholders Change in foreign currency translation adjustments Comprehensive loss available to common stockholders Beginning balance, value Beginning balance, shares Stock-based compensation Exercise of warrants Exercise of warrant, shares Reclass of derivative liabilities to APIC Conversion of Series C Preferred Stock into Common Stock Conversion of Series C Preferred Stock into Common Stock, shares Conversion of Series D Preferred Stock into Common Stock Conversion of Series D Preferred Stock into Common Stock, shares Conversion of Series E Preferred Stock into Common Stock Conversion of Series E Preferred Stock into Common Stock, shares Currency translation adjustment Net loss Issuance of common stock, net of offering costs of $310,424 Issuance of common stock, shares Issuance of redeemable Series F preferred stock Redemption of redeemable Series F preferred stock Exercise of options Exercise of stock options, shares Other comprehensive loss Ending balance, value Ending balance, shares Statement of Stockholders' Equity [Abstract] Net offering costs Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Noncash interest expense Arbitration settlement expense Warrant modification expense Change in fair value of equity investment Change in fair value of derivative liabilities Gain on purchase of warrants Changes in operating assets and liabilities: Trade receivable Other accounts receivable and prepaid expenses Inventory Trade payables Other accounts payable and accrued expenses Deferred revenue Accrued severance pay, net Net cash used in operating activities Cash flows from investing activities: Purchases of fixed assets Net cash used in investing activities Cash flows from financing activities: Proceeds from sale of common stock, net Proceeds from exercise of options Proceeds from exercise of warrants Buy back of warrants from investor Net cash provided by financing activities Effects of currency translation on cash Net (decrease) increase in cash Cash at beginning of period Cash at end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for taxes Supplemental non-cash financing and investing activities: Exchange of common stock into preferred stock Shares issued from exercise of warrants previously classified as derivative liability Reclass derivative liability to equity due to increase in authorized shares Reclass liability to equity after increase in authorized shares Organization, Consolidation and Presentation of Financial Statements [Abstract] DESCRIPTION OF BUSINESS Liquidity And Plan Of Operations LIQUIDITY AND PLAN OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER RECEIVABLES Inventory Disclosure [Abstract] INVENTORY Equity [Abstract] STOCKHOLDERS’ EQUITY Derivative Liabilities DERIVATIVE LIABILITIES Leases LEASES Earnings Per Share [Abstract] LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Segment Reporting [Abstract] GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA OTHER ASSETS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTION Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation and principles of consolidation Use of estimates Foreign currency translation Earnings per share Inventory Property and equipment Impairment of Long-Lived Assets Sequencing Severance pay Leases Revenue recognition Income taxes Stock-based compensation Recently adopted accounting standards SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES SCHEDULE OF INVENTORY SCHEDULE OF OPTIONS ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS SCHEDULE OF WARRANTS ASSUMPTIONS SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN SCHEDULE OF DEFERRED TAX ASSETS Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Line Items] Net cash used in operating activities Net proceeds received Cash balance Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Estimated useful life Gains and losses from foreign currency translation Inventory allowance Severance expenses Prepaid expenses Other receivables Prepaid expenses and other receivables Raw materials Finished goods Inventory Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Options, Outstanding - Beginning balance Weighted Average Exercise Price per Share, Outstanding - beginning balance Weighted Average Remaining Life (Years), Outstanding - beginning balance Options, Granted Weighted Average Exercise Price per Share, Granted Weighted Average Remaining Life (Years), Granted Options, Forfeited Weighted Average Exercise Price per Share, Forfeited Options, Expired Weighted Average Exercise Price per Share, Exercised Options, Exercised Weighted Average Exercise Price per Share, Exercised Weighted Average Remaining Life (Years), Granted Options, Outstanding - Ending balance Weighted Average Exercise Price per Share, Outstanding - ending balance Weighted Average Remaining Life (Years), Outstanding - ending balance Price at valuation Exercise price Risk free interest, minimum Risk free interest, maximum Expected term (in years) Volatility, minimum Volatility, maximum Total Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants, measurement input, percentage Contractual term (in years) Warrants, Outstanding - Beginning balance Warrants, Granted Warrants, Exercised Warrants, Exercised - cashless Warrants, Expired Warrants, Canceled Warrants, Outstanding - Ending balance Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Sale of stock, number of shares issued Sale of stock, price per share Proceeds from sale of common stock Gross proceeds of aggregate cash fee percentage Gross proceeds of management fee percentage Non-accountable expense allowance Clearing fees Number of warrants to purchase Warrants expire date Warrants exercise price Preferred stock, conversion description Number of shares converted Shares issued upon conversion Preferred stock, par value Common stock, par value Preferred stock, voting rights, description Preferred stock, redemption price per share Number of options, exercised Number of options, granted Fair value options vesting term Number of options, vested Stock-based compensation expense Non-vested stock options granted, unrecognized estimated compensation cost Non-vested stock options granted, weighted average period Gross proceeds from private placement Net proceeds from private placement Stock issued during period warrants Proceeds from warrant exercises Warrants, modification expense Increase in additional paid in capital warrants Stock price Warrants, measurement input Warrants, measurement input, term Offsetting Assets [Table] Offsetting Assets [Line Items] Number of warrants acquired Payments for repurchase of warrants Class of warrant or right, exercise price of warrants or rights Derivative liability Schedule Of Liabilities Arising From Operating Leases 2023 2024 Total undiscounted operating lease payments Less: Imputed interest Present value of operating lease liabilities Lease term Weighted-average remaining lease term Weighted-average discount rate Operating lease, expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Schedule of Revenues from External Customers and Long-Lived Assets [Table] Revenues from External Customers and Long-Lived Assets [Line Items] Total Warrants and rights outstanding, measurement input Expected term (in years) Balance beginning New Issuances Fair value adjustments - Sanuwave warrants Fair value adjustments - Warrant liability Reclassification liability to equity Buy back of warrants Balance ending Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrants issued to purchase common stock Exercise price of warrants per share Fair value of warrants Change in fair value of warrants Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Litigation damages sought value Escrow amount Litigation settlement, amount Damages awarded value Legal fees paid Federal State Foreign Total Federal State Foreign Total Less: Valuation Allowance Total Tax Federal income tax benefit at statutory rate State income taxes, net of federal benefit Foreign rate differential Permanent Items Change in valuation allowance Return to provision adjustments Forfeited options Other Effective tax rate Domestic Foreign Loss before taxes Net operating loss carry forward Arbitration accrual Stock compensation and other Deferred tax assets before valuation allowance Valuation allowance Net deferred tax asset Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Net operating loss carry forward Federal net operating loss carried forward Federal net operating loss offset against taxable income Operating loss carryforwards expiration term Corporate tax rate Net increases in valuation allowance Subsequent Event [Table] Subsequent Event [Line Items] Reverse stock split description Stock splits Reverse stock splits Minimum bid price per share Severance assets, noncurrent. August Underwriting Agreement [Member] H.C. Wainwright &amp; Co., LLC [Member] Price at Valuation [Member] Financial expenses net. September Underwriting Agreement [Member] Gain loss on purchase of warrants. Warrant modification expense. Gross proceeds of aggregate cash fee percentage. Gross proceeds of management fee percentage. Licensing Agreement [Member] Sanuwave Health, Inc. [Member] Change in fair value of warrants. Noncash interest expense. The amount refers to arbitration settlement expense. Increase (decrease) in accrued severance pay, net. Exchange of common stock into Preferred Stock. Shares issued from exercise of warrants previously classified as derivative liability. Reclass derivative liability to equity due to increase in authorized shares. Reclass liability to equity after increase in authorized shares. Adjustments to additional paid in capital reclass of derivative liabilities. Conversion of series c preferred stock value into common stock. Jona Zumeris [Member] Conversion of series D preferred stock value into common stock. Former Officer [Member] Conversion of series E preferred stock value into common stock. Conversion of series C preferred stock shares into common stock. Exercise of warrants shares. Conversion of series D preferred stock shares into common stock. Conversion of series E preferred stock shares into common stock. Represents information related to federal net operating loss carried forward. Series F Common Stock [Member] Represents information related to federal net operating loss offset against taxable income. Represents as a operating loss carryforwards expiration term. Liquidity and plan of operations [Text Block] Valuation allowance of income tax expense benefit. Effective income tax rate reconciliation,permanent items, percent. Effective income tax rate reconciliation,forfeited options, percent. Schedule of depreciation calculated over estimated useful lives of assets [Table Text Block] Employees and Consultants [Member]. Employee Options [Member] Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Minimum bid price per share. Number of shares warrants exercised. Two Investors [Member]. Warrants [Member] Accredited Investors [Member]. New Warrants [Member]. Schedule Of Estimating Fair Value Of Warrants Assumptions [Table Text Blcok] Derivative Asset [Member] Derivative Liabilities [Member] Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation fair value adjustments warrants. Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation reclassification liability to equity. Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation buy back of warrants. Private Investors [Member] Warrants Exercised - cashless. Number of warrants acquired. Derivative Liability Warrants [Member] Investors [Member] Derivative Liability [Member] Value of stock issued as a result of the exercise of warrants. Number of share warrants exercised during the current period. Sale of Equity Securities [Member] Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Equity Securities, FV-NI, Gain (Loss) Gain (Loss) on Derivative Instruments, Net, Pretax Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Inventories Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Inventory, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Preferred Stock, Dividends Per Share, Declared Common Stock, Dividends, Per Share, Declared Lessee, Operating Lease, Liability, to be Paid Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Valuation allowance of income tax expense benefit Other Tax Expense (Benefit) Income (Loss) from Continuing Operations before Income Taxes, Foreign Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net Operating Loss Carryforwards EX-101.PRE 18 naov-20221231_pre.xml XBRL PRESENTATION FILE XML 19 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2022
Apr. 17, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --12-31    
Entity File Number 001-36445    
Entity Registrant Name NanoVibronix, Inc.    
Entity Central Index Key 0001326706    
Entity Tax Identification Number 01-0801232    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 525 Executive Blvd    
Entity Address, City or Town Elmsford    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10523    
City Area Code (914)    
Local Phone Number 233-3004    
Title of 12(b) Security Common stock, par value $0.001 per share    
Trading Symbol NOAV    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 17,539,360
Entity Common Stock, Shares Outstanding   1,662,377  
Documents Incorporated by Reference [Text Block] The information required by Part III of this Form 10-K, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders. Such proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 688    
Auditor Name Marcum LLP    
Auditor Location New York, NY    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash $ 2,713 $ 7,737
Trade receivables 9 200
Prepaid expenses and other accounts receivable 712 230
Inventory 2,175 175
Total current assets 5,609 8,342
Noncurrent assets:    
Fixed assets, net 7 5
Other assets 3 19
Severance pay fund 179 207
Operating lease right-of-use assets, net 81 49
Total non-current assets 270 280
Total assets 5,879 8,622
Current liabilities:    
Trade payables 66 87
Other accounts payable and accrued expenses 2,148 1,723
Deferred revenue 21 44
Operating lease liabilities, current 81 49
Total current liabilities 2,316 1,903
Non-current liabilities:    
Accrued severance pay 223 253
Deferred licensing income 107 153
Total liabilities 2,646 2,309
Commitments and contingencies
Stockholders’ equity:    
Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 1,641,146 and 1,399,890 shares at December 31, 2022 and December 31, 2021, respectively 2 1
Additional paid in capital 65,634 63,189
Accumulated other comprehensive income (18) 60
Accumulated deficit (62,385) (56,937)
Total stockholders’ equity 3,233 6,313
Total liabilities and stockholders’ equity 5,879 8,622
Series C Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock, value
Series D Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock, value
Series E Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock, value
Series F Preferred Stock [Member]    
Stockholders’ equity:    
Preferred stock, value
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 40,000,000 40,000,000
Common stock, shares issued 1,641,146 1,399,890
Common stock, shares outstanding 1,641,146 1,399,890
Series C Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 3,000,000 3,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series D Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 506 506
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series E Preferred Stock [Member]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,999,494 1,999,494
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Series F Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 40,000 0
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]    
Revenues $ 752 $ 1,695
Cost of revenues 585 925
Gross profit 167 770
Operating expenses:    
Research and development 283 293
Selling and marketing 965 1,101
General and administrative 3,931 5,059
Total operating expenses 5,179 6,453
Loss from operations (5,012) (5,683)
Interest expense (347)
Financial expense, net (54) (48)
Change in fair value of derivative liabilities (6,956)
Gain on purchase of warrants 64
Warrant modification expense (1,627)
Loss before taxes (5,413) (14,250)
Income tax expense (35) (32)
Net loss $ (5,448) $ (14,282)
Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock $ (3.84) $ (11.35)
Weighted average common shares outstanding:    
Basic and diluted 1,419,670 1,258,141
Comprehensive loss:    
Net loss available to common stockholders $ (5,448) $ (14,282)
Change in foreign currency translation adjustments (78) (6)
Comprehensive loss available to common stockholders $ (5,526) $ (14,288)
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 1 $ 1 $ 1 $ 44,980 $ 66 $ (42,655) $ 2,394
Beginning balance, shares at Dec. 31, 2020 666,667 153 875,000 1,062,326        
Stock-based compensation 190 190
Exercise of warrants 7,056 7,056
Exercise of warrant, shares         252,830        
Reclass of derivative liabilities to APIC 10,963 10,963
Conversion of Series C Preferred Stock into Common Stock $ (1) (1)
Conversion of Series C Preferred Stock into Common Stock, shares (666,667)       33,333        
Conversion of Series D Preferred Stock into Common Stock
Conversion of Series D Preferred Stock into Common Stock, shares   (153)     7,650        
Conversion of Series E Preferred Stock into Common Stock $ (1) (1)
Conversion of Series E Preferred Stock into Common Stock, shares     (875,000)   43,750        
Currency translation adjustment (6) (6)
Net loss (14,282) (14,282)
Ending balance, value at Dec. 31, 2021 $ 1 63,189 60 (56,937) 6,313
Ending balance, shares at Dec. 31, 2021 1,399,890        
Stock-based compensation 354 354
Net loss (5,448) (5,448)
Issuance of common stock, net of offering costs of $310,424 $ 1 2,089 2,090
Issuance of common stock, shares         240,000        
Issuance of redeemable Series F preferred stock
Redemption of redeemable Series F preferred stock
Exercise of options 2 2
Exercise of stock options, shares         1,256        
Other comprehensive loss (78) (78)
Ending balance, value at Dec. 31, 2022 $ 2 $ 65,634 $ (18) $ (62,385) $ 3,233
Ending balance, shares at Dec. 31, 2022 1,641,146        
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statement of Stockholders' Equity (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Statement of Stockholders' Equity [Abstract]  
Net offering costs $ 310,424
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (5,448) $ (14,282)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1 2
Stock-based compensation 354 382
Noncash interest expense 347
Arbitration settlement expense 1,500
Warrant modification expense 1,627
Change in fair value of equity investment 16 6
Change in fair value of derivative liabilities 6,956
Gain on purchase of warrants (64)
Changes in operating assets and liabilities:    
Trade receivable 191 (175)
Other accounts receivable and prepaid expenses (482) 37
Inventory (2,000) (30)
Trade payables (21) (59)
Other accounts payable and accrued expenses 78 (265)
Deferred revenue (69) (2)
Accrued severance pay, net (2)
Net cash used in operating activities (7,035) (4,367)
Cash flows from investing activities:    
Purchases of fixed assets (3) (3)
Net cash used in investing activities (3) (3)
Cash flows from financing activities:    
Proceeds from sale of common stock, net 2,090
Proceeds from exercise of options 2
Proceeds from exercise of warrants 4,968
Buy back of warrants from investor (388)
Net cash provided by financing activities 2,092 4,580
Effects of currency translation on cash (78) (6)
Net (decrease) increase in cash (5,024) 204
Cash at beginning of period 7,737 7,533
Cash at end of period 2,713 7,737
Supplemental disclosures of cash flow information:    
Cash paid for interest
Cash paid for taxes
Supplemental non-cash financing and investing activities:    
Exchange of common stock into preferred stock 1
Shares issued from exercise of warrants previously classified as derivative liability 2,087
Reclass derivative liability to equity due to increase in authorized shares 8,706
Reclass liability to equity after increase in authorized shares $ 2,257
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.23.1
DESCRIPTION OF BUSINESS
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

 

NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.

 

The Company’s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix Ltd., a company registered in Israel, which commenced operations in October 2003.

 
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.23.1
LIQUIDITY AND PLAN OF OPERATIONS
 12 Months Ended
Dec. 31, 2022
Liquidity And Plan Of Operations  
LIQUIDITY AND PLAN OF OPERATIONS

NOTE 2 - LIQUIDITY AND PLAN OF OPERATIONS

 

The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. In 2022, the Company’s cash used in operations was $7,035 and received net proceeds of $2,090 (net of offering costs of $310,424) from the sale of our equity securities, leaving a cash balance of $2,713 as of December 31, 2022. Because the Company does not have sufficient resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company’s ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.

 
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of presentation and principles of consolidation

 

The accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”).

 

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Foreign currency translation

 

Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2022 and 2021 were $85 and $6, respectively.

 

Earnings per share

 

Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred stock as of December 31, 2022 and 2021, respectively, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been antidilutive.

 

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.

 

Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was no allowance on inventory.

 

Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:

 

   Years 
     
Computers and peripheral equipment  3 
Office furniture and equipment  5-7 

 

Impairment of Long-Lived Assets

 

Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.

 

Sequencing

 

The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

 

Severance pay

 

The Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet. Accrued severance pay liability at December 31, 2022 and 2021 was $223 and $253, respectively.

 

Leases

 

The Company accounts for its leases in accordance with ASU 2016-02, “Leases” (Topic 842). This topic requires that a lessee recognize the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classify them as operating leases. For leases with a term of 12 months or less, the Company elects to implement in a class of underlying asset not to recognize lease assets and lease liabilities. The right-of-use assets and lease liabilities have been measured by the present value of the Company’s remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.

 

Revenue recognition

 

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

 

 

Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.

 

Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

 

Income taxes

 

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.

 

The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

 

Stock-based compensation

 

The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical share price movements. The expected option term represents the period that the Company’s stock options are expected to be outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.

 

Recently adopted accounting standards

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect on the Company’s consolidated financial statements.

 

 
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.23.1
PREPAID EXPENSES AND OTHER RECEIVABLES
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
PREPAID EXPENSES AND OTHER RECEIVABLES

NOTE 4 - PREPAID EXPENSES AND OTHER RECEIVABLES

 

Prepaid expenses and other receivables consist of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Prepaid expenses  $612   $166 
Other receivables   100    64 
           
Prepaid expenses and other receivables  $712   $230 

 
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
INVENTORY

NOTE 5 – INVENTORY

 

Inventory consists of the following components:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Raw materials  $30   $- 
Finished goods   2,145    175 
           
Inventory  $2,175   $175 

 
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 6 - STOCKHOLDERS’ EQUITY

 

Common Stock

 

The common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the event of liquidation, dissolution or winding up of the Company.

 

On August 17, 2021, the Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of the Company’s Common Stock authorized for issuance from 24,109,635 shares to 40,000,000 shares. As a result of the vote to increase the number of shares authorized for issuance, the warrants that were previously accounted for as derivative liabilities were marked to market through the date of approval and then reclassified to additional paid in capital (equity), as the Company had sufficient authorized shares to settle the exercise of the warrants.

 

Issuance of common stock for cash

 

On November 29, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell in a registered direct offering (the “Offering”), 240,000 shares of the Company’s common stock at an offering price of $10.00 per share. The Company received net proceeds from the sale of such offering, after deducting placement agent fees and expenses and offering expenses payable by the Company, of approximately $2.1 million. The Company intends to use the net proceeds for general working capital purposes.

 

On October 6, 2022, the Company entered into an engagement letter with H.C. Wainwright & Co., LLC (the “Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the Company, on a reasonable best-efforts basis, in connection with the Offering. The Company will pay Wainwright an aggregate cash fee equal to 7.5% of the gross proceeds of the Offering, a management fee equal to 1.0% of the gross proceeds of the Offering, a non-accountable expense allowance of $50,000 and $15,950 for clearing fees. Additionally, the Company has agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to 18,000 shares of common stock. The warrants expire on November 29, 2027 and have an exercise price of $12.50 per share.

 

 

Series C, D and E Preferred Stock conversion to common stock

 

Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one twentieth of a share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 875,000 shares of Series E Preferred Stock into 0 and 43,750 shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made to convert these shares.

 

Each share of Series D Preferred Stock is convertible into fifty shares of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 153 shares of Series D Preferred Stock into 0 and 7,650 shares of common stock, respectively, at a conversion rate of 1 to 50. No purchase was made in order to convert these shares.

 

Each share of Series C Preferred Stock is convertible into one twentieth of a share of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.

 

During the years ended December 31, 2022 and 2021, shareholders converted 0 and 666,667 shares of Series C Preferred Stock into 0 and 33,333 shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made in order to convert these shares.

 

Series F Preferred Stock

 

On September 13, 2022, the Board declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $0.001 per share (“Series F Preferred Stock”), for each one share of the Company’s common stock, par value $0.001 per share, to stockholders of record at 5:00 p.m. Eastern Time on October 14, 2022.

 

Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate of Incorporation to reclassify the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series F Preferred Stock is not entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

 

 

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Company’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). As of December 31, 2022, both the Initial Redemption and the Subsequent Redemption have occurred. As a result, no shares of Series F Preferred Stock remain outstanding.

 

Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.10 in cash for each one hundred whole shares of Series F Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the Certificate of Designation) thereof as of the applicable redemption time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder to the corporate secretary of the Company (each a “Redemption Payment Request”) following the applicable redemption time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company (ii) set forth in reasonable detail the number of shares of Series F Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by the Company with respect to the shares of Series F Preferred Stock that were redeemed at the applicable redemption time. However, the redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than one hundred whole shares of Series F Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of one hundred, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of one hundred (such, that for example, the former beneficial owner of 150 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 100 shares of Series F Preferred Stock redeemed pursuant to such redemption).

 

No shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of common stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred Stock equal to the number of shares of common stock to be transferred by such holder will be automatically transferred to the transferee of such shares of common stock. The holders of Series F Preferred Stock, as such, are not entitled to receive dividends of any kind.

 

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on September 14, 2022.

 

As described in the proxy statement filed on October 31, 2022, holders of The Company’s common stock and Series F Preferred Stock as of the close of business on October 17, 2022, are entitled to vote on the amendment to the Company’s Certificate of Incorporation to effect, at the discretion of the Company’s Board but prior to the six-month anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined by the Board in its discretion and included in a public announcement, and the proposal to adjourn the Annual Meeting to a later date at the Annual Meeting held on December 15, 2022.

 

 

Stock-based compensation and options

 

During the years ended December 31, 2022 and 2021, 1,256 and 0 employee options were exercised, and 21,875 and 43,875 options were granted, respectively. The options granted during 2022 and 2021 vest at different schedules ranging from date granted to 9 years and were recorded at fair values of $201 and $583, respectively. During the years ended December 31, 2022 and 2021, stock-based compensation expense of $148 and $258 was recorded for options that vested, respectively.

 

  

Shares Under

Options

  

Weighted

Average

Exercise Price

per Share

  

Weighted

Average

Remaining

Life (Years)

 
Outstanding – December 31, 2021   127,000   $31.86    7.77 
Granted   21,875    10.76    9.55 
Forfeited   -    -    - 
Expired   -    -    - 
Exercised   (1,256)   1.40    0.24 
Outstanding – December 31, 2022   147,619   $24.42    7.24 

 

The fair value for options granted in 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions:

 

   2022   2021 
Price at valuation  $0.45 – 0.78   $0.72 – 2.07 
Exercise price  $ 0.45 – 0.78   $0.72 – 2.07 
Risk free interest   2.32 – 3.58 %   0.27 – 1.29%
Expected term (in years)   5    5 
Volatility   125.3 – 127.9 %   60.9 – 82.7%

 

The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table.

 

   2022   2021 
   Year Ended 
   December 31, 
   2022   2021 
         
Research and development  $6   $13 
Selling and marketing   25    28 
General and administrative   323    341 
Total  $354   $382 

 

As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $328, which is expected to be recognized over a weighted average period of approximately 7.24 years.

 

Warrants

 

On December 2, 2020, we entered into a Securities Purchase Agreement with certain institutional and accredited investors pursuant to which the Company issued and sold to such investors in a private placement an aggregate of (i) 295,714 shares of the Company’s common stock at an offering price of $14.00 per share and (ii) pre-funded warrants to purchase up to 132,857 shares of common stock at a purchase price of $13.98 per pre-funded warrant, for gross proceeds of approximately $6.0 million, and net proceeds of approximately $5.4 million. In January 2021, two investors exercised an aggregate of 82,857 warrants at $0.02 per share.

 

On January 21, 2021, Company entered into letter agreements (the “Letter Agreements”) with certain existing accredited investors to exercise certain outstanding warrants (the “Existing Warrants”) to purchase up to an aggregate of 60,298 shares of the Company’s common stock at an exercise price per share of $23.30 (the “Exercise”). Certain of the Existing Warrants (the “Registered Existing Warrants”) and the shares of common stock underlying the Registered Existing Warrants have been registered pursuant to a registration statement on Form S-3 (File No. 333-251264) and a registration statement on Form S-1 (File No. 333-218871). In consideration for the exercise of the Existing Warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of 60,298 shares of common stock (the “New Warrants”) at an exercise price of $20.80 per share and with an exercise period of seven years from the initial closing date. The gross proceeds to the Company from the Exercise were approximately $1.4 million.

 

 

The New Warrants were accounted for in warrant modification expense, which was measured at the amount equal to the incremental value reflecting the change in the fair value of the warrants before and after the Warrant Amendment. Accordingly, warrant modification expense in the amount of $1,627 was recorded with a corresponding increase in additional paid in capital.

 

In August and September 2021, investors exercised warrants to purchase 109,675 shares of common stock between $17.60 and $50.00 per share for proceeds of approximately $3.6 million.

 

On June 14, 2022, the Company issued warrants to two sales consultants to purchase 12,500 shares of common stock which will expire on June 14, 2029 and have an exercise price of $20.00 per share. Accordingly, expense related to these warrants in the amount of $135,000 was recorded with a corresponding increase in additional paid in capital.

 

On September 30, 2022, the Company and the two sales consultants mutually agreed to cancel the latter’s annual stock warrants to purchase 12,500 shares of common stock. Accordingly, expense related to these warrants were reversed in the amount of $135,000 with a corresponding decrease in additional paid in capital.

 

On November 29, 2022, the Company granted 18,000 warrants to purchase Company’s common stock in conjunction with the private placements.

 

In estimating the warrants’ fair value, the Company used the following assumptions:

 

   2022   2021 
Risk free interest   0.34%   1.44%
Dividend yield   0%   0%
Volatility   60.7%   55.6 - 56.5 % 
Contractual term (in years)   5    2 

 

 

   Warrants 
Outstanding – December 31, 2020   386,237 
Granted   60,298 
Exercised   (252,830)
Exercised - cashless   (14,071)
Expired   (31,000)
Canceled   (33,167)
Outstanding – December 31, 2021   115,467 
Granted   30,500 
Expired   (55,215)
Canceled   (12,500)
Outstanding – December 31, 2022   78,252 

 
XML 32 R14.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES
 12 Months Ended
Dec. 31, 2022
Derivative Liabilities  
DERIVATIVE LIABILITIES

NOTE 7 - DERIVATIVE LIABILITIES

 

During 2020, the Company established a sequencing policy to which common stock equivalents are exercisable to shares of common stock more than the Company’s authorized limit. It was determined that all options and warrants by the end of the year were no longer permitted to be classified as equity and were valued at fair market value using Black Scholes and recorded as derivative liabilities.

 

On April 6, 2021, the Company agreed to buy back 33,167 warrants from investors for a total of $368. The warrants had exercise prices between $17.6 and $18.8 per share. The value of the derivative liabilities associated with these warrants was $451. The Company recorded a $64 gain in connection with the buyback of the warrants.

 

 

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s purchase warrants that were categorized within Level 3 of the fair value hierarchy during the years ended December 31, 2022 and 2021 is as follows:

 

   2022    2021 
Stock price  $ 1.01 – 2.94   $1.01 – 2.94  
Conversion price  $ 0.72 – 6.90   $0.72 – 6.90   
Contractual term (in years)   0.67 – 6.56    0.67 – 6.56 
Volatility (annual)   82.70 – 211%    82.70 - 211%
Risk-free rate   0.09 – 1.21%    0.09 – 1.21%

 

The foregoing assumptions were reviewed quarterly and were subject to change based primarily on management’s assessment of the probability of the events described occurring.

 
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES
 12 Months Ended
Dec. 31, 2022
Leases  
LEASES

NOTE 8 – LEASES

 

The Company has operating lease agreements with terms up to 2-3 years, including car and office space leases.

 

The Company’s weighted-average remaining lease term relating to its operating leases is 1.05 years, with a weighted-average discount rate of 10%.

 

The Company incurred $75 of lease expense for its operating leases for the year ended December 31, 2022.

 

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2022:

 

      
2023   73 
2024   4 
Total undiscounted operating lease payments   77 
Less: Imputed interest   4 
Present value of operating lease liabilities  $73 

 
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.23.1
LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

NOTE 9 - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

 

Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December 31, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented.

 

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

   December 31, 2022   December 31, 2021 
Stock options - employee and non-employee   147,619    127,000 
Warrants   78,252    115,467 
Total   225,871    242,467 

 

The diluted loss per share equals basic loss per share in the year ended December 31, 2022 and 2021 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.

 

 
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA

NOTE 10 - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA

 

Summary information about geographic areas:

 

The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
United States  $710   $1,627 
Europe   25    18 
Australia   9    6 
India   3    - 
Israel   -    5 
Other   5    39 
Total  $752   $1,695 

 

The Company’s long-lived assets are all located in Israel.

 
XML 36 R18.htm IDEA: XBRL DOCUMENT v3.23.1
OTHER ASSETS
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
OTHER ASSETS

NOTE 11 – OTHER ASSETS

 

On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:

  2022   2021 
Price at valuation  $0.02   $ 0.19 – 0.26   
Exercise price  $0.19   $0.19 
Risk free interest   3.96%   0.66 – 0.73 %
Expected term (in years)   8    10 
Volatility   155.6%   140.6 – 143.9%

 

The Company considers this to be Level 3 inputs and is valued at each reporting period. The fair value of these warrants for the years ended December 31, 2022 and 2021 was $3 and $19, respectively. There was a net $16 and $6 change in fair value during the year ended December 31, 2022 and 2021, respectively.

 

Financial Liabilities Measured at Fair Value on a Recurring Basis

 

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

 

● Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;
   
● Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and
   
● Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

There were no transfers between Level 3 during the years ended December 31, 2022 and 2021.

 

 

The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2022 and 2021:

 

   As of December 31, 2022 
   Asset   Liability 
Balance – December 31, 2020  $25   $2,471 
New Issuances   -    1,819 
Fair value adjustments – Sanuwave warrants   (6)   - 
Fair value adjustments – Warrant liability   -    6,956 
Reclassification liability to equity   -    (10,793)
Buy back of warrants   -    (453)
Balance – December 31, 2021  $19   $- 
New Issuances   -    - 
Fair value adjustments – Sanuwave warrants   (16)   - 
Balance – December 31, 2022  $3   $- 

 

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2022 
   Level I   Level II   Level III   Total 
Asset:                
Other assets  $     -   $     -   $    3   $3 

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2021 
   Level I   Level II   Level III   Total 
Asset:                    
Other assets  $     -   $     -   $19   $19 

 
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 12 - COMMITMENTS AND CONTINGENCIES

 

Pending and settled litigation

 

On December 17, 2019, a lawsuit was filed by a former officer and director, Jona Zumeris, in the Haifa Israel District Financial Court, seeking damages of approximately $900 for breach of the Separation Agreement executed on July 4, 2018. The Israeli court issued a court order demanding that we restrict approximately $700 of the Company’s money until the matter is adjudicated. The Company appealed the court order and in February 2020, the Company agreed to restrict approximately 1,187 NIS (“New Israeli Shekel”) and agreed to try to settle the matter in mediation. On November 30, 2020, the Company funded the escrow account with $391. In January 2021, the parties reached a settlement in which the Company paid the plaintiff approximately $366 as settlement in full.

 

On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $3 million. The Company vigorously defended the claims asserted by Protrade.

 

On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $1.5 million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.

 

On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.

 

On July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.

 

 

On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award and denying the cross-motion.

 

On November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newel information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. On March 21, 2023, the Court denied the motion to re-argue and renew. The Company intends to file a notice of appeal with the Appellate Division, Second Department and to continue to vigorously pursue its opposition to the award in all appropriate fora.

 

Other Risks

 

On March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares.

 
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTION
 12 Months Ended
Dec. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTION

NOTE 13 – RELATED PARTY TRANSACTION

 

The firm of FisherBroyles LLP is handling our Protrade litigation and appeals. For the year ended December 31, 2022, we have been billed and paid legal fees from Fisher Broyles amounting to $256,908 and recorded as part of “General and administrative expenses” in the condensed consolidated statements of operations. As has been previously disclosed, one of our board members, Aurora Cassirer, is a partner at Fisher Broyles. Ms. Cassirer does not provide any legal services or legal advice to the Company.

 
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 14 – INCOME TAXES

 

As of December 31, 2022, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $33,000 and $6,000, respectively. $19,200 of the federal net operating loss can be carried forward indefinitely but can only offset up to 80% of taxable income in a given year, and $14,000 of the federal net operating loss can be used to fully offset taxable income in the period it is utilized but can only be carried forward for 20 years. Utilization of the U.S. net operating losses may be subject to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the fact that the respective DTAs are fully offset by a valuation allowance.

 

Income tax expense is comprised of the following:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
Current Tax          
Federal  $-   $- 
State   -    - 
Foreign   37    32 
Total  $37   $32 
           
Deferred Tax          
Federal  $(1,545)  $(1,263)
State   653   (131)
Foreign  $(1)   (4)
Total  $(893)  $(1,398)
Less: Valuation Allowance   893    1,398 
Total Tax  $37   $32 

 

 

The difference between the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation of the statutory U.S Federal rate to the Company’s effective tax rate is as follows:

   2022   2021 
   Year ended December 31, 
   2022   2021 
Federal income tax benefit at statutory rate   21.00%   21.00%
State income taxes, net of federal benefit   -12.06%   0.92%
Foreign rate differential   -0.03%   0.02%
Permanent Items   -0.61%   -13.04%
Change in valuation allowance   -16.61%   -9.81%
Return to provision adjustments   7.54%   -0.01%
Forfeited options   0.00%   -0.16%
Other   0.09%   0.86%
Effective tax rate   -0.68%   -0.22%

 

Foreign tax

 

Tax rates applicable to the income of the Israeli subsidiary:

 

The Israeli corporate tax rate in 2022 and 2021 is 23%.

 

The subsidiary has final tax assessments through 2016.

 

Loss before taxes:

   2022   2021 
   Year ended December 31, 
   2022   2021 
         
Domestic  $5,557   $14,333 
Foreign   (144)   (82)
Loss before taxes  $5,413   $14,250 

 

Deferred income taxes

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carry forward  $7,306   $6,563 
Arbitration accrual   414    414 
Stock compensation and other   483    327 
Deferred tax assets before valuation allowance   8,203    7,304 
Valuation allowance   (8,203)   (7,304)
Net deferred tax asset  $-   $- 

 

For the year ended December 31, 2022 and 2021, the net increases in valuation allowance of $894 and $1,417, respectively was primarily driven by the increase in net operating loss carryforwards.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

 

 

The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance at December 31, 2022 and 2021.

 

The Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be indefinitely invested outside the United States.

 

Reconciliation of the theoretical tax expense to the actual tax expense

 

The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and its subsidiary due to the uncertainty of the realization of such tax benefits.

 

The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2022 and 2021, the Company does not have any liabilities recorded for uncertain tax positions and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company did not recognize any interest or penalties during fiscal 2022 or 2021 related to unrecognized tax benefits.

 

U.S. federal and New York State income taxes are open for examination for years 2019-2022 and Israel tax returns are open for examination for years 2018-2022.

 
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 15 - SUBSEQUENT EVENTS

 

On February 8, 2023, the Company effected a reverse stock split of its common stock at a ratio of 1 post-split share for every 20 pre-split shares. The Company’s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023.

 

At an annual meeting of stockholders held on December 15, 2022, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50, with such ratio to be determined by the Company’s Board of Directors.

 

At the effective time of the reverse stock split, every 20 shares of the Company’s issued and outstanding common stock was converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account had their shares automatically adjusted to reflect the 1-for-20 reverse stock split. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof.

 

Accordingly, on February 28, 2023, the Company received official notice from Nasdaq that the Company evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $1.00 bid price requirement. As previously disclosed, the Company was granted an extension by the Nasdaq Hearings Panel through February 23, 2023 to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Basis of presentation and principles of consolidation

Basis of presentation and principles of consolidation

 

The accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”).

 
Use of estimates

Use of estimates

 

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 
Foreign currency translation

Foreign currency translation

 

Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2022 and 2021 were $85 and $6, respectively.

 
Earnings per share

Earnings per share

 

Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred stock as of December 31, 2022 and 2021, respectively, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been antidilutive.

 

 
Inventory

Inventory

 

Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.

 

Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was no allowance on inventory.

 
Property and equipment

Property and equipment

 

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:

 

   Years 
     
Computers and peripheral equipment  3 
Office furniture and equipment  5-7 

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.

 
Sequencing

Sequencing

 

The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.

 
Severance pay

Severance pay

 

The Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet. Accrued severance pay liability at December 31, 2022 and 2021 was $223 and $253, respectively.

 
Leases

Leases

 

The Company accounts for its leases in accordance with ASU 2016-02, “Leases” (Topic 842). This topic requires that a lessee recognize the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classify them as operating leases. For leases with a term of 12 months or less, the Company elects to implement in a class of underlying asset not to recognize lease assets and lease liabilities. The right-of-use assets and lease liabilities have been measured by the present value of the Company’s remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.

 
Revenue recognition

Revenue recognition

 

It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.

 

 

Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.

 

Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.

 
Income taxes

Income taxes

 

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.

 

The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.

 

The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

 
Stock-based compensation

Stock-based compensation

 

The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical share price movements. The expected option term represents the period that the Company’s stock options are expected to be outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.

 
Recently adopted accounting standards

Recently adopted accounting standards

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect on the Company’s consolidated financial statements.

 

 
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:

 

   Years 
     
Computers and peripheral equipment  3 
Office furniture and equipment  5-7 
XML 43 R25.htm IDEA: XBRL DOCUMENT v3.23.1
PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES

Prepaid expenses and other receivables consist of the following:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Prepaid expenses  $612   $166 
Other receivables   100    64 
           
Prepaid expenses and other receivables  $712   $230 
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.23.1
INVENTORY (Tables)
 12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
SCHEDULE OF INVENTORY

Inventory consists of the following components:

 

   2022   2021 
   December 31, 
   2022   2021 
         
Raw materials  $30   $- 
Finished goods   2,145    175 
           
Inventory  $2,175   $175 
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Tables)
 12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
SCHEDULE OF OPTIONS ACTIVITY

 

  

Shares Under

Options

  

Weighted

Average

Exercise Price

per Share

  

Weighted

Average

Remaining

Life (Years)

 
Outstanding – December 31, 2021   127,000   $31.86    7.77 
Granted   21,875    10.76    9.55 
Forfeited   -    -    - 
Expired   -    -    - 
Exercised   (1,256)   1.40    0.24 
Outstanding – December 31, 2022   147,619   $24.42    7.24 
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED

The fair value for options granted in 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions:

 

   2022   2021 
Price at valuation  $0.45 – 0.78   $0.72 – 2.07 
Exercise price  $ 0.45 – 0.78   $0.72 – 2.07 
Risk free interest   2.32 – 3.58 %   0.27 – 1.29%
Expected term (in years)   5    5 
Volatility   125.3 – 127.9 %   60.9 – 82.7%
SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES

The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table.

 

   2022   2021 
   Year Ended 
   December 31, 
   2022   2021 
         
Research and development  $6   $13 
Selling and marketing   25    28 
General and administrative   323    341 
Total  $354   $382 
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS

In estimating the warrants’ fair value, the Company used the following assumptions:

 

   2022   2021 
Risk free interest   0.34%   1.44%
Dividend yield   0%   0%
Volatility   60.7%   55.6 - 56.5 % 
Contractual term (in years)   5    2 
SCHEDULE OF WARRANTS ACTIVITY

 

   Warrants 
Outstanding – December 31, 2020   386,237 
Granted   60,298 
Exercised   (252,830)
Exercised - cashless   (14,071)
Expired   (31,000)
Canceled   (33,167)
Outstanding – December 31, 2021   115,467 
Granted   30,500 
Expired   (55,215)
Canceled   (12,500)
Outstanding – December 31, 2022   78,252 
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES (Tables)
 12 Months Ended
Dec. 31, 2022
Derivative Liabilities  
SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s purchase warrants that were categorized within Level 3 of the fair value hierarchy during the years ended December 31, 2022 and 2021 is as follows:

 

   2022    2021 
Stock price  $ 1.01 – 2.94   $1.01 – 2.94  
Conversion price  $ 0.72 – 6.90   $0.72 – 6.90   
Contractual term (in years)   0.67 – 6.56    0.67 – 6.56 
Volatility (annual)   82.70 – 211%    82.70 - 211%
Risk-free rate   0.09 – 1.21%    0.09 – 1.21%
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2022
Leases  
SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES

The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2022:

 

      
2023   73 
2024   4 
Total undiscounted operating lease payments   77 
Less: Imputed interest   4 
Present value of operating lease liabilities  $73 

 
XML 48 R30.htm IDEA: XBRL DOCUMENT v3.23.1
LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)
 12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE

The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:

 

   December 31, 2022   December 31, 2021 
Stock options - employee and non-employee   147,619    127,000 
Warrants   78,252    115,467 
Total   225,871    242,467 
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.23.1
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS

The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
United States  $710   $1,627 
Europe   25    18 
Australia   9    6 
India   3    - 
Israel   -    5 
Other   5    39 
Total  $752   $1,695 
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.23.1
OTHER ASSETS (Tables)
 12 Months Ended
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
SCHEDULE OF WARRANTS ASSUMPTIONS

  2022   2021 
Price at valuation  $0.02   $ 0.19 – 0.26   
Exercise price  $0.19   $0.19 
Risk free interest   3.96%   0.66 – 0.73 %
Expected term (in years)   8    10 
Volatility   155.6%   140.6 – 143.9%
SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE

The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2022 and 2021:

 

   As of December 31, 2022 
   Asset   Liability 
Balance – December 31, 2020  $25   $2,471 
New Issuances   -    1,819 
Fair value adjustments – Sanuwave warrants   (6)   - 
Fair value adjustments – Warrant liability   -    6,956 
Reclassification liability to equity   -    (10,793)
Buy back of warrants   -    (453)
Balance – December 31, 2021  $19   $- 
New Issuances   -    - 
Fair value adjustments – Sanuwave warrants   (16)   - 
Balance – December 31, 2022  $3   $- 
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2022 
   Level I   Level II   Level III   Total 
Asset:                
Other assets  $     -   $     -   $    3   $3 

 

   Level I   Level II   Level III   Total 
   Fair Value Measurements as of December 31, 2021 
   Level I   Level II   Level III   Total 
Asset:                    
Other assets  $     -   $     -   $19   $19 
XML 51 R33.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES

Income tax expense is comprised of the following:

 

   2022   2021 
   Year ended December 31, 
   2022   2021 
Current Tax          
Federal  $-   $- 
State   -    - 
Foreign   37    32 
Total  $37   $32 
           
Deferred Tax          
Federal  $(1,545)  $(1,263)
State   653   (131)
Foreign  $(1)   (4)
Total  $(893)  $(1,398)
Less: Valuation Allowance   893    1,398 
Total Tax  $37   $32 
SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE

   2022   2021 
   Year ended December 31, 
   2022   2021 
Federal income tax benefit at statutory rate   21.00%   21.00%
State income taxes, net of federal benefit   -12.06%   0.92%
Foreign rate differential   -0.03%   0.02%
Permanent Items   -0.61%   -13.04%
Change in valuation allowance   -16.61%   -9.81%
Return to provision adjustments   7.54%   -0.01%
Forfeited options   0.00%   -0.16%
Other   0.09%   0.86%
Effective tax rate   -0.68%   -0.22%
SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN

   2022   2021 
   Year ended December 31, 
   2022   2021 
         
Domestic  $5,557   $14,333 
Foreign   (144)   (82)
Loss before taxes  $5,413   $14,250 
SCHEDULE OF DEFERRED TAX ASSETS

   2022   2021 
   Year ended December 31, 
   2022   2021 
Deferred tax assets:          
Net operating loss carry forward  $7,306   $6,563 
Arbitration accrual   414    414 
Stock compensation and other   483    327 
Deferred tax assets before valuation allowance   8,203    7,304 
Valuation allowance   (8,203)   (7,304)
Net deferred tax asset  $-   $- 
XML 52 R34.htm IDEA: XBRL DOCUMENT v3.23.1
LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Financing Receivable, Past Due [Line Items]    
Net cash used in operating activities $ 7,035 $ 4,367
Net proceeds received 2,090
Net offering costs 310,424  
Cash balance 2,713 $ 7,737
Sale of Equity Securities [Member]    
Financing Receivable, Past Due [Line Items]    
Cash balance $ 2,713  
XML 53 R35.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)
 12 Months Ended
Dec. 31, 2022
Computer Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 3 years
Office Equipment [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 5 years
Office Equipment [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful life 7 years
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Gains and losses from foreign currency translation $ 85 $ 6
Inventory allowance 0 0
Severance expenses $ 223 $ 253
XML 55 R37.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid expenses $ 612 $ 166
Other receivables 100 64
Prepaid expenses and other receivables $ 712 $ 230
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INVENTORY (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 30
Finished goods 2,145 175
Inventory $ 2,175 $ 175
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF OPTIONS ACTIVITY (Details) - Employee Options [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Options, Outstanding - Beginning balance 127,000  
Weighted Average Exercise Price per Share, Outstanding - beginning balance $ 31.86  
Weighted Average Remaining Life (Years), Outstanding - beginning balance 7 years 9 months 7 days  
Options, Granted 21,875 43,875
Weighted Average Exercise Price per Share, Granted $ 10.76  
Weighted Average Remaining Life (Years), Granted 9 years 6 months 18 days  
Options, Forfeited  
Weighted Average Exercise Price per Share, Forfeited  
Options, Expired  
Weighted Average Exercise Price per Share, Exercised  
Options, Exercised (1,256) 0
Weighted Average Exercise Price per Share, Exercised $ 1.40  
Weighted Average Remaining Life (Years), Granted 2 months 26 days  
Options, Outstanding - Ending balance 147,619 127,000
Weighted Average Exercise Price per Share, Outstanding - ending balance $ 24.42 $ 31.86
Weighted Average Remaining Life (Years), Outstanding - ending balance 7 years 2 months 26 days  
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Risk free interest, minimum 2.32% 0.27%
Risk free interest, maximum 3.58% 1.29%
Expected term (in years) 5 years 5 years
Volatility, minimum 125.30% 60.90%
Volatility, maximum 127.90% 82.70%
Minimum [Member]    
Price at valuation $ 0.45 $ 0.72
Exercise price 0.45 0.72
Maximum [Member]    
Price at valuation 0.78 2.07
Exercise price $ 0.78 $ 2.07
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Total $ 354 $ 382
Research and Development Expense [Member]    
Total 6 13
Selling and Marketing Expense [Member]    
Total 25 28
General and Administrative Expense [Member]    
Total $ 323 $ 341
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)
Dec. 31, 2022
Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contractual term (in years) 5 years 2 years
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, measurement input, percentage 0.34 1.44
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, measurement input, percentage 0 0
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, measurement input, percentage 60.7  
Measurement Input, Price Volatility [Member] | Minimum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, measurement input, percentage 55.6  
Measurement Input, Price Volatility [Member] | Maximum [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, measurement input, percentage 56.5  
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] - Private Investors [Member] - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Warrants, Outstanding - Beginning balance 115,467 386,237
Warrants, Granted 30,500 60,298
Warrants, Exercised   (252,830)
Warrants, Exercised - cashless   (14,071)
Warrants, Expired (55,215) (31,000)
Warrants, Canceled (12,500) (33,167)
Warrants, Outstanding - Ending balance 78,252 115,467
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 29, 2022
Oct. 06, 2022
Sep. 30, 2022
Sep. 13, 2022
Jun. 14, 2022
Jan. 21, 2021
Dec. 02, 2020
Sep. 30, 2021
Jan. 31, 2021
Jun. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Aug. 17, 2021
Aug. 16, 2021
Subsidiary, Sale of Stock [Line Items]                            
Common stock, shares authorized                     40,000,000 40,000,000 40,000,000 24,109,635
Proceeds from sale of common stock                     $ 2,090,000    
Number of warrants to purchase 18,000   12,500   12,500     109,675            
Warrants expire date         Jun. 14, 2029                  
Warrants exercise price         $ 20.00                  
Stock-based compensation expense                     354,000 382,000    
Proceeds from warrant exercises                     4,968,000    
Warrants, modification expense                     $ 3,000 $ 19,000    
Increase in additional paid in capital warrants     $ 135,000   $ 135,000,000                  
Minimum [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Warrants exercise price               $ 17.60            
Maximum [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Warrants exercise price               $ 50.00            
Warrants [Member] | Accredited Investors [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of warrants to purchase           60,298                
Warrants exercise price           $ 23.30                
New Warrants [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of warrants to purchase           60,298                
Warrants exercise price           $ 20.80                
Proceeds from warrant exercises           $ 1,400,000                
Warrants, modification expense                   $ 1,627,000        
Two Investors [Member] | Warrants [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Warrants exercise price                 $ 0.02          
Stock issued during period warrants                 82,857          
Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of options, exercised                     1,256      
Employee Options [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Number of options, exercised                     1,256 0    
Number of options, granted                     21,875 43,875    
Fair value options vesting term                     9 years      
Number of options, vested                     $ 201,000 $ 583,000    
Stock-based compensation expense                     $ 148,000 $ 258,000    
Warrant [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Proceeds from warrant exercises               $ 3,600,000            
Series E Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Preferred stock, conversion description                     Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one twentieth of a share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.      
Number of shares converted                     0 875,000    
Series E Preferred Stock [Member] | Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Shares issued upon conversion                     0 43,750    
Series D Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Preferred stock, conversion description                     Each share of Series D Preferred Stock is convertible into fifty shares of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.      
Number of shares converted                     0 153    
Series D Preferred Stock [Member] | Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Shares issued upon conversion                     0 7,650    
Series C Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Preferred stock, conversion description                       Each share of Series C Preferred Stock is convertible into one twentieth of a share of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.    
Number of shares converted                     0 666,667    
Series C Preferred Stock [Member] | Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Shares issued upon conversion                     0 33,333    
Series F Preferred Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Preferred stock, par value       $ 0.001                    
Preferred stock, voting rights, description                     Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes.      
Preferred stock, redemption price per share                     $ 0.10      
Series F Common Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Common stock, par value       $ 0.001                    
Employee Stock [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Non-vested stock options granted, unrecognized estimated compensation cost                     $ 328,000      
Non-vested stock options granted, weighted average period                     7 years 2 months 26 days      
H.C. Wainwright &amp; Co., LLC [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Non-accountable expense allowance   $ 50,000                        
Clearing fees   $ 15,950                        
Number of warrants to purchase   18,000                        
Warrants expire date   Nov. 29, 2027                        
Warrants exercise price   $ 12.50                        
H.C. Wainwright &amp; Co., LLC [Member] | IPO [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Gross proceeds of aggregate cash fee percentage   7.50%                        
Gross proceeds of management fee percentage   1.00%                        
Securities Purchase Agreement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Sale of stock, number of shares issued 240,000                          
Sale of stock, price per share $ 10.00                          
Proceeds from sale of common stock $ 2,100,000                          
Gross proceeds from private placement             $ 6,000,000.0              
Net proceeds from private placement             $ 5,400,000              
Securities Purchase Agreement [Member] | Pre Funded Warrants [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Sale of stock, number of shares issued             132,857              
Sale of stock, price per share             $ 13.98              
Securities Purchase Agreement [Member] | Private Placement [Member]                            
Subsidiary, Sale of Stock [Line Items]                            
Sale of stock, number of shares issued             295,714              
Sale of stock, price per share             $ 14.00              
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details)
Dec. 31, 2022
$ / shares
Dec. 31, 2021
$ / shares
Warrants, measurement input, term 5 years 2 years
Measurement Input, Price Volatility [Member]    
Warrants, measurement input 60.7  
Measurement Input, Risk Free Interest Rate [Member]    
Warrants, measurement input 0.34 1.44
Minimum [Member]    
Stock price $ 0.45 $ 0.72
Minimum [Member] | Measurement Input, Expected Term [Member] | Derivative Liability [Member]    
Warrants, measurement input, term 8 months 1 day 8 months 1 day
Minimum [Member] | Measurement Input, Price Volatility [Member]    
Warrants, measurement input 55.6  
Maximum [Member]    
Stock price $ 0.78 $ 2.07
Maximum [Member] | Measurement Input, Expected Term [Member] | Derivative Liability [Member]    
Warrants, measurement input, term 6 years 6 months 21 days 6 years 6 months 21 days
Maximum [Member] | Measurement Input, Price Volatility [Member]    
Warrants, measurement input 56.5  
Warrant [Member] | Minimum [Member]    
Stock price $ 1.01 $ 1.01
Warrant [Member] | Minimum [Member] | Measurement Input, Conversion Price [Member]    
Warrants, measurement input 0.72 0.72
Warrant [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]    
Warrants, measurement input 0.8270 0.8270
Warrant [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Warrants, measurement input 0.0009 0.0009
Warrant [Member] | Maximum [Member]    
Stock price $ 2.94 $ 2.94
Warrant [Member] | Maximum [Member] | Measurement Input, Conversion Price [Member]    
Warrants, measurement input 6.90 6.90
Warrant [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]    
Warrants, measurement input 2.11 2.11
Warrant [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Warrants, measurement input 0.0121 0.0121
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.23.1
DERIVATIVE LIABILITIES (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Apr. 06, 2021
Dec. 31, 2022
Dec. 31, 2021
Jun. 14, 2022
Sep. 30, 2021
Offsetting Assets [Line Items]          
Payments for repurchase of warrants   $ 388    
Class of warrant or right, exercise price of warrants or rights       $ 20.00  
Gain on purchase of warrants   $ 64    
Minimum [Member]          
Offsetting Assets [Line Items]          
Class of warrant or right, exercise price of warrants or rights         $ 17.60
Maximum [Member]          
Offsetting Assets [Line Items]          
Class of warrant or right, exercise price of warrants or rights         $ 50.00
Derivative Liability Warrants [Member] | Investors [Member]          
Offsetting Assets [Line Items]          
Number of warrants acquired 33,167        
Payments for repurchase of warrants $ 368        
Derivative liability 451        
Gain on purchase of warrants $ 64        
Derivative Liability Warrants [Member] | Investors [Member] | Minimum [Member]          
Offsetting Assets [Line Items]          
Class of warrant or right, exercise price of warrants or rights $ 17.6        
Derivative Liability Warrants [Member] | Investors [Member] | Maximum [Member]          
Offsetting Assets [Line Items]          
Class of warrant or right, exercise price of warrants or rights $ 18.8        
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)
$ in Thousands
Dec. 31, 2022
USD ($)
Leases  
2023 $ 73
2024 4
Total undiscounted operating lease payments 77
Less: Imputed interest 4
Present value of operating lease liabilities $ 73
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.23.1
LEASES (Details Narrative)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Weighted-average remaining lease term 1 year 18 days
Weighted-average discount rate 10.00%
Operating lease, expense $ 75
Minimum [Member]  
Lease term 2 years
Maximum [Member]  
Lease term 3 years
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details) - shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 225,871 242,467
Stock Options Employee And Non Employee [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 147,619 127,000
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 78,252 115,467
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total $ 752 $ 1,695
UNITED STATES    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total 710 1,627
Europe [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total 25 18
AUSTRALIA    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total 9 6
INDIA    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total 3
ISRAEL    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total 5
Other Country [Member]    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total $ 5 $ 39
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF WARRANTS ASSUMPTIONS (Details)
Dec. 31, 2022
$ / shares
Dec. 31, 2021
$ / shares
Expected term (in years) 5 years 2 years
Sanuwave Health, Inc. [Member]    
Expected term (in years) 8 years 10 years
Price at Valuation [Member] | Sanuwave Health, Inc. [Member]    
Warrants and rights outstanding, measurement input 0.02  
Price at Valuation [Member] | Sanuwave Health, Inc. [Member] | Minimum [Member]    
Warrants and rights outstanding, measurement input   0.19
Price at Valuation [Member] | Sanuwave Health, Inc. [Member] | Maximum [Member]    
Warrants and rights outstanding, measurement input   0.26
Measurement Input, Exercise Price [Member] | Sanuwave Health, Inc. [Member]    
Warrants and rights outstanding, measurement input 0.19 0.19
Measurement Input, Risk Free Interest Rate [Member]    
Warrants and rights outstanding, measurement input 0.34 1.44
Measurement Input, Risk Free Interest Rate [Member] | Sanuwave Health, Inc. [Member]    
Warrants and rights outstanding, measurement input 0.0396  
Measurement Input, Risk Free Interest Rate [Member] | Sanuwave Health, Inc. [Member] | Minimum [Member]    
Warrants and rights outstanding, measurement input   0.0066
Measurement Input, Risk Free Interest Rate [Member] | Sanuwave Health, Inc. [Member] | Maximum [Member]    
Warrants and rights outstanding, measurement input   0.0073
Measurement Input, Price Volatility [Member]    
Warrants and rights outstanding, measurement input 60.7  
Measurement Input, Price Volatility [Member] | Minimum [Member]    
Warrants and rights outstanding, measurement input 55.6  
Measurement Input, Price Volatility [Member] | Maximum [Member]    
Warrants and rights outstanding, measurement input 56.5  
Measurement Input, Price Volatility [Member] | Sanuwave Health, Inc. [Member]    
Warrants and rights outstanding, measurement input 1.556  
Measurement Input, Price Volatility [Member] | Sanuwave Health, Inc. [Member] | Minimum [Member]    
Warrants and rights outstanding, measurement input   1.406
Measurement Input, Price Volatility [Member] | Sanuwave Health, Inc. [Member] | Maximum [Member]    
Warrants and rights outstanding, measurement input   1.439
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Offsetting Assets [Line Items]    
Fair value adjustments - Warrant liability $ 3 $ 19
Derivative Asset [Member]    
Offsetting Assets [Line Items]    
Balance beginning 19 25
New Issuances
Fair value adjustments - Sanuwave warrants (16) (6)
Fair value adjustments - Warrant liability  
Reclassification liability to equity  
Buy back of warrants  
Balance ending 3 19
Derivative Liabilities [Member]    
Offsetting Assets [Line Items]    
Balance beginning 2,471
New Issuances 1,819
Fair value adjustments - Sanuwave warrants
Fair value adjustments - Warrant liability   6,956
Reclassification liability to equity   (10,793)
Buy back of warrants   (453)
Balance ending
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]    
Other assets $ 3 $ 19
Fair Value, Inputs, Level 1 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Other assets
Fair Value, Inputs, Level 2 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Other assets
Fair Value, Inputs, Level 3 [Member]    
Defined Benefit Plan Disclosure [Line Items]    
Other assets $ 3 $ 19
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.23.1
OTHER ASSETS (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Nov. 29, 2022
Sep. 30, 2022
Jun. 14, 2022
Sep. 30, 2021
Apr. 09, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contractual term (in years) 5 years 2 years          
Warrants issued to purchase common stock     18,000 12,500 12,500 109,675  
Exercise price of warrants per share         $ 20.00    
Fair value of warrants $ 3 $ 19          
Change in fair value of warrants $ 16 $ 6          
Sanuwave Health, Inc. [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contractual term (in years) 8 years 10 years          
Licensing Agreement [Member] | Sanuwave Health, Inc. [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contractual term (in years)             10 years
Warrants issued to purchase common stock             127,000
Exercise price of warrants per share             $ 0.19
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
$ in Thousands
 1 Months Ended
Mar. 15, 2022
Feb. 26, 2021
Dec. 17, 2019
Jan. 31, 2021
Nov. 30, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Litigation damages sought value   $ 3,000      
Escrow amount         $ 391
Litigation settlement, amount       $ 366  
Jona Zumeris [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Litigation damages sought value     $ 900    
Former Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Litigation damages sought value     $ 700    
Arbitrator [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Damages awarded value $ 1,500        
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTION (Details Narrative)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
USD ($)
Related Party Transactions [Abstract]  
Legal fees paid $ 256,908
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal
State
Foreign 37 32
Total 37 32
Federal (1,545) (1,263)
State 653 (131)
Foreign (1) (4)
Total (893) (1,398)
Less: Valuation Allowance 893 1,398
Total Tax $ 37 $ 32
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Federal income tax benefit at statutory rate 21.00% 21.00%
State income taxes, net of federal benefit (12.06%) 0.92%
Foreign rate differential (0.03%) 0.02%
Permanent Items (0.61%) (13.04%)
Change in valuation allowance (16.61%) (9.81%)
Return to provision adjustments 7.54% (0.01%)
Forfeited options 0.00% (0.16%)
Other 0.09% 0.86%
Effective tax rate (0.68%) (0.22%)
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Domestic $ 5,557 $ 14,333
Foreign (144) (82)
Loss before taxes $ 5,413 $ 14,250
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carry forward $ 7,306 $ 6,563
Arbitration accrual 414 414
Stock compensation and other 483 327
Deferred tax assets before valuation allowance 8,203 7,304
Valuation allowance (8,203) (7,304)
Net deferred tax asset
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating Loss Carryforwards [Line Items]    
Federal net operating loss carried forward $ 19,200  
Federal net operating loss offset against taxable income $ 14,000  
Corporate tax rate 21.00% 21.00%
Net increases in valuation allowance $ 894 $ 1,417
ISRAEL    
Operating Loss Carryforwards [Line Items]    
Corporate tax rate 23.00% 23.00%
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carry forward $ 33,000  
Operating loss carryforwards expiration term 20 years  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards [Line Items]    
Net operating loss carry forward $ 6,000  
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative) - $ / shares
Feb. 08, 2023
Dec. 15, 2022
Feb. 28, 2023
Subsequent Event [Line Items]      
Reverse stock split description   Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50  
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Reverse stock split description common stock at a ratio of 1 post-split share for every 20 pre-split shares    
Stock splits 20    
Reverse stock splits 1    
Minimum bid price per share     $ 1.00
XML 81 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001326706 2022-01-01 2022-12-31 0001326706 2022-06-30 0001326706 2023-04-17 0001326706 2022-12-31 0001326706 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2021-12-31 0001326706 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001326706 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001326706 us-gaap:CommonStockMember 2020-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001326706 us-gaap:RetainedEarningsMember 2020-12-31 0001326706 2020-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001326706 us-gaap:CommonStockMember 2021-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001326706 us-gaap:RetainedEarningsMember 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001326706 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001326706 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001326706 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001326706 us-gaap:CommonStockMember 2022-12-31 0001326706 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001326706 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001326706 us-gaap:RetainedEarningsMember 2022-12-31 0001326706 NAOV:SaleOfEquitySecuritiesMember 2022-12-31 0001326706 us-gaap:ComputerEquipmentMember 2022-01-01 2022-12-31 0001326706 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001326706 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-12-31 0001326706 2021-08-16 0001326706 2021-08-17 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2022-11-28 2022-11-29 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2022-11-29 0001326706 us-gaap:IPOMember NAOV:HCWainwrightAndCoLLCMember 2022-10-05 2022-10-06 0001326706 NAOV:HCWainwrightAndCoLLCMember 2022-10-05 2022-10-06 0001326706 NAOV:HCWainwrightAndCoLLCMember 2022-10-06 0001326706 us-gaap:SeriesEPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesDPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesCPreferredStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:SeriesCPreferredStockMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001326706 us-gaap:SeriesFPreferredStockMember 2022-09-12 2022-09-13 0001326706 NAOV:SeriesFCommonStockMember 2022-09-12 2022-09-13 0001326706 us-gaap:SeriesFPreferredStockMember 2022-01-01 2022-12-31 0001326706 NAOV:EmployeeOptionsMember 2022-01-01 2022-12-31 0001326706 NAOV:EmployeeOptionsMember 2021-01-01 2021-12-31 0001326706 us-gaap:EmployeeStockMember 2022-12-31 0001326706 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001326706 us-gaap:PrivatePlacementMember NAOV:SecuritiesPurchaseAgreementMember 2020-12-01 2020-12-02 0001326706 us-gaap:PrivatePlacementMember NAOV:SecuritiesPurchaseAgreementMember 2020-12-02 0001326706 NAOV:PreFundedWarrantsMember NAOV:SecuritiesPurchaseAgreementMember 2020-12-01 2020-12-02 0001326706 NAOV:PreFundedWarrantsMember NAOV:SecuritiesPurchaseAgreementMember 2020-12-02 0001326706 NAOV:SecuritiesPurchaseAgreementMember 2020-12-01 2020-12-02 0001326706 NAOV:WarrantsMember NAOV:TwoInvestorsMember 2021-01-01 2021-01-31 0001326706 NAOV:WarrantsMember NAOV:TwoInvestorsMember 2021-01-31 0001326706 NAOV:AccreditorInvestorsMember NAOV:WarrantsMember 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-01-20 2021-01-21 0001326706 NAOV:NewWarrantsMember 2021-04-01 2021-06-30 0001326706 2021-09-30 0001326706 srt:MinimumMember 2021-09-30 0001326706 srt:MaximumMember 2021-09-30 0001326706 us-gaap:WarrantMember 2021-09-01 2021-09-30 0001326706 2022-06-14 0001326706 2022-06-13 2022-06-14 0001326706 2022-09-30 0001326706 2022-09-29 2022-09-30 0001326706 2022-11-29 0001326706 NAOV:EmployeeOptionsMember 2021-12-31 0001326706 NAOV:EmployeeOptionsMember 2022-12-31 0001326706 srt:MinimumMember 2022-12-31 0001326706 srt:MaximumMember 2022-12-31 0001326706 srt:MinimumMember 2021-12-31 0001326706 srt:MaximumMember 2021-12-31 0001326706 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001326706 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001326706 us-gaap:MeasurementInputExpectedDividendRateMember 2022-12-31 0001326706 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001326706 NAOV:PrivateInvestorsMember us-gaap:WarrantMember 2020-12-31 0001326706 NAOV:PrivateInvestorsMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001326706 NAOV:PrivateInvestorsMember us-gaap:WarrantMember 2021-12-31 0001326706 NAOV:PrivateInvestorsMember us-gaap:WarrantMember 2022-01-01 2022-12-31 0001326706 NAOV:PrivateInvestorsMember us-gaap:WarrantMember 2022-12-31 0001326706 NAOV:InvestorsMember NAOV:DerivativeLiabilityWarrantsMember 2021-04-05 2021-04-06 0001326706 srt:MinimumMember NAOV:InvestorsMember NAOV:DerivativeLiabilityWarrantsMember 2021-04-06 0001326706 srt:MaximumMember NAOV:InvestorsMember NAOV:DerivativeLiabilityWarrantsMember 2021-04-06 0001326706 NAOV:InvestorsMember NAOV:DerivativeLiabilityWarrantsMember 2021-04-06 0001326706 srt:MinimumMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MaximumMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputConversionPriceMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputConversionPriceMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputConversionPriceMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputConversionPriceMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MinimumMember NAOV:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001326706 srt:MaximumMember NAOV:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001326706 srt:MinimumMember NAOV:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001326706 srt:MaximumMember NAOV:DerivativeLiabilityMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-12-31 0001326706 NAOV:StockOptionsEmployeeAndNonEmployeeMember 2022-01-01 2022-12-31 0001326706 NAOV:StockOptionsEmployeeAndNonEmployeeMember 2021-01-01 2021-12-31 0001326706 NAOV:WarrantsMember 2022-01-01 2022-12-31 0001326706 NAOV:WarrantsMember 2021-01-01 2021-12-31 0001326706 country:US 2022-01-01 2022-12-31 0001326706 country:US 2021-01-01 2021-12-31 0001326706 srt:EuropeMember 2022-01-01 2022-12-31 0001326706 srt:EuropeMember 2021-01-01 2021-12-31 0001326706 country:AU 2022-01-01 2022-12-31 0001326706 country:AU 2021-01-01 2021-12-31 0001326706 country:IN 2022-01-01 2022-12-31 0001326706 country:IN 2021-01-01 2021-12-31 0001326706 country:IL 2022-01-01 2022-12-31 0001326706 country:IL 2021-01-01 2021-12-31 0001326706 NAOV:OtherCountryMember 2022-01-01 2022-12-31 0001326706 NAOV:OtherCountryMember 2021-01-01 2021-12-31 0001326706 NAOV:LicensingAgreementMember NAOV:SanuwaveHealthIncMember 2020-04-09 0001326706 NAOV:PriceAtValuationMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 srt:MinimumMember NAOV:PriceAtValuationMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 srt:MaximumMember NAOV:PriceAtValuationMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputExercisePriceMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 us-gaap:MeasurementInputExercisePriceMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputRiskFreeInterestRateMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 us-gaap:MeasurementInputPriceVolatilityMember NAOV:SanuwaveHealthIncMember 2022-12-31 0001326706 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember NAOV:SanuwaveHealthIncMember 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2020-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2020-12-31 0001326706 NAOV:DerivativeAssetMember 2021-01-01 2021-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2021-01-01 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2021-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2021-12-31 0001326706 NAOV:DerivativeAssetMember 2022-01-01 2022-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2022-01-01 2022-12-31 0001326706 NAOV:DerivativeAssetMember 2022-12-31 0001326706 NAOV:DerivativeLiabilitiesMember 2022-12-31 0001326706 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001326706 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001326706 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001326706 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001326706 NAOV:JonaZumerisMember 2019-12-16 2019-12-17 0001326706 NAOV:FormerOfficerMember 2019-12-16 2019-12-17 0001326706 2020-11-30 0001326706 2021-01-01 2021-01-31 0001326706 2021-02-25 2021-02-26 0001326706 NAOV:ArbitratorMember 2022-03-14 2022-03-15 0001326706 us-gaap:DomesticCountryMember 2022-12-31 0001326706 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001326706 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001326706 us-gaap:SubsequentEventMember 2023-02-07 2023-02-08 0001326706 2022-12-14 2022-12-15 0001326706 us-gaap:SubsequentEventMember 2023-02-28 iso4217:USD shares iso4217:USD shares pure 0001326706 false FY 10-K true 2022-12-31 --12-31 2022 false 001-36445 NanoVibronix, Inc. DE 01-0801232 525 Executive Blvd Elmsford NY 10523 (914) 233-3004 Common stock, par value $0.001 per share NOAV NASDAQ No No Yes Yes Non-accelerated Filer true false false false 17539360 1662377 The information required by Part III of this Form 10-K, to the extent not set forth herein, is incorporated by reference from the registrant’s definitive proxy statement for its 2023 Annual Meeting of Stockholders. Such proxy statement shall be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates 688 Marcum LLP New York, NY 2713000 7737000 9000 200000 712000 230000 2175000 175000 5609000 8342000 7000 5000 3000 19000 179000 207000 81000 49000 270000 280000 5879000 8622000 66000 87000 2148000 1723000 21000 44000 81000 49000 2316000 1903000 223000 253000 107000 153000 2646000 2309000 0.001 0.001 3000000 3000000 0 0 0 0 0.001 0.001 506 506 0 0 0 0 0.001 0.001 1999494 1999494 0 0 0 0 0.01 0.01 40000 0 0 0 0 0 0.001 0.001 40000000 40000000 1641146 1641146 1399890 1399890 2000 1000 65634000 63189000 -18000 60000 -62385000 -56937000 3233000 6313000 5879000 8622000 752000 1695000 585000 925000 167000 770000 283000 293000 965000 1101000 3931000 5059000 5179000 6453000 -5012000 -5683000 347000 -54000 -48000 -6956000 64000 1627000 -5413000 -14250000 35000 32000 -5448000 -14282000 -3.84 -11.35 1419670 1258141 -5448000 -14282000 78000 6000 -5526000 -14288000 666667 1000 153 875000 1000 1062326 1000 44980000 66000 -42655000 2394000 190000 190000 252830 7056000 7056000 10963000 10963000 -666667 -1000 33333 -1000 -153 7650 -875000 -1000 43750 -1000 -6000 -6000 -14282000 -14282000 1399890 1000 63189000 60000 -56937000 6313000 1399890 1000 63189000 60000 -56937000 6313000 354000 354000 310424000 240000 1000 2089000 2090000 1256 2000 2000 -78000 -78000 -5448000 -5448000 1641146 2000 65634000 -18000 -62385000 3233000 1641146 2000 65634000 -18000 -62385000 3233000 -5448000 -14282000 1000 2000 354000 382000 347000 1500000 1627000 -16000 -6000 -6956000 64000 -191000 175000 482000 -37000 2000000 30000 -21000 -59000 78000 -265000 -69000 -2000 -2000 -7035000 -4367000 3000 3000 -3000 -3000 2090000 2000 4968000 388000 2092000 4580000 -78000 -6000 -5024000 204000 7737000 7533000 2713000 7737000 1000 2087000 8706000 2257000 <p id="xdx_80C_eus-gaap--NatureOfOperations_zcF1RDIDnLSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_827_zLGFE3WMewC2">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix Ltd., a company registered in Israel, which commenced operations in October 2003.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_807_ecustom--LiquidityAndPlanOfOperationsTextBlock_z1GjelwNGK94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_822_zru0f8udJ2F7">LIQUIDITY AND PLAN OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. In 2022, the Company’s cash used in operations was $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20220101__20221231_ztc9nJZMIF1l" title="Net cash used in operating activities">7,035</span> and received net proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20220101__20221231_zM0Dyym1Lr5a" title="Net proceeds received">2,090</span> (net of offering costs of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220101__20221231_zD4B5yLCNCH7" title="Net offering costs">310,424</span>) from the sale of our equity securities, leaving a cash balance of $<span id="xdx_90B_eus-gaap--Cash_iI_pn3n3_c20221231__us-gaap--CollateralAxis__custom--SaleOfEquitySecuritiesMember_z4jzLxOAT6xf" title="Cash balance">2,713</span> as of December 31, 2022. Because the Company does not have sufficient resources to fund our operation for the next twelve months from the date of this filing, management has substantial doubt of the Company’s ability to continue as a going concern. The Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -7035000 2090000 310424000 2713000 <p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zH8PcOrg0y8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_82E_z0CbPaRVVqh8">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrxWu0j9I8Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z419wmkSb7a4">Basis of presentation and principles of consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_znYuURL50lX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z56OCZsDuUth">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z2mgryBmoKu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z9XLs3Tn62Ad">Foreign currency translation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2022 and 2021 were $<span id="xdx_904_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20221231_zgPql4ylJY07" title="Gains and losses from foreign currency translation">85</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20210101__20211231_zXUBsk1XIMX8" title="Gains and losses from foreign currency translation">6</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zMPfBtf6tCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zraUxxUXUql2">Earnings per share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred stock as of December 31, 2022 and 2021, respectively, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zTTvdTmXY7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z1E0yV9EL1Qf">Inventory</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was <span id="xdx_903_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20211231_zlBiwHRfp6Bb" title="Inventory allowance"><span id="xdx_905_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20221231_zfHE9qM5JRne" title="Inventory allowance">no</span></span> allowance on inventory.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJEUIXOi5UWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zoNxICdbIGIg">Property and equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zcpQTZ7Qvvj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPfG9Y0lnQ93" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Years</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsR7rOuB0tz2" title="Estimated useful life">3</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office furniture and equipment</td><td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z2dnSWCT2Ps4" title="Estimated useful life">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNG1f93xqsHa" title="Estimated useful life">7</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zpb9rvplhYR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1ALIMbPOZDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_ziQ41vunKV28">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--SequencingPolicyTextBlock_zwdjGoEP3DF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zUZdvGPvNwE">Sequencing</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--SeverancePayPolicyTextBlock_zcQ9exyFDzL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zSBP3URaVKj3">Severance pay</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet. Accrued severance pay liability at December 31, 2022 and 2021 was $<span id="xdx_903_eus-gaap--SeveranceCosts1_pn3n3_c20220101__20221231_zA2s7jVhLn82" title="Severance expenses">223</span> and $<span id="xdx_900_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zcNOzTUqDGL9" title="Severance expenses">253</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zVNGZCIHAXf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zkeOjoKTSnr">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company accounts for its leases in accordance with ASU 2016-02, “Leases” (Topic 842). This topic requires that a lessee recognize the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classify them as operating leases. For leases with a term of 12 months or less, the Company elects to implement in a class of underlying asset not to recognize lease assets and lease liabilities. The right-of-use assets and lease liabilities have been measured by the present value of the Company’s remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zNVjCQc90GT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z48Ri2RT6zng">Revenue recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpIaO8Akpiq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zz2Au21UBS3">Income taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zi6EPIU4mhbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z2DNLZ9D5Wdi">Stock-based compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical share price movements. The expected option term represents the period that the Company’s stock options are expected to be outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuUmiAOfQnyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_znw8Ee6VStH7">Recently adopted accounting standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrxWu0j9I8Le" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_z419wmkSb7a4">Basis of presentation and principles of consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of NanoVibronix, Inc. and its wholly owned subsidiary. Intercompany accounts and transactions have been eliminated. The consolidated financial statements and accompanying notes have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_znYuURL50lX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_z56OCZsDuUth">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_z2mgryBmoKu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z9XLs3Tn62Ad">Foreign currency translation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as other comprehensive income, as appropriate. The cumulative translation losses and gains as of the years ended December 31, 2022 and 2021 were $<span id="xdx_904_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20220101__20221231_zgPql4ylJY07" title="Gains and losses from foreign currency translation">85</span> and $<span id="xdx_905_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_pn3n3_c20210101__20211231_zXUBsk1XIMX8" title="Gains and losses from foreign currency translation">6</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 85000 6000 <p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zMPfBtf6tCz7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86C_zraUxxUXUql2">Earnings per share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. Potentially dilutive securities from the exercise of stock option, warrants and exercise of preferred stock as of December 31, 2022 and 2021, respectively, were excluded from the computation of diluted net loss per share because the effect of their inclusion would have been antidilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_84E_eus-gaap--InventoryPolicyTextBlock_zTTvdTmXY7Nk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_z1E0yV9EL1Qf">Inventory</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the “first-in, first-out” method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation, provisions are made when required to write-down inventory to its net market value. As of December 31, 2022 and 2021, there was <span id="xdx_903_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20211231_zlBiwHRfp6Bb" title="Inventory allowance"><span id="xdx_905_eus-gaap--InventoryAdjustments_iI_pn3n3_do_c20221231_zfHE9qM5JRne" title="Inventory allowance">no</span></span> allowance on inventory.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zJEUIXOi5UWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zoNxICdbIGIg">Property and equipment</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zcpQTZ7Qvvj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPfG9Y0lnQ93" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Years</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsR7rOuB0tz2" title="Estimated useful life">3</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office furniture and equipment</td><td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z2dnSWCT2Ps4" title="Estimated useful life">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNG1f93xqsHa" title="Estimated useful life">7</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zpb9rvplhYR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_ecustom--ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock_zcpQTZ7Qvvj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, at the following annual rates:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPfG9Y0lnQ93" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Years</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: justify">Computers and peripheral equipment</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zsR7rOuB0tz2" title="Estimated useful life">3</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Office furniture and equipment</td><td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_z2dnSWCT2Ps4" title="Estimated useful life">5</span>-<span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20220101__20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zNG1f93xqsHa" title="Estimated useful life">7</span></span></td><td style="text-align: left"> </td></tr> </table> P3Y P5Y P7Y <p id="xdx_842_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z1ALIMbPOZDb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_ziQ41vunKV28">Impairment of Long-Lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable under the provisions of accounting for the impairment of long-lived assets. If it is determined that an impairment loss has occurred based upon expected future cash flows, the loss is recognized in the Consolidated Statements of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--SequencingPolicyTextBlock_zwdjGoEP3DF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zUZdvGPvNwE">Sequencing</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted a sequencing policy under ASC 815-40-35 whereby if reclassification of contracts from equity to liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares. This was due to the Company committing more shares than authorized. While temporary suspensions are in place to keep the potential exercises beneath the number authorized, certain instruments are classified as liabilities, after allocating available authorized shares on the basis of the most recent grant date of potentially dilutive instruments. Pursuant to ASC 815, issuances of securities granted as compensation in a share-based payment arrangement are not subject to the sequencing policy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--SeverancePayPolicyTextBlock_zcQ9exyFDzL8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zSBP3URaVKj3">Severance pay</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company’s balance sheet. Accrued severance pay liability at December 31, 2022 and 2021 was $<span id="xdx_903_eus-gaap--SeveranceCosts1_pn3n3_c20220101__20221231_zA2s7jVhLn82" title="Severance expenses">223</span> and $<span id="xdx_900_eus-gaap--SeveranceCosts1_pn3n3_c20210101__20211231_zcNOzTUqDGL9" title="Severance expenses">253</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> 223000 253000 <p id="xdx_841_eus-gaap--LesseeLeasesPolicyTextBlock_zVNGZCIHAXf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zkeOjoKTSnr">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">The Company accounts for its leases in accordance with ASU 2016-02, “Leases” (Topic 842). This topic requires that a lessee recognize the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the consolidated balance sheet for all leases with a term longer than 12 months and classify them as operating leases. For leases with a term of 12 months or less, the Company elects to implement in a class of underlying asset not to recognize lease assets and lease liabilities. The right-of-use assets and lease liabilities have been measured by the present value of the Company’s remaining lease payments over the lease term using our incremental borrowing rates or implicit rates, when readily determinable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zNVjCQc90GT3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z48Ri2RT6zng">Revenue recognition</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--IncomeTaxPolicyTextBlock_zpIaO8Akpiq9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zz2Au21UBS3">Income taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides full valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes interest and penalties related to uncertain tax positions on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zi6EPIU4mhbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z2DNLZ9D5Wdi">Stock-based compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its stock-options awards. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon similar traded companies’ historical share price movements. The expected option term represents the period that the Company’s stock options are expected to be outstanding. The Company currently uses the simplified method and will continue to do so until sufficient historical exercise data supports using expected life assumptions. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with an equivalent term. The expected dividend yield assumption is based on the Company’s historical experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable plans to pay cash dividends in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuUmiAOfQnyg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_znw8Ee6VStH7">Recently adopted accounting standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. This ASU is effective for interim and annual reporting periods beginning after December 15, 2022. The adoption of Topic 326 did not have a material effect on the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_80B_eus-gaap--OtherCurrentAssetsTextBlock_z2sBkIYDDKY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span id="xdx_825_zOV53GTqy8of">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zF2DYoVusDh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other receivables consist of the following:</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zVYsL8dcsHOb" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zUUe6N7KBvjg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_zQBSoYJdv0q3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maPEAOAzR3N_zkBQgBYPsZ6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Prepaid expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">612</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">166</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzR3N_zKurmtZ7Sck3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzR3N_zyj5oM9Y1Sxf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other receivables</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_z0BFKwXIfuh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_zF2DYoVusDh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other receivables consist of the following:</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zVYsL8dcsHOb" style="display: none">SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20221231_zUUe6N7KBvjg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_zQBSoYJdv0q3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_maPEAOAzR3N_zkBQgBYPsZ6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Prepaid expenses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">612</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">166</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzR3N_zKurmtZ7Sck3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzR3N_zyj5oM9Y1Sxf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses and other receivables</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">712</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 612000 166000 100000 64000 712000 230000 <p id="xdx_80A_eus-gaap--InventoryDisclosureTextBlock_z8IPMuXUtS6j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82F_z5p3wdU73xE1">INVENTORY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zcH53jRHFQdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following components:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zGzyyJwSpaZ9" style="display: none">SCHEDULE OF INVENTORY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zrqVtLMtt9jh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zjZYOfEtcB58" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzmOi_zGCxZIAndlFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzmOi_zQ9N2qTlEOE6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_mtINzmOi_zGP3vlahGydj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zJVmOG9xV78i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zcH53jRHFQdb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following components:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zGzyyJwSpaZ9" style="display: none">SCHEDULE OF INVENTORY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zrqVtLMtt9jh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20211231_zjZYOfEtcB58" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzmOi_zGCxZIAndlFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzmOi_zQ9N2qTlEOE6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,145</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryNet_iTI_pn3n3_mtINzmOi_zGP3vlahGydj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 30000 2145000 175000 2175000 175000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zunN11Hkcss" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 - <span id="xdx_82D_zDu4FS7DVoul">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the event of liquidation, dissolution or winding up of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2021, the Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of the Company’s Common Stock authorized for issuance from <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210816_zbCDLUFHMG3d" title="Common stock, shares authorized">24,109,635</span> shares to <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210817_zhRO2NLvoLn8" title="Common stock, shares authorized">40,000,000</span> shares. As a result of the vote to increase the number of shares authorized for issuance, the warrants that were previously accounted for as derivative liabilities were marked to market through the date of approval and then reclassified to additional paid in capital (equity), as the Company had sufficient authorized shares to settle the exercise of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance of common stock for cash</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 29, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell in a registered direct offering (the “Offering”), <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zaHjAe1D1Wb4" title="Sale of stock, number of shares issued">240,000</span> shares of the Company’s common stock at an offering price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWxPhIsuhaO6" title="Sale of stock, price per share">10.00</span> per share. The Company received net proceeds from the sale of such offering, after </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deducting placement agent fees and expenses and offering expenses payable by the Company, of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20221128__20221129__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTqhJU9W2EA5" title="Proceeds from sale of common stock">2.1</span> million. <span style="background-color: white">The Company intends to use the net proceeds for general working capital purposes.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 6, 2022, the Company entered into an engagement letter with H.C. Wainwright &amp; Co., LLC (the “Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the Company, on a reasonable best-efforts basis, in connection with the Offering. The Company will pay Wainwright an aggregate cash fee equal to <span id="xdx_905_ecustom--GrossProceedsOfAggregateCashFeePercentage_pid_dp_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zCEDMpJvh47e" title="Gross proceeds of aggregate cash fee percentage">7.5</span>% of the gross proceeds of the Offering, a management fee equal to <span id="xdx_901_ecustom--GrossProceedsOfManagementFeePercentage_pid_dp_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpmO2ZhUTkeh" title="Gross proceeds of management fee percentage">1.0</span>% of the gross proceeds of the Offering, a non-accountable expense allowance of $<span id="xdx_903_eus-gaap--OtherNoncashExpense_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zjjvR1k8KSIb" title="Non-accountable expense allowance">50,000</span> and $<span id="xdx_900_eus-gaap--ClearanceFees_c20221005__20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zOjYoTBPXyFk" title="Clearing fees">15,950</span> for clearing fees. Additionally, the Company has agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zA8kjq5LAep4" title="Warrants issued to purchase common stock">18,000</span> shares of common stock. The warrants expire on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zFmcPxNf8fJg" title="Warrants expiration date">November 29, 2027</span> and have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20221006__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zm6OGybzBiTk" title="Exercise price of warrants per share">12.50</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C, D and E Preferred Stock conversion to common stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PreferredStockConversionBasis_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zYZWTRIEuctb" title="Preferred stock, conversion description">Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one twentieth of a share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, shareholders converted <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zwahOdlsuDr6" title="Number of shares converted">0</span> and <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zLjz6WoPaUWe" title="Number of shares converted">875,000</span> shares of Series E Preferred Stock into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNdpYmVoZZL1" title="Shares issued upon conversion">0</span> and <span id="xdx_908_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLYjy4hp994k" title="Shares issued upon conversion">43,750</span> shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made to convert these shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PreferredStockConversionBasis_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zxAlzQKhqQS7" title="Preferred stock, conversion description">Each share of Series D Preferred Stock is convertible into fifty shares of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, shareholders converted <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zKyudUqJXU88" title="Number of shares converted">0</span> and <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zXCCTjOzVJRi" title="Number of shares converted">153</span> shares of Series D Preferred Stock into <span id="xdx_901_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEpTgEwYjgn4" title="Shares issued upon conversion">0</span> and <span id="xdx_90F_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKgxM7Pg3Nr3" title="Shares issued upon conversion">7,650</span> shares of common stock, respectively, at a conversion rate of 1 to 50. No purchase was made in order to convert these shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PreferredStockConversionBasis_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zmA4iVu0rV2g" title="Preferred stock, conversion description">Each share of Series C Preferred Stock is convertible into one twentieth of a share of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, shareholders converted <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zSgHs2X6KNp4" title="Number of shares converted">0</span> and <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Number of shares converted">666,667</span> shares of Series C Preferred Stock into <span id="xdx_905_eus-gaap--ConversionOfStockSharesIssued1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFlVQ535H4uh" title="Shares issued upon conversion">0</span> and <span id="xdx_907_eus-gaap--ConversionOfStockSharesIssued1_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVDVQMcqCmcb" title="Shares issued upon conversion">33,333</span> shares of common stock, respectively, at a conversion rate of 20 to 1. No purchase was made in order to convert these shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series F Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, the Board declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $<span id="xdx_90C_eus-gaap--PreferredStockDividendsPerShareDeclared_pid_c20220912__20220913__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zUirIzVyFw2d" title="Preferred stock, par value">0.001</span> per share (“Series F Preferred Stock”), for each one share of the Company’s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockDividendsPerShareDeclared_pid_c20220912__20220913__us-gaap--StatementClassOfStockAxis__custom--SeriesFCommonStockMember_zSPq70rY71S9" title="Common stock, par value">0.001</span> per share, to stockholders of record at 5:00 p.m. Eastern Time on October 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PreferredStockVotingRights_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zFVwCaugE9Lg" title="Preferred stock, voting rights, description">Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes.</span> The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of common stock of the Company as a single class exclusively with respect to (1) any proposal to adopt an amendment to Certificate of Incorporation to reclassify the outstanding shares of common stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series F Preferred Stock is not entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal will be cast in the same manner as the vote, if any, of the share of common stock (or fraction thereof) in respect of which such share of Series F Preferred Stock (or fraction thereof) was issued as a dividend is cast on the Reverse Stock Split, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of common stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the approval by the Company’s stockholders of the Reverse Stock Split at any meeting of the stockholders held for the purpose of voting on such proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). As of December 31, 2022, both the Initial Redemption and the Subsequent Redemption have occurred. As a result, no shares of Series F Preferred Stock remain outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $<span id="xdx_909_eus-gaap--PreferredStockRedemptionPricePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_ziyh9e8jTsVk" title="Preferred stock, redemption price per share">0.10</span> in cash for each one hundred whole shares of Series F Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the Certificate of Designation) thereof as of the applicable redemption time and redeemed pursuant to such redemption, payable upon receipt by the Company of a written request submitted by the applicable holder to the corporate secretary of the Company (each a “Redemption Payment Request”) following the applicable redemption time. Such Redemption Payment Request shall (i) be in a form reasonably acceptable to the Company (ii) set forth in reasonable detail the number of shares of Series F Preferred Stock beneficially owned by the holder at the applicable redemption time and include evidence reasonably satisfactory to the Company regarding the same, and (iii) set forth a calculation specifying the amount in cash owed to such Holder by the Company with respect to the shares of Series F Preferred Stock that were redeemed at the applicable redemption time. However, the redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than one hundred whole shares of Series F Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of one hundred, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of one hundred (such, that for example, the former beneficial owner of 150 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 100 shares of Series F Preferred Stock redeemed pursuant to such redemption).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of common stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred Stock equal to the number of shares of common stock to be transferred by such holder will be automatically transferred to the transferee of such shares of common stock. The holders of Series F Preferred Stock, as such, are not entitled to receive dividends of any kind.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Certificate of Designation was filed with the Delaware Secretary of State and became effective on September 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in the proxy statement filed on October 31, 2022, holders of The Company’s common stock and Series F Preferred Stock as of the close of business on October 17, 2022, are entitled to vote on the amendment to the Company’s Certificate of Incorporation to effect, at the discretion of the Company’s Board but prior to the six-month anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Annual Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined by the Board in its discretion and included in a public announcement, and the proposal to adjourn the Annual Meeting to a later date at the Annual Meeting held on December 15, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Stock-based compensation and options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2022 and 2021, <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zL820TvQS1Eh" title="Number of options, exercised">1,256</span> and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zu97Hzdw8nc7" title="Number of options, exercised">0</span> employee options were exercised, and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zSBtdj1q5eNj" title="Number of options, granted">21,875</span> and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zG7G6VC0gDT8" title="Number of options, granted">43,875</span> options were granted, respectively. The options granted during 2022 and 2021 vest at different schedules ranging from date granted to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zt9lZ4fErSkb" title="Fair value options vesting term">9</span> years and were recorded at fair values of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zRekzzfs6eXa" title="Number of options, vested">201</span> and $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zswCBArOKb9e" title="Number of options, vested">583</span>, respectively. During the years ended December 31, 2022 and 2021, stock-based compensation expense of $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z8xBs7R20CXj" title="Stock-based compensation expense">148</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z89aYgwSqMQf" title="Stock-based compensation expense">258</span> was recorded for options that vested, respectively.</span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z30VKZRo0cb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zH8UhOJK2cY7" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7CHiS3iYTx8" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance">127,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVgmMGmwdpEg" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - beginning balance">31.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJZVmDmjxeZ4" title="Weighted Average Remaining Life (Years), Outstanding - beginning balance">7.77</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKoyPAf1frb4" style="text-align: right" title="Options, Granted">21,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbVeHWjUw6G8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">10.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYJq689xuwpi" title="Weighted Average Remaining Life (Years), Granted">9.55</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z819M3PsBGj7" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9R97ABWAIvl" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDtEX4mDeh0h" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zvE8IEcrevHj" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKyGn4Vvjcp" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercised">(1,256</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zR5ulaTp2o97" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">1.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaXLpY9ImEJ5" title="Weighted Average Remaining Life (Years), Granted">0.24</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbYB36R4Rszi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - Ending balance">147,619</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdEzDTDhNWT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">24.42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPhnDNYAwl5d" title="Weighted Average Remaining Life (Years), Outstanding - ending balance">7.24</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zwAClg3STnge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z4FJLGneExk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value for options granted in 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zRGg8xnH606e" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Price at valuation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zYF7qdWaahM2" title="Price at valuation">0.45</span> – <span id="xdx_90D_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zxWbaQoRw3ib" title="Price at valuation">0.78</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MinimumMember_zdvJJCmXezv3" title="Price at valuation">0.72</span> – <span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MaximumMember_znmU1WkS6EZ1" title="Price at valuation">2.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zLWtV2wWmTR2" title="Exercise price">0.45</span> – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zkV0M9RllJA3" title="Exercise price">0.78</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MinimumMember_znsjpMmLgKA" title="Exercise price">0.72</span> – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MaximumMember_zGx8DBph5tOe" title="Exercise price">2.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zMeZyX2f7WG5" title="Risk free interest, minimum">2.32 </span>– <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231_zXSuwZ7WN6a2" title="Risk free interest, maximum">3.58</span> </td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zZ4836RB5pca" title="Risk free interest, minimum">0.27</span> – <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20211231_zo9BSaaPPm5k" title="Risk free interest, maximum">1.29</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zlE5fNjTmgi" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zX0UnhGUdBWh" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_zWpcwM6zV90j" title="Volatility, minimum">125.3</span> – <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zq5HzgJ9SPub" title="Volatility, maximum">127.9</span> </td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_zaFc1rlWwO0f" title="Volatility, minimum">60.9</span> – <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_z8AhHnDIIy98" title="Volatility, maximum">82.7</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zx4xGcG3zcO5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zudJNsbEBuxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zUpAM5UqtSQc" style="display: none">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_z4p7WkRAICX6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zOyjKad5Qhuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlfqVBnoy3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zrZFplrieFUj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXBeBkOkZKWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">323</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">341</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z09u2cnuf8pj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zWAqkmV9mGH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_zq3JeWKgrT5" title="Non-vested stock options granted, unrecognized estimated compensation cost">328</span>, which is expected to be recognized over a weighted average period of approximately <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z4LllJMr28gi" title="Non-vested stock options granted, weighted average period">7.24</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On December 2, 2020, we entered into a Securities Purchase Agreement with certain institutional and accredited investors pursuant to which the Company issued and sold to such investors in a private placement an aggregate of (i) <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201201__20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zcXSnCjWJM98" title="Sale of stock, number of shares issued">295,714</span> shares of the Company’s common stock at an offering price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIkfHXbkPV8" title="Sale of stock, price per share">14.00</span> per share and (ii) pre-funded warrants to purchase up to <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201201__20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zF5xYLMwRflk" title="Sale of stock, number of shares issued">132,857</span> shares of common stock at a purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_za9oFmmBqxRc" title="Sale of stock, price per share">13.98</span> per pre-funded warrant, for gross proceeds of approximately $<span id="xdx_90A_ecustom--GrossProceedsFromPrivatePlacement_pn5n6_c20201201__20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ziPyA7AVqs9e" title="Gross proceeds from private placement">6.0</span> million, and net proceeds of approximately $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20201201__20201202__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zB98EiqGVDbd" title="Net proceeds from private placement">5.4</span> million. In January 2021, two investors exercised an aggregate of <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesWarrantsExercise_pid_c20210101__20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--AwardTypeAxis__custom--WarrantsMember_zQMQftrLxhLh" title="Stock issued during period warrants">82,857</span> warrants at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--AwardTypeAxis__custom--WarrantsMember_z5Zs4G8vOFO1" title="Warrants exercise price">0.02 </span>per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2021, Company entered into letter agreements (the “Letter Agreements”) with certain existing accredited investors to exercise certain outstanding warrants (the “Existing Warrants”) to purchase up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210121__srt--TitleOfIndividualAxis__custom--AccreditorInvestorsMember__us-gaap--AwardTypeAxis__custom--WarrantsMember_zqBHiKpeHaai" title="Warrants to purchase shares">60,298</span> shares of the Company’s common stock at an exercise price per share of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210121__srt--TitleOfIndividualAxis__custom--AccreditorInvestorsMember__us-gaap--AwardTypeAxis__custom--WarrantsMember_zrDnWzzjN40i" title="Warrants exercise price">23.30</span> (the “Exercise”). Certain of the Existing Warrants (the “Registered Existing Warrants”) and the shares of common stock underlying the Registered Existing Warrants have been registered pursuant to a registration statement on Form S-3 (File No. 333-251264) and a registration statement on Form S-1 (File No. 333-218871). In consideration for the exercise of the Existing Warrants for cash, the exercising holders received new unregistered warrants to purchase up to an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210121__us-gaap--AwardTypeAxis__custom--NewWarrantsMember_zuNSqmYmKNfe" title="Warrants to purchase shares">60,298</span> shares of common stock (the “New Warrants”) at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210121__us-gaap--AwardTypeAxis__custom--NewWarrantsMember_z3mJzLBtq4zj" title="Warrants exercise price">20.80</span> per share and with an exercise period of seven years from the initial closing date. The gross proceeds to the Company from the Exercise were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20210120__20210121__us-gaap--AwardTypeAxis__custom--NewWarrantsMember_zTkLUFuQQ9Sc" title="Proceeds from warrant exercises">1.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The New Warrants were accounted for in warrant modification expense, which was measured at the amount equal to the incremental value reflecting the change in the fair value of the warrants before and after the Warrant Amendment. Accordingly, warrant modification expense in the amount of $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210401__20210630__us-gaap--AwardTypeAxis__custom--NewWarrantsMember_znbiD8LFf4Z9" title="Warrants, modification expense">1,627</span> was recorded with a corresponding increase in additional paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August and September 2021, investors exercised warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210930_zHL0GfYbb533" title="Number of warrants to purchase">109,675</span> shares of common stock between $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__srt--RangeAxis__srt--MinimumMember_zIM3LkYEZRF3" title="Exercise price of warrants">17.60</span> and $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__srt--RangeAxis__srt--MaximumMember_zwiBrKBRM93f" title="Exercise price of warrants">50.00</span> per share for proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20210901__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXwBUHd8XGLk" title="Proceeds from warrant exercises">3.6</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 14, 2022, the Company issued warrants to two sales consultants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220614_zaAS6kRZeFd3" title="Purchase of warrants">12,500</span> shares of common stock which will expire on <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220614_zL19FWJ5Ya85" title="Warrants expire date">June 14, 2029</span> and have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220614_zS43lIDdyba4" title="Warrants exercise price">20.00</span> per share. Accordingly, expense related to these warrants in the amount of $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_pn3n3_c20220613__20220614_zhoyZ2k9N9Il" title="Increase in additional paid in capital warrants">135,000</span> was recorded with a corresponding increase in additional paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2022, the Company and the two sales consultants mutually agreed to cancel the latter’s annual stock warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220930_z5F5kBMuS8ng" title="Purchase of warrants">12,500</span> shares of common stock. Accordingly, expense related to these warrants were reversed in the amount of $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220929__20220930_z7JnLM9oATu4" title="Increase in additional paid in capital warrants">135,000</span> with a corresponding decrease in additional paid in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 29, 2022, the Company granted <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221129_zT0xQ8OWNSL8" title="Number of warrants to purchase">18,000</span> warrants to purchase Company’s common stock in conjunction with the private placements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_zKo7Yi6H7J1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In estimating the warrants’ fair value, the Company used the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zmKy0LJL6X13" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk free interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgWLnXUWADvh" title="Warrants, measurement input, percentage">0.34</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTsJ8rRRK5g8" title="Warrants, measurement input, percentage">1.44</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z46EJg2EVu6c" title="Warrants, measurement input, percentage">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkCu3xemXknf" title="Warrants, measurement input, percentage">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zG9rNIGqF327" title="Warrants, measurement input, percentage">60.7</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIQvMK5vlpj5" title="Warrants, measurement input, percentage">55.6</span> - <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zrGivKwsdYPj" title="Warrants, measurement input, percentage">56.5</span> %</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zXYLmKvfubRi" title="Contractual term (in years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zeASoWFPeoPe" title="Contractual term (in years)">2</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_z9DXxa3ziVH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlqFhO2T1EJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zN8AwLBDiNEf" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Outstanding – December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zL1LFEgAAAu7" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance">386,237</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z0cHCi1ouZ96" style="text-align: right" title="Warrants, Granted">60,298</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zFZDoIrfGgDd" style="text-align: right" title="Warrants, Exercised">(252,830</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Exercised - cashless</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedCashless_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zKl4hMzZdO52" style="text-align: right" title="Warrants, Exercised - cashless">(14,071</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zJ55Ugi78r3f" style="text-align: right" title="Warrants, Expired">(31,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zY2RA9yOUnO3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(33,167</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXSnrdcKoz7b" style="text-align: right" title="Warrants, Outstanding - Beginning balance">115,467</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zOey06hYY8C3" style="text-align: right" title="Warrants, Granted">30,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zJXEQpFG8K0i" style="text-align: right" title="Warrants, Expired">(55,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zoRhOrV5Vsn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(12,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zvbWB9CxHY0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Ending balance">78,252</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zcNotNJG6Hwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 24109635 40000000 240000 10.00 2100000 0.075 0.010 50000 15950 18000 2027-11-29 12.50 Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one twentieth of a share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. 0 875000 0 43750 Each share of Series D Preferred Stock is convertible into fifty shares of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series D Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 4.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. 0 153 0 7650 Each share of Series C Preferred Stock is convertible into one twentieth of a share of common stock at any time at the option of the holders, provided that each holder would be prohibited from converting Series C Preferred Stock into shares of common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. 0 666667 0 33333 0.001 0.001 Each share of Series F Preferred Stock entitles the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock has a ratable number of votes). Thus, each one-thousandth of a share of Series F Preferred Stock entitles the holder thereof to 1,000 votes. 0.10 1256 0 21875 43875 P9Y 201000 583000 148000 258000 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z30VKZRo0cb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zH8UhOJK2cY7" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares Under</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>per Share</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding – December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z7CHiS3iYTx8" style="width: 14%; text-align: right" title="Options, Outstanding - Beginning balance">127,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zVgmMGmwdpEg" style="width: 14%; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - beginning balance">31.86</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zJZVmDmjxeZ4" title="Weighted Average Remaining Life (Years), Outstanding - beginning balance">7.77</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKoyPAf1frb4" style="text-align: right" title="Options, Granted">21,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbVeHWjUw6G8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted">10.76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zYJq689xuwpi" title="Weighted Average Remaining Life (Years), Granted">9.55</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z819M3PsBGj7" style="text-align: right" title="Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_z9R97ABWAIvl" style="text-align: right" title="Weighted Average Exercise Price per Share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zDtEX4mDeh0h" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zvE8IEcrevHj" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zKyGn4Vvjcp" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercised">(1,256</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zR5ulaTp2o97" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Exercised">1.40</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zaXLpY9ImEJ5" title="Weighted Average Remaining Life (Years), Granted">0.24</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zbYB36R4Rszi" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - Ending balance">147,619</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2d_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zdEzDTDhNWT4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Outstanding - ending balance">24.42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__custom--EmployeeOptionsMember_zPhnDNYAwl5d" title="Weighted Average Remaining Life (Years), Outstanding - ending balance">7.24</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 127000 31.86 P7Y9M7D 21875 10.76 P9Y6M18D 1256 1.40 P0Y2M26D 147619 24.42 P7Y2M26D <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z4FJLGneExk5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value for options granted in 2022 and 2021 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zRGg8xnH606e" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Price at valuation</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zYF7qdWaahM2" title="Price at valuation">0.45</span> – <span id="xdx_90D_eus-gaap--SharePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zxWbaQoRw3ib" title="Price at valuation">0.78</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MinimumMember_zdvJJCmXezv3" title="Price at valuation">0.72</span> – <span id="xdx_905_eus-gaap--SharePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MaximumMember_znmU1WkS6EZ1" title="Price at valuation">2.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MinimumMember_zLWtV2wWmTR2" title="Exercise price">0.45</span> – <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20221231__srt--RangeAxis__srt--MaximumMember_zkV0M9RllJA3" title="Exercise price">0.78</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MinimumMember_znsjpMmLgKA" title="Exercise price">0.72</span> – <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pp2d_c20211231__srt--RangeAxis__srt--MaximumMember_zGx8DBph5tOe" title="Exercise price">2.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231_zMeZyX2f7WG5" title="Risk free interest, minimum">2.32 </span>– <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20220101__20221231_zXSuwZ7WN6a2" title="Risk free interest, maximum">3.58</span> </td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20210101__20211231_zZ4836RB5pca" title="Risk free interest, minimum">0.27</span> – <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_c20210101__20211231_zo9BSaaPPm5k" title="Risk free interest, maximum">1.29</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Expected term (in years)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zlE5fNjTmgi" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231_zX0UnhGUdBWh" title="Expected term (in years)">5</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220101__20221231_zWpcwM6zV90j" title="Volatility, minimum">125.3</span> – <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220101__20221231_zq5HzgJ9SPub" title="Volatility, maximum">127.9</span> </td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20210101__20211231_zaFc1rlWwO0f" title="Volatility, minimum">60.9</span> – <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20210101__20211231_z8AhHnDIIy98" title="Volatility, maximum">82.7</span></span></td><td style="text-align: left">%</td></tr> </table> 0.45 0.78 0.72 2.07 0.45 0.78 0.72 2.07 0.0232 0.0358 0.0027 0.0129 P5Y P5Y 1.253 1.279 0.609 0.827 <p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zudJNsbEBuxh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zUpAM5UqtSQc" style="display: none">SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_z4p7WkRAICX6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231_zOyjKad5Qhuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zlfqVBnoy3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">13</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingAndMarketingExpenseMember_zrZFplrieFUj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zXBeBkOkZKWd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">323</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">341</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z09u2cnuf8pj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">354</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">382</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6000 13000 25000 28000 323000 341000 354000 382000 328000 P7Y2M26D 295714 14.00 132857 13.98 6000000.0 5400000 82857 0.02 60298 23.30 60298 20.80 1400000 1627000 109675 17.60 50.00 3600000 12500 2029-06-14 20.00 135000000 12500 135000 18000 <p id="xdx_893_ecustom--ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock_zKo7Yi6H7J1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In estimating the warrants’ fair value, the Company used the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zmKy0LJL6X13" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Risk free interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zgWLnXUWADvh" title="Warrants, measurement input, percentage">0.34</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTsJ8rRRK5g8" title="Warrants, measurement input, percentage">1.44</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z46EJg2EVu6c" title="Warrants, measurement input, percentage">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkCu3xemXknf" title="Warrants, measurement input, percentage">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zG9rNIGqF327" title="Warrants, measurement input, percentage">60.7</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zIQvMK5vlpj5" title="Warrants, measurement input, percentage">55.6</span> - <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zrGivKwsdYPj" title="Warrants, measurement input, percentage">56.5</span> %</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231_zXYLmKvfubRi" title="Contractual term (in years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zeASoWFPeoPe" title="Contractual term (in years)">2</span></td><td style="text-align: left"> </td></tr> </table> 0.34 1.44 0 0 60.7 55.6 56.5 P5Y P2Y <p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlqFhO2T1EJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zN8AwLBDiNEf" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Outstanding – December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zL1LFEgAAAu7" style="width: 16%; text-align: right" title="Warrants, Outstanding - Beginning balance">386,237</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_z0cHCi1ouZ96" style="text-align: right" title="Warrants, Granted">60,298</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zFZDoIrfGgDd" style="text-align: right" title="Warrants, Exercised">(252,830</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Exercised - cashless</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedCashless_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zKl4hMzZdO52" style="text-align: right" title="Warrants, Exercised - cashless">(14,071</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zJ55Ugi78r3f" style="text-align: right" title="Warrants, Expired">(31,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zY2RA9yOUnO3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(33,167</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding – December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zXSnrdcKoz7b" style="text-align: right" title="Warrants, Outstanding - Beginning balance">115,467</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zOey06hYY8C3" style="text-align: right" title="Warrants, Granted">30,500</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zJXEQpFG8K0i" style="text-align: right" title="Warrants, Expired">(55,215</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zoRhOrV5Vsn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants, Canceled">(12,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; padding-bottom: 2.5pt">Outstanding – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--PrivateInvestorsMember_zvbWB9CxHY0i" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding - Ending balance">78,252</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 386237 60298 252830 -14071 31000 33167 115467 30500 55215 12500 78252 <p id="xdx_804_eus-gaap--DerivativesAndFairValueTextBlock_z5XH3xfSgITh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_82A_zatPRgQGMYEi">DERIVATIVE LIABILITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2020, the Company established a sequencing policy to which common stock equivalents are exercisable to shares of common stock more than the Company’s authorized limit. It was determined that all options and warrants by the end of the year were no longer permitted to be classified as equity and were valued at fair market value using Black Scholes and recorded as derivative liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On April 6, 2021, the Company agreed to buy back <span id="xdx_90E_ecustom--NumberOfWarrantsAcquired_pid_c20210405__20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zDriLUA4bHcf" title="Number of warrants acquired">33,167</span> warrants from investors for a total of $<span id="xdx_908_eus-gaap--PaymentsForRepurchaseOfWarrants_pn3n3_c20210405__20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_z7M2mxFIAaDb" title="Payments for repurchase of warrants">368</span>. The warrants had exercise prices between $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__srt--RangeAxis__srt--MinimumMember_zbXxQP0Wvkvi" title="Class of warrant or right, exercise price of warrants or right">17.6</span> and $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember__srt--RangeAxis__srt--MaximumMember_zIXeRVKtYLna" title="Class of warrant or right, exercise price of warrants or rights">18.8</span> per share. The value of the derivative liabilities associated with these warrants was $<span id="xdx_906_eus-gaap--DerivativeLiabilities_iI_pn3n3_c20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zsfe9we2mJDk" title="Derivative liability">451</span>. The Company recorded a $<span id="xdx_905_ecustom--GainLossOnPurchaseOfWarrants_pn3n3_c20210405__20210406__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilityWarrantsMember__srt--TitleOfIndividualAxis__custom--InvestorsMember_zYThDS3uoC13" title="Gain on purchase of warrants">64</span> gain in connection with the buyback of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zDcj9bBpJATe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s purchase warrants that were categorized within Level 3 of the fair value hierarchy during the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjTT8sznWPm9" style="display: none">SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; width: 64%; text-align: left"/><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center">2022</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center">2021</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z4qOTMD5idJa" title="Stock price">1.01</span> – <span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDhQxT4OVat1" title="Stock price">2.94</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5p0CXLD5jR2" title="Stock price">1.01</span> – <span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zM7tsxN5vB8c" title="Stock price">2.94</span> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPlVRkvwTzoc" title="Warrants, measurement input">0.72 </span>– <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpHShRwkVYG8" title="Warrants, measurement input">6.90</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zloq3rtC99O3" title="Warrants, measurement input">0.72</span> – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpsqKg7WAvH1" title="Warrants, measurement input">6.90</span>  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z8wso3e5C2Z" title="Warrants, measurement input, term">0.67</span> –<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zXLq0ovLqXGi" title="Warrants, measurement input, term"> 6.56</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zJmrQbznHbsg" title="Warrants, measurement input, term">0.67</span> – <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zHUvAefylIN7" title="Warrants, measurement input, term">6.56</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbf7ByudLTif" title="Warrants, measurement input">82.70</span> – <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zocuZvIuFJae" title="Warrants, measurement input">211</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5WvMk1kvkjd" title="Warrants, measurement input">82.70</span> - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3FiPuGPxMZ4" title="Warrants, measurement input">211</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k8cV81oE3b" title="Warrants, measurement input">0.09</span> – <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJbEo9DlQTSj" title="Warrants, measurement input">1.21</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcSB69NPFBG9" title="Warrants, measurement input">0.09 </span>– <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQg8ybnaXoCb" title="Warrants, measurement input">1.21</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AF_zaep9d2oloR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The foregoing assumptions were reviewed quarterly and were subject to change based primarily on management’s assessment of the probability of the events described occurring.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 33167 368000 17.6 18.8 451000 64000 <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zDcj9bBpJATe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s purchase warrants that were categorized within Level 3 of the fair value hierarchy during the years ended December 31, 2022 and 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zjTT8sznWPm9" style="display: none">SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; width: 64%; text-align: left"/><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center">2022</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1.5pt; width: 2%"> </td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center">2021</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z4qOTMD5idJa" title="Stock price">1.01</span> – <span id="xdx_90F_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zDhQxT4OVat1" title="Stock price">2.94</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z5p0CXLD5jR2" title="Stock price">1.01</span> – <span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zM7tsxN5vB8c" title="Stock price">2.94</span> </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPlVRkvwTzoc" title="Warrants, measurement input">0.72 </span>– <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpHShRwkVYG8" title="Warrants, measurement input">6.90</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zloq3rtC99O3" title="Warrants, measurement input">0.72</span> – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpsqKg7WAvH1" title="Warrants, measurement input">6.90</span>  </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_z8wso3e5C2Z" title="Warrants, measurement input, term">0.67</span> –<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zXLq0ovLqXGi" title="Warrants, measurement input, term"> 6.56</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zJmrQbznHbsg" title="Warrants, measurement input, term">0.67</span> – <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--FairValueByLiabilityClassAxis__custom--DerivativeLiabilityMember_zHUvAefylIN7" title="Warrants, measurement input, term">6.56</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Volatility (annual)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbf7ByudLTif" title="Warrants, measurement input">82.70</span> – <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zocuZvIuFJae" title="Warrants, measurement input">211</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5WvMk1kvkjd" title="Warrants, measurement input">82.70</span> - <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3FiPuGPxMZ4" title="Warrants, measurement input">211</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2k8cV81oE3b" title="Warrants, measurement input">0.09</span> – <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJbEo9DlQTSj" title="Warrants, measurement input">1.21</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcSB69NPFBG9" title="Warrants, measurement input">0.09 </span>– <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQg8ybnaXoCb" title="Warrants, measurement input">1.21</span></span></td><td style="text-align: left">%</td></tr> </table> 1.01 2.94 1.01 2.94 0.72 6.90 0.72 6.90 P0Y8M1D P6Y6M21D P0Y8M1D P6Y6M21D 0.8270 2.11 0.8270 2.11 0.0009 0.0121 0.0009 0.0121 <p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_z6mD9Q0ZIH32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_825_zrfD0qqV1uae">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has operating lease agreements with terms up to <span id="xdx_904_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zpW8W3MhNiLj" title="Lease term">2</span>-<span id="xdx_90A_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zG3HyWi1Ry0b" title="Lease term">3</span> years, including car and office space leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s weighted-average remaining lease term relating to its operating leases is <span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zlFfRIegGqBg" title="Weighted-average remaining lease term">1.05</span> years, with a weighted-average discount rate of <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zLrflODzSP61" title="Weighted-average discount rate">10</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_pn3n3_c20220101__20221231_zLGLvosTMs4f" title="Operating lease, expense">75</span> of lease expense for its operating leases for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbDDzWKseoZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zWDPgl5495Ej" style="display: none">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20221231_zCy2Bn1f34t2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zWATlP4hxT6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">73</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zXmVvDEwqPQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zB6UfjJzHi8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z752HhTIQc91" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zjeOJ6Co61T7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P2Y P3Y P1Y18D 0.10 75000 <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zbDDzWKseoZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zWDPgl5495Ej" style="display: none">SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20221231_zCy2Bn1f34t2" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzL7T_zWATlP4hxT6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">73</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzL7T_zXmVvDEwqPQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzL7T_zB6UfjJzHi8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted operating lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_z752HhTIQc91" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zjeOJ6Co61T7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">73</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 73000 4000 77000 4000 73000 <p id="xdx_809_eus-gaap--EarningsPerShareTextBlock_zRyctFXAsqy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 - <span id="xdx_82C_zfpc5q5l6AVh">LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. All outstanding share options and warrants for the years ended December 31, 2022 and 2021 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzeHwwnc8DWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zi29Z6zmzpQ8" style="display: none">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zDEL4Rpt3eie" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zfTIc1zXjR43" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zHkDscEW2WBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options - employee and non-employee</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">147,619</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">127,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zGJBzUAFHqgc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,467</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zFGhOHQulgce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">225,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">242,467</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z3f1qFfbuZo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The diluted loss per share equals basic loss per share in the year ended December 31, 2022 and 2021 because the Company had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zzeHwwnc8DWk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zi29Z6zmzpQ8" style="display: none">SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zDEL4Rpt3eie" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zfTIc1zXjR43" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zHkDscEW2WBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options - employee and non-employee</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">147,619</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">127,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zGJBzUAFHqgc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,252</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">115,467</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zFGhOHQulgce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">225,871</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">242,467</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 147619 127000 78252 115467 225871 242467 <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zRok4ZVOZvT" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 - <span id="xdx_827_z8YnKHIcaGbf">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary information about geographic areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z7tMyG1C9DG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B7_zWbb5OE3YFea" style="display: none">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zzDrft1vdrWk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zooDYnzQAXWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zAZDc85uZKeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">710</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,627</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zkIp75Z8an05" style="vertical-align: bottom; background-color: White"> <td>Europe</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_z1TIBH6P0rmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Australia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IN_z7Tj0UaeLmKb" style="vertical-align: bottom; background-color: White"> <td>India</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_z6T66gGhPVaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z2dOr4Et47W9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z2Q3NeE3JwRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">752</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zay8YP7uS2ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s long-lived assets are all located in Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_z7tMyG1C9DG3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor agreements. The following is a summary of revenues within geographic areas:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B7_zWbb5OE3YFea" style="display: none">SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zzDrft1vdrWk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zooDYnzQAXWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--US_zAZDc85uZKeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">710</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,627</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__srt--EuropeMember_zkIp75Z8an05" style="vertical-align: bottom; background-color: White"> <td>Europe</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--AU_z1TIBH6P0rmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Australia</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IN_z7Tj0UaeLmKb" style="vertical-align: bottom; background-color: White"> <td>India</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__country--IL_z6T66gGhPVaf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Israel</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z2dOr4Et47W9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z2Q3NeE3JwRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">752</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,695</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 710000 1627000 25000 18000 9000 6000 3000 5000 5000 39000 752000 1695000 <p id="xdx_802_eus-gaap--OtherAssetsDisclosureTextBlock_zF40it0wPaK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_826_zbNEr6UCGg1">OTHER ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zCRCyuaIbV52" title="Warrants and rights outstanding term">10</span>-year warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zPaVPPdZR6tb" title="Warrants issued to purchase common stock">127,000</span> shares of Sanuwave Health, Inc. at a price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20200409__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zoYAwamso0L1" title="Exercise price of warrants per share">0.19</span> per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:</span></p> <p id="xdx_89C_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zsFDpsCaR98e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zdW0IGADBngd" style="display: none">SCHEDULE OF WARRANTS ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Price at valuation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zGMQVwIiOEDf" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zgqQN5ilUVUe" title="Warrants and rights outstanding, measurement input">0.19</span> – <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zIX1qT60RjI" title="Warrants and rights outstanding, measurement input">0.26</span>  </span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zgPLWhtT8VZ5" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z6omVbAVQoq5" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp7UfoBBNJ8k" title="Warrants and rights outstanding, measurement input">3.96</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbE32ViD78Y5" title="Warrants and rights outstanding, measurement input">0.66</span> – <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zdOcWr40osRb" title="Warrants and rights outstanding, measurement input">0.73</span> </span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zHZflXCRmfr5" title="Expected term (in years)">8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zOskxOn5pp2d" title="Expected term (in years)">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zucceAgasicd" title="Warrants and rights outstanding, measurement input">155.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp5H0k65pOK3" title="Warrants and rights outstanding, measurement input">140.6</span> – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zhh0KWfLNPc3" title="Warrants and rights outstanding, measurement input">143.9</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AC_zJsMdt5CkP0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers this to be Level 3 inputs and is valued at each reporting period. The fair value of these warrants for the years ended December 31, 2022 and 2021 was $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20220101__20221231_zXF7ly0o0TJ2" title="Fair value of warrants">3</span> and $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231_zY2MbGC80bV6" title="Fair value of warrants">19</span>, respectively. There was a net $<span id="xdx_90E_ecustom--ChangeInFairValueOfWarrants_pn3n3_c20220101__20221231_zDAYM1QIn3C3" title="Change in fair value of warrants">16</span> and $<span id="xdx_909_ecustom--ChangeInFairValueOfWarrants_pn3n3_c20210101__20211231_zgNPThHXl9tj" title="Change in fair value of warrants">6</span> change in fair value during the year ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial Liabilities Measured at Fair Value on a Recurring Basis</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no transfers between Level 3 during the years ended December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zrTLP1MSoCpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B1_zr3vf4Yv2WVl" style="display: none">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Asset</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 64%">Balance – December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zBU4fMUqjxVh" style="width: 14%; text-align: right" title="Balance beginning">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zLKtayPk5hs" style="width: 14%; text-align: right" title="Balance beginning">2,471</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">New Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJIRBhSmquLd" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zlrH1ZmOKi0d" style="text-align: right" title="New Issuances">1,819</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Fair value adjustments – Sanuwave warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zlEdtZyalfD2" style="text-align: right" title="Fair value adjustments - Sanuwave warrants">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zIJ0TL86nEV8" style="text-align: right" title="Fair value adjustments - Sanuwave warrants"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fair value adjustments – Warrant liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zWfyLDMtyWUk" style="text-align: right" title="Fair value adjustments - Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zKrsoreQBu56" style="text-align: right" title="Fair value adjustments - Warrant liability">6,956</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassification liability to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zBAvui4SRHna" style="text-align: right" title="Reclassification liability to equity"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_z6rHI5LGoyYl" style="text-align: right" title="Reclassification liability to equity">(10,793</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Buy back of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zrwmfkq3klU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Buy back of warrants"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zWFirYfSj2p6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Buy back of warrants">(453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance – December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zccrx6KYjtYj" style="text-align: right" title="Balance beginning">19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zcEKGW56A9t6" style="text-align: right" title="Balance beginning"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">New Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zYFgeMsUjs4e" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zQmZrvTMnzRe" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Fair value adjustments – Sanuwave warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJCodITTskx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(16</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zKJ9bweXRzik" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zL5GG1h3B0z4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zcqCH15BzPk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zCNn3OnI4ehe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zk5hkZYhr0K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zsXcW0NIdumd" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFbbtfhcrc98" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6dLiA9Ks9Q5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zX4lJIefRAQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zMVctJhFCKN5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Asset:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zYwdkeA3u5I9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Other assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">    3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6YC0JWMrRh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ftvRr1mYPg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEfuUpLvMyn6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_z2NTUNXfZBAg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zdSNLzlV2DRb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Other assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zSL4EXsIA2I3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P10Y 127000 0.19 <p id="xdx_89C_ecustom--ScheduleOfWarrantsAssumptionsTableTextBlock_zsFDpsCaR98e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zdW0IGADBngd" style="display: none">SCHEDULE OF WARRANTS ASSUMPTIONS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: right"/><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Price at valuation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zGMQVwIiOEDf" title="Warrants and rights outstanding, measurement input">0.02</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zgqQN5ilUVUe" title="Warrants and rights outstanding, measurement input">0.19</span> – <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__custom--PriceAtValuationMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zIX1qT60RjI" title="Warrants and rights outstanding, measurement input">0.26</span>  </span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zgPLWhtT8VZ5" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_z6omVbAVQoq5" title="Warrants and rights outstanding, measurement input">0.19</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp7UfoBBNJ8k" title="Warrants and rights outstanding, measurement input">3.96</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zbE32ViD78Y5" title="Warrants and rights outstanding, measurement input">0.66</span> – <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zdOcWr40osRb" title="Warrants and rights outstanding, measurement input">0.73</span> </span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20221231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zHZflXCRmfr5" title="Expected term (in years)">8</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zOskxOn5pp2d" title="Expected term (in years)">10</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20221231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zucceAgasicd" title="Warrants and rights outstanding, measurement input">155.6</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zp5H0k65pOK3" title="Warrants and rights outstanding, measurement input">140.6</span> – <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--SanuwaveHealthIncMember_zhh0KWfLNPc3" title="Warrants and rights outstanding, measurement input">143.9</span></span></td><td style="text-align: left">%</td></tr> </table> 0.02 0.19 0.26 0.19 0.19 0.0396 0.0066 0.0073 P8Y P10Y 1.556 1.406 1.439 3000 19000 16000 6000 <p id="xdx_891_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zrTLP1MSoCpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 asset and liability measured at fair value for the years ended December 31, 2022 and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span id="xdx_8B1_zr3vf4Yv2WVl" style="display: none">SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Asset</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liability</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 64%">Balance – December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zBU4fMUqjxVh" style="width: 14%; text-align: right" title="Balance beginning">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zLKtayPk5hs" style="width: 14%; text-align: right" title="Balance beginning">2,471</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">New Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJIRBhSmquLd" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zlrH1ZmOKi0d" style="text-align: right" title="New Issuances">1,819</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Fair value adjustments – Sanuwave warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zlEdtZyalfD2" style="text-align: right" title="Fair value adjustments - Sanuwave warrants">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zIJ0TL86nEV8" style="text-align: right" title="Fair value adjustments - Sanuwave warrants"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fair value adjustments – Warrant liability</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zWfyLDMtyWUk" style="text-align: right" title="Fair value adjustments - Warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl1237">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zKrsoreQBu56" style="text-align: right" title="Fair value adjustments - Warrant liability">6,956</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reclassification liability to equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zBAvui4SRHna" style="text-align: right" title="Reclassification liability to equity"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_z6rHI5LGoyYl" style="text-align: right" title="Reclassification liability to equity">(10,793</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Buy back of warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zrwmfkq3klU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Buy back of warrants"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants_pn3n3_c20210101__20211231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zWFirYfSj2p6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Buy back of warrants">(453</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance – December 31, 2021</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zccrx6KYjtYj" style="text-align: right" title="Balance beginning">19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zcEKGW56A9t6" style="text-align: right" title="Balance beginning"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">New Issuances</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zYFgeMsUjs4e" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zQmZrvTMnzRe" style="text-align: right" title="New Issuances"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Fair value adjustments – Sanuwave warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zJCodITTskx7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants">(16</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zKJ9bweXRzik" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value adjustments - Sanuwave warrants"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance – December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeAssetMember_zL5GG1h3B0z4" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_pn3n3_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__custom--DerivativeLiabilitiesMember_zcqCH15BzPk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 25000 2471000 1819000 -6000 6956000 -10793000 -453000 19000 -16000 3000 <p id="xdx_895_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zk5hkZYhr0K9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the Company’s assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zsXcW0NIdumd" style="display: none">SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFbbtfhcrc98" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z6dLiA9Ks9Q5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zX4lJIefRAQe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20221231_zMVctJhFCKN5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Asset:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zYwdkeA3u5I9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Other assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1268">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">    3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zd6YC0JWMrRh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ftvRr1mYPg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEfuUpLvMyn6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_z2NTUNXfZBAg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measurements as of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level I</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level II</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level III</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Asset:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_zdSNLzlV2DRb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Other assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">     <span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td></tr> </table> 3000 3000 19000 19000 <p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zpLW1EyqYUx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 - <span id="xdx_828_zYecAeR3ltah">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pending and settled litigation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 17, 2019, a lawsuit was filed by a former officer and director, Jona Zumeris, in the Haifa Israel District Financial Court, seeking damages of approximately $<span id="xdx_907_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20191216__20191217__srt--TitleOfIndividualAxis__custom--JonaZumerisMember_zJ4DDrZiStzl" title="Litigation damages sought value">900</span> for breach of the Separation Agreement executed on July 4, 2018. The Israeli court issued a court order demanding that we restrict approximately $<span id="xdx_90D_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20191216__20191217__srt--TitleOfIndividualAxis__custom--FormerOfficerMember_z8DARpMXCNv7" title="Litigation damages sought value">700</span> of the Company’s money until the matter is adjudicated. The Company appealed the court order and in February 2020, the Company agreed to restrict approximately 1,187 NIS (“New Israeli Shekel”) and agreed to try to settle the matter in mediation. On November 30, 2020, the Company funded the escrow account with $<span id="xdx_902_eus-gaap--EscrowDeposit_iI_pn3n3_c20201130_zGfgfCEpI1t7" title="Escrow amount">391</span>. In January 2021, the parties reached a settlement in which the Company paid the plaintiff approximately $<span id="xdx_901_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20210101__20210131_zW4Ed0ZD0fnl" title="Litigation settlement, amount">366</span> as settlement in full.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 26, 2021, Protrade Systems, Inc. (“Protrade”) filed a Request for Arbitration (the “Request”) with the International Court of Arbitration (the “ICA”) of the International Chamber of Commerce alleging the Company is in breach of an Exclusive Distribution Agreement dated March 7, 2019 (the “Agreement”) between Protrade and the Company. Protrade alleges, in part, that the Company has breached the Agreement by discontinuing the manufacture of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zOncBVNza74g" title="Litigation damages sought value">3</span> million. The Company vigorously defended the claims asserted by Protrade.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2022, the arbitrator issued a final award, which, although denied all Protrade’s claims, nevertheless awarded Protrade about $<span id="xdx_908_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20220314__20220315__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zlP99gZ0o1K2" title="Damages awarded value">1.5</span> million, on the grounds that the Company allegedly failed to fulfill an order for reusable hydrogel patches placed after the Agreement was terminated. The arbitrator based her decision on the basis of testimony of Protrade’s president who asserted that a patient would use in excess of 33 reusable patches per each device, which the Company believes is a grossly inflated number.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2022, Protrade filed a Petition with the Supreme Court of New York Nassau County seeking to confirm the Award. On April 13, 2022, the Company submitted an application to the ICA seeking to correct an error in the award based on the evidence that the Company only sold 2-3 reusable patches per device contrary to the 33 reusable patches claimed by Protrade. The same arbitrator who issued the award, denied the application.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority, that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular, the Company averred in its motion that Protrade’s witness made false statements in arbitration, and that the arbitrator resolved a claim that was never raised by Protrade and that has no factual basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 3, 2022, the court issued a decision granting Protrade its petition to confirm the Award </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and denying the cross-motion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newel information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate Division, Second Department. On March 21, 2023, the Court denied the motion to re-argue and renew. The Company intends to file a notice of appeal with the Appellate Division, Second Department and to continue to vigorously pursue its opposition to the award in all appropriate fora.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Risks</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 900000 700000 391000 366000 3000000 1500000 <p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfn8lo08Q55b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 – <span id="xdx_829_zSbiaXG6tOZe">RELATED PARTY TRANSACTION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The firm of FisherBroyles LLP is handling our Protrade litigation and appeals. For the year ended December 31, 2022, we have been billed and paid legal fees from Fisher Broyles amounting to $<span id="xdx_90E_eus-gaap--LegalFees_pn3n3_c20220101__20221231_zTpHLOa6AJkd" title="Legal fees paid">256,908</span> and recorded as part of “General and administrative expenses” in the condensed consolidated statements of operations. As has been previously disclosed, one of our board members, Aurora Cassirer, is a partner at Fisher Broyles. Ms. Cassirer does not provide any legal services or legal advice to the Company<b>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 256908000 <p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zZnlKKbN06ck" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 – <span id="xdx_82D_zRwT4BljW9Ol">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the U.S. Company had federal and state net operating loss carry forward for tax purposes of approximately $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zzZafsVJOxKe" title="Net operating loss carry forward">33,000</span> and $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_z4GwU2QaAnpk" title="Net operating loss carry forward">6,000</span>, respectively. $<span id="xdx_90B_ecustom--FederalNetOperatingLossCarriedForward_iI_pn3n3_c20221231_zsUMH8kXOhF4" title="Federal net operating loss carried forward">19,200</span> of the federal net operating loss can be carried forward indefinitely but can only offset up to 80% of taxable income in a given year, and $<span id="xdx_906_ecustom--FederalNetOperatingLossOffsetAgainstTaxableIncome_pn3n3_c20220101__20221231_zjoB6oxRwKQ" title="Federal net operating loss offset against taxable income">14,000</span> of the federal net operating loss can be used to fully offset taxable income in the period it is utilized but can only be carried forward for <span id="xdx_90D_ecustom--OperatingLossCarryforwardsExpirationTerm_dtY_c20220101__20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ztTPqNdtFB7i" title="Operating loss carryforwards expiration term">20</span> years. Utilization of the U.S. net operating losses may be subject to substantial limitations in the event of a change of ownership under the provisions of the Internal Revenue Code of 1986. The Company has not performed an analysis, but the potential impact of any limitation would not be material to the financial statements due to the fact that the respective DTAs are fully offset by a valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHZHaW2RjIXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense is comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z81QjWFgOAs3" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zBgWQjrdjq2k" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zMcNTGkkdAC2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current Tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzPkK_zmsTCLYQiVFl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzPkK_zL19fElBSYTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_maCITEBzPkK_zciZLL0qrgme" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">37</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">32</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzPkK_maOTEBzPz3_zNFslG95q77c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred Tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zYekO5RNqmt3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,545</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,263</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zA2NOAVUjWL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zzQ2gOvne6qb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzsCS_maOTEBzPz3_zvd9eitw0Jwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(893</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,398</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_pn3n3_di_msOTEBzPz3_zTeqZ1VoRSN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherTaxExpenseBenefit_iT_pn3n3_mtOTEBzPz3_zDdr3KolYhT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zYZKsj6aQ8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The difference between the statutory tax rate of the Company and the effective tax rate is primarily the result of tax benefits generated by the Company and its subsidiary which have not been recognized due to the uncertainty that such tax benefits will ultimately be realized. A reconciliation of the statutory U.S Federal rate to the Company’s effective tax rate is as follows:</span></p> <p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMl1jBuTbJAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zpcQiZLSls21" style="display: none">SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zub35UEDc684" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zk1ORZs7hrsd" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zLzWvA55m5W7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_z8vSwR0S1xQ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-12.06</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zPCJwbKaXzfh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_z4Ud4nxOiNy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-13.04</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_zJHM4W2nXaR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-16.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-9.81</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_zJ3GeMR3grH" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Return to provision adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.54</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.01</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_zSsQG4A7wf2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.16</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_zW9h9GKhp6r5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.09</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.86</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zJZFmIyQFTf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.68</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.22</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AE_ze9WfHab5Khi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign tax</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax rates applicable to the income of the Israeli subsidiary:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Israeli corporate tax rate in 2022 and 2021 is <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20220101__20221231__srt--StatementGeographicalAxis__country--IL_zO3VmjZPhPN9" title="Corporate tax rate"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210101__20211231__srt--StatementGeographicalAxis__country--IL_zo2wZhvEzkY4" title="Corporate tax rate">23</span></span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The subsidiary has final tax assessments through 2016.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes:</span></p> <p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zdVwnaxLGOPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zSwUvm8TT866" style="display: none">SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zcDWNPdBERci" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210101__20211231_z5LdBDcQXyW8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOz5C4_zufS2oZCGtVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,557</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,333</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn3n3_di_maILFCOz5C4_zYGJ5104sIza" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(82</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_pn3n3_di_mtILFCOz5C4_za5CqTpohfzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,250</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zYp5aJa9Mo0d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Deferred income taxes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zO7QbBuuRBki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zxhjVGKgS4x3" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_z0SfYsHkYoRd" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zHe3mkXD5kK8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNu2_zttiYVAKtBe2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Net operating loss carry forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,306</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,563</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_pn3n3_maDTAGzNu2_zup10eZEIcXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Arbitration accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_pn3n3_maDTAGzNu2_zJXMN4ZrThT" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Stock compensation and other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">483</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNu2_maDTALNzt1d_zpFIdXdDJr9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,203</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzt1d_zTp5gwVdnskd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzt1d_zaBRnRY40yVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zKrBpUhC3fQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022 and 2021, the net increases in valuation allowance of $<span id="xdx_90D_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20220101__20221231_zGErltnBDQB1" title="Net increases in valuation allowance">894</span> and $<span id="xdx_902_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20210101__20211231_zKthSBgJlmEc" title="Net increases in valuation allowance">1,417</span>, respectively was primarily driven by the increase in net operating loss carryforwards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are able to be utilized. Based on consideration of these factors, the Company concluded that all of its recorded deferred tax assets are not more likely than not realizable and recorded a full valuation allowance at December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers the earnings of its non-U.S. subsidiary to be indefinitely invested outside the United States on the basis of estimates that future domestic cash generation will be sufficient to meet future domestic cash needs and our specific plans for reinvestment of those subsidiary earnings. We have not recorded a deferred tax liability related to the U.S. federal and state income taxes as an estimate of undistributed earnings of foreign subsidiaries would not be practicable to estimate at this time. If the Company does decide to repatriate the foreign earnings, we would need to adjust our income tax provision in the period we determined that the earnings will no longer be indefinitely invested outside the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reconciliation of the theoretical tax expense to the actual tax expense</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and its subsidiary due to the uncertainty of the realization of such tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statement of operations. As of December 31, 2022 and 2021, the Company does not have any liabilities recorded for uncertain tax positions and does not expect there to be any events which could potentially result in the need for a material liability to be recorded. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2022 and 2021. The Company did not recognize any interest or penalties during fiscal 2022 or 2021 related to unrecognized tax benefits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. federal and New York State income taxes are open for examination for years 2019-2022 and Israel tax returns are open for examination for years 2018-2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 33000000 6000000 19200000 14000000 P20Y <p id="xdx_893_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zHZHaW2RjIXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax expense is comprised of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z81QjWFgOAs3" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zBgWQjrdjq2k" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zMcNTGkkdAC2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Current Tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzPkK_zmsTCLYQiVFl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1309">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1310">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzPkK_zL19fElBSYTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1313">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentForeignTaxExpenseBenefit_pn3n3_maCITEBzPkK_zciZLL0qrgme" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">37</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">32</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzPkK_maOTEBzPz3_zNFslG95q77c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred Tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zYekO5RNqmt3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Federal</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,545</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,263</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zA2NOAVUjWL4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">653</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3n3_maDITEBzsCS_zzQ2gOvne6qb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzsCS_maOTEBzPz3_zvd9eitw0Jwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(893</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,398</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--ValuationAllowanceOfIncomeTaxExpenseBenefit_iN_pn3n3_di_msOTEBzPz3_zTeqZ1VoRSN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation Allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherTaxExpenseBenefit_iT_pn3n3_mtOTEBzPz3_zDdr3KolYhT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total Tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 37000 32000 37000 32000 -1545000 -1263000 653000 -131000 -1000 -4000 -893000 -1398000 -893000 -1398000 37000 32000 <p id="xdx_895_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zMl1jBuTbJAj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zpcQiZLSls21" style="display: none">SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20221231_zub35UEDc684" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zk1ORZs7hrsd" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zLzWvA55m5W7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_z8vSwR0S1xQ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-12.06</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.92</td><td style="text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_dp_zPCJwbKaXzfh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign rate differential</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.02</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationPermanentItems_pid_dp_z4Ud4nxOiNy4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent Items</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-13.04</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_zJHM4W2nXaR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-16.61</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-9.81</td><td style="text-align: left">%</td></tr> <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_pid_dp_zJ3GeMR3grH" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Return to provision adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7.54</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.01</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationForfeitedOptions_pid_dp_zSsQG4A7wf2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Forfeited options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.16</td><td style="text-align: left">%</td></tr> <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_zW9h9GKhp6r5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.09</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.86</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zJZFmIyQFTf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.68</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-0.22</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.2100 0.2100 -0.1206 0.0092 -0.0003 0.0002 -0.0061 -0.1304 -0.1661 -0.0981 0.0754 -0.0001 0.0000 -0.0016 0.0009 0.0086 -0.0068 -0.0022 0.23 0.23 <p id="xdx_899_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zdVwnaxLGOPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zSwUvm8TT866" style="display: none">SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20221231_zcDWNPdBERci" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210101__20211231_z5LdBDcQXyW8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOz5C4_zufS2oZCGtVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Domestic</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,557</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,333</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_iN_pn3n3_di_maILFCOz5C4_zYGJ5104sIza" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(144</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(82</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iNT_pn3n3_di_mtILFCOz5C4_za5CqTpohfzl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before taxes</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,413</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,250</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5557000 14333000 144000 82000 -5413000 -14250000 <p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zO7QbBuuRBki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zxhjVGKgS4x3" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20221231_z0SfYsHkYoRd" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zHe3mkXD5kK8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzNu2_zttiYVAKtBe2" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Net operating loss carry forward</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">7,306</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,563</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccruals_iI_pn3n3_maDTAGzNu2_zup10eZEIcXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Arbitration accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">414</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_iI_pn3n3_maDTAGzNu2_zJXMN4ZrThT" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Stock compensation and other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">483</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzNu2_maDTALNzt1d_zpFIdXdDJr9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,203</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzt1d_zTp5gwVdnskd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,203</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,304</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNzt1d_zaBRnRY40yVg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1400">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 7306000 6563000 414000 414000 483000 327000 8203000 7304000 8203000 7304000 894000 1417000 <p id="xdx_802_eus-gaap--SubsequentEventsTextBlock_zWeHCWRhrLZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 - <span id="xdx_820_zRj1AL5qnne2">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2023, the Company effected a reverse stock split of its <span id="xdx_907_eus-gaap--StockholdersEquityReverseStockSplit_c20230207__20230208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYrHM6h0sbN7" title="Reverse stock split description">common stock at a ratio of 1 post-split share for every 20 pre-split shares</span>. The Company’s common stock begin trading on a split-adjusted basis when the market opened on February 9, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At an annual meeting of stockholders held on December 15, 2022, the Company’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of the Company’s common stock through an amendment to its <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20221214__20221215_zSrIaYYZgH2g" title="Reverse stock split description">Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50</span>, with such ratio to be determined by the Company’s Board of Directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the effective time of the reverse stock split, every <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_pid_uShares_c20230207__20230208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQQ0Yl8tDf14" title="Stock splits">20</span> shares of the Company’s issued and outstanding common stock was converted automatically into <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_dc_uShares_c20230207__20230208__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7ze5rpdkpr7" title="Reverse stock splits">one</span> issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account had their shares automatically adjusted to reflect the 1-for-20 reverse stock split. The reverse stock split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split resulted in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split was rounded up to the nearest whole number of shares. Proportional adjustments were made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, on February 28, 2023, the Company received official notice from Nasdaq that the Company evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $<span id="xdx_906_ecustom--MinimumBidPricePerShare_iI_pid_c20230228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z58YhbesBuT" title="Minimum bid price per share">1.00</span> bid price requirement. As previously disclosed, the Company was granted an extension by the Nasdaq Hearings Panel through February 23, 2023 to regain compliance with the $<span id="xdx_90E_ecustom--MinimumBidPricePerShare_iI_pid_c20230228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKpKyNZuBCnd" title="Minimum bid price per share">1.00</span> bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).</span></p> common stock at a ratio of 1 post-split share for every 20 pre-split shares Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-2 and not more than 1-for-50 20 1 1.00 1.00 EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 211 312 1 false 62 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nanovibronix.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://nanovibronix.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://nanovibronix.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Stockholders' Equity Sheet http://nanovibronix.com/role/StatementOfStockholdersEquity Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical) Sheet http://nanovibronix.com/role/StatementOfStockholdersEquityParenthetical Consolidated Statement of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://nanovibronix.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://nanovibronix.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 00000009 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS Sheet http://nanovibronix.com/role/LiquidityAndPlanOfOperations LIQUIDITY AND PLAN OF OPERATIONS Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES Sheet http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables PREPAID EXPENSES AND OTHER RECEIVABLES Notes 11 false false R12.htm 00000012 - Disclosure - INVENTORY Sheet http://nanovibronix.com/role/Inventory INVENTORY Notes 12 false false R13.htm 00000013 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://nanovibronix.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 13 false false R14.htm 00000014 - Disclosure - DERIVATIVE LIABILITIES Sheet http://nanovibronix.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 14 false false R15.htm 00000015 - Disclosure - LEASES Sheet http://nanovibronix.com/role/Leases LEASES Notes 15 false false R16.htm 00000016 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Sheet http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Notes 16 false false R17.htm 00000017 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA Sheet http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA Notes 17 false false R18.htm 00000018 - Disclosure - OTHER ASSETS Sheet http://nanovibronix.com/role/OtherAssets OTHER ASSETS Notes 18 false false R19.htm 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://nanovibronix.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 00000020 - Disclosure - RELATED PARTY TRANSACTION Sheet http://nanovibronix.com/role/RelatedPartyTransaction RELATED PARTY TRANSACTION Notes 20 false false R21.htm 00000021 - Disclosure - INCOME TAXES Sheet http://nanovibronix.com/role/IncomeTaxes INCOME TAXES Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://nanovibronix.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) Sheet http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) Tables http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables 25 false false R26.htm 00000026 - Disclosure - INVENTORY (Tables) Sheet http://nanovibronix.com/role/InventoryTables INVENTORY (Tables) Tables http://nanovibronix.com/role/Inventory 26 false false R27.htm 00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://nanovibronix.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://nanovibronix.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - DERIVATIVE LIABILITIES (Tables) Sheet http://nanovibronix.com/role/DerivativeLiabilitiesTables DERIVATIVE LIABILITIES (Tables) Tables http://nanovibronix.com/role/DerivativeLiabilities 28 false false R29.htm 00000029 - Disclosure - LEASES (Tables) Sheet http://nanovibronix.com/role/LeasesTables LEASES (Tables) Tables http://nanovibronix.com/role/Leases 29 false false R30.htm 00000030 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) Sheet http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) Tables http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder 30 false false R31.htm 00000031 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables) Sheet http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables) Tables http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData 31 false false R32.htm 00000032 - Disclosure - OTHER ASSETS (Tables) Sheet http://nanovibronix.com/role/OtherAssetsTables OTHER ASSETS (Tables) Tables http://nanovibronix.com/role/OtherAssets 32 false false R33.htm 00000033 - Disclosure - INCOME TAXES (Tables) Sheet http://nanovibronix.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://nanovibronix.com/role/IncomeTaxes 33 false false R34.htm 00000034 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) Sheet http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative) Details http://nanovibronix.com/role/LiquidityAndPlanOfOperations 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details) Sheet http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details) Details 35 false false R36.htm 00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) Sheet http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF INVENTORY (Details) Sheet http://nanovibronix.com/role/ScheduleOfInventoryDetails SCHEDULE OF INVENTORY (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details) Sheet http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails SCHEDULE OF OPTIONS ACTIVITY (Details) Details 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) Sheet http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) Sheet http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details) Sheet http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) Sheet http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails SCHEDULE OF WARRANTS ACTIVITY (Details) Details 43 false false R44.htm 00000044 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://nanovibronix.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://nanovibronix.com/role/StockholdersEquityTables 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details) Sheet http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details) Details 45 false false R46.htm 00000046 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) Details http://nanovibronix.com/role/DerivativeLiabilitiesTables 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details) Sheet http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details) Details 47 false false R48.htm 00000048 - Disclosure - LEASES (Details Narrative) Sheet http://nanovibronix.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://nanovibronix.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details) Sheet http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details) Details 49 false false R50.htm 00000050 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) Sheet http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details) Details 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details) Sheet http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails SCHEDULE OF WARRANTS ASSUMPTIONS (Details) Details 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) Sheet http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details) Details 52 false false R53.htm 00000053 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) Sheet http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) Details 53 false false R54.htm 00000054 - Disclosure - OTHER ASSETS (Details Narrative) Sheet http://nanovibronix.com/role/OtherAssetsDetailsNarrative OTHER ASSETS (Details Narrative) Details http://nanovibronix.com/role/OtherAssetsTables 54 false false R55.htm 00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://nanovibronix.com/role/CommitmentsAndContingencies 55 false false R56.htm 00000056 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative) Sheet http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative RELATED PARTY TRANSACTION (Details Narrative) Details http://nanovibronix.com/role/RelatedPartyTransaction 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details) Sheet http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details) Details 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details) Sheet http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details) Details 58 false false R59.htm 00000059 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details) Sheet http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details) Details 59 false false R60.htm 00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details) Sheet http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails SCHEDULE OF DEFERRED TAX ASSETS (Details) Details 60 false false R61.htm 00000061 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://nanovibronix.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://nanovibronix.com/role/IncomeTaxesTables 61 false false R62.htm 00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://nanovibronix.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://nanovibronix.com/role/SubsequentEvents 62 false false All Reports Book All Reports form10-k.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex4-15.htm naov-20221231.xsd naov-20221231_cal.xml naov-20221231_def.xml naov-20221231_lab.xml naov-20221231_pre.xml form10-k_001.jpg form10-k_002.jpg form10-k_003.jpg form10-k_004.jpg form10-k_005.jpg form10-k_006.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 20, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 676, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 211, "dts": { "calculationLink": { "local": [ "naov-20221231_cal.xml" ] }, "definitionLink": { "local": [ "naov-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "naov-20221231_lab.xml" ] }, "presentationLink": { "local": [ "naov-20221231_pre.xml" ] }, "schema": { "local": [ "naov-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 502, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 136, "http://nanovibronix.com/20221231": 70, "http://xbrl.sec.gov/dei/2022": 3, "total": 209 }, "keyCustom": 49, "keyStandard": 263, "memberCustom": 24, "memberStandard": 37, "nsprefix": "NAOV", "nsuri": "http://nanovibronix.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://nanovibronix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES", "menuCat": "Notes", "order": "11", "role": "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVENTORY", "menuCat": "Notes", "order": "12", "role": "http://nanovibronix.com/role/Inventory", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "13", "role": "http://nanovibronix.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - DERIVATIVE LIABILITIES", "menuCat": "Notes", "order": "14", "role": "http://nanovibronix.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - LEASES", "menuCat": "Notes", "order": "15", "role": "http://nanovibronix.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER", "menuCat": "Notes", "order": "16", "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder", "shortName": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA", "menuCat": "Notes", "order": "17", "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - OTHER ASSETS", "menuCat": "Notes", "order": "18", "role": "http://nanovibronix.com/role/OtherAssets", "shortName": "OTHER ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "19", "role": "http://nanovibronix.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://nanovibronix.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - RELATED PARTY TRANSACTION", "menuCat": "Notes", "order": "20", "role": "http://nanovibronix.com/role/RelatedPartyTransaction", "shortName": "RELATED PARTY TRANSACTION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "21", "role": "http://nanovibronix.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "22", "role": "http://nanovibronix.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "23", "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "menuCat": "Tables", "order": "25", "role": "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - INVENTORY (Tables)", "menuCat": "Tables", "order": "26", "role": "http://nanovibronix.com/role/InventoryTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "menuCat": "Tables", "order": "27", "role": "http://nanovibronix.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - DERIVATIVE LIABILITIES (Tables)", "menuCat": "Tables", "order": "28", "role": "http://nanovibronix.com/role/DerivativeLiabilitiesTables", "shortName": "DERIVATIVE LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "29", "role": "http://nanovibronix.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://nanovibronix.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)", "menuCat": "Tables", "order": "30", "role": "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables", "shortName": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)", "menuCat": "Tables", "order": "31", "role": "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables", "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - OTHER ASSETS (Tables)", "menuCat": "Tables", "order": "32", "role": "http://nanovibronix.com/role/OtherAssetsTables", "shortName": "OTHER ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "33", "role": "http://nanovibronix.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "shortName": "LIQUIDITY AND PLAN OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "NAOV:LiquidityAndPlanOfOperationsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_SaleOfEquitySecuritiesMember", "decimals": "-3", "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)", "menuCat": "Details", "order": "35", "role": "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails", "shortName": "SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_ComputerEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "menuCat": "Details", "order": "37", "role": "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails", "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF INVENTORY (Details)", "menuCat": "Details", "order": "38", "role": "http://nanovibronix.com/role/ScheduleOfInventoryDetails", "shortName": "SCHEDULE OF INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_EmployeeOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)", "menuCat": "Details", "order": "39", "role": "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "shortName": "SCHEDULE OF OPTIONS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_EmployeeOptionsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)", "menuCat": "Details", "order": "40", "role": "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)", "menuCat": "Details", "order": "41", "role": "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails", "shortName": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)", "menuCat": "Details", "order": "42", "role": "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedDividendRateMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)", "menuCat": "Details", "order": "43", "role": "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember_custom_PrivateInvestorsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-08-17", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details)", "menuCat": "Details", "order": "45", "role": "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "shortName": "SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_custom_DerivativeLiabilityMember", "decimals": null, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsForRepurchaseOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)", "menuCat": "Details", "order": "46", "role": "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "shortName": "DERIVATIVE LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DerivativesAndFairValueTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-04-052021-04-06_custom_DerivativeLiabilityWarrantsMember_custom_InvestorsMember", "decimals": "INF", "lang": null, "name": "NAOV:NumberOfWarrantsAcquired", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)", "menuCat": "Details", "order": "47", "role": "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails", "shortName": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - LEASES (Details Narrative)", "menuCat": "Details", "order": "48", "role": "http://nanovibronix.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details)", "menuCat": "Details", "order": "49", "role": "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails", "shortName": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://nanovibronix.com/role/StatementOfStockholdersEquity", "shortName": "Consolidated Statement of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesCPreferredStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)", "menuCat": "Details", "order": "50", "role": "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails", "shortName": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SCHEDULE OF WARRANTS ASSUMPTIONS (Details)", "menuCat": "Details", "order": "51", "role": "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "shortName": "SCHEDULE OF WARRANTS ASSUMPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfWarrantsAssumptionsTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_custom_PriceAtValuationMember_custom_SanuwaveHealthIncMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)", "menuCat": "Details", "order": "52", "role": "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails", "shortName": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_custom_DerivativeAssetMember", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)", "menuCat": "Details", "order": "53", "role": "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member", "decimals": "-3", "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "NAOV:ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - OTHER ASSETS (Details Narrative)", "menuCat": "Details", "order": "54", "role": "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "shortName": "OTHER ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "NAOV:ChangeInFairValueOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-02-252021-02-26", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "55", "role": "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-02-252021-02-26", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - RELATED PARTY TRANSACTION (Details Narrative)", "menuCat": "Details", "order": "56", "role": "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative", "shortName": "RELATED PARTY TRANSACTION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)", "menuCat": "Details", "order": "57", "role": "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails", "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentForeignTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)", "menuCat": "Details", "order": "58", "role": "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails", "shortName": "SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)", "menuCat": "Details", "order": "59", "role": "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails", "shortName": "SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://nanovibronix.com/role/StatementOfStockholdersEquityParenthetical", "shortName": "Consolidated Statement of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS (Details)", "menuCat": "Details", "order": "60", "role": "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "NAOV:FederalNetOperatingLossCarriedForward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "61", "role": "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "NAOV:FederalNetOperatingLossCarriedForward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-12-142022-12-15", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "62", "role": "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-12-142022-12-15", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://nanovibronix.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - DESCRIPTION OF BUSINESS", "menuCat": "Notes", "order": "8", "role": "http://nanovibronix.com/role/DescriptionOfBusiness", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:LiquidityAndPlanOfOperationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - LIQUIDITY AND PLAN OF OPERATIONS", "menuCat": "Notes", "order": "9", "role": "http://nanovibronix.com/role/LiquidityAndPlanOfOperations", "shortName": "LIQUIDITY AND PLAN OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NAOV:LiquidityAndPlanOfOperationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 62, "tag": { "NAOV_AccreditorInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accredited Investors [Member].", "label": "Accredited Investors [Member]" } } }, "localname": "AccreditorInvestorsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_AdjustmentsToAdditionalPaidInCapitalReclassOfDerivativeLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital reclass of derivative liabilities.", "label": "Reclass of derivative liabilities to APIC" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassOfDerivativeLiabilities", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_ArbitrationSettlementExpense": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount refers to arbitration settlement expense.", "label": "Arbitration settlement expense" } } }, "localname": "ArbitrationSettlementExpense", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_ArbitratorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Arbitrator [Member]" } } }, "localname": "ArbitratorMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_ChangeInFairValueOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of warrants.", "label": "Change in fair value of warrants" } } }, "localname": "ChangeInFairValueOfWarrants", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NAOV_ConversionOfSeriesCPreferredStockSharesIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series C preferred stock shares into common stock.", "label": "Conversion of Series C Preferred Stock into Common Stock, shares" } } }, "localname": "ConversionOfSeriesCPreferredStockSharesIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NAOV_ConversionOfSeriesCPreferredStockValueIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of series c preferred stock value into common stock.", "label": "Conversion of Series C Preferred Stock into Common Stock" } } }, "localname": "ConversionOfSeriesCPreferredStockValueIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_ConversionOfSeriesDPreferredStockSharesIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series D preferred stock shares into common stock.", "label": "Conversion of Series D Preferred Stock into Common Stock, shares" } } }, "localname": "ConversionOfSeriesDPreferredStockSharesIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NAOV_ConversionOfSeriesEPreferredStockIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of series E preferred stock value into common stock.", "label": "Conversion of Series E Preferred Stock into Common Stock" } } }, "localname": "ConversionOfSeriesEPreferredStockIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_ConversionOfSeriesEPreferredStockSharesIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of series E preferred stock shares into common stock.", "label": "Conversion of Series E Preferred Stock into Common Stock, shares" } } }, "localname": "ConversionOfSeriesEPreferredStockSharesIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NAOV_ConversionofSeriesDPreferredStockValueIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of series D preferred stock value into common stock.", "label": "Conversion of Series D Preferred Stock into Common Stock" } } }, "localname": "ConversionofSeriesDPreferredStockValueIntoCommonStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_DeferredTaxAssetsTaxDeferredExpenseAccruals": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Arbitration accrual" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseAccruals", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "NAOV_DerivativeAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Asset [Member]", "label": "Derivative Asset [Member]" } } }, "localname": "DerivativeAssetMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "NAOV_DerivativeLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liabilities [Member]", "label": "Derivative Liabilities [Member]" } } }, "localname": "DerivativeLiabilitiesMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "NAOV_DerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liability [Member]", "label": "Derivative Liability [Member]" } } }, "localname": "DerivativeLiabilityMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "NAOV_DerivativeLiabilityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative Liability Warrants [Member]", "label": "Derivative Liability Warrants [Member]" } } }, "localname": "DerivativeLiabilityWarrantsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_DisclosureDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DisclosureDerivativeLiabilitiesAbstract", "nsuri": "http://nanovibronix.com/20221231", "xbrltype": "stringItemType" }, "NAOV_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "verboseLabel": "Schedule Of Liabilities Arising From Operating Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://nanovibronix.com/20221231", "xbrltype": "stringItemType" }, "NAOV_DisclosureLiquidityAndPlanOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity And Plan Of Operations" } } }, "localname": "DisclosureLiquidityAndPlanOfOperationsAbstract", "nsuri": "http://nanovibronix.com/20221231", "xbrltype": "stringItemType" }, "NAOV_EffectiveIncomeTaxRateReconciliationForfeitedOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation,forfeited options, percent.", "label": "Forfeited options" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForfeitedOptions", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "NAOV_EffectiveIncomeTaxRateReconciliationPermanentItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation,permanent items, percent.", "label": "Permanent Items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "NAOV_EmployeeOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Options [Member]", "label": "Employee Options [Member]" } } }, "localname": "EmployeeOptionsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_ExchangeOfCommonStocksIntoPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange of common stock into Preferred Stock.", "label": "Exchange of common stock into preferred stock" } } }, "localname": "ExchangeOfCommonStocksIntoPreferredStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation buy back of warrants.", "label": "Buy back of warrants" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationBuyBackOfWarrants", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "NAOV_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation fair value adjustments warrants.", "label": "Fair value adjustments - Sanuwave warrants" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationFairValueAdjustmentsWarrants", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "NAOV_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation reclassification liability to equity.", "label": "Reclassification liability to equity" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationLiabilityToEquity", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "NAOV_FederalNetOperatingLossCarriedForward": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information related to federal net operating loss carried forward.", "label": "Federal net operating loss carried forward" } } }, "localname": "FederalNetOperatingLossCarriedForward", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NAOV_FederalNetOperatingLossOffsetAgainstTaxableIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents information related to federal net operating loss offset against taxable income.", "label": "Federal net operating loss offset against taxable income" } } }, "localname": "FederalNetOperatingLossOffsetAgainstTaxableIncome", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NAOV_FinancialExpensesNet": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financial expenses net.", "label": "Financial expense, net" } } }, "localname": "FinancialExpensesNet", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "NAOV_FormerOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Officer [Member]", "label": "Former Officer [Member]" } } }, "localname": "FormerOfficerMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_GainLossOnPurchaseOfWarrants": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain loss on purchase of warrants.", "label": "Gain on purchase of warrants", "negatedLabel": "Gain on purchase of warrants" } } }, "localname": "GainLossOnPurchaseOfWarrants", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/StatementsOfCashFlows", "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "NAOV_GrossProceedsFromPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross proceeds from private placement" } } }, "localname": "GrossProceedsFromPrivatePlacement", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NAOV_GrossProceedsOfAggregateCashFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross proceeds of aggregate cash fee percentage.", "label": "Gross proceeds of aggregate cash fee percentage" } } }, "localname": "GrossProceedsOfAggregateCashFeePercentage", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "NAOV_GrossProceedsOfManagementFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross proceeds of management fee percentage.", "label": "Gross proceeds of management fee percentage" } } }, "localname": "GrossProceedsOfManagementFeePercentage", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "NAOV_HCWainwrightAndCoLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "H.C. Wainwright &amp; Co., LLC [Member]", "label": "H.C. Wainwright &amp; Co., LLC [Member]" } } }, "localname": "HCWainwrightAndCoLLCMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_IncreaseDecreaseInAccruedSeverancePayNet": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued severance pay, net.", "label": "Accrued severance pay, net" } } }, "localname": "IncreaseDecreaseInAccruedSeverancePayNet", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investors [Member]", "label": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_IssuanceOfRedeemableSeriesFPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of redeemable Series F preferred stock" } } }, "localname": "IssuanceOfRedeemableSeriesFPreferredStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_JonaZumerisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jona Zumeris [Member]", "label": "Jona Zumeris [Member]" } } }, "localname": "JonaZumerisMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_LicensingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing Agreement [Member]", "label": "Licensing Agreement [Member]" } } }, "localname": "LicensingAgreementMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_LiquidityAndPlanOfOperationsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity and plan of operations [Text Block]", "label": "LIQUIDITY AND PLAN OF OPERATIONS" } } }, "localname": "LiquidityAndPlanOfOperationsTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperations" ], "xbrltype": "textBlockItemType" }, "NAOV_MinimumBidPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum bid price per share.", "label": "Minimum bid price per share" } } }, "localname": "MinimumBidPricePerShare", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "NAOV_NewWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Warrants [Member].", "label": "New Warrants [Member]" } } }, "localname": "NewWarrantsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash interest expense.", "label": "Noncash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_NumberOfWarrantsAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants acquired.", "label": "Number of warrants acquired" } } }, "localname": "NumberOfWarrantsAcquired", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "NAOV_OperatingLossCarryforwardsExpirationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents as a operating loss carryforwards expiration term.", "label": "Operating loss carryforwards expiration term" } } }, "localname": "OperatingLossCarryforwardsExpirationTerm", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "durationItemType" }, "NAOV_OtherCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Country [Member]" } } }, "localname": "OtherCountryMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "NAOV_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_PriceAtValuationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price at Valuation [Member]", "label": "Price at Valuation [Member]" } } }, "localname": "PriceAtValuationMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "NAOV_PrivateInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Investors [Member]", "label": "Private Investors [Member]" } } }, "localname": "PrivateInvestorsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "domainItemType" }, "NAOV_ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclass derivative liability to equity due to increase in authorized shares.", "label": "Reclass derivative liability to equity due to increase in authorized shares" } } }, "localname": "ReclassDerivativeLiabilityToEquityDueToIncreaseInAuthorizedShares", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclass liability to equity after increase in authorized shares.", "label": "Reclass liability to equity after increase in authorized shares" } } }, "localname": "ReclassLiabilityToEquityAfterIncreaseInAuthorizedShares", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_RedemptionOfRedeemableSeriesFPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Redemption of redeemable Series F preferred stock" } } }, "localname": "RedemptionOfRedeemableSeriesFPreferredStock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_SaleOfEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Equity Securities [Member]", "label": "Sale of Equity Securities [Member]" } } }, "localname": "SaleOfEquitySecuritiesMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_SanuwaveHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanuwave Health, Inc. [Member]", "label": "Sanuwave Health, Inc. [Member]" } } }, "localname": "SanuwaveHealthIncMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "NAOV_ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of depreciation calculated over estimated useful lives of assets [Table Text Block]", "label": "SCHEDULE OF DEPRECIATION CALCULATED OVER ESTIMATED USEFUL LIVES OF ASSETS" } } }, "localname": "ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsTableTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "NAOV_ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Estimating Fair Value Of Warrants Assumptions [Table Text Blcok]", "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR WARRANTS" } } }, "localname": "ScheduleOfEstimatingFairValueOfWarrantsAssumptionsTableTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "NAOV_ScheduleOfWarrantsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WARRANTS ASSUMPTIONS" } } }, "localname": "ScheduleOfWarrantsAssumptionsTableTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/OtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "NAOV_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_SequencingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sequencing" } } }, "localname": "SequencingPolicyTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "NAOV_SeriesFCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Common Stock [Member]", "label": "Series F Common Stock [Member]" } } }, "localname": "SeriesFCommonStockMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_SeveranceAssetsNoncurent": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Severance assets, noncurrent.", "label": "Severance pay fund" } } }, "localname": "SeveranceAssetsNoncurent", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "NAOV_SeverancePayPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Severance pay" } } }, "localname": "SeverancePayPolicyTextBlock", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "NAOV_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedCashless": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Exercised - cashless.", "label": "Warrants, Exercised - cashless" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedCashless", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm", "verboseLabel": "Weighted Average Remaining Life (Years), Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life (Years), Granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "NAOV_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life (Years), Outstanding - ending balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "NAOV_SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued from exercise of warrants previously classified as derivative liability.", "label": "Shares issued from exercise of warrants previously classified as derivative liability" } } }, "localname": "SharesIssuedFromExerciseOfWarrantsPreviouslyClassifiedAsDerivativeLiability", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NAOV_StockIssuedDuringPeriodSharesWarrantsExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares warrants exercised.", "label": "Stock issued during period warrants" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercise", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "NAOV_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share warrants exercised during the current period.", "label": "Exercise of warrant, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NAOV_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NAOV_StockOptionsEmployeeAndNonEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Employee And Non Employee [Member]" } } }, "localname": "StockOptionsEmployeeAndNonEmployeeMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "domainItemType" }, "NAOV_TwoInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Investors [Member].", "label": "Two Investors [Member]" } } }, "localname": "TwoInvestorsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NAOV_ValuationAllowanceOfIncomeTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Valuation allowance of income tax expense benefit.", "label": "Valuation allowance of income tax expense benefit", "negatedLabel": "Less: Valuation Allowance" } } }, "localname": "ValuationAllowanceOfIncomeTaxExpenseBenefit", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "NAOV_WarrantModificationExpense": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrant modification expense.", "label": "Warrant modification expense", "negatedLabel": "Warrant modification expense" } } }, "localname": "WarrantModificationExpense", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows", "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "NAOV_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://nanovibronix.com/20221231", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative", "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "domainItemType" }, "country_AU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AUSTRALIA" } } }, "localname": "AU", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative", "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "country_IN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INDIA" } } }, "localname": "IN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r502", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r502", "r504", "r505" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r502", "r504", "r505" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r502", "r504", "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r497" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r502", "r504", "r505" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nanovibronix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r259", "r260", "r261", "r262", "r308", "r416", "r441", "r464", "r465", "r480", "r485", "r490", "r543", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r259", "r260", "r261", "r262", "r308", "r416", "r441", "r464", "r465", "r480", "r485", "r490", "r543", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r259", "r260", "r261", "r262", "r300", "r308", "r331", "r332", "r333", "r415", "r416", "r441", "r464", "r465", "r480", "r485", "r490", "r535", "r543", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r259", "r260", "r261", "r262", "r300", "r308", "r331", "r332", "r333", "r415", "r416", "r441", "r464", "r465", "r480", "r485", "r490", "r535", "r543", "r572", "r573", "r574", "r575", "r576" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r241", "r242", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r481", "r489", "r545" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative", "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r241", "r242", "r450", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r481", "r489", "r545" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative", "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r531", "r567" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Trade payables" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r246", "r247" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Trade receivables" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r23", "r24", "r150", "r436", "r446", "r447" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r164", "r165", "r384", "r385", "r386", "r387", "r388", "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r20", "r24", "r108", "r402", "r442", "r443", "r520", "r521", "r522", "r527", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r3", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r337", "r338", "r339", "r527", "r528", "r529", "r559" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r64", "r67", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Increase in additional paid in capital warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r125", "r132", "r146", "r177", "r227", "r231", "r236", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r368", "r370", "r381", "r488", "r541", "r542", "r569" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r142", "r155", "r177", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r368", "r370", "r381", "r488", "r541", "r542", "r569" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r177", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r368", "r370", "r381", "r541", "r542", "r569" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation and principles of consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r448", "r449", "r488", "r512" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "verboseLabel": "Cash balance" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r38", "r43", "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r38", "r122" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r147", "r148", "r149", "r177", "r197", "r198", "r201", "r203", "r211", "r212", "r248", "r263", "r265", "r266", "r267", "r270", "r271", "r273", "r274", "r276", "r280", "r286", "r381", "r466", "r511", "r524", "r530" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price", "terseLabel": "Exercise price of warrants per share", "verboseLabel": "Class of warrant or right, exercise price of warrants or rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Number of warrants to purchase", "verboseLabel": "Warrants issued to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClearanceFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense in the period for clearance fees.", "label": "Clearing fees" } } }, "localname": "ClearanceFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralAxis": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by category of collateral or no collateral, from lender's perspective.", "label": "Collateral Held [Axis]" } } }, "localname": "CollateralAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of collateral or no collateral, from lender's perspective." } } }, "localname": "CollateralDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r128", "r136" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r63", "r257", "r258", "r451", "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Common stock, par value" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r527", "r528", "r559" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r67" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock of $0.001 par value - Authorized: 40,000,000 shares at December 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 1,641,146 and 1,399,890 shares at December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r160", "r162", "r169", "r432", "r438" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss available to common stockholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r45", "r46", "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares issued upon conversion" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r32", "r177", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r381", "r541" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r526", "r552", "r555" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r526", "r552" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r352", "r360", "r526" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r526", "r552", "r555" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER RECEIVABLES" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r526", "r553", "r555" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r104", "r526", "r553" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeNoncurrent": { "auth_ref": [ "r540" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred licensing income" } } }, "localname": "DeferredIncomeNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r41", "r104", "r353", "r359", "r360", "r526" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r513" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r526", "r553", "r555" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r347" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred tax assets before valuation allowance" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r550" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r102", "r551" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r102", "r551" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Stock compensation and other" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r348" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r41", "r225" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r558" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Change in fair value of derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r109", "r110", "r111", "r112", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r156", "r157", "r380", "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r113", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r170", "r187", "r188", "r189", "r190", "r191", "r195", "r197", "r201", "r202", "r203", "r207", "r374", "r375", "r433", "r439", "r473" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r204", "r205", "r206", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholder" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r563" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effects of currency translation on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r180", "r343", "r362" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal income tax benefit at statutory rate", "verboseLabel": "Corporate tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Foreign rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Return to provision adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r549", "r556" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfReconciliationOfStatutoryU.s.FederalRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Non-vested stock options granted, weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r547" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Non-vested stock options granted, unrecognized estimated compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r67", "r140", "r164", "r165", "r166", "r182", "r183", "r184", "r186", "r192", "r194", "r210", "r249", "r288", "r337", "r338", "r339", "r355", "r356", "r373", "r384", "r385", "r386", "r387", "r388", "r391", "r402", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r532" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Change in fair value of equity investment" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r127", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow amount" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r41", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Warrants, modification expense", "terseLabel": "Fair value of warrants", "verboseLabel": "Fair value adjustments - Warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "SCHEDULE OF QUANTITATIVE INFORMATION TO VALUATION METHODOLOGY AND UNOBSERVABLE INPUTS" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r272", "r301", "r302", "r303", "r304", "r305", "r306", "r377", "r412", "r413", "r414", "r478", "r479", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r118", "r120" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r272", "r301", "r306", "r377", "r412", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r272", "r301", "r306", "r377", "r413", "r478", "r479", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r272", "r301", "r302", "r303", "r304", "r305", "r306", "r377", "r414", "r478", "r479", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r272", "r301", "r302", "r303", "r304", "r305", "r306", "r412", "r413", "r414", "r478", "r479", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r116", "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "SCHEDULE OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "auth_ref": [ "r117", "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "New Issuances" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r114", "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Balance ending", "periodStartLabel": "Balance beginning" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Financing Receivable, Past Due [Line Items]" } } }, "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign currency translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r109" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Change in fair value of derivative liabilities" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r31", "r177", "r227", "r230", "r235", "r238", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r381", "r475", "r541" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r59", "r62" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r179", "r361" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r28", "r124", "r129", "r138", "r227", "r230", "r235", "r238", "r434", "r475" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "negatedTotalLabel": "Loss before taxes", "totalLabel": "Loss before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails", "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r179", "r361" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "negatedLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfIncomeBeforeTaxesOnDomesticAndForeignDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r180", "r344", "r345", "r351", "r357", "r363", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r181", "r193", "r194", "r226", "r342", "r358", "r364", "r440" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r163", "r340", "r341", "r345", "r346", "r350", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "verboseLabel": "Trade payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r470" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "verboseLabel": "Other accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Other accounts receivable and prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r123", "r131", "r167", "r224", "r394" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r171", "r173", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r58", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Inventory allowance" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r516" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfInventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r152", "r467", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://nanovibronix.com/role/ScheduleOfInventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r144", "r151", "r209", "r250", "r251", "r252", "r417", "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r517" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfInventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfInventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal fees paid" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/RelatedPartyTransactionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF LIABILITIES ARISING FROM OPERATING LEASES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r400" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r400" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r400" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r565" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r177", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r369", "r370", "r371", "r381", "r474", "r541", "r569", "r570" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r126", "r134", "r488", "r525", "r533", "r562" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r143", "r177", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r369", "r370", "r371", "r381", "r488", "r541", "r569", "r570" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation settlement, amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r536", "r537", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Damages awarded value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r536", "r537", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Litigation damages sought value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputConversionPriceMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using price per share at which convertible share can be converted into common stock.", "label": "Measurement Input, Conversion Price [Member]" } } }, "localname": "MeasurementInputConversionPriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r213", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r172" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r38", "r39", "r42" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r29", "r42", "r130", "r137", "r141", "r158", "r161", "r166", "r177", "r185", "r187", "r188", "r189", "r190", "r193", "r194", "r199", "r227", "r230", "r235", "r238", "r248", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r375", "r381", "r475", "r541" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StatementsOfCashFlows", "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r187", "r188", "r189", "r190", "r195", "r196", "r200", "r203", "r227", "r230", "r235", "r238", "r475" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net loss available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently adopted accounting standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental non-cash financing and investing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r17", "r18" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfChangesInLevel3AndLiabilityMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r227", "r230", "r235", "r238", "r475" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r564" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease, expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfLiabilitiesArisingFromOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r396" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r395" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r399", "r487" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r398", "r487" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "verboseLabel": "Net operating loss carry forward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.", "label": "Other accounts payable and accrued expenses" } } }, "localname": "OtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Accrued severance pay" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r154", "r488" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other receivables" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r145" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "auth_ref": [ "r105", "r106", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "auth_ref": [ "r19", "r22", "r382", "r383", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Gains and losses from foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r19", "r22", "r383", "r390" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedLabel": "Change in foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r67", "r159", "r162", "r168", "r384", "r389", "r391", "r431", "r437", "r520", "r521" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "PREPAID EXPENSES AND OTHER RECEIVABLES" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/PrepaidExpensesAndOtherReceivables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNoncashExpense": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.", "label": "Non-accountable expense allowance" } } }, "localname": "OtherNoncashExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r178", "r548", "r554" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "totalLabel": "Total Tax" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfProvisionForIncomeTaxesExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "auth_ref": [ "r37" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "Payments for repurchase of warrants", "negatedLabel": "Buy back of warrants from investor" } } }, "localname": "PaymentsForRepurchaseOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/DerivativeLiabilitiesDetailsNarrative", "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r1", "r68" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred stock, conversion description" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "verboseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r1", "r273" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionPricePerShare": { "auth_ref": [ "r66", "r68", "r69" ], "lang": { "en-us": { "role": { "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.", "label": "Preferred stock, redemption price per share" } } }, "localname": "PreferredStockRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r1", "r273" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r1", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r1", "r68" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock, voting rights, description" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r519" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other accounts receivable", "totalLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r153", "r253", "r254", "r468" ], "calculation": { "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfPrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock, net", "terseLabel": "Proceeds from sale of common stock", "verboseLabel": "Net proceeds received" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://nanovibronix.com/role/StatementsOfCashFlows", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Net proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Net offering costs" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative", "http://nanovibronix.com/role/StatementOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r36", "r95" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r523" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants", "verboseLabel": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r61", "r135", "r435", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r61", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r307", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r307", "r405", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r403", "r404", "r406", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTION" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/RelatedPartyTransaction" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r96", "r139", "r577" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r70", "r133", "r445", "r447", "r488" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r140", "r182", "r183", "r184", "r186", "r192", "r194", "r249", "r337", "r338", "r339", "r355", "r356", "r373", "r442", "r444" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r222", "r223", "r229", "r233", "r234", "r240", "r241", "r244", "r297", "r298", "r418" ], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenues", "verboseLabel": "Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss", "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r299", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "SUMMARY OF REVENUE WITHIN GEOGRAPHIC AREAS" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of stock, number of shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfCommonShareEquivalentsBeenExcludedFromDilutiveLossPerShareAsAnti-DilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI- DILUTIVE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LossPerShareApplicableToCommonShareholderTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF PROVISION FOR INCOME TAXES EXPENSES" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r76", "r77", "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF RECONCILIATION OF STATUTORY U.S. FEDERAL RATE" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "SCHEDULE OF STOCK BASED EXPENSES RECOGNIZED FOR SERVICES FROM EMPLOYEES AND NON-EMPLOYEES" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "auth_ref": [ "r477", "r534" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about aging analysis for financing receivable.", "label": "Financing Receivable, Past Due [Table]" } } }, "localname": "ScheduleOfFinancingReceivablesPastDueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/LiquidityAndPlanOfOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "SCHEDULE OF INCOME BEFORE TAXES ON DOMESTIC AND FOREIGN" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r8", "r9", "r10" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORY" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfDepreciationCalculatedOverEstimatedUsefulLivesOfAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r27", "r56" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfRevenueWithinGeographicAreasDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r83", "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF OPTIONS ACTIVITY" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS FOR OPTIONS GRANTED" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r72", "r81" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r219", "r220", "r221", "r227", "r228", "r232", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/GeographicInformationAndMajorCustomerData" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r514", "r515", "r544" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r514", "r515", "r544" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [ "r514", "r515", "r544" ], "lang": { "en-us": { "role": { "documentation": "Series E preferred stock.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesFPreferredStockMember": { "auth_ref": [ "r514", "r515", "r544" ], "lang": { "en-us": { "role": { "documentation": "Series F preferred stock.", "label": "Series F Preferred Stock [Member]" } } }, "localname": "SeriesFPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance expenses" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r40" ], "calculation": { "http://nanovibronix.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Fair value options vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Warrants, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "negatedLabel": "Warrants, Canceled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Warrants, Outstanding - Ending balance", "periodStartLabel": "Warrants, Outstanding - Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted Average Exercise Price per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options, Granted", "verboseLabel": "Number of options, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, Outstanding - Ending balance", "periodStartLabel": "Options, Outstanding - Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding - ending balance", "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding - beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Weighted Average Exercise Price per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Price at valuation", "verboseLabel": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Life (Years), Outstanding - beginning balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Number of options, vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r49", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r147", "r148", "r149", "r177", "r197", "r198", "r201", "r203", "r211", "r212", "r248", "r263", "r265", "r266", "r267", "r270", "r271", "r273", "r274", "r276", "r280", "r286", "r381", "r466", "r511", "r524", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r67", "r140", "r164", "r165", "r166", "r182", "r183", "r184", "r186", "r192", "r194", "r210", "r249", "r288", "r337", "r338", "r339", "r355", "r356", "r373", "r384", "r385", "r386", "r387", "r388", "r391", "r402", "r442", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r182", "r183", "r184", "r210", "r418" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/BalanceSheetsParenthetical", "http://nanovibronix.com/role/LeasesDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForOptionsGrantedDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfStockBasedExpensesRecognizedForServicesFromEmployeesAndNon-employeesDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails", "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r1", "r2", "r67", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Reverse stock splits" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r67", "r70", "r317" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options, shares", "negatedLabel": "Options, Exercised", "verboseLabel": "Number of options, exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfOptionsActivityDetails", "http://nanovibronix.com/role/StatementOfStockholdersEquity", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockSplits": { "auth_ref": [ "r1", "r2", "r67", "r70" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a stock split.", "label": "Stock splits" } } }, "localname": "StockIssuedDuringPeriodSharesStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r1", "r2", "r67", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock, net of offering costs of $310,424" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r16", "r67", "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r57", "r488", "r525", "r533", "r562" ], "calculation": { "http://nanovibronix.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets", "http://nanovibronix.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r73", "r176", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r392", "r410" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r392", "r410" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r392", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r392", "r410" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r52", "r53", "r54", "r214", "r215", "r216", "r217" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Net increases in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsActivityDetails", "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants expire date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants, measurement input, percentage", "terseLabel": "Warrants and rights outstanding, measurement input", "verboseLabel": "Warrants, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Contractual term (in years)", "terseLabel": "Expected term (in years)", "verboseLabel": "Warrants, measurement input, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/OtherAssetsDetailsNarrative", "http://nanovibronix.com/role/ScheduleOfFairValueAssumptionsForWarrantsDetails", "http://nanovibronix.com/role/ScheduleOfQuantitativeInformationToValuationMethodologyAndUnobservableInputsDetails", "http://nanovibronix.com/role/ScheduleOfWarrantsAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r195", "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://nanovibronix.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "https://asc.fasb.org/topic&trid=2229140", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r496": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r497": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r498": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r499": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r502": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r503": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r504": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r505": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r506": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r507": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r508": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r509": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 88 0001493152-23-012570-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-012570-xbrl.zip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�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ɡ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

PN/S*VX6LBQ+N%A M5N^SS2] ,==G+CX&?F8=H? MVM,I3B;44;1T@B+9V2YA:YX(;5QBVFA10.SXNU2N&1]&HGH8B-%A"K M5EU;Y-RHK4)[J%!S66/( AUX=%>9LWV%$NL[0>U4]];ISX?K=-#_Y:'?Z\]^ M[5C#7F<\L++E.AK;$XNMW68+EG.T[#XLFKA@O;%15 =I\VP4?7%&\;OQ^=<: M8%^LY=2$M=5S3XE!ABRB:;I:.='K:#'UED&6""Q(BF>6K((+W5#<3F] M__9P.4T?[N^MR:]L#4W[=\/^;;]K#6<=J]L=/0QG_>%=9SP:]+M]&^DDK!(& MR,8KZ(-D!! M^\.U-Y[88ZO?Z]C_&-O#J3W-3K31[),]Z4SLKMW_;-T,L-;=YG%N-XR3N'CZ MR?3^@OC]'"$[JN2+\^B!,KLM:$G;#\594I 1:2N!?R2@) 4_%:R9E@ MR#+AUVK;7R\?*XKE;-3]^Z?1H&=/IO_^;S]]>/_C7SLVO;K-D!80M(:3&<6: MJFP?A@E16C,*0R O(%"-)F6.&+* JG9S[N7LNZI-F-5YMA,BBGIMXX79<5K 6M'WM,,LP<(M$J!#1A7#%D_ M ^9YX"R8[RO&0=N:ZEH@^43@QKZ#YCA+8$"H$DZV65GR20$6@*R?&>)?#\F! MO,-88(JTAS&+\,^\:]9Z[7MNEGDO+"(NV*_S,[!^0?Q061"CZ;0SMB>=Z2=K M8G>L\7C0[S*S0FC8?ZG7%-#4LV<**#([ B7*VG<'DB/RP[F UAA M@B[8ZI@$CL-'6#+:#5E:=R1<1L[ZR7/+X87!_-[Y9QAUTS@)5R3J.8E3O[1^ M/%Q:=_;H;F*-/_6[G?[P=C2YS_Q/F0WOWOKOT:33?:!WH'NZ]GK6S$*JJ$F6 MS&\X(6M6/"M8 J*MN3V0+D('\U&[ D$Z8]?*E$!T> V"\\.0=5>72WIO955" M,7(3N#6=VK.K]=L(JUWMI* &<$&_R[6!2YEER.IDBJ67URBAY':SATA+$O ] MR)6 #*9%]F?W]G"6.["ZH\QO; _QG,8"HE06J^(P2,\'(9,$+%75<9"7;B.( M#]_S-6*=(0MW0GR6>F7L1,GK+'*"F-)9+J197K0?*F$?$WM@S>Q>9VQ-9K]V M9A-K.+6Z3'_%6; <8@"Q'O*>.,N2-R^E-:DT"/*"A$)XL 8;\,F0!5AZ>E:_ MZ"KQ'OTA/2OMSLSZ!];!N)VSFA=9T GYU:.B%UG4"]V++(6&]_;1_+4R31]C M\D=*A[29YYNS8"HQ%].'FZG]RP-5+3LVB[Y 6C6'LX>\6>?UP'J$OS\?B.V$ MWP7;8B*!H_+$7D*[,6L$$M8K#._]4(W" (?W=OYC,_1_7B-]FU-QX\1>/%H< M3.PU_V_ LH/V/[=(7S6^H#_>?V!/7.TX\594.Q4\,#IL!ZXY:PHN]82B\_\V MC C=!O-(4G?_0A',LQ_]_)4&>&4=,22X_H8IJ![-/G0!./0J@F&6=@1G##0% M3" KT"';1K6"L>+W +^F-@4D&?%G7=N.6\4%C#1\!"#RVO(1*2.ORAS\=;I: M.UZ4I>J)-LGH1HM!&"P'WC-+WL$\5_ UW&@T(,K:LA6IK^\CF*8K$4YVJW6W MNK3L0:^@/1 .;7F)X'!("-',\%T50RC+!3V 3->6&$B5Z5+BT7>V/-0SC_ $ M;V#"3D",M&7N4=ZG "PX:U6D*!;+=K$[X%15QT'?+$W1A*: M<0I]#6^]&@JW"%X/*&CFF&-DU*/#TPU7[-E[QL+"=YM%3X'1 @\ !<\H1B[GIY5C''=]-L]QG1G6)CVY\_Q&21^NRVROPP M>6Z&['&1[ [3\D?.QG.E@WBCEK4\D8UH25<>7\+2V2 OYVMD?RO\ +VA/G;D MBWP=T!;##=E#MGX/T591>9:Z3::#O!M<2E:=W3&UG5R1A$EZQ&^BI, CH,=) MJF;;466.(2NKFO!$M,0JSU/Y^7>0U]R9)>+9"D_F>[]Q8K9U[^[YY3+71;W4 M5_4UUWQL[+?BH-0]K?$0W?Q51TI19-GZZD3S,BDLK4J.0QRGJ_QWQXC&,=_! MCDMK+"?',]<@F;%7:S]\)61*HF?/)?6KP?*S:60IP.E5+%P&F7J8%7/+E$8E M\6G]D]BQ<(J2I(GENCS,NWGG1@4O6&XS-.UJKJAL*/M6C*;#8@?-B5%OAT;C MMHOZE'<;2D;1Q%L^*6X'RD-B!^*I'AS-6&:(RE^;SDVD]==4,:G+&'B7VL9-%0S*Z(;7@[^S2+.SW/"A)O[ODI.S6F M;%?/-G[[A=58SRM5LOM=NBFEU2 _HXYO81OKU!([ZN.V(9L".".D:%.H9/E0 MRPN)O">HU/:C$Z16CF/-VBV9[L\DS 29?(-,6MN;^Q#DNQN_!G5 MNZM$]>*>W=0?@O Q)E$6D]8/J*+!C/2!2_OD]W=5JXK^*6#[V_3$+IT<0W2I MW:TT58M31K2ZN[>5SV#[Z/1(GQ8L#-%=2LD$1;I+);]3.:4@>BS=9>06W(D9 MN]2& 7NDP4+'BHD6T=(W)" +KT%X78-!T2/N5#,3ML!"@W9^>[$@+"J); F8 M. EIIH(<-RJV5G&,)#3GHD&BD,_]ABS":$='C_Y/G- ;1X[&]B2S M(5,-KQBXLQU9ET]70!SS$22\EF?R!;FW2,62K MM"+:6IV^"NCR+V%2FLLY,9",3M4Y,HV#SFO.WH+$6?&'8M)T3R#]A*P$V3X; M#H>,?0/DZJT_S:C?ZB!H4M -??98-W)\Z\43P'O8[D)P.R2K=$O QH.J>XX7 M0!#9M#0#DWJ)XO)],_G=1;U5=XJ3W:^R:->==_Z>K!YW94(/_2?"+MBW"IY\ M[+E $2C7Q*&).DZ\=,XHNHCW25O7A]BME=N ZF*QTZ>*,.TRAC(AJ*C3MM* MQA15UJFGT_DY5^0#LF39&[ SK+J$S&/FAN_'<*@+_86KUTB:GF%?B"P+4V@[61_Q;;GM E-F=Z6 MUR/*D_PCLP$5UIMZ:U EG\ZT^\GN/0QL9@/JV>.)W>WGH81=:]!]R.OWC3[; MDXX]G?7OLQ\?IO;MPZ SZ'^VIZS;)JBI^/"?.856BQ8C;L9OL+U(-H(9MQSE M-'=P O%-0]P9 NQ D+YF0*@JM-#<]D;9=[BSO'F=T<^*C3Z@SI<-9IE2=.,0 MGS3Z49F]"-39## 5A!:*8YG((TU-K>0)3A.J#FTFQ[5';8T^G [8EU<%@:S) M!RS@ ?IM9+18>"X!(\1ICGV5;(Z/D'X]Z,114D*&_K1#A?[PV\0)EKSSBOZ] M]&Y]?];S<3%7+SB]AYKT7>*MT)6+G M01.T7>.0715FUM*"LAO<.R]2KNXW0;,=R;E:1POZ"!A#7 ME3C-:YK>48V/Y7NP(B^FA/12]@0D3^8V+UI)IR;):N M<+)R$$+_534#=NHNK#G]RVHQV6)*)*FBQ3BVN:7]?Y>3*LANVN) M(BEJ=6VQSSH]F/&Y@@[8OCCMTZ>X[CB=L8_-4RQ#(=\:QY\D(9VJ4=$GNQH8 MH@.YDARV?""7*K#@GKF74H)E.Z6)\_6>12][C@^Y8^PW1W_JK5I<14@V^K:Z MG=VM%W@Q73YW83B'H'+0'OL\/ *76LK- 69((,L\:X5]@AT!0HG*"SJ&#DJV M" ^C2FKB\F$T&N?/6ZWNK/\YJU"$>R:=5XDBRW7351& RC'@,1.=)#A1;10S MW,^@X@!JA.$')@+G.Y"'*:J/9 :L302Z&>@#D\(8IY3/64WH7*QWJ7/$ 8R2 M;A<#J81.],#%@VG)0A4YS/+RCIS =-M)$I0WU&VR)DOA-6.(G.+>?.6Q'XAD>O%9!QYKNC-SZDF M@+V=F2?*$, N0\ ?Y?QZ5.;7A+ #B?Z^&P;9_2IU_!F)5A\DPG[JR6";A=H4 M?!P@SUZ'N,MRH/>#//#H+J+LUK\'4T5/)V^:WGT,2IAU]*%0PQBD(UUY)D#1_O'<15L3 MA&>_N=HO:Z_(UJM_?3%VVQ#<8"F^M-EZ;&?+SL'5*F MNVS8@:U\*LX#*K9G[V;2@A]F2EI-)JGMLL8U2ZE/ RK)QOJ-<-B&+\CHVBUF MQ,IO<(?G^TMW-M4RIQ6WOAT8KEU<2-2*BC2?O9>J/9:9(..:U GU* 9-"D63 MB4!%^:+=7OKN6]&KIUNK/^E\M@8/-LO3 M_G!?/(*Z'4VV#Z+N)M:0Y76_OH=J\HY"EH[]H)T9H?>@-TV'4\=_M;2=465S M$3!^8-K+HWK1X3%_H/WUT*6EBQ6RMS8I;,OO>:Y)82\@*6S[QL5K4EB<5+M& M)H7-U%O(!5G-)JY+Z>>?O'4W5,.\<$TOS76JN6[;!N";V(]PU&1!*^,O2[8F M7OS[;43H)3HA%%.ZKR6D.!-.)&G"&6"_@<&1.P H?P(IS,]03"GOJ35C('[# )@_A2R>]+R5S '[D8M1LB@]?.YWZ>]O)Z/[CGT_'HQ^M8M<[>J"K0(\_$#[,J;(4*(2O9"NJ,;;0&B>,!: IBWPFK' 2$3]X3V^36!#LH/]"!NR,!B1R?3M2:KU@:]22OYP=$ M#]@=VY[0!$(ESJ#C:/G9N&1>?PLM)LT'$MK_7!S!:OPP[B+-"O]JAEJ+NA6KI<1^'=\3?0!+ ;ZOVR& MF)UB 9]&:(VRC11DL+.Z'ZS39$:_)3:,\'O\:06%SQ)T TO=U&36%5$?,S"6 M22T 'U.,*H=SJXWAD%SO5,; -K'(!5("GIQ!Z+>\PREOO(0][]F;T]M&$TQ% M8V";7H[&5,X@XS#-(DQW;E]5.#G=L2TP1R,I9 O**X5S>YET2OVE]IW3A^L[ MI^L[)^UA.]=W3CK2HI[I.Z>-P93N91/V4+_\=/_PA.&?L6JC()O(3V4Q.CBO MFW#::/'@)-X D*N6*>-/) =&9\+83AQ0ZO>[CR(?R]:1ZWU>ZWU>ZWU M>ZWU>ZWURP]IO=;Z_1/5^FU+9969!0^:82NCH$+ ]5-'O)_/F,XW6O2I\OKL MS5/'YUO[.$W-$/]C=BL^;2A6O7K^)V\]"^T@8>H[;[^J(T@V M"+YU4"B*(JQDI.FI73Z.O&^2V.MN)=\G2=[&3-9F\3U;@N>RJ:.HLXE8;/*D\"V:! M'3QHKG1+H;O*NM$F H7J/!=;15V17:W8":J5>5""/UBZJJ?0I_C&.?%%G,:0 MN2#88^_ZZ(_O*M$?+//4I]&@9T^F__YO/WUX_^-?._8O#^70C\YVS&L0"&3K M21]C;^XYT>LHRF=T3Y*G<)Y;4PF9.KM\8Z_5QIMFLG14K7[%#&67'% E ?3\S(-6Q&+@"4<\(_' 2]F)DM"B=9^(P$D[S/PV@'/K1 MPTK*]8?SD%-G]YL9_5=,=RVF08N&^7X?.[.?'R54?_L5ML M](??!O0"Z><^:LY.25M5&IFQ2'3NCW54MQK*(H=&$J%"FQ@5?E+'L0I/3Q%5 M\JG[A8[^-6+O"NAJ[8:#05>X XDZH!FU*LRJ[BER0O$M^74*HR2RE]_E\K<= M.0]*9QT2I+L9#9T5_6?I )2%_T+ZF@8R1W /$0-0AAT4W!^/9.IRJ0FV.1\N M9X=I; _)1-\%-UGL,V)D$-0VAD98Z*MOT!0- >WHN!2QEV/?<<7WE*(#KST4 MG9^,0T?, 72 MB\RNKX3QS#U@=_%M)-%G_K YT$IQ 'TO*49.I"75M#0)0) MY@$B=91@JP-3$GDDML<;QQSH=!)V NZ#VK9!OFQ5$F]+2IB(^0=D/PZ3;!A],)BH\V)4\1'R'MAN!SVP0?3B=PF+,A^ AI/Q8? MKA<@^W(W7*W"0,SRW"S.:PYEMK8G#7)FBPDP91E<\/OZ4ZK2PO?WWU_?WU_? MW^_=<@#[WV:?:;SWO==VT*@\Q->V]7%.F(U!*8]&%+\9YK2%GBW: O%!_!40 MH)7!5&NX35F,Y";7E>19-JA'N-9D'M]IN^T9FLU#@?'92WX6 M!ATEK^4PCYO7\E_$BI3*&(83'^TL);+*,MYQI)6WA(F?"[C_K)N_;$!%/ICIV=40U:1.*WF MS8-YW#N!DYL&&R#$[8S^(/%8>"1L0=\WL[QRPS!PJ?2PDMA!+#C4:AMC)\EK MM#<*R$:'I.L3)V*;-948@2_VH!D0AO;KOQZEV=>1:@ 611XX9@815FURJVR MNDWJTG5\G\QO7C<.C**A$+(C!\9^;-40Y%;8B2X6PCJV3L+(>.W1@YB//WP$ M(- _&P6T*H/0$:V5S$V*].R>LRO^NA'']XK+6SX<>N1W>ZL:RCMTY/=?277# MX)E>92B_L]K&HJNBL!L42;,L,B!>H".VFU=!5FXURG^=D+EH7;Q+,XXWMKT=4"DPQ-JC1-L%B,"^N'\.$ZK6RVZ\ MHC[HJ0]:6/1U7#!LWYZ0.5EE3PF!KBM@=RA\9EF?:6>_/C*)B:S9%.( MUBD"^EC0Z&&B<$@L7WT_*+J&6':!5!FR9=3'^0+ $\8)-P?1-'NM"G=T94@5 M6:0V41(;:Q1GF2F. 47+$/-L PH-7'[%)#=S%#I&1+WPBTL=* T ^7KU8P?PC"QYBJ\BPI0#]8ITE[]S"P.Z/;SB\/UG#6GUFS_F>[TQ_>CB;W]-^C86YV$XNIG:D\_6S8#U&C_,IMLZ\R33A2B+!I[S MZ/E9,+:@&#SK#NZ-G/]<5N3]H!UR'@4ESG(\G_L$&5!^?3.CRJXC@*/4UI!L M([4"Q6-^:?KXQ=$ONA: $BS";/YX9<^OV?R-S.:O-0&W-C^?H?FW+RWYE'#? MJ4T?U4X!\6OZJ$M*'X61YNCRLT>U[T0_T^11]\1A]PBV3V6767EZ;WZ/<]AW MI42@EU&OFYI,WQ/U,0,5F9P!\#%%Z3NZEH#/2G2$?C*><0.JA;A]_-Z\8@ M_9HE@1#KE))N9J@P(,520DDI4QPR0"5_02%G\U$P88EV6%!%EM:AXNEB<6:! M2WMEG#^D4*:DGN#39@@*:!'PY$8?<_0D[:]ZH/@'<.:[XK?'UIE.MC;*\4Q2 M_J'OZ5EH5:9+"#Q!I3;8V:.YSL2ZERM[=)UUW)$PL=:!)B%U50!'P?9D@+%N MPIR+E09VI6LF 7E/].34;:!>9D++2&/$,]4&@A0Q04/&!O:G^@BE'PXCE'KV MI/\YCTD:]*V;_J _Z]N[$*/.=KQKL!%T.8X6BY@D[ 6M%=-_Q)*8(T[SLP\] MXM"%'X%T.+'*SB+':&!:/))0YB3 #$R*3MI)6C^@XI6RK9_90L0V!7&O\X-( M3 ]ZA-)N>MTPR/8 B.-*W,L,D"#BQ\6JCJR37<1!E44!_;#5?(AL2>[4UP*B M.)N7M!+H:6.>KI5 SZ(2**S^9].JGUI"JEHH^GDM]:E_,ZH&7;8V(?2L"XP0ER!#$SJK@BC8GARJZ;95:.3]7 M5ZTA&F)RVFN.=H8UQ%M(M:[D3_3B,@BIF 5CR$::94@2=@$R75L^+Z6C#D*] M<=D-RKZ9R(LII2SQRFA-F %=YW8RNN^, MQO;$FK$?![8UM;4G*,@) 3L)#YOC[%P#0J6.[(.QM5ANCNM>2H94!&9?B?], M[L,@>1)L;LU'Q%(ZQ;C4;GW'L@U=PX$2\"MQHMG7\'BXMP.AZ:P:83[@TMF@ M>SRLB%JJ1CR/5DH3ECP35245DOH0S"GCPC1(R-Q^<6E3:\5^:B@/_.'05-JV MA4/&,?0ESYFW('B$UP%-(VZ F81J0W3A/157$@KWTZ&N>Z"\:@]].TLU]B(R M:8$D_IHZ2\\]W+3461?F'&V0BJ;E0+*K5_0"O*+75#375#0GOC1-" N6V?PD M?K@"[7\N[]/4^($.W_Y$OQ#F82)SZYG^=EDS;X''3GTD;%[G?K]6Q8,E>TUSX1PM#@F1F6U:_HX9=V(9_H?& MAY:9@&\Y.I(.@+VIO2^8(3)Z%MQA88W6F(;_ZP<0O_O4^M&K(+;# M1_3GJO63&SHKZ9-5>4\SA.0$BP\D,67.Z'DM5J[1NBFV:07S81AL?A(^(X-W MQS8S0(6V4B]/@3F:0D=!3Y$;OCO6=J%LPN]3/C0^W5$LBU!I:7ADTVS;*G&[ M)RHWYN5<*B".,3?[^6X'58F)_MHOBS*>")I?(JABBE%B<8J-JSP; M43(407/\.!VI\)5QX!/29A1/3-RWR_#Y7>8+C%YS)(H?=D 4O_CM85K#]>*/ M[&^8D3M20=DPMS1?G;[ VQW!5J9FX>RK,?,D/)1M/,S4?%"W;ZG_G, M>9%>J=0&0[;*'7NQK+] ->'G)=C7;<:>.$Y7N7] :&M[+\H#\,6:3"P6 M$F1-IP_WXUE_-$2WL/4*A+IAG,1=9^TECN_]B\S'$5D[WIQ*3K;J7W0=1HKB6$/NA0 N%;$K:^(BQ>K<:V(*R%(3UA%EC3, M2EA%K(PU0O6?UQ@[9 )>=%%$A2%7@6J-UE)Z-_6JM36=L1-RM5"VELL2X^ S MI.+I#\:">08%3\VJ16S -JI&F$9CX)QX.8#T'SOTL&3M'L:.M M*HW,T!K$NES=O%NMLR!GKBTNGT";[+= 9FL=QRH\W9^QIB!6)TB_.L_D$W'\ MY*D?N.*855YK-'VKPJ:J=B4A\5KG0$\JCVN!@VLJ#Q.23EQ^*H]+*7!PM%9L M<"UB],?G)RU%3.]-UT+$^&D_M!Q(QMPMP$WW\0>1Z[GZSAG3WM](>=@?W9'G0^=JQA;YN8_-?.O6U- M'R9VKV/-.K=6?]+Y; T>T-,/7)V3%U@@6:NK\EH[V;1R:\MMB[:O$9R#H* M^>@W]ZU&/B3)@8A4]/=1,&&OF".Z!=\XL1>S,,J'('R,2?3,-N/L"BLX971\ MZUQJ)VIDP9%7R36=1CBG5]LH034<',.:*EOHW\/ I9TR2>C'<2JJ$7>*;V,? M&*<4534\-)T^.@G8CFW-_YG&25;*1E(9#V\ZV.>F4M4];-3,.9%WDX24KY5T MPTZMTWCW$7&AY?<9IF\Z]"=6]-5;>&YAP"T&G(4L4VQM_2'=2PHP)^P80V.V M'S!^9W@@WJ2O-X[[N[0^[(GG@/;ZV#39X^)CSGEWEC?0WS[@Q]WB7T(9%UJY MAMK!W"BO9L[0DC,SL^"HN3,_BMR9UG1JLV>4)1@Q-S)R>4 +KH MYC, KN; 7DC<:]X M>T $XSM2MWO[S>OVGY\\$E&./;UF,2YBERJT_^5 "Z48W?VZG5TI_"ZN3EGF MCU45%/5S.GV?T7S$E@*7Y IL?VON6&_S"-V2T0 O WM'N M5\R0,GUK]4#PVF4>OHF%14^.%J69BBTJG.9_,B'@< '=J%*EU*DG3G894![( M# $0"O-A82!5$O5$P0\\EP0Q4-09M MA=>T-]>T-]>T-V?\0E_70:#C$G/\TWZD"QV+-=S&>XVB;+;#E(GB:+$K1]AU M?)_,;UXW=!4-17>X8P?&5A=.("4M,1\SP%F/ .[EZ]Q%(VX(?Z\H=O+AL!T_ M6,(&9?09IYJYS)<2)Q 8O8\KCA8,CNJ89YCI[U[Q2(/-A3VPGR7HQ%E*O%%. MK6ZX6GG)AG;VMIKJ4B1PZ0$)WM8A-9V1\-9?WAG#[LL MN-88KY>(< 4?E^(PV!ZMG5=FM294EO,%MQ5P%F'>I^KTLS=/Z85U4YXG*XE] MX\1D/G9>-[2.0TH42;S<*U]X?>.;UQD3C]%B-PQM2W^;F>CJ/J\2H&OHW,VP M_322:%$,L*'=-Y7 1.=?US\$,^3X'V:Q=5*>$"J?P=)5;W"S/G*97 M$6LF8GR.HA2TKLR%,6I"_(R ^,E;ST*)];Z.(-D@^)FMA0M A)6,-#V>@/\. M ^=_TA6)/'%*J)IV: ;$)MRKWLRXE.MZ]QU&*V9W7'@NB82\KFV)F6*\!6X+ MJ-?$;RMZ]*B"2YL+F5UMAO:0N!U.\^A&=X4,PCC>W45>>\[*69)X&J;+IZSV ME^#J!^B*'_)\XHO @6H)YBZZ'-@QY>O7'EF'L2>PIQPTPW97H0- MXBTS9DQ)0O>N+.9JQ4IZ6U\="LE\%F;1O6,GJLV,LY%>M6&PW4GHPM"([?C" M4KM'%3-N= 3L]\5V&N&+!9C!AC@=,M6&$4[%M.13@3DYVQ M-9G]VIE-K.'4ZK*JZ.8X&S@$QW+_@KPGTJ)F$6VW1)38L]0$64V#LO]P71W2 M:,CRV5FIQA']<\RR*X91/Z -R,QY(;']PC:BK0>O?AW]*$J-,YZ,/O>G; W= MCB:=_K [NK<[,^L?]K1C_V-L#Z$KH$')]. MK4"OV/T%KD=91^15!P#H,)@&Q@ITC::89U:2B.6GHA]I )RL._;=IS%^,+Z8 M@B+=.HFW#!HL/&Y'[(M*\Y4GX84IF&T)5(2,VP_[#M$8,0DGF@>2A8GCHT88 M;JY5Q6F@##FT/W8LFCKT:IPYZSCF#:E[1TIC48"-@IVWMKE J'#I(L2B.*^: M[PV2_MC998_8&T"A,K!EZ5N]+,6+:BP5Q\]*3Q=P8B/M@6QO#WA;S MO<:"F( V!C\[8VB++$4WVT!HJ;^\B!Q,QXUZ?N;5-KAX%J)P>'G)#@2/=F1L M]1S_.)&0CWY^]MLVN:HI,A,RQ3&)5D[ S)JO07<>*Y M]-)9W#"$MKN?1;:[(M#PQKX=33;QAJ-AIT=_.9WUNUD^$?:G_MWP:KEKDPX6 M0GY+);Q.&'.T2XK"!G$9G0T'/3M+70LL1-^]&]!0K/96I6 [YOE9YX[GX%G[ M[AJ0;[]0?E(@O<")7C,K1I9[*T@H471JRWZ0$ J[=#_5]-'SLP*> (-C971F MG$>R8A@1J2\_?"M27WKVK3UAE8.IYG)8YN>JIK02[+-%J9#I8)F]?G.BZ)5* M-GOR!LB9!!KD[-20!BS29.JIS(214?RNB'"P7#=*'9]GX5$:X8QT!67:#%$/ M 7/>>_X:;,K Q9F]0F%)J@Y\?J=T2[PT3R;N(KK/*$!=M#\CWYR$DJ8JDG%O M+AHYY"[4R=;,<79^%[@*G0//>?3\+%?^D #"J;D=S\^%!N3%V<=EEBU2D.0+ M/[P_O/[L/0TW)M_"I=QZ^!J\)&NRM*,9^38;!$K+",//#LR?XD">UA?4V0SP M@,()!G!@4GW,K61::?(41OQ:<(>2?-#^G*'BT81>[[(Z,6XZ62XIAN2.E; : MB$M+V6*/UR$+MU:7Y22+7F7E1CG-C;'G<,3K4%D4$8U^2]\+"/_O-/+BN9=E M/Y*!(^UHC.4%!A.0$7H DZ3-SN;&PGGN2+B,G/63YXIRJ N:F[&=*9XW8I): MK2X*1H0L#V;ALBKRZ^9Z9(U'\L .B^,5O_4$- MUXL_LK]AYFZ6"LJ&N:7Y&G(T-'&A&>PQ4[AW@>\D1UMZ6DB4P,LLG[_\&Y*D M,GTOR__ "."XUX!]L16Q!H@J4*?5!G^$"=4=6&G8:['J"$E M&@=;+VL7-3G'-"'()\-^67MY/ VG9#/K#^^.[?]JB)[P\;SM?H-1'PG:S-9>>IEPSY7E$^AB3/U(ZI/W, MGN3 7&D?*I&$#S=3^Y<'>SCKV)^S\JG&^-,.*90[T_@]D,Q@^_.1%1VM;6V& M;46&Q:'9JY84?"_9P;PJ6X04E(%I_C"1B(E!&9CD^3HD@WY*[/KB=CAW6':4 MH'N\:F8FMU,#6I8Z6^.;:Q12IB8D",\7F!]F8->/XY3,>VE$+Q1C M$GGA/*N8%._F*SJ2P",8MNI ,"JPQFPL*R+8%-*Z@;#-H&TBRV>4)N/GO1=X MJW1UX\W'D><2.I=L(AQ;)[G9C0W_Q_4$L! A0# M% @ V(:15OO[M/74 P PQ0 H ( ! &5X,C,M M,2YH=&U02P$"% ,4 " #8AI%6Z%9#"&(( !W4 "@ M@ '\ P 97@S,2TQ+FAT;5!+ 0(4 Q0 ( -B&D5;A7'?(7 @ #50 * M " 88, !E>#,Q+3(N:'1M4$L! A0#% @ V(:15@#0M,34N:'1M4$L! A0#% @ V(:15H82 7CM# , G>D= P M ( !BT &9O00 ;F%O=BTR,#(R M,3(S,5]D968N>&UL4$L! A0#% @ V(:15JK:C^,O:P :1@& !4 M ( !(*\$ &YA;W8M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0 ( M -B&D5;^S7)4V$P /SX! 5 " 8(:!0!N86]V+3(P,C(Q A,C,Q7W!R92YX;6Q02P4& !( $@!)! C6<% end

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